{"0a4f30f5fd02ad89dc9ba18964325c6738807465": [["IntroductionMiddle East Respiratory Syndrome (MERS) is a new, emerging infectious disease that was first reported in 2012 and confirmed with human-to-human transmission in 2013 [1] .", [["IntroductionMiddle East Respiratory Syndrome", "DISEASE", 0, 44], ["MERS", "DISEASE", 46, 50], ["infectious disease", "DISEASE", 71, 89], ["human-to-human transmission", "DISEASE", 141, 168], ["human", "ORGANISM", 141, 146], ["human", "ORGANISM", 150, 155], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 150, 155], ["IntroductionMiddle East Respiratory Syndrome", "PROBLEM", 0, 44], ["emerging infectious disease", "PROBLEM", 62, 89], ["Respiratory Syndrome", "OBSERVATION", 24, 44], ["new", "OBSERVATION_MODIFIER", 57, 60], ["infectious", "OBSERVATION", 71, 81]]], ["MERS is caused by a coronavirus from the same family as the one that triggered China's deadly outbreak of Severe Acute Respiratory Syndrome (SARS) in 2003.", [["MERS", "DISEASE", 0, 4], ["Acute Respiratory Syndrome", "DISEASE", 113, 139], ["SARS", "DISEASE", 141, 145], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 106, 146], ["a coronavirus", "PROBLEM", 18, 31], ["Severe Acute Respiratory Syndrome", "PROBLEM", 106, 139], ["SARS", "PROBLEM", 141, 145], ["Severe", "OBSERVATION_MODIFIER", 106, 112], ["Acute", "OBSERVATION_MODIFIER", 113, 118], ["Respiratory Syndrome", "OBSERVATION", 119, 139]]], ["Previous cases have shown that medical students, especially the pre-clinical year medical students, are at high risk of newly emerging diseases, including SARS [2] .", [["SARS", "DISEASE", 155, 159], ["newly emerging diseases", "PROBLEM", 120, 143], ["SARS", "PROBLEM", 155, 159]]], ["While doctors and nurses played a crucial role in the prevention, detection, and containment of SARS [3] most documented \"super-spreading events\" of SARS occurred in hospitals.", [["SARS", "DISEASE", 96, 100], ["SARS", "DISEASE", 149, 153], ["SARS", "PROBLEM", 96, 100], ["SARS", "PROBLEM", 149, 153]]], ["The underlying causes remain unclear [4] , but it has been suggested that lack of systematic training in emerging infectious diseases could be the cause.", [["infectious diseases", "DISEASE", 114, 133], ["systematic training", "TREATMENT", 82, 101], ["emerging infectious diseases", "PROBLEM", 105, 133], ["infectious", "OBSERVATION", 114, 124]]], ["A similar case was reported with swine flu [5] In China, medical education is comprised of basic medical sciences courses in the first four years and an internship in the fifth year.", [["swine", "SPECIES", 33, 38]]], ["Although courses regarding preventive medicine are provided to all students, there is no specific course that addresses new emergency infectious diseases.", [["infectious diseases", "DISEASE", 134, 153], ["preventive medicine", "TREATMENT", 27, 46], ["new emergency infectious diseases", "PROBLEM", 120, 153]]], ["This is concerning because contact with newly emerging infectious diseases such as MERS, H7N9, andH1N1 is not rare in their practice.", [["infectious diseases", "DISEASE", 55, 74], ["MERS", "DISEASE", 83, 87], ["H1N1", "DISEASE", 98, 102], ["H7N9", "SPECIES", 89, 93], ["newly emerging infectious diseases", "PROBLEM", 40, 74], ["MERS", "PROBLEM", 83, 87], ["H7N9", "PROBLEM", 89, 93], ["H1N1", "PROBLEM", 98, 102], ["infectious", "OBSERVATION", 55, 65]]], ["Chinese medical students' knowledge on emergency infectious diseases is low.", [["infectious diseases", "DISEASE", 49, 68], ["emergency infectious diseases", "PROBLEM", 39, 68], ["low", "OBSERVATION_MODIFIER", 72, 75]]], ["For example, only 35.2% of medical students washed their hands before and 72.5% washed their hands after they physically examined patients in the wards in 2003 before SARS [6] A study from Saudi Arabia addressing the awareness of all procedures concerning prevention of and protection from MERSamong dental students suggested that more information needs to be provided by the authorities for the medical staff [7] .", [["SARS", "DISEASE", 167, 171], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["A study", "TEST", 176, 183], ["all procedures", "TREATMENT", 230, 244]]], ["After the first case of MERS was found in China, we designed a study to assess the knowledge of a group of Chinese medical students regarding MERS.MethodWe conducted a knowledge, attitudes, and practices survey that addressed MERS and its diagnosis and prevention among medical students in May 2015.", [["MERS", "PROBLEM", 24, 28], ["a study", "TEST", 61, 68]]], ["The study selected individuals to represent the 9000 medical students in Wannan medical college.", [["The study", "TEST", 0, 9]]], ["A multi-stage, random cluster sampling design was used to designate study subjects.", [["A multi-stage", "PROBLEM", 0, 13]]], ["Each of the above randomly selected grades was divided into multiple majors.", [["multiple", "OBSERVATION_MODIFIER", 60, 68]]], ["Then, one to two classes from these majors were randomly selected to represent the population.", [["population", "OBSERVATION", 83, 93]]], ["The response rate was 95.6%.", [["The response rate", "TEST", 0, 17]]], ["This study was approved by the Institutional Review Board at Wannan Medical College and followed the tenets of the Declaration of Helsinki.", [["This study", "TEST", 0, 10]]], ["A written form of consent was obtained from all participants.MeasuresA structured questionnaire was adapted from the information released by the National Health and Family Commission of China and a previous MERS-related survey [7] .", [["participants", "SPECIES", 48, 60]]], ["The questionnaire was comprised of 18 items including demographics and knowledge about MERS in three areas: diagnosis, treatment, and preventive measures.", [["treatment", "TREATMENT", 119, 128], ["preventive measures", "TREATMENT", 134, 153]]], ["A knowledge score was calculated by giving +1 for the correct answer (Yes/No), and 0 for \"Don't know\", with the highest possible score being 18.", [["A knowledge score", "TEST", 0, 17]]], ["Higher scores indicated a greater level of knowledge.Statistical AnalysisMeans and standard deviations were used to describe the distribution of continuous variables.", [["Higher scores", "PROBLEM", 0, 13]]], ["Percentages were used to describe the distribution of categorical variables.", [["Percentages", "TEST", 0, 11]]], ["A chi-square test was performed to examine the differences in educational background and MERS-related knowledge, diagnosis, and prevention between different major groups among medical students.", [["A chi-square test", "TEST", 0, 17]]], ["SAS 9.3 (SAS Institute, INC, Cary, NC) was used for all statistical analyses.ResultsOf 214 participants, 11 were excluded because of missing information on demographic questions.", [["participants", "SPECIES", 91, 103], ["SAS", "TEST", 0, 3], ["INC, Cary, NC)", "TREATMENT", 24, 38], ["all statistical analyses", "TEST", 52, 76]]], ["Thus, 203 medical students with a mean age of 21 \u00b1 1.4 (mean \u00b1 SD) years participated.", [["a mean age", "TEST", 32, 42]]], ["Table 2 shows the difference in knowledge of MERS among the different majors of medical students (p < 0.05), e.g., management majors scored significantly higher than students of other majors (p < 0.05) (data not shown).DiscussionOur study showed that medical students had good knowledge of MERS.", [["DiscussionOur study", "TEST", 219, 238]]], ["Nursing students had the lowest scores in comparison to the students from the other majors, while management students had relatively higher scores compared to the students of the other majors, especially in the categories of \"diagnosis and treatment\" and \"prevention\".DiscussionPrevious medical knowledge or background might have some impact on the understanding of the disease.", [["treatment", "TREATMENT", 240, 249], ["the disease", "PROBLEM", 366, 377], ["disease", "OBSERVATION", 370, 377]]], ["The results also reflected the insufficient education on disease prevention and control in the medical school curriculum.", [["disease prevention", "TREATMENT", 57, 75]]], ["The lack of related knowledge among the medical students raises a public concern since they should be prepared with knowledge to confront a potential epidemic and/or pandemic.", [["pandemic", "PROBLEM", 166, 174]]], ["Although MERS was a newly emergent infectious disease, which people were less familiar with, there are some common principles for dealing with it.", [["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["a newly emergent infectious disease", "PROBLEM", 18, 53], ["infectious", "OBSERVATION", 35, 45]]], ["The medical staff and public health agencies play a critical role in controlling new emergency infectious diseases.", [["infectious diseases", "DISEASE", 95, 114], ["infectious", "OBSERVATION", 95, 105]]], ["Therefore, it is crucial that healthcare professionals, as well as medical students, be provided with training in controlling infectious diseases [8] .DiscussionRegarding the contents of the training, the National Health and Family Commission of the People's Republic of China published the second edition of the MERS Prevention and Control Plan on 5 June 2015 [9] .", [["infectious diseases", "DISEASE", 126, 145], ["the MERS Prevention", "TREATMENT", 309, 328]]], ["In addition, the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) also have issued recommendations for the prevention and control of MERS infections in healthcare settings [7] .", [["infections", "DISEASE", 178, 188], ["Disease Control", "TREATMENT", 69, 84], ["MERS infections", "PROBLEM", 173, 188]]], ["The prevention of MERS includes hand hygiene, wearing personal protective equipment, and patient placement [10] .", [["hand", "ANATOMY", 32, 36], ["MERS", "DISEASE", 18, 22], ["hand", "ORGANISM_SUBDIVISION", 32, 36], ["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["hand hygiene", "TREATMENT", 32, 44], ["personal protective equipment", "TREATMENT", 54, 83]]], ["In terms of general training, courses such as new emergency diseases, field epidemiology, and tropical medicine can be provided [11, 12] .", [["general training", "TREATMENT", 12, 28], ["new emergency diseases", "PROBLEM", 46, 68], ["tropical medicine", "TREATMENT", 94, 111]]], ["In terms of specific outbreaks, a special course to improve the students' knowledge of MERS can be provided.DiscussionOur study had several limitations.", [["DiscussionOur study", "TEST", 108, 127], ["specific", "OBSERVATION_MODIFIER", 12, 20], ["outbreaks", "OBSERVATION", 21, 30]]], ["A comparison group consisting of randomly sampled non-medical general population might be needed in the study design to better understand the findings.", [["the study", "TEST", 100, 109]]], ["Future studies addressing those points are warranted.DiscussionOur study had a special public health implication.", [["Future studies", "TEST", 0, 14], ["DiscussionOur study", "TEST", 53, 72]]], ["Special medical education programs on general training on disease control, as well as healthcare guidance on new emergency diseases/outbreaks are warranted.", [["Special medical education programs", "TREATMENT", 0, 34], ["general training", "TREATMENT", 38, 54], ["disease control", "TREATMENT", 58, 73]]], ["It could be a workshop in the classroom or an online program with updated information on new emergency infectious diseases including the topics of prevention, diagnosis, treatment, and patient education.ConclusionsOur findings indicated that Chinese medical students had good knowledge of MERS.", [["infectious diseases", "DISEASE", 103, 122], ["patient", "ORGANISM", 185, 192], ["patient", "SPECIES", 185, 192], ["treatment", "TREATMENT", 170, 179]]], ["Education on new emergency disease prevention and control should be addressed among all medical students.", [["new emergency disease prevention", "TREATMENT", 13, 45]]]], "0a41475b83b570dd0056b3ba82a25aab93d5f981": [["IntroductionThere a number of different dynamic loads, including the effects of earthquakes, wind, vibrating machines, jumping of spectators, piling works or passing of vehicles, which can induce vibrations of buildings (see [1] [2] [3] for example).", [["earthquakes", "DISEASE", 80, 91], ["dynamic loads", "OBSERVATION", 40, 53]]], ["Traffic-induced vibrations, even that they are not as severe as vibrations caused by wind or earthquakes [4, 5] , can also lead to major problems.", [["earthquakes", "DISEASE", 93, 104], ["major problems", "PROBLEM", 131, 145]]], ["They can cause plaster scratches and cracks, scratches on the structure, structural elements cracking or even collapsing of the building (see [6] ).", [["plaster scratches", "PROBLEM", 15, 32], ["cracks", "PROBLEM", 37, 43], ["scratches on the structure", "PROBLEM", 45, 71], ["plaster scratches", "OBSERVATION", 15, 32], ["cracks", "OBSERVATION_MODIFIER", 37, 43], ["scratches", "OBSERVATION_MODIFIER", 45, 54], ["elements", "OBSERVATION_MODIFIER", 84, 92], ["cracking", "OBSERVATION_MODIFIER", 93, 101], ["collapsing", "OBSERVATION_MODIFIER", 110, 120]]], ["The harmfulness of vibrations on structural elements is influenced by many factors regarding the road on which vehicles move.", [["vibrations on structural elements", "PROBLEM", 19, 52], ["vibrations", "OBSERVATION_MODIFIER", 19, 29]]], ["Vibration measurements on real structures are labour-intensive and costly projects, and what is important, they are not justified in every case.", [["Vibration measurements", "TEST", 0, 22], ["labour", "PROBLEM", 46, 52]]], ["Therefore, approximate methods are increasingly used.", [["approximate methods", "TREATMENT", 11, 30]]], ["These methods allow the engineering problem to be solved accurately enough and the result is satisfactory, even if it is approximate (for example, see [7] ).", [["These methods", "TREATMENT", 0, 13]]], ["An example of this methodology is the support vector machine (SVM).", [["this methodology", "TREATMENT", 14, 30]]], ["The purpose and sense of operation of ML was described by Tom Michael Mitchell in the basic publication regarding ML algorithms [10] .", [["operation of ML", "TREATMENT", 25, 40]]], ["In turn, Chen et al. [11] used SVM to detect burglars.", [["burglars", "PROBLEM", 45, 53]]], ["An example is the publication [12] which presents a system based on ML techniques supporting the detection of a threat, for example in the form of a fire, based on the analysis of the image from monitoring.", [["the analysis", "TEST", 164, 176], ["the image from monitoring", "TEST", 180, 205]]], ["Related works also include the paper [13] aiming to create a model of technical degradation of buildings located in mining areas and subjected to paraseismic tremors.", [["tremors", "DISEASE", 158, 165], ["paraseismic tremors", "PROBLEM", 146, 165], ["paraseismic tremors", "OBSERVATION", 146, 165]]], ["The authors presented the idea of detecting defects in a wind mill.IntroductionA review of the literature indicates that ML can be widely used.", [["detecting defects", "PROBLEM", 34, 51], ["defects", "OBSERVATION", 44, 51], ["wind mill", "OBSERVATION", 57, 66]]], ["The implementation of this method in various fields can positively affect the development of technology and reduce costs while minimizing the risk of adverse effects.", [["this method in various fields", "TREATMENT", 22, 51], ["adverse effects", "PROBLEM", 150, 165]]], ["Therefore, the aim of this research is to implement this methodology for such a purpose.Problem of Traffic-Induced VibrationsVibrations are described by movement of building structure particles, most often caused by waves propagated in the ground and reaching the foundations [15] .", [["this methodology", "TREATMENT", 52, 68]]], ["It should be noted that vibrations and noise are defined as environmental pollution.", [["vibrations and noise", "PROBLEM", 24, 44]]], ["A very important factor in analysing the impact of traffic-induced vibrations on buildings is the soil in which the wave propagates.", [["traffic-induced vibrations on buildings", "TREATMENT", 51, 90]]], ["Both of them depend mainly on the type of medium in which the wave propagates.", [["wave", "OBSERVATION_MODIFIER", 62, 66]]], ["Therefore, the soil impact parameter was also included in this ML model.", [["the soil impact parameter", "TREATMENT", 11, 36], ["this ML model", "TREATMENT", 58, 71]]], ["It is also important to determine the source of vibration, propagation path and indicate the vibration receiver, which can be a structure itself, people or equipment located inside a building.Problem of Traffic-Induced VibrationsSpecial attention should be paid to the possibility of traffic-induced vibrations already during the design phase of building, and also in the exploitation phase.", [["people", "SPECIES", 146, 152], ["the vibration receiver", "TEST", 89, 111], ["Traffic-Induced Vibrations", "TREATMENT", 203, 229], ["traffic-induced vibrations", "PROBLEM", 284, 310]]], ["According to the standard [15] , the load of the building caused by vibrations transmitted through the ground can generally be omitted if a building is located at a distance of more than 25 m from the axis of the railway line or at a distance of more than 15 m from the axis of the tram line, the axis of the first category road or a thoroughfare street.", [["tram line", "ANATOMY", 282, 291], ["tram line", "CELL", 282, 291], ["railway line", "CELL_LINE", 213, 225], ["railway line", "OBSERVATION", 213, 225], ["tram line", "OBSERVATION", 282, 291]]], ["However, after performing field tests using specialized equipment, it often appears that there is no immediate danger to the structure.", [["performing field tests", "TEST", 15, 37], ["specialized equipment", "TREATMENT", 44, 65], ["no", "UNCERTAINTY", 98, 100]]], ["Moreover, carrying out such tests for all buildings located along the road may not be economically justified.", [["such tests", "TEST", 23, 33]]], ["Therefore, there is a need to develop effective methods for forecasting impact of trafficinduced vibrations on buildings.", [["effective methods", "TREATMENT", 38, 55], ["trafficinduced vibrations on buildings", "TREATMENT", 82, 120]]], ["The experience and acquired knowledge of experts are the basis of systems and calculation programs.", [["calculation programs", "TREATMENT", 78, 98]]], ["Therefore, the aim of the operation is to create an expert model based on ML which allows us to predict with high probability the threat of negative dynamic impact on the tested building without performing laborious and expensive field measurements.Problem of Traffic-Induced VibrationsIt should be added that vibrations may also have significant impact on people in buildings.", [["people", "ORGANISM", 357, 363], ["people", "SPECIES", 357, 363], ["the operation", "TREATMENT", 22, 35], ["expensive field measurements", "TEST", 220, 248], ["negative", "OBSERVATION", 140, 148]]], ["This problem is particularly noticeable when people are exposed to long-term vibrations (see [6, 16] ).", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51]]], ["Traffic-induced vibrations can cause discomfort to people in the affected area.", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["discomfort", "PROBLEM", 37, 47]]], ["Test results show that the threshold of human vibration perception is lower than the limit, after which damage may occur in the building itself [16] .", [["human", "ORGANISM", 40, 45], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["human vibration perception", "TEST", 40, 66], ["lower", "OBSERVATION_MODIFIER", 70, 75]]], ["In European standards (see [17] [18] [19] [20] ), three parameters are described for assessing the impact of vibrations: the corrected value of acceleration or velocity of vibrations in the frequency range 1-80 Hz, spectrum (frequency structure) for effective acceleration or velocity values in 1/3 octave bands and the dose of vibration.Experimental StudyThe extensive experimental study has been firstly carried out for 11 buildings (see Table 1 ).", [["effective acceleration", "PROBLEM", 250, 272], ["velocity values", "TEST", 276, 291], ["octave bands", "TEST", 299, 311], ["Experimental Study", "TEST", 338, 356], ["The extensive experimental study", "TEST", 356, 388], ["velocity", "OBSERVATION_MODIFIER", 276, 284], ["extensive", "OBSERVATION_MODIFIER", 360, 369]]], ["The measurements have been conducted for different types of passing vehicles in accordance with standard [15] .", [["The measurements", "TEST", 0, 16]]], ["A separate detailed analysis has been performed for each building.", [["A separate detailed analysis", "TEST", 0, 28]]], ["The extreme amplitude values of measured vibrations have been obtained and compared with the values of the dynamic influence scale so as to determine to which zone the structure is assigned to (see [15] for details).", [["The extreme amplitude values", "TEST", 0, 28], ["the dynamic influence scale", "TEST", 103, 130], ["extreme", "OBSERVATION_MODIFIER", 4, 11], ["amplitude", "OBSERVATION_MODIFIER", 12, 21]]], ["All tested buildings in experimental study have been divided into 2 sets: firstly, buildings with small external dimensions of the horizontal projection (maximum length of 15 m) with one or two stories and secondly, buildings up to five stories high.Experimental StudyTo create the ML model, all cases have been divided into 2 groups with descriptions of zones defined in [15] :Experimental Study\u2022 zone I: vibrations unnoticed by a building; the lower limit of impact of vibrations on a building and the lower limit of taking into account the dynamic influences; \u2022 zones II-V: vibrations noticed by a building; minimum, mean and significant impact of vibrations on a building.Input and Output InformationThe purpose of the SVM algorithm in the present paper is to classify the variables and assign them to certain zones.", [["experimental study", "TEST", 24, 42], ["the ML model", "TREATMENT", 278, 290], ["Experimental Study", "TEST", 378, 396], ["a building", "TREATMENT", 485, 495], ["vibrations", "PROBLEM", 577, 587], ["the SVM algorithm", "TEST", 719, 736], ["small", "OBSERVATION_MODIFIER", 98, 103], ["external dimensions", "OBSERVATION_MODIFIER", 104, 123], ["lower limit", "OBSERVATION_MODIFIER", 446, 457], ["lower limit", "OBSERVATION_MODIFIER", 504, 515], ["significant", "OBSERVATION_MODIFIER", 629, 640]]], ["The SVM task is to set a separator that will split the data into obvious subsets.", [["a separator", "TREATMENT", 23, 34]]], ["Before the final set of parameters has been adopted, different combinations of these parameters have been examined.", [["these parameters", "TEST", 79, 95]]], ["The output signal has been defined in this way that it contains the information whether there is a risk of negative impact of vibrations on buildings or not.", [["The output signal", "TEST", 0, 17], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["No impact indicates zone I of dynamic influence scale, i.e. no influence on a building.", [["zone", "OBSERVATION_MODIFIER", 20, 24]]], ["If the algorithm predicts a possible threat, it is an indication for performing in situ measurements, as it may mean that the building falls in zone II-V of dynamic influence scale.", [["dynamic influence scale", "TREATMENT", 157, 180]]], ["The construction of SVM has been based on the principles described in the literature [22] [23] [24] [25] [26] [27] [28] [29] .", [["[22] [23] [24] [25] [26] [27] [28]", "CHEMICAL", 85, 119], ["[22] [23] [24] [25] [26] [27] [28] [29]", "SIMPLE_CHEMICAL", 85, 124], ["The construction of SVM", "TREATMENT", 0, 23]]], ["Firstly, the database necessary to start the algorithm has been created.", [["the algorithm", "TEST", 41, 54]]], ["63 samples have been collected, including 33 input data samples by independent own measurements (see chapter 3 and [21] ) and 30 samples based on measurements of other researchers [30, 31] .", [["samples", "ANATOMY", 3, 10], ["samples", "CANCER", 3, 10]]], ["The input signals have been defined as factors (independent variables) determined during field measurements, i.e. B C -condition of building, B DRdistance from the edge of the building, S A -soil absorption, R S -type of road surface, R C -condition of road surface, V T -type of vehicle.", [["road surface", "ANATOMY", 221, 233], ["road surface", "ANATOMY", 253, 265]]], ["The input vector has therefore been adopted as follows: Two classes as the output signal have been adopted: 0 -no impact of vibrations on the building; 1 -probable impact of vibrations on the building.", [["the output signal", "TEST", 71, 88]]], ["Thus, the output vector has been assumed to have the form: y (1\u00d71) = {y}; y {0, 1}.Input and Output InformationThe SVM algorithm has been tested for four different kernel functions.", [["the output vector", "TEST", 6, 23], ["The SVM algorithm", "TEST", 111, 128]]], ["The optimization problem has been solved, in which the margin (weak margin) has been minimized because it had been not linearly separable.", [["solved", "OBSERVATION_MODIFIER", 34, 40], ["margin", "OBSERVATION_MODIFIER", 55, 61], ["weak", "OBSERVATION_MODIFIER", 63, 67], ["margin", "OBSERVATION_MODIFIER", 68, 74], ["linearly", "OBSERVATION_MODIFIER", 119, 127], ["separable", "OBSERVATION_MODIFIER", 128, 137]]], ["A binary classification algorithm has been used since two classes of sets have been assumed: a set of cases for which there is a threat of impact of vibrations on buildings and a set of safe cases.", [["A binary classification algorithm", "PROBLEM", 0, 33]]], ["All cases have been randomly divided into 2 sets: learning and testing.", [["testing", "TEST", 63, 70]]], ["47 samples have been randomly assigned to the learning set (74.6% of all samples) and 16 samples for the test set (25.4% of the total).Input and Output InformationBecause the cases have been unevenly distributed into classes (for 47 samples empirically determined during measurements, no risk of impact of vibrations on buildingclass \"0\" and for 16 samples a result indicating the risk of vibration impact -class \"1\") a penalty has been used to avoid incorrectly classifying cases of class \"1\" into a larger class, that is class \"0\".", [["samples", "ANATOMY", 3, 10], ["samples", "ANATOMY", 73, 80], ["samples", "CANCER", 3, 10], ["samples", "CANCER", 73, 80], ["the test set", "TEST", 101, 113]]], ["The kernel functions have been adopted in turn as a linear, polynomial, radial base and sigmoidal function [24] .", [["radial", "ANATOMY_MODIFIER", 72, 78], ["base", "ANATOMY_MODIFIER", 79, 83], ["sigmoidal function", "OBSERVATION", 88, 106]]], ["To determine the optimal values of the learning constants, a cross-validation has been used for each machine with each type of kernel according to formulas (1) (2) (3) (4) .", [["a cross-validation", "TEST", 59, 77]]], ["The algorithm's reliability has been assessed on the basis of errors recognizing the assignment of structures from the set of all data and the set of learning and testing data to previously defined patterns.Input and Output InformationIn the first case, the linear function of the form described in [24] has been adopted as the kernel function K(x, y) according to formula (1):Input and Output Informationwhere: c -optional constant;Input and Output InformationIn accordance with the principle described in [26] , a 10-fold cross-validation has been carried out, the validity of which has been equal to 78.72%.", [["c", "PROTEIN", 412, 413], ["The algorithm's reliability", "TEST", 0, 27], ["testing data", "TEST", 163, 175]]], ["Classification accuracy in the learning set has been found to be equal to 82.98%, and in the testing set 81.25%.", [["Classification accuracy", "TEST", 0, 23], ["the testing set", "TEST", 89, 104]]], ["The algorithm's reliability has been assessed on the basis of errors recognizing the assignment of structures from the set of all data and the set of learning and testing data to previously defined patterns.Input and Output InformationIn the next stage, the machine with polynomial function K(x, y) of the third degree has been analysed [25] :Input and Output Informationwhere: c -optional constant; \u03b1 -slope, \u03b1 = 1/N, where N is the data dimension; d -degree of polynomial;Input and Output InformationThe cross-validation and reliability of the algorithm have been carried out in the same way as for the previous machine.", [["c", "PROTEIN", 378, 379], ["\u03b1", "PROTEIN", 400, 401], ["The algorithm's reliability", "TEST", 0, 27], ["testing data", "TEST", 163, 175], ["polynomial function K", "TEST", 271, 292], ["the algorithm", "TEST", 542, 555]]], ["The accuracy of the cross test has been found to be equal to 78.72%.", [["the cross test", "TEST", 16, 30]]], ["Classification accuracy in the learning set has been found to be equal to 85.11%, and in the testing set 81.25%.", [["Classification accuracy", "TEST", 0, 23], ["the testing set", "TEST", 89, 104]]], ["Overall validity has been equal to 84.13%.Input and Output InformationIn the third step to build the algorithm, the radial base function has been adopted as the function K(x, y) [24] :Input and Output Informationwhere: \u03c3 -parameter regulating data noise and ensuring non-linearity of functions.Input and Output InformationThe accuracy of the cross-validation test has been found to be equal to 78.72%.", [["\u03c3", "PROTEIN", 219, 220], ["Overall validity", "TEST", 0, 16], ["the radial base function", "TEST", 112, 136], ["the function K", "TEST", 157, 171], ["the cross-validation test", "TEST", 338, 363], ["equal", "OBSERVATION_MODIFIER", 26, 31], ["radial", "ANATOMY_MODIFIER", 116, 122], ["base", "ANATOMY_MODIFIER", 123, 127]]], ["Classification accuracy in the training set has been found to be equal to 85.11%, and in the test set 81.25%.", [["Classification accuracy", "TEST", 0, 23], ["the test set", "TEST", 89, 101]]], ["Overall validity has been equal to 84.13%.Input and Output InformationIn the last case, the sigmoidal function has been adopted according to the formula (4) for the algorithm [24] :Input and Output Informationwhere: c -optional constant;Input and Output InformationThe accuracy of the cross-validation has been found to be equal to 76.60%.", [["Overall validity", "TEST", 0, 16], ["the cross-validation", "TEST", 281, 301], ["equal", "OBSERVATION_MODIFIER", 26, 31]]], ["Classification accuracy in the learning set has been found to be equal to 74.47%, and in the testing set 81.25%.", [["Classification accuracy", "TEST", 0, 23], ["the testing set", "TEST", 89, 104]]], ["Overall relevance has been equal to 76.19%.Input and Output InformationThe application of the classification algorithm using SVM has allowed us to obtain results for all cases: learning and testing.", [["testing", "TEST", 190, 197], ["equal", "OBSERVATION_MODIFIER", 27, 32]]], ["The result for each sample has been compared with the result obtained from the experiment.", [["each sample", "TEST", 15, 26]]], ["The overall reliability of the machines has been calculated as a weighted average taking into account the size of the learning and testing sets.", [["testing sets", "TEST", 131, 143], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["reliability", "OBSERVATION_MODIFIER", 12, 23], ["size", "OBSERVATION_MODIFIER", 106, 110]]], ["It can be seen from the table that, considering the four kernel functions used for construction, they all have achieved the same correctness (81.25%) in the testing set.", [["the testing set", "TEST", 153, 168]]], ["However, in the case of learning samples, the third degree polynomial kernel and radial base function have achieved better prediction, equal to 85.11%.", [["learning samples", "TEST", 24, 40], ["radial base function", "TEST", 81, 101], ["polynomial kernel", "OBSERVATION", 59, 76], ["radial", "ANATOMY_MODIFIER", 81, 87], ["base", "ANATOMY_MODIFIER", 88, 92]]], ["Table 2 also shows that the best overall validity (84.13% of the prediction) has been obtained using the third degree polynomial and the radial base function.ConclusionsIn this paper, the model for forecasting the impact of traffic-induced vibrations on buildings using machine learning method has been considered.", [["radial base", "ANATOMY", 137, 148], ["radial base", "MULTI-TISSUE_STRUCTURE", 137, 148], ["machine learning method", "TREATMENT", 270, 293], ["radial", "ANATOMY_MODIFIER", 137, 143], ["base", "ANATOMY_MODIFIER", 144, 148]]], ["Firstly, a database has been created on the results of vibration measurements for buildings using both own research and other researchers.", [["vibration measurements", "TEST", 55, 77]]], ["In the next stage, the rules for creating ML have been presented.", [["creating ML", "PROBLEM", 33, 44]]], ["Finally, the model proposed by authors has been presented.ConclusionsThe SVM algorithm has been tested for four different kernel functions: linear, polynomial, radial base and sigmoidal functions.", [["The SVM algorithm", "TEST", 69, 86], ["kernel functions", "OBSERVATION", 122, 138], ["linear", "OBSERVATION_MODIFIER", 140, 146], ["radial", "ANATOMY_MODIFIER", 160, 166], ["base", "ANATOMY_MODIFIER", 167, 171], ["sigmoidal functions", "OBSERVATION", 176, 195]]], ["The model has been created for the input variable vector x (6\u00d71) = {B C , B DR , S A , R S , R C , V T }.", [["{B C", "TEST", 67, 71], ["R S", "TEST", 87, 90]]], ["Other combinations of input parameters have been also considered at the testing stage, but the presented model achieved the best results.", [["input parameters", "TEST", 22, 38]]], ["This means that the best combination of input factors for the analysed cases of traffic-induced vibrations prediction are: technical condition of the building, distance between the building and the road edge, absorption of vibrations in the ground, type of surface, technical condition of the surface and type of vehicles moving on the way.", [["surface", "ANATOMY", 257, 264], ["surface", "ANATOMY", 293, 300], ["surface", "CELLULAR_COMPONENT", 293, 300], ["input factors", "PROTEIN", 40, 53], ["road edge", "OBSERVATION", 198, 207], ["vibrations", "OBSERVATION_MODIFIER", 223, 233], ["surface", "OBSERVATION_MODIFIER", 257, 264], ["surface", "OBSERVATION_MODIFIER", 293, 300]]]], "37457c9cb57e90f8a66c4ea12cd9cb285715097f": [["Living evidence in response to controversies about the use of antimalarials in COVID-19Sr.", [["COVID-19Sr", "CHEMICAL", 79, 89], ["COVID-19Sr", "SIMPLE_CHEMICAL", 79, 89], ["antimalarials", "TREATMENT", 62, 75]]], ["Editor:Living evidence in response to controversies about the use of antimalarials in COVID-19Debido a la crisis sanitaria derivada de la pandemia de SARS-CoV-2, se ha creado un \u00e1rea de incertidumbre cl\u00ednica considerable.", [["COVID-19Debido", "CHEMICAL", 86, 100], ["antimalarials", "TREATMENT", 69, 82], ["a la crisis", "PROBLEM", 101, 112], ["CoV", "TEST", 155, 158]]], ["Actualmente nos encontramos con que hay pocos estudios primarios sobre COVID-19 finalizados, y los datos preliminares que ya se han publicado proporcionan niveles de evidencia bajos.", [["COVID", "TEST", 71, 76]]], ["En esta situaci\u00f3n de incertidumbre, lo m\u00e1s adecuado es interpretar la evidencia disponible con precauci\u00f3n y evitar una toma de decisiones precipitada que pueda ser m\u00e1s perjudicial que beneficiosa 1 .Living evidence in response to controversies about the use of antimalarials in COVID-19En el \u00e1mbito de la cardiolog\u00eda han surgido diversos temas controvertidos como el tratamiento con inhibidores de la enzima de conversi\u00f3n de la angiotensina o antagonistas del receptor de la angiotensina II aplicado a la COVID-19 2 y hay otro debate abierto sobre el uso de la cloroquina o hidroxicloroquina que, combinados o no con antibi\u00f3ticos como la azitromicina y antivirales, se est\u00e1n utilizando para tratarla.Living evidence in response to controversies about the use of antimalarials in COVID-19El auge de estos medicamentos antimal\u00e1ricos en el abordaje de la COVID-19 tiene su origen en una reuni\u00f3n cient\u00edfica en China, a mediados de febrero de 2020, en la cual se reunieron autores de ensayos cl\u00ednicos, autoridades gubernamentales y representantes de las agencias reguladoras de ese pa\u00eds.", [["COVID-19En el \u00e1mbito", "CHEMICAL", 278, 298], ["antimalarials", "TREATMENT", 261, 274], ["surgido diversos temas", "TREATMENT", 321, 343], ["como el tratamiento con inhibidores", "TREATMENT", 359, 394], ["a la COVID", "TREATMENT", 500, 510], ["antimalarials", "TREATMENT", 762, 775], ["en la cual", "TREATMENT", 944, 954]]], ["En esa reuni\u00f3n se concluy\u00f3 que la cloroquina ten\u00eda una potente actividad contra la COVID-19 y se recomend\u00f3 incluirla en la gu\u00eda de prevenci\u00f3n, diagn\u00f3stico y tratamiento de la neumon\u00eda causada por COVID-19, emitida por la Comisi\u00f3n Nacional de Salud de la Rep\u00fablica Popular China 3 .Living evidence in response to controversies about the use of antimalarials in COVID-19Otro momento fundamental en la propagaci\u00f3n de esta idea fue cuando el 19 de marzo se dio a conocer un estudio no aleatorizado franc\u00e9s apoyando la hip\u00f3tesis china 4 .", [["COVID-19Otro momento", "CHEMICAL", 360, 380], ["antimalarials", "TREATMENT", 343, 356], ["aleatorizado", "PROBLEM", 481, 493]]], ["Pese a las graves limitaciones metodol\u00f3gicas de dicho estudio, en pocas horas el mensaje hab\u00eda calado e incluso el presidente de Estados Unidos expres\u00f3 el 21 de marzo en su cuenta de Twitter que \u00abla hidroxicloroquina y la azitromicina, tomadas en combinaci\u00f3n, tienen una oportunidad real de ser uno de los mayores puntos de inflexi\u00f3n en la historia de la medicina\u00bb 5 .Living evidence in response to controversies about the use of antimalarials in COVID-19Ante este entusiasmo se han revisado los efectos cardiovasculares de estos f\u00e1rmacos, y se ha encontrado que, aunque la incidencia de eventos cardiacos es baja, pueden darse efectos no deseados como hipotensi\u00f3n y taquicardia (principalmente en administraci\u00f3n intravenosa), prolongaci\u00f3n del QT (mayor en tratamiento concomitante con azitromicina) e interacciones con la amiodarona, la digoxina y los bloqueadores beta.", [["COVID-19Ante este entusiasmo", "CHEMICAL", 447, 475], ["hidroxicloroquina y la azitromicina", "TREATMENT", 199, 234], ["tomadas en combinaci\u00f3n", "TREATMENT", 236, 258], ["antimalarials", "TREATMENT", 430, 443], ["deseados", "PROBLEM", 639, 647], ["principalmente en administraci\u00f3n intravenosa", "TREATMENT", 680, 724], ["mayor en tratamiento concomitante con azitromicina", "TREATMENT", 748, 798]]], ["Se est\u00e1n emitiendo recomendaciones cl\u00ednicas que desaconsejan el uso concomitante de amiodarona, y se ha propuesto monitorizar la digoxina y el intervalo QT de los pacientes que toman hidroxicloroquina con azitromicina 6 .Living evidence in response to controversies about the use of antimalarials in COVID-19No obstante, la producci\u00f3n cient\u00edfica respecto a la COVID-19 est\u00e1 aumentando de una manera vertiginosa e ins\u00f3lita y aparecen nuevas publicaciones con celeridad, por lo que resulta imprescindible que el cl\u00ednico cuente con herramientas que le aseguren evidencia cient\u00edfica de calidad y, adem\u00e1s, actualizada casi al instante.", [["COVID-19No obstante", "CHEMICAL", 300, 319], ["hidroxicloroquina con azitromicina", "TREATMENT", 183, 217], ["antimalarials", "TREATMENT", 283, 296], ["a la COVID", "TEST", 355, 365]]], ["Por eso las denominadas Living Systematic Reviews -en las cuales se realiza una revisi\u00f3n sistem\u00e1tica dejando abierta la ventana de revisi\u00f3n para poder incorporar la nueva evidencia a medida que se publica e incluso llegan a producirse cambios en las recomendaciones derivadas de nuevos datos que hayan podido surgir-resultan extremadamente \u00fatiles y pertinentes en el contexto actual.Living evidence in response to controversies about the use of antimalarials in COVID-19En este sentido, ya existe un repositorio vivo de la evidencia cient\u00edfica sobre la efectividad de los antimal\u00e1ricos contra la infecci\u00f3n por coronavirus que actualmente incluye 20 revisiones sistem\u00e1ticas, 4 ensayos cl\u00ednicos que aportan resultados y 115 registros de ensayos aleatorizados en curso, entre otros muchos elementos, lo cual favorece la toma de decisiones r\u00e1pida y eficaz, con los mejores y m\u00e1s actuales datos disponibles 7 .Living evidence in response to controversies about the use of antimalarials in COVID-19La pandemia COVID-19 nos ha obligado a modificar la atenci\u00f3n sanitaria y tambi\u00e9n nos ha ense\u00f1ado que el conocimiento cient\u00edfico debe estar a disposici\u00f3n de los cl\u00ednicos cuando lo necesitan, lo cual precisa capacidad de respuesta inmediata.", [["COVID-19En este sentido", "CHEMICAL", 462, 485], ["COVID-19La pandemia COVID-19 nos ha obligado", "CHEMICAL", 984, 1028], ["respuesta inmediata", "DISEASE", 1211, 1230], ["antimalarials", "TREATMENT", 445, 458], ["contra la infecci\u00f3n", "TREATMENT", 586, 605], ["antimalarials", "TREATMENT", 967, 980], ["COVID", "TEST", 984, 989], ["a modificar la atenci\u00f3n", "TREATMENT", 1029, 1052]]]], "19bc9c316614e8057f6c917116671f5d05452ed5": [["IntroductionThe COVID-19 pandemic may be considered 'the cough that changed the world.'", [["cough", "DISEASE", 57, 62], ["The COVID", "TREATMENT", 12, 21], ["the cough", "PROBLEM", 53, 62]]], ["On March 11, 2020 , the World Health Organization declared the COVID-19 virus a pandemic [1] which is extremely fast as the first case was reported to the WHO China office on December 31, 2019 [2] .", [["COVID-19 virus", "ORGANISM", 63, 77], ["COVID-19 virus", "SPECIES", 63, 77], ["the COVID", "TEST", 59, 68]]], ["COVID-19 is a coronavirus SARS-CoV-2 which started in Wuhan, China and it is short for coronavirus disease first found in 2019.", [["COVID-19", "CHEMICAL", 0, 8], ["coronavirus disease", "DISEASE", 87, 106], ["coronavirus SARS-CoV-2", "ORGANISM", 14, 36], ["COVID-19", "SPECIES", 0, 8], ["COVID", "TEST", 0, 5], ["a coronavirus SARS", "PROBLEM", 12, 30], ["CoV", "TEST", 31, 34], ["coronavirus disease", "PROBLEM", 87, 106]]], ["The virus jumped species to humans originating in the pangolins or horseshoe bats [3] .", [["pangolins", "ANATOMY", 54, 63], ["humans", "ORGANISM", 28, 34], ["humans", "SPECIES", 28, 34], ["humans", "SPECIES", 28, 34], ["The virus jumped species", "PROBLEM", 0, 24], ["virus", "OBSERVATION", 4, 9], ["horseshoe bats", "OBSERVATION", 67, 81]]], ["The pangolins are widely smuggled and sold in wet markets illegally in China.", [["pangolins", "CHEMICAL", 4, 13], ["pangolins", "SIMPLE_CHEMICAL", 4, 13], ["widely", "OBSERVATION_MODIFIER", 18, 24], ["smuggled", "OBSERVATION_MODIFIER", 25, 33], ["sold", "OBSERVATION_MODIFIER", 38, 42], ["wet", "OBSERVATION_MODIFIER", 46, 49], ["markets", "OBSERVATION", 50, 57]]], ["The signs and symptoms of COVID-19 vary from no symptoms (carrier), to a mild respiratory tract infection to fever, cough, and bilateral pneumonitis.", [["respiratory tract", "ANATOMY", 78, 95], ["respiratory tract infection", "DISEASE", 78, 105], ["fever", "DISEASE", 109, 114], ["cough", "DISEASE", 116, 121], ["pneumonitis", "DISEASE", 137, 148], ["COVID-19", "CHEMICAL", 26, 34], ["tract", "ORGANISM_SUBDIVISION", 90, 95], ["The signs and symptoms", "PROBLEM", 0, 22], ["COVID", "TEST", 26, 31], ["symptoms", "PROBLEM", 48, 56], ["a mild respiratory tract infection", "PROBLEM", 71, 105], ["fever", "PROBLEM", 109, 114], ["cough", "PROBLEM", 116, 121], ["bilateral pneumonitis", "PROBLEM", 127, 148], ["mild", "OBSERVATION_MODIFIER", 73, 77], ["respiratory tract", "ANATOMY", 78, 95], ["infection", "OBSERVATION", 96, 105], ["bilateral", "ANATOMY_MODIFIER", 127, 136], ["pneumonitis", "OBSERVATION", 137, 148]]], ["The latter can result in death with a varying mortality rate [4] .", [["death", "DISEASE", 25, 30], ["death", "PROBLEM", 25, 30]]], ["There are six other strains of coronavirus including four which cause only mild colds and severe acute respiratory syndrome (SARS CoV) which had an outbreak in 2003 with approximately a 10% mortality, and Middle East respiratory syndrome (MERS CoV) which is still endemic [5] .", [["coronavirus", "DISEASE", 31, 42], ["colds", "DISEASE", 80, 85], ["acute respiratory syndrome (SARS CoV)", "DISEASE", 97, 134], ["Middle East respiratory syndrome", "DISEASE", 205, 237], ["coronavirus", "ORGANISM", 31, 42], ["coronavirus", "SPECIES", 31, 42], ["SARS CoV", "SPECIES", 125, 133], ["Middle East respiratory syndrome (MERS CoV", "SPECIES", 205, 247], ["coronavirus", "PROBLEM", 31, 42], ["mild colds", "PROBLEM", 75, 85], ["severe acute respiratory syndrome", "PROBLEM", 90, 123], ["SARS CoV", "PROBLEM", 125, 133], ["Middle East respiratory syndrome", "PROBLEM", 205, 237], ["coronavirus", "OBSERVATION", 31, 42], ["mild", "OBSERVATION_MODIFIER", 75, 79], ["colds", "OBSERVATION", 80, 85], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory syndrome", "OBSERVATION", 103, 123], ["Middle", "ANATOMY_MODIFIER", 205, 211], ["respiratory syndrome", "OBSERVATION", 217, 237]]], ["The risk factors are age, comorbidities including chronic obstructive lung disease (COPD), diabetes mellitus, and coronary artery disease.", [["lung", "ANATOMY", 70, 74], ["coronary artery", "ANATOMY", 114, 129], ["chronic obstructive lung disease", "DISEASE", 50, 82], ["COPD", "DISEASE", 84, 88], ["diabetes mellitus", "DISEASE", 91, 108], ["coronary artery disease", "DISEASE", 114, 137], ["lung", "ORGAN", 70, 74], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 114, 129], ["The risk factors", "PROBLEM", 0, 16], ["comorbidities", "PROBLEM", 26, 39], ["chronic obstructive lung disease", "PROBLEM", 50, 82], ["COPD)", "PROBLEM", 84, 89], ["diabetes mellitus", "PROBLEM", 91, 108], ["coronary artery disease", "PROBLEM", 114, 137], ["chronic", "OBSERVATION_MODIFIER", 50, 57], ["obstructive", "OBSERVATION_MODIFIER", 58, 69], ["lung", "ANATOMY", 70, 74], ["disease", "OBSERVATION", 75, 82], ["COPD", "OBSERVATION", 84, 88], ["diabetes mellitus", "OBSERVATION", 91, 108], ["coronary artery", "ANATOMY", 114, 129], ["disease", "OBSERVATION", 130, 137]]], ["Immune-suppressed patients are also thought to be at a higher risk for worse outcomes.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["worse outcomes", "PROBLEM", 71, 85]]], ["It is uncertain if patients with autoimmune rheumatic diseases are at a higher risk to contract the virus, and if they are infected whether they have worse outcomes.", [["autoimmune rheumatic diseases", "DISEASE", 33, 62], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["autoimmune rheumatic diseases", "PROBLEM", 33, 62], ["the virus", "PROBLEM", 96, 105], ["autoimmune", "OBSERVATION_MODIFIER", 33, 43], ["rheumatic", "OBSERVATION", 44, 53]]], ["There are also different degrees of immune suppression.", [["immune suppression", "TREATMENT", 36, 54], ["different degrees", "OBSERVATION_MODIFIER", 15, 32], ["immune suppression", "OBSERVATION", 36, 54]]], ["We can consider the host factors and treatment.", [["the host factors", "TREATMENT", 16, 32], ["treatment", "TREATMENT", 37, 46]]], ["Some patients will have more infections due to their rheumatic disease (such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, other connective tissue diseases, and vasculitis).", [["connective tissue", "ANATOMY", 158, 175], ["infections", "DISEASE", 29, 39], ["rheumatic disease", "DISEASE", 53, 70], ["rheumatoid arthritis", "DISEASE", 80, 100], ["systemic lupus erythematosus", "DISEASE", 102, 130], ["systemic sclerosis", "DISEASE", 132, 150], ["connective tissue diseases", "DISEASE", 158, 184], ["vasculitis", "DISEASE", 190, 200], ["patients", "ORGANISM", 5, 13], ["connective tissue", "TISSUE", 158, 175], ["patients", "SPECIES", 5, 13], ["more infections", "PROBLEM", 24, 39], ["their rheumatic disease", "PROBLEM", 47, 70], ["rheumatoid arthritis", "PROBLEM", 80, 100], ["systemic lupus erythematosus", "PROBLEM", 102, 130], ["systemic sclerosis", "PROBLEM", 132, 150], ["other connective tissue diseases", "PROBLEM", 152, 184], ["vasculitis", "PROBLEM", 190, 200], ["rheumatic disease", "OBSERVATION", 53, 70], ["rheumatoid arthritis", "OBSERVATION", 80, 100], ["systemic", "OBSERVATION_MODIFIER", 102, 110], ["lupus erythematosus", "OBSERVATION", 111, 130], ["systemic", "OBSERVATION_MODIFIER", 132, 140], ["sclerosis", "OBSERVATION", 141, 150], ["connective tissue diseases", "OBSERVATION", 158, 184], ["vasculitis", "OBSERVATION", 190, 200]]], ["Additionally, corticosteroids (especially high dose) increase the risk of infection.", [["corticosteroids", "CHEMICAL", 14, 29], ["infection", "DISEASE", 74, 83], ["corticosteroids", "CHEMICAL", 14, 29], ["corticosteroids", "SIMPLE_CHEMICAL", 14, 29], ["corticosteroids", "TREATMENT", 14, 29], ["infection", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 74, 83]]], ["It is less certain how much of an increased risk immune modulators such as methotrexate, azathioprine, biologics, and Janus kinase inhibitors have on the outcomes of COVID-19 but to date this is not a major risk [6, 7] .Rheumatology concernsRheumatology patients with systemic autoimmune diseases may have several concerns.", [["methotrexate", "CHEMICAL", 75, 87], ["azathioprine", "CHEMICAL", 89, 101], ["concernsRheumatology", "DISEASE", 233, 253], ["systemic autoimmune diseases", "DISEASE", 268, 296], ["methotrexate", "CHEMICAL", 75, 87], ["azathioprine", "CHEMICAL", 89, 101], ["COVID-19", "CHEMICAL", 166, 174], ["methotrexate", "SIMPLE_CHEMICAL", 75, 87], ["azathioprine", "SIMPLE_CHEMICAL", 89, 101], ["Janus kinase inhibitors", "SIMPLE_CHEMICAL", 118, 141], ["patients", "ORGANISM", 254, 262], ["patients", "SPECIES", 254, 262], ["an increased risk immune modulators", "TREATMENT", 31, 66], ["methotrexate", "TREATMENT", 75, 87], ["azathioprine", "TREATMENT", 89, 101], ["biologics", "TREATMENT", 103, 112], ["Janus kinase inhibitors", "TREATMENT", 118, 141], ["COVID", "TEST", 166, 171], ["systemic autoimmune diseases", "PROBLEM", 268, 296], ["less certain", "OBSERVATION_MODIFIER", 6, 18], ["systemic", "OBSERVATION_MODIFIER", 268, 276], ["autoimmune", "OBSERVATION", 277, 287]]], ["They do not know if they should continue with their immune suppressive medications and they are concerned about drug shortages of hydroxychloroquine.", [["hydroxychloroquine", "CHEMICAL", 130, 148], ["hydroxychloroquine", "CHEMICAL", 130, 148], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 130, 148], ["their immune suppressive medications", "TREATMENT", 46, 82], ["hydroxychloroquine", "TREATMENT", 130, 148]]], ["The advice that is given to patients is tailored to the individual.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36]]], ["The Canadian Rheumatology Association has a statement that includes patients should not stop their rheumatic medications unless if ill with a high fever or serious infection.", [["fever", "DISEASE", 147, 152], ["infection", "DISEASE", 164, 173], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["their rheumatic medications", "TREATMENT", 93, 120], ["a high fever", "PROBLEM", 140, 152], ["serious infection", "PROBLEM", 156, 173], ["serious", "OBSERVATION_MODIFIER", 156, 163], ["infection", "OBSERVATION", 164, 173]]], ["They should not suddenly stop their corticosteroids if on them chronically.", [["corticosteroids", "CHEMICAL", 36, 51], ["their corticosteroids", "TREATMENT", 30, 51]]], ["They should not seek medical attention for suspected COVID-19 infection unless if they meet the case definition for testing (which is region specific but may include fever and dyspnea and cough).", [["infection", "DISEASE", 62, 71], ["fever", "DISEASE", 166, 171], ["dyspnea", "DISEASE", 176, 183], ["cough", "DISEASE", 188, 193], ["suspected COVID-19 infection", "PROBLEM", 43, 71], ["testing", "TEST", 116, 123], ["fever", "PROBLEM", 166, 171], ["dyspnea", "PROBLEM", 176, 183], ["cough", "PROBLEM", 188, 193], ["infection", "OBSERVATION", 62, 71]]], ["If they go to the emergency room, they should say they are receiving medications that may increase immune suppression.", [["medications", "TREATMENT", 69, 80], ["immune suppression", "PROBLEM", 99, 117]]], ["Like all patients, they should cough into their arm or a tissue, wash hands frequently (for 20 s each time) especially after returning home if they have been out of their home, avoid touching their face (especially nose, mouth, and eyes), avoid crowds, avoid unnecessary travel, quarantine if told to do so, and to get the flu shot if not already received as influenza is still present in many jurisdictions [8] .Rheumatology concernsTheir infection risk is related also to the virulence of the strain (and there have been two strains of COVID-19 identified thus far) and the dose of the exposure which is why health care workers have a higher risk of poor outcomes with a high mortality already reported in Italy [9] .Rheumatology concernsOther medications such as NSAIDs do not alter the course of COVID-19 despite an earlier report that ibuprofen use caused worse outcomes [10].", [["tissue", "ANATOMY", 57, 63], ["nose", "ANATOMY", 215, 219], ["mouth", "ANATOMY", 221, 226], ["eyes", "ANATOMY", 232, 236], ["influenza", "DISEASE", 359, 368], ["infection", "DISEASE", 440, 449], ["ibuprofen", "CHEMICAL", 840, 849], ["COVID-19", "CHEMICAL", 800, 808], ["ibuprofen", "CHEMICAL", 840, 849], ["patients", "ORGANISM", 9, 17], ["arm", "ORGANISM_SUBDIVISION", 48, 51], ["tissue", "TISSUE", 57, 63], ["nose", "ORGANISM_SUBDIVISION", 215, 219], ["mouth", "ORGANISM_SUBDIVISION", 221, 226], ["eyes", "ORGAN", 232, 236], ["NSAIDs", "SIMPLE_CHEMICAL", 766, 772], ["ibuprofen", "SIMPLE_CHEMICAL", 840, 849], ["patients", "SPECIES", 9, 17], ["influenza", "PROBLEM", 359, 368], ["Their infection risk", "PROBLEM", 434, 454], ["the strain", "PROBLEM", 491, 501], ["COVID", "TEST", 538, 543], ["a high mortality", "PROBLEM", 671, 687], ["Rheumatology concernsOther medications", "TREATMENT", 719, 757], ["NSAIDs", "TREATMENT", 766, 772], ["COVID", "TREATMENT", 800, 805], ["ibuprofen", "TREATMENT", 840, 849], ["arm", "ANATOMY", 48, 51], ["mouth", "ANATOMY", 221, 226], ["eyes", "ANATOMY", 232, 236], ["infection", "OBSERVATION", 440, 449]]], ["The conclusions were likely premature (and there could be confounding where people with worse fever or myalgias from COVID-19 would be more likely to take an NSAID than those with milder symptoms and the former would be expected to have a worse outcome.Rheumatology concernsAntimalarial shortages (particularly hydroxychloroquine as chloroquine was already on back order in many jurisdictions) occurred after a small publication may have shown that the viral PCR decreased more in patients treated with hydroxychloroquine than controls [11] .", [["fever", "DISEASE", 94, 99], ["myalgias", "DISEASE", 103, 111], ["hydroxychloroquine", "CHEMICAL", 311, 329], ["chloroquine", "CHEMICAL", 333, 344], ["hydroxychloroquine", "CHEMICAL", 503, 521], ["hydroxychloroquine", "CHEMICAL", 311, 329], ["chloroquine", "CHEMICAL", 333, 344], ["hydroxychloroquine", "CHEMICAL", 503, 521], ["people", "ORGANISM", 76, 82], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 311, 329], ["chloroquine", "SIMPLE_CHEMICAL", 333, 344], ["patients", "ORGANISM", 481, 489], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 503, 521], ["people", "SPECIES", 76, 82], ["patients", "SPECIES", 481, 489], ["premature", "PROBLEM", 28, 37], ["worse fever", "PROBLEM", 88, 99], ["myalgias", "PROBLEM", 103, 111], ["COVID", "TEST", 117, 122], ["an NSAID", "TREATMENT", 155, 163], ["milder symptoms", "PROBLEM", 180, 195], ["Antimalarial shortages", "TREATMENT", 274, 296], ["hydroxychloroquine", "TREATMENT", 311, 329], ["chloroquine", "TREATMENT", 333, 344], ["a small publication", "PROBLEM", 409, 428], ["the viral PCR", "TEST", 449, 462], ["hydroxychloroquine than controls", "TREATMENT", 503, 535]]], ["This report contained 20 patients who were treated with hydroxychloroquine but 6 were not included of whom 1 died and 3 went to the intensive care unit and one did not tolerate the treatment.", [["hydroxychloroquine", "CHEMICAL", 56, 74], ["hydroxychloroquine", "CHEMICAL", 56, 74], ["patients", "ORGANISM", 25, 33], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 56, 74], ["patients", "SPECIES", 25, 33], ["hydroxychloroquine", "TREATMENT", 56, 74], ["the treatment", "TREATMENT", 177, 190]]], ["This resulted in a shortage of medication.", [["a shortage of medication", "TREATMENT", 17, 41]]], ["For instance, in Canada monthly, there are approximately 47,000 doses of hydroxychloroquine sold monthly and the level has been constant for 5 years, and in March, 2020 after the results of the small study were announced, the sales more than doubled in a couple of weeks causing a shortage for patients and high anxiety in many of them [12] .", [["hydroxychloroquine", "CHEMICAL", 73, 91], ["anxiety", "DISEASE", 312, 319], ["hydroxychloroquine", "CHEMICAL", 73, 91], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 73, 91], ["patients", "ORGANISM", 294, 302], ["patients", "SPECIES", 294, 302], ["hydroxychloroquine", "TREATMENT", 73, 91], ["the small study", "TEST", 190, 205], ["high anxiety", "PROBLEM", 307, 319]]], ["This is being resolved in many countries with more suppliers producing hydroxychloroquine.", [["hydroxychloroquine", "CHEMICAL", 71, 89], ["hydroxychloroquine", "CHEMICAL", 71, 89], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 71, 89], ["hydroxychloroquine", "TREATMENT", 71, 89], ["resolved", "OBSERVATION_MODIFIER", 14, 22]]], ["This has led to statements from Rheumatology organizations to ensure a constant supply to patients with rheumatic diseases [13] and a need for evidence-based treatment [14] .", [["rheumatic diseases", "DISEASE", 104, 122], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["rheumatic diseases", "PROBLEM", 104, 122], ["evidence-based treatment", "TREATMENT", 143, 167]]], ["Despite a lack of strong data supporting antimalarial use, the WHO has facilitated a multi-arm trial (SOLIDARITY) [15] where standard of care will be compared to several other treatment arms including those randomized to hydroxy/chloroquine, or HIV antivirals (ritonavir + iopinavir) or ritonavir + iopinavir + interferon beta, or an antiviral used for Ebola (remdesivir).", [["chloroquine", "CHEMICAL", 229, 240], ["ritonavir", "CHEMICAL", 261, 270], ["iopinavir", "CHEMICAL", 273, 282], ["ritonavir", "CHEMICAL", 287, 296], ["iopinavir", "CHEMICAL", 299, 308], ["Ebola", "DISEASE", 353, 358], ["remdesivir", "CHEMICAL", 360, 370], ["hydroxy", "CHEMICAL", 221, 228], ["chloroquine", "CHEMICAL", 229, 240], ["ritonavir", "CHEMICAL", 261, 270], ["iopinavir", "CHEMICAL", 273, 282], ["ritonavir", "CHEMICAL", 287, 296], ["iopinavir", "CHEMICAL", 299, 308], ["hydroxy", "SIMPLE_CHEMICAL", 221, 228], ["chloroquine", "SIMPLE_CHEMICAL", 229, 240], ["HIV", "ORGANISM", 245, 248], ["ritonavir", "SIMPLE_CHEMICAL", 261, 270], ["iopinavir", "SIMPLE_CHEMICAL", 273, 282], ["ritonavir", "SIMPLE_CHEMICAL", 287, 296], ["iopinavir", "SIMPLE_CHEMICAL", 299, 308], ["interferon beta", "GENE_OR_GENE_PRODUCT", 311, 326], ["Ebola", "ORGANISM", 353, 358], ["interferon beta", "PROTEIN", 311, 326], ["HIV", "SPECIES", 245, 248], ["a multi-arm trial (SOLIDARITY)", "TREATMENT", 83, 113], ["several other treatment arms", "TREATMENT", 162, 190], ["hydroxy", "TREATMENT", 221, 228], ["chloroquine", "TREATMENT", 229, 240], ["HIV antivirals", "TREATMENT", 245, 259], ["ritonavir", "TREATMENT", 261, 270], ["iopinavir", "TREATMENT", 273, 282], ["ritonavir", "TREATMENT", 287, 296], ["iopinavir", "TREATMENT", 299, 308], ["interferon beta", "TREATMENT", 311, 326], ["an antiviral", "TREATMENT", 331, 343], ["Ebola (remdesivir)", "TREATMENT", 353, 371], ["arm", "ANATOMY", 91, 94]]], ["Not all countries will have all comparators [16] .Rheumatology concernsAfter the pandemic is over, the world economy will be harmed and patients will have suffered from stress, income, or job loss and possibly lack of access to their care for their chronic diseases and the uncertainties of medication supply.", [["chronic diseases", "DISEASE", 249, 265], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["stress", "PROBLEM", 169, 175], ["job loss", "PROBLEM", 188, 196], ["their chronic diseases", "PROBLEM", 243, 265], ["medication supply", "TREATMENT", 291, 308], ["chronic", "OBSERVATION_MODIFIER", 249, 256], ["diseases", "OBSERVATION", 257, 265]]], ["Many people will die due to the pandemic and others may have worse outcomes from their chronic disease as they may not have access to their physicians due to quarantines and diversion of hospital resources to treat the seriously ill infected from COVID-19.", [["ill infected", "DISEASE", 229, 241], ["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11], ["their chronic disease", "PROBLEM", 81, 102], ["diversion of hospital resources", "TREATMENT", 174, 205], ["COVID", "TEST", 247, 252], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["disease", "OBSERVATION", 95, 102]]], ["Hopefully, lessons will quickly be learned about stopping the spread, communicating clear messages to our patients and providing high-quality health care to those who need it.Funding InformationThere was no financial support for this project.Conflict of InterestThe author declares that she has no conflict of interest.Human and Animal Rights and Informed ConsentThis article does not contain any studies with human or animal subjects performed by any of the authors.Ethical ApprovalThere was no institutional ethics approval as this is a commentary.Ethical ApprovalWhat Does the COVID-19 Pandemic Mean for Rheumatology Patients?", [["patients", "ORGANISM", 106, 114], ["Human", "ORGANISM", 319, 324], ["human", "ORGANISM", 410, 415], ["Patients", "ORGANISM", 620, 628], ["patients", "SPECIES", 106, 114], ["Human", "SPECIES", 319, 324], ["human", "SPECIES", 410, 415], ["Patients", "SPECIES", 620, 628], ["Human", "SPECIES", 319, 324], ["human", "SPECIES", 410, 415], ["financial support", "TREATMENT", 207, 224], ["the COVID", "TEST", 576, 585]]]], "PMC7253977": [["Conflict of interestThe authors declare that there is no conflict of interest", [["no", "UNCERTAINTY", 54, 56]]]], "PMC6004766": [["IntroductionMultiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS), characterized by demyelination and axonal damage.", [["central nervous system", "ANATOMY", 77, 99], ["CNS", "ANATOMY", 101, 104], ["axonal", "ANATOMY", 142, 148], ["IntroductionMultiple Sclerosis", "DISEASE", 0, 30], ["MS", "DISEASE", 32, 34], ["disease of the central nervous system", "DISEASE", 62, 99], ["demyelination", "DISEASE", 124, 137], ["axonal damage", "DISEASE", 142, 155], ["central nervous system", "ANATOMICAL_SYSTEM", 77, 99], ["CNS", "ANATOMICAL_SYSTEM", 101, 104], ["IntroductionMultiple Sclerosis (MS)", "PROBLEM", 0, 35], ["a chronic inflammatory disease of the central nervous system", "PROBLEM", 39, 99], ["demyelination", "PROBLEM", 124, 137], ["axonal damage", "PROBLEM", 142, 155], ["Sclerosis", "OBSERVATION", 21, 30], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["inflammatory", "OBSERVATION", 49, 61], ["central", "ANATOMY_MODIFIER", 77, 84], ["nervous system", "ANATOMY", 85, 99], ["CNS", "ANATOMY", 101, 104], ["demyelination", "OBSERVATION", 124, 137], ["axonal damage", "OBSERVATION", 142, 155]]], ["Active demyelinating lesions are characterized by CD8 T cells, CD4 T cells expressing both Th1 and Th17 cytokines, bone marrow-derived macrophages (BMDM) and activated CNS resident microglia (1, 2).", [["lesions", "ANATOMY", 21, 28], ["CD8 T cells", "ANATOMY", 50, 61], ["CD4 T cells", "ANATOMY", 63, 74], ["bone marrow-derived macrophages", "ANATOMY", 115, 146], ["BMDM", "ANATOMY", 148, 152], ["CNS resident microglia", "ANATOMY", 168, 190], ["demyelinating lesions", "DISEASE", 7, 28], ["demyelinating lesions", "CANCER", 7, 28], ["CD8 T cells", "CELL", 50, 61], ["CD4 T cells", "CELL", 63, 74], ["Th1", "CELL", 91, 94], ["bone marrow-derived macrophages", "CELL", 115, 146], ["BMDM", "CELL", 148, 152], ["CNS resident microglia", "CELL", 168, 190], ["CD8 T cells", "CELL_TYPE", 50, 61], ["CD4 T cells", "CELL_TYPE", 63, 74], ["Th1 and Th17 cytokines", "PROTEIN", 91, 113], ["bone marrow-derived macrophages", "CELL_TYPE", 115, 146], ["BMDM", "CELL_TYPE", 148, 152], ["activated CNS resident microglia", "CELL_TYPE", 158, 190], ["Active demyelinating lesions", "PROBLEM", 0, 28], ["CD8 T cells", "PROBLEM", 50, 61], ["CD4 T cells", "TEST", 63, 74], ["Th17 cytokines", "TEST", 99, 113], ["bone marrow", "TEST", 115, 126], ["demyelinating", "OBSERVATION_MODIFIER", 7, 20], ["lesions", "OBSERVATION", 21, 28], ["CD8 T cells", "OBSERVATION", 50, 61], ["Th1", "ANATOMY", 91, 94], ["Th17 cytokines", "ANATOMY", 99, 113], ["bone marrow", "ANATOMY", 115, 126], ["macrophages", "OBSERVATION", 135, 146], ["CNS", "ANATOMY", 168, 171]]], ["Myeloid cells activated by T cell effector functions are thought to participate in tissue damage by removing or \u201cstripping\u201d myelin (3), and secreting toxic factors, such as reactive oxygen species, nitric oxide and the pro-inflammatory cytokines, tumor necrosis factor (TNF), and IL-1\u03b2 (4, 5).", [["Myeloid cells", "ANATOMY", 0, 13], ["T cell", "ANATOMY", 27, 33], ["tissue", "ANATOMY", 83, 89], ["oxygen", "CHEMICAL", 182, 188], ["nitric oxide", "CHEMICAL", 198, 210], ["tumor necrosis", "DISEASE", 247, 261], ["oxygen", "CHEMICAL", 182, 188], ["nitric oxide", "CHEMICAL", 198, 210], ["Myeloid cells", "CELL", 0, 13], ["T cell", "CELL", 27, 33], ["tissue", "TISSUE", 83, 89], ["myelin (3", "GENE_OR_GENE_PRODUCT", 124, 133], ["reactive oxygen species", "SIMPLE_CHEMICAL", 173, 196], ["nitric oxide", "SIMPLE_CHEMICAL", 198, 210], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 247, 268], ["TNF", "GENE_OR_GENE_PRODUCT", 270, 273], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 280, 285], ["4", "GENE_OR_GENE_PRODUCT", 287, 288], ["Myeloid cells", "CELL_TYPE", 0, 13], ["pro-inflammatory cytokines", "PROTEIN", 219, 245], ["tumor necrosis factor", "PROTEIN", 247, 268], ["TNF", "PROTEIN", 270, 273], ["IL", "PROTEIN", 280, 282], ["Myeloid cells", "PROBLEM", 0, 13], ["tissue damage", "PROBLEM", 83, 96], ["\u201cstripping\u201d myelin", "TREATMENT", 112, 130], ["secreting toxic factors", "PROBLEM", 140, 163], ["reactive oxygen species", "TREATMENT", 173, 196], ["nitric oxide", "TREATMENT", 198, 210], ["the pro-inflammatory cytokines", "PROBLEM", 215, 245], ["tumor necrosis factor", "PROBLEM", 247, 268], ["TNF", "TEST", 270, 273], ["damage", "OBSERVATION", 90, 96], ["reactive", "OBSERVATION_MODIFIER", 173, 181], ["oxygen species", "OBSERVATION", 182, 196], ["pro-inflammatory cytokines", "OBSERVATION", 219, 245], ["tumor", "OBSERVATION_MODIFIER", 247, 252], ["necrosis", "OBSERVATION", 253, 261]]], ["Activated microglia also secrete chemokines, which recruit innate and adaptive immune cells into the parenchyma, further amplifying the destructive inflammatory response (5).", [["microglia", "ANATOMY", 10, 19], ["immune cells", "ANATOMY", 79, 91], ["parenchyma", "ANATOMY", 101, 111], ["microglia", "CELL", 10, 19], ["immune cells", "CELL", 79, 91], ["parenchyma", "TISSUE", 101, 111], ["microglia", "CELL_TYPE", 10, 19], ["chemokines", "PROTEIN", 33, 43], ["innate and adaptive immune cells", "CELL_TYPE", 59, 91], ["secrete chemokines", "PROBLEM", 25, 43], ["the destructive inflammatory response", "PROBLEM", 132, 169], ["parenchyma", "ANATOMY", 101, 111], ["destructive", "OBSERVATION_MODIFIER", 136, 147]]], ["However, both BMDM and microglia effector functions are highly heterogeneous depending on the environment and may not only contribute to disease progression but also to resolution (6, 7).", [["BMDM", "ANATOMY", 14, 18], ["microglia", "ANATOMY", 23, 32], ["BMDM", "CELL", 14, 18], ["microglia", "CELL", 23, 32], ["BMDM", "CELL_TYPE", 14, 18], ["disease progression", "PROBLEM", 137, 156], ["both", "OBSERVATION_MODIFIER", 9, 13], ["BMDM", "OBSERVATION", 14, 18], ["microglia effector", "OBSERVATION", 23, 41], ["highly", "OBSERVATION_MODIFIER", 56, 62], ["heterogeneous", "OBSERVATION_MODIFIER", 63, 76], ["may not only contribute to", "UNCERTAINTY", 110, 136], ["disease", "OBSERVATION", 137, 144]]], ["For example, by removing apoptotic cells and debris, their phagocytic activity favors tissue repair and is essential for disease resolution (3).", [["cells", "ANATOMY", 35, 40], ["tissue", "ANATOMY", 86, 92], ["cells", "CELL", 35, 40], ["tissue", "TISSUE", 86, 92], ["apoptotic cells", "CELL_TYPE", 25, 40], ["apoptotic cells", "PROBLEM", 25, 40], ["debris", "PROBLEM", 45, 51], ["tissue repair", "TREATMENT", 86, 99], ["disease resolution", "PROBLEM", 121, 139], ["apoptotic cells", "OBSERVATION", 25, 40], ["debris", "OBSERVATION", 45, 51], ["phagocytic activity", "OBSERVATION", 59, 78], ["tissue repair", "OBSERVATION", 86, 99], ["essential for", "UNCERTAINTY", 107, 120]]], ["In addition, both cell populations secrete anti-inflammatory cytokines, such as IL-10 and TGF-\u03b2, as well as trophic factors, which provide an environment that promotes tissue repair and neuronal protection (8).", [["cell", "ANATOMY", 18, 22], ["tissue", "ANATOMY", 168, 174], ["neuronal", "ANATOMY", 186, 194], ["cell populations", "CELL", 18, 34], ["IL-10", "GENE_OR_GENE_PRODUCT", 80, 85], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 90, 95], ["tissue", "TISSUE", 168, 174], ["neuronal", "CELL", 186, 194], ["anti-inflammatory cytokines", "PROTEIN", 43, 70], ["IL-10", "PROTEIN", 80, 85], ["TGF-\u03b2", "PROTEIN", 90, 95], ["trophic factors", "PROTEIN", 108, 123], ["both cell populations", "TREATMENT", 13, 34], ["anti-inflammatory cytokines", "TREATMENT", 43, 70], ["IL", "TEST", 80, 82], ["trophic factors", "TREATMENT", 108, 123], ["tissue repair", "TREATMENT", 168, 181], ["neuronal protection", "TREATMENT", 186, 205], ["both cell", "OBSERVATION", 13, 22], ["populations", "OBSERVATION_MODIFIER", 23, 34], ["secrete", "OBSERVATION_MODIFIER", 35, 42], ["anti-inflammatory cytokines", "OBSERVATION", 43, 70], ["tissue repair", "OBSERVATION", 168, 181]]], ["The heterogeneity of the inflammatory response associated with MS lesions at the cellular and functional levels, thus makes it difficult to establish detrimental versus disease resolving functions of BMDM and microglia in MS pathogenesis.", [["MS lesions", "ANATOMY", 63, 73], ["cellular", "ANATOMY", 81, 89], ["BMDM", "ANATOMY", 200, 204], ["microglia", "ANATOMY", 209, 218], ["MS", "DISEASE", 222, 224], ["MS lesions", "PATHOLOGICAL_FORMATION", 63, 73], ["cellular", "CELL", 81, 89], ["BMDM", "CELL", 200, 204], ["microglia", "CELL", 209, 218], ["BMDM", "CELL_TYPE", 200, 204], ["microglia", "CELL_TYPE", 209, 218], ["the inflammatory response", "PROBLEM", 21, 46], ["MS lesions at the cellular and functional levels", "PROBLEM", 63, 111], ["disease", "PROBLEM", 169, 176], ["BMDM", "PROBLEM", 200, 204], ["microglia in MS pathogenesis", "PROBLEM", 209, 237], ["heterogeneity", "OBSERVATION_MODIFIER", 4, 17], ["inflammatory", "OBSERVATION_MODIFIER", 25, 37], ["MS", "OBSERVATION_MODIFIER", 63, 65], ["lesions", "OBSERVATION", 66, 73], ["cellular", "OBSERVATION_MODIFIER", 81, 89], ["functional levels", "OBSERVATION", 94, 111], ["BMDM", "OBSERVATION", 200, 204]]], ["In addition to the inherent limitations associated with sampling CNS tissues for longitudinal studies, the individual role of BMDM versus microglia as pathological mediators remains ambiguous due to morphological similarities and lack of reagents uniquely identifying each population.", [["CNS tissues", "ANATOMY", 65, 76], ["microglia", "ANATOMY", 138, 147], ["CNS tissues", "TISSUE", 65, 76], ["BMDM", "CELL", 126, 130], ["microglia", "CELL", 138, 147], ["BMDM", "CELL_TYPE", 126, 130], ["microglia", "CELL_TYPE", 138, 147], ["sampling CNS tissues", "PROBLEM", 56, 76], ["longitudinal studies", "TEST", 81, 101], ["BMDM", "PROBLEM", 126, 130], ["BMDM", "OBSERVATION", 126, 130]]], ["However, increasing evidence from animal models supports the concept that microglia and BMDM comprise two effector populations with distinct origins (derived from progenitors in the embryonic yolk sac and circulating monocytes respectively) and functions during MS and other neuroinflammatory disorders (9).IntroductionA variety of murine models, including autoimmune- and viral-induced demyelination, have been developed to study pathogenic features of MS (10).", [["microglia", "ANATOMY", 74, 83], ["BMDM", "ANATOMY", 88, 92], ["progenitors", "ANATOMY", 163, 174], ["embryonic yolk sac", "ANATOMY", 182, 200], ["monocytes", "ANATOMY", 217, 226], ["MS", "DISEASE", 262, 264], ["neuroinflammatory disorders", "DISEASE", 275, 302], ["autoimmune- and viral-induced demyelination", "DISEASE", 357, 400], ["MS", "DISEASE", 454, 456], ["microglia", "CELL", 74, 83], ["BMDM", "CELL", 88, 92], ["progenitors", "CELL", 163, 174], ["embryonic yolk sac", "MULTI-TISSUE_STRUCTURE", 182, 200], ["monocytes", "CELL", 217, 226], ["murine", "ORGANISM", 332, 338], ["microglia", "CELL_TYPE", 74, 83], ["BMDM", "CELL_TYPE", 88, 92], ["progenitors", "CELL_TYPE", 163, 174], ["circulating monocytes", "CELL_TYPE", 205, 226], ["murine", "SPECIES", 332, 338], ["microglia and BMDM", "PROBLEM", 74, 92], ["the embryonic yolk sac", "TREATMENT", 178, 200], ["other neuroinflammatory disorders", "PROBLEM", 269, 302], ["murine models", "PROBLEM", 332, 345], ["autoimmune", "PROBLEM", 357, 367], ["viral-induced demyelination", "PROBLEM", 373, 400], ["MS", "TEST", 454, 456], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["distinct", "OBSERVATION_MODIFIER", 132, 140], ["origins", "OBSERVATION_MODIFIER", 141, 148], ["yolk sac", "ANATOMY", 192, 200], ["demyelination", "OBSERVATION", 387, 400]]], ["The most common is the experimental autoimmune encephalomyelitis (EAE), an autoreactive CD4 T cell-induced autoimmune demyelination characterized by infiltration of myelin-specific Th1 and Th17 cells, BMDM and microglial activation (11, 12).", [["CD4 T cell", "ANATOMY", 88, 98], ["myelin", "ANATOMY", 165, 171], ["Th17 cells", "ANATOMY", 189, 199], ["BMDM", "ANATOMY", 201, 205], ["microglial", "ANATOMY", 210, 220], ["autoimmune encephalomyelitis", "DISEASE", 36, 64], ["EAE", "DISEASE", 66, 69], ["autoimmune demyelination", "DISEASE", 107, 131], ["CD4 T cell", "CELL", 88, 98], ["myelin", "GENE_OR_GENE_PRODUCT", 165, 171], ["Th1", "CELL", 181, 184], ["Th17 cells", "CELL", 189, 199], ["BMDM", "CELL", 201, 205], ["microglial", "CELL", 210, 220], ["autoreactive CD4 T cell", "CELL_TYPE", 75, 98], ["myelin-specific Th1 and Th17 cells", "CELL_TYPE", 165, 199], ["the experimental autoimmune encephalomyelitis", "PROBLEM", 19, 64], ["an autoreactive CD4 T cell", "PROBLEM", 72, 98], ["autoimmune demyelination", "PROBLEM", 107, 131], ["infiltration of myelin", "PROBLEM", 149, 171], ["BMDM", "PROBLEM", 201, 205], ["microglial activation", "TEST", 210, 231], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["experimental", "OBSERVATION_MODIFIER", 23, 35], ["autoimmune encephalomyelitis", "OBSERVATION", 36, 64], ["autoreactive CD4 T cell", "OBSERVATION", 75, 98], ["autoimmune demyelination", "OBSERVATION", 107, 131], ["infiltration", "OBSERVATION", 149, 161], ["specific Th1", "OBSERVATION_MODIFIER", 172, 184], ["Th17 cells", "OBSERVATION", 189, 199], ["microglial activation", "OBSERVATION", 210, 231]]], ["Pathogenesis during EAE is associated with temporally distinct microglial activation and BMDM CNS infiltration.", [["microglial", "ANATOMY", 63, 73], ["CNS", "ANATOMY", 94, 97], ["EAE", "DISEASE", 20, 23], ["microglial", "CELL", 63, 73], ["BMDM CNS", "CELL", 89, 97], ["Pathogenesis during EAE", "PROBLEM", 0, 23], ["temporally distinct microglial activation", "PROBLEM", 43, 84], ["BMDM CNS infiltration", "PROBLEM", 89, 110], ["associated with", "UNCERTAINTY", 27, 42], ["temporally", "OBSERVATION_MODIFIER", 43, 53], ["distinct", "OBSERVATION_MODIFIER", 54, 62], ["microglial activation", "OBSERVATION", 63, 84], ["BMDM CNS infiltration", "OBSERVATION", 89, 110]]], ["Early microglia activation is insufficient to trigger clinical disease, whereas delayed CNS recruitment of BMDM directly correlates with disease progression.", [["microglia", "ANATOMY", 6, 15], ["CNS", "ANATOMY", 88, 91], ["microglia", "CELL", 6, 15], ["CNS", "ANATOMICAL_SYSTEM", 88, 91], ["BMDM", "CELL", 107, 111], ["BMDM", "CELL_TYPE", 107, 111], ["Early microglia activation", "PROBLEM", 0, 26], ["clinical disease", "PROBLEM", 54, 70], ["delayed CNS recruitment of BMDM", "PROBLEM", 80, 111], ["disease progression", "PROBLEM", 137, 156], ["microglia activation", "OBSERVATION", 6, 26]]], ["Importantly, depletion of BMDM but not microglia inhibits EAE (13, 14).", [["BMDM", "ANATOMY", 26, 30], ["microglia", "ANATOMY", 39, 48], ["EAE", "DISEASE", 58, 61], ["BMDM", "CELL", 26, 30], ["microglia", "CELL", 39, 48], ["BMDM", "CELL_TYPE", 26, 30], ["microglia", "CELL_TYPE", 39, 48], ["BMDM", "PROBLEM", 26, 30], ["depletion", "OBSERVATION_MODIFIER", 13, 22], ["BMDM", "OBSERVATION", 26, 30], ["not", "UNCERTAINTY", 35, 38], ["microglia", "OBSERVATION_MODIFIER", 39, 48]]], ["Similarly, mice deficient in CCL2 (CCL2\u2212/\u2212), a chemokine essential for inflammatory monocyte recruitment into the CNS (15), are resistant to EAE (16).", [["monocyte", "ANATOMY", 84, 92], ["CNS", "ANATOMY", 114, 117], ["EAE", "DISEASE", 141, 144], ["mice", "ORGANISM", 11, 15], ["CCL2", "GENE_OR_GENE_PRODUCT", 29, 33], ["CCL2\u2212", "GENE_OR_GENE_PRODUCT", 35, 40], ["\u2212", "GENE_OR_GENE_PRODUCT", 41, 42], ["monocyte", "CELL", 84, 92], ["CNS", "ANATOMICAL_SYSTEM", 114, 117], ["CCL2", "PROTEIN", 29, 33], ["CCL2\u2212", "PROTEIN", 35, 40], ["\u2212", "PROTEIN", 41, 42], ["chemokine", "PROTEIN", 47, 56], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["mice deficient in CCL2", "PROBLEM", 11, 33], ["inflammatory monocyte recruitment", "TREATMENT", 71, 104], ["CCL2", "ANATOMY", 29, 33], ["inflammatory monocyte", "OBSERVATION", 71, 92], ["CNS", "ANATOMY", 114, 117]]], ["In support of detrimental BMDM functions, a combined histological and gene profiling study showed that demyelination is mediated by BMDM associated with nodes of Ranvier, whereas debris clearance is achieved by microglia (17).", [["nodes", "ANATOMY", 153, 158], ["debris", "ANATOMY", 179, 185], ["microglia", "ANATOMY", 211, 220], ["demyelination", "DISEASE", 103, 116], ["BMDM", "CELL", 26, 30], ["BMDM", "CELL", 132, 136], ["nodes", "MULTI-TISSUE_STRUCTURE", 153, 158], ["Ranvier", "MULTI-TISSUE_STRUCTURE", 162, 169], ["microglia", "CELL", 211, 220], ["BMDM", "PROTEIN", 132, 136], ["microglia", "CELL_TYPE", 211, 220], ["detrimental BMDM functions", "PROBLEM", 14, 40], ["gene profiling study", "TEST", 70, 90], ["demyelination", "PROBLEM", 103, 116], ["nodes of Ranvier", "PROBLEM", 153, 169], ["debris clearance", "PROBLEM", 179, 195], ["demyelination", "OBSERVATION", 103, 116], ["nodes", "OBSERVATION", 153, 158]]], ["Altogether, studies in the EAE model demonstrate that BMDM recruitment into the CNS is essential for the process of myelin loss and clinical manifestation.IntroductionInflammatory demyelination is also induced following infection with two natural viral mouse pathogens, Theiler\u2019s murine encephalomyelitis virus (TMEV) and members of the neurotropic mouse hepatitis viruses (MHV).", [["CNS", "ANATOMY", 80, 83], ["myelin", "ANATOMY", 116, 122], ["myelin loss", "DISEASE", 116, 127], ["Inflammatory demyelination", "DISEASE", 167, 193], ["infection", "DISEASE", 220, 229], ["Theiler\u2019s murine encephalomyelitis", "DISEASE", 270, 304], ["neurotropic mouse hepatitis viruses", "DISEASE", 337, 372], ["BMDM", "CELL", 54, 58], ["CNS", "ANATOMICAL_SYSTEM", 80, 83], ["myelin", "GENE_OR_GENE_PRODUCT", 116, 122], ["mouse", "ORGANISM", 253, 258], ["Theiler\u2019s murine encephalomyelitis virus", "ORGANISM", 270, 310], ["TMEV", "ORGANISM", 312, 316], ["neurotropic", "ORGANISM", 337, 348], ["mouse hepatitis viruses", "ORGANISM", 349, 372], ["MHV", "ORGANISM", 374, 377], ["mouse", "SPECIES", 253, 258], ["Theiler\u2019s", "SPECIES", 270, 279], ["murine encephalomyelitis virus", "SPECIES", 280, 310], ["TMEV", "SPECIES", 312, 316], ["mouse", "SPECIES", 349, 354], ["mouse", "SPECIES", 253, 258], ["Theiler\u2019s murine encephalomyelitis virus", "SPECIES", 270, 310], ["TMEV", "SPECIES", 312, 316], ["mouse hepatitis viruses", "SPECIES", 349, 372], ["MHV", "SPECIES", 374, 377], ["the EAE model", "TEST", 23, 36], ["myelin loss", "PROBLEM", 116, 127], ["IntroductionInflammatory demyelination", "PROBLEM", 155, 193], ["infection", "PROBLEM", 220, 229], ["two natural viral mouse pathogens", "PROBLEM", 235, 268], ["Theiler\u2019s murine encephalomyelitis virus", "PROBLEM", 270, 310], ["the neurotropic mouse hepatitis viruses", "PROBLEM", 333, 372], ["BMDM recruitment", "OBSERVATION", 54, 70], ["CNS", "ANATOMY", 80, 83], ["myelin loss", "OBSERVATION", 116, 127], ["Inflammatory", "OBSERVATION_MODIFIER", 167, 179], ["demyelination", "OBSERVATION", 180, 193], ["viral mouse pathogens", "OBSERVATION", 247, 268], ["neurotropic mouse", "OBSERVATION", 337, 354], ["hepatitis viruses", "OBSERVATION", 355, 372]]], ["TMEV infection induces an autoimmune disease in which BMDM are essential for both viral persistence and demyelination (18, 19).", [["TMEV infection", "DISEASE", 0, 14], ["autoimmune disease", "DISEASE", 26, 44], ["demyelination", "DISEASE", 104, 117], ["TMEV", "ORGANISM", 0, 4], ["BMDM", "CELL", 54, 58], ["BMDM", "CELL_TYPE", 54, 58], ["TMEV", "SPECIES", 0, 4], ["TMEV", "SPECIES", 0, 4], ["TMEV infection", "PROBLEM", 0, 14], ["an autoimmune disease", "PROBLEM", 23, 44], ["both viral persistence", "PROBLEM", 77, 99], ["demyelination", "PROBLEM", 104, 117], ["infection", "OBSERVATION", 5, 14], ["autoimmune disease", "OBSERVATION", 26, 44], ["viral", "OBSERVATION_MODIFIER", 82, 87], ["persistence", "OBSERVATION_MODIFIER", 88, 99], ["demyelination", "OBSERVATION", 104, 117]]], ["However, the function of BMDM as a main reservoir of active viral replication during chronic TMEV infection, limits efforts to assess their role in demyelination independent of virus load (20).", [["TMEV infection", "DISEASE", 93, 107], ["demyelination", "DISEASE", 148, 161], ["BMDM", "CELL", 25, 29], ["TMEV", "ORGANISM", 93, 97], ["BMDM", "PROTEIN", 25, 29], ["TMEV", "SPECIES", 93, 97], ["BMDM", "PROBLEM", 25, 29], ["active viral replication", "TREATMENT", 53, 77], ["chronic TMEV infection", "PROBLEM", 85, 107], ["demyelination", "PROBLEM", 148, 161], ["active", "OBSERVATION_MODIFIER", 53, 59], ["viral replication", "OBSERVATION", 60, 77], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["TMEV", "OBSERVATION_MODIFIER", 93, 97], ["infection", "OBSERVATION", 98, 107], ["demyelination", "OBSERVATION", 148, 161]]], ["In contrast, infection with the non-lethal glia tropic MHV strain designated JHMV predominantly targets oligodendrocytes (OLG) and to a lesser extent microglia and astrocytes.", [["oligodendrocytes", "ANATOMY", 104, 120], ["OLG", "ANATOMY", 122, 125], ["microglia", "ANATOMY", 150, 159], ["astrocytes", "ANATOMY", 164, 174], ["infection", "DISEASE", 13, 22], ["glia tropic MHV strain", "ORGANISM", 43, 65], ["JHMV", "GENE_OR_GENE_PRODUCT", 77, 81], ["oligodendrocytes", "CELL", 104, 120], ["OLG", "CANCER", 122, 125], ["microglia", "CELL", 150, 159], ["astrocytes", "CELL", 164, 174], ["JHMV", "PROTEIN", 77, 81], ["oligodendrocytes", "CELL_TYPE", 104, 120], ["OLG", "CELL_TYPE", 122, 125], ["microglia", "CELL_TYPE", 150, 159], ["astrocytes", "CELL_TYPE", 164, 174], ["JHMV", "SPECIES", 77, 81], ["infection", "PROBLEM", 13, 22], ["the non-lethal glia tropic MHV strain", "PROBLEM", 28, 65], ["infection", "OBSERVATION", 13, 22], ["non-lethal glia", "ANATOMY", 32, 47], ["tropic MHV", "OBSERVATION", 48, 58], ["predominantly", "OBSERVATION_MODIFIER", 82, 95], ["targets oligodendrocytes", "OBSERVATION", 96, 120], ["lesser extent", "OBSERVATION_MODIFIER", 136, 149], ["microglia", "OBSERVATION", 150, 159], ["astrocytes", "ANATOMY", 164, 174]]], ["Viral replication peaks at day 5 post infection (p.i.), but infectious virus is reduced below detection by day 14 p.i.", [["infection", "DISEASE", 38, 47], ["Viral", "ORGANISM", 0, 5], ["Viral replication peaks", "PROBLEM", 0, 23], ["infection", "PROBLEM", 38, 47], ["infectious virus", "PROBLEM", 60, 76], ["peaks", "OBSERVATION_MODIFIER", 18, 23], ["infection", "OBSERVATION", 38, 47], ["infectious virus", "OBSERVATION", 60, 76]]], ["Acute infection initiates rapid CNS recruitment of predominantly BMDM, but also neutrophils and NK cells, followed by infiltration of both CD8 and CD4 T cells, as observed in active MS lesions.", [["CNS", "ANATOMY", 32, 35], ["BMDM", "ANATOMY", 65, 69], ["neutrophils", "ANATOMY", 80, 91], ["NK cells", "ANATOMY", 96, 104], ["CD8", "ANATOMY", 139, 142], ["CD4 T cells", "ANATOMY", 147, 158], ["MS lesions", "ANATOMY", 182, 192], ["infection", "DISEASE", 6, 15], ["MS", "DISEASE", 182, 184], ["CNS", "ANATOMICAL_SYSTEM", 32, 35], ["BMDM", "CELL", 65, 69], ["neutrophils", "CELL", 80, 91], ["NK cells", "CELL", 96, 104], ["CD8", "GENE_OR_GENE_PRODUCT", 139, 142], ["CD4", "GENE_OR_GENE_PRODUCT", 147, 150], ["MS lesions", "CANCER", 182, 192], ["BMDM", "CELL_TYPE", 65, 69], ["neutrophils", "CELL_TYPE", 80, 91], ["NK cells", "CELL_TYPE", 96, 104], ["CD8 and CD4 T cells", "CELL_TYPE", 139, 158], ["Acute infection", "PROBLEM", 0, 15], ["predominantly BMDM", "PROBLEM", 51, 69], ["neutrophils", "TEST", 80, 91], ["NK cells", "PROBLEM", 96, 104], ["infiltration", "TEST", 118, 130], ["CD4 T cells", "PROBLEM", 147, 158], ["active MS lesions", "PROBLEM", 175, 192], ["infection", "OBSERVATION", 6, 15], ["rapid", "OBSERVATION_MODIFIER", 26, 31], ["CNS", "OBSERVATION_MODIFIER", 32, 35], ["recruitment", "OBSERVATION_MODIFIER", 36, 47], ["predominantly", "OBSERVATION_MODIFIER", 51, 64], ["BMDM", "OBSERVATION", 65, 69], ["NK cells", "OBSERVATION", 96, 104], ["active", "OBSERVATION_MODIFIER", 175, 181], ["MS", "OBSERVATION_MODIFIER", 182, 184], ["lesions", "OBSERVATION", 185, 192]]], ["The T cell response, which is essential to reduce viral replication, is highly Th1 polarized with no evidence of IL-17 or GM-CSF production (21\u201323).", [["T cell", "ANATOMY", 4, 10], ["T cell", "CELL", 4, 10], ["IL-17", "GENE_OR_GENE_PRODUCT", 113, 118], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 122, 128], ["viral replication", "TREATMENT", 50, 67], ["IL", "TEST", 113, 115], ["CSF production", "TEST", 125, 139], ["T cell response", "OBSERVATION", 4, 19], ["no evidence of", "UNCERTAINTY", 98, 112]]], ["Importantly, T cell-mediated virus control coincides with initiation of demyelination, which peaks between days 14\u201321 p.i. after infectious virus is cleared (24, 25).", [["T cell", "ANATOMY", 13, 19], ["demyelination", "DISEASE", 72, 85], ["T cell", "CELL", 13, 19], ["T cell-mediated virus control", "TREATMENT", 13, 42], ["demyelination", "PROBLEM", 72, 85], ["infectious virus", "PROBLEM", 129, 145], ["demyelination", "OBSERVATION", 72, 85], ["infectious", "OBSERVATION_MODIFIER", 129, 139]]], ["Although OLG tropism is a requirement for demyelination, immunodeficient mice demonstrated that infection of OLG in the absence of adaptive immunity is insufficient to cause demyelination.", [["demyelination", "DISEASE", 42, 55], ["infection", "DISEASE", 96, 105], ["demyelination", "DISEASE", 174, 187], ["OLG", "CANCER", 9, 12], ["immunodeficient mice", "ORGANISM", 57, 77], ["OLG", "GENE_OR_GENE_PRODUCT", 109, 112], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 73, 77], ["OLG tropism", "PROBLEM", 9, 20], ["demyelination", "PROBLEM", 42, 55], ["immunodeficient mice", "PROBLEM", 57, 77], ["infection of OLG", "PROBLEM", 96, 112], ["adaptive immunity", "PROBLEM", 131, 148], ["demyelination", "PROBLEM", 174, 187], ["infection", "OBSERVATION", 96, 105]]], ["However, transfer of either virus-specific CD4 or CD8 T cells into virus infected immunodeficient mice leads to demyelination (26, 27).", [["CD4", "ANATOMY", 43, 46], ["CD8 T cells", "ANATOMY", 50, 61], ["infected immunodeficient", "DISEASE", 73, 97], ["demyelination", "DISEASE", 112, 125], ["CD4", "GENE_OR_GENE_PRODUCT", 43, 46], ["CD8", "GENE_OR_GENE_PRODUCT", 50, 53], ["immunodeficient mice", "ORGANISM", 82, 102], ["CD4 or CD8 T cells", "CELL_TYPE", 43, 61], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 98, 102], ["either virus", "PROBLEM", 21, 33], ["CD8 T cells", "PROBLEM", 50, 61], ["demyelination", "PROBLEM", 112, 125]]], ["Furthermore, IFN-\u03b3 dependent control of infectious virus within OLG and no evidence for OLG apoptosis, suggested that direct T cell-mediated cytolysis of OLG does not play a major role in myelin loss (28).", [["T cell", "ANATOMY", 125, 131], ["myelin", "ANATOMY", 188, 194], ["myelin loss", "DISEASE", 188, 199], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 13, 18], ["infectious virus", "ORGANISM", 40, 56], ["OLG", "CANCER", 64, 67], ["OLG", "GENE_OR_GENE_PRODUCT", 88, 91], ["T cell", "CELL", 125, 131], ["OLG", "GENE_OR_GENE_PRODUCT", 154, 157], ["myelin", "GENE_OR_GENE_PRODUCT", 188, 194], ["IFN", "PROTEIN", 13, 16], ["OLG", "PROTEIN", 154, 157], ["IFN", "PROBLEM", 13, 16], ["infectious virus", "PROBLEM", 40, 56], ["OLG apoptosis", "PROBLEM", 88, 101], ["direct T cell-mediated cytolysis of OLG", "PROBLEM", 118, 157], ["myelin loss", "PROBLEM", 188, 199], ["infectious virus", "OBSERVATION", 40, 56], ["no evidence for", "UNCERTAINTY", 72, 87]]], ["This implicates T cell activated BMDM and microglia as the most probable mediators of myelin destruction.", [["T cell", "ANATOMY", 16, 22], ["BMDM", "ANATOMY", 33, 37], ["microglia", "ANATOMY", 42, 51], ["myelin", "ANATOMY", 86, 92], ["myelin destruction", "DISEASE", 86, 104], ["T cell", "CELL", 16, 22], ["BMDM", "CELL", 33, 37], ["microglia", "CELL", 42, 51], ["myelin", "GENE_OR_GENE_PRODUCT", 86, 92], ["T cell", "CELL_TYPE", 16, 22], ["BMDM", "CELL_TYPE", 33, 37], ["microglia", "CELL_TYPE", 42, 51], ["T cell activated BMDM", "PROBLEM", 16, 37], ["microglia", "PROBLEM", 42, 51], ["myelin destruction", "PROBLEM", 86, 104], ["T cell activated BMDM", "OBSERVATION", 16, 37], ["myelin destruction", "OBSERVATION", 86, 104]]], ["Moreover, both myeloid populations are abundant in lesions and occasionally associated with damaged axons (29).", [["myeloid populations", "ANATOMY", 15, 34], ["lesions", "ANATOMY", 51, 58], ["axons", "ANATOMY", 100, 105], ["myeloid populations", "CELL", 15, 34], ["lesions", "CANCER", 51, 58], ["axons", "CELLULAR_COMPONENT", 100, 105], ["myeloid populations", "CELL_TYPE", 15, 34], ["both myeloid populations", "PROBLEM", 10, 34], ["lesions", "PROBLEM", 51, 58], ["both", "OBSERVATION_MODIFIER", 10, 14], ["myeloid populations", "OBSERVATION", 15, 34], ["abundant", "OBSERVATION_MODIFIER", 39, 47], ["lesions", "OBSERVATION", 51, 58]]], ["However, in contrast to EAE, genetic or chemical depletion of monocytes during JHMV infection does not alter disease severity, virus replication or myelin loss (30, 31), suggesting that BMDM are dispensable for JHMV-induced demyelination.IntroductionThis study takes advantage of the distinct tissue environments established during EAE and JHMV infection to characterize temporal alterations in gene expression profiles of BMDM versus microglia in a Th1 biased demyelination model.", [["monocytes", "ANATOMY", 62, 71], ["myelin", "ANATOMY", 148, 154], ["tissue", "ANATOMY", 293, 299], ["BMDM", "ANATOMY", 423, 427], ["microglia", "ANATOMY", 435, 444], ["EAE", "DISEASE", 24, 27], ["infection", "DISEASE", 84, 93], ["myelin loss", "DISEASE", 148, 159], ["JHMV", "CHEMICAL", 211, 215], ["demyelination", "DISEASE", 224, 237], ["EAE", "DISEASE", 332, 335], ["infection", "DISEASE", 345, 354], ["demyelination", "DISEASE", 461, 474], ["monocytes", "CELL", 62, 71], ["JHMV", "ORGANISM", 79, 83], ["myelin", "GENE_OR_GENE_PRODUCT", 148, 154], ["BMDM", "CELL", 186, 190], ["JHMV", "GENE_OR_GENE_PRODUCT", 211, 215], ["tissue", "TISSUE", 293, 299], ["BMDM", "CELL", 423, 427], ["microglia", "CELL", 435, 444], ["monocytes", "CELL_TYPE", 62, 71], ["BMDM", "CELL_TYPE", 186, 190], ["BMDM", "CELL_TYPE", 423, 427], ["microglia", "CELL_TYPE", 435, 444], ["JHMV", "SPECIES", 79, 83], ["JHMV", "SPECIES", 211, 215], ["JHMV", "SPECIES", 340, 344], ["chemical depletion of monocytes", "PROBLEM", 40, 71], ["JHMV infection", "PROBLEM", 79, 93], ["alter disease severity", "PROBLEM", 103, 125], ["virus replication", "PROBLEM", 127, 144], ["myelin loss", "PROBLEM", 148, 159], ["BMDM", "PROBLEM", 186, 190], ["JHMV", "PROBLEM", 211, 215], ["demyelination", "PROBLEM", 224, 237], ["This study", "TEST", 250, 260], ["the distinct tissue environments", "PROBLEM", 280, 312], ["EAE", "PROBLEM", 332, 335], ["JHMV infection", "PROBLEM", 340, 354], ["temporal alterations", "PROBLEM", 371, 391], ["BMDM", "PROBLEM", 423, 427], ["microglia", "PROBLEM", 435, 444], ["a Th1 biased demyelination model", "TREATMENT", 448, 480], ["chemical depletion", "OBSERVATION", 40, 58], ["monocytes", "OBSERVATION", 62, 71], ["infection", "OBSERVATION", 84, 93], ["myelin loss", "OBSERVATION", 148, 159], ["BMDM", "OBSERVATION", 186, 190], ["demyelination", "OBSERVATION", 224, 237], ["BMDM", "OBSERVATION", 423, 427]]], ["To date, we are not aware of any reports evaluating the signature profile of microglia associated with pathogenic functions during demyelination.", [["microglia", "ANATOMY", 77, 86], ["demyelination", "DISEASE", 131, 144], ["microglia", "CELL", 77, 86], ["microglia", "CELL_TYPE", 77, 86], ["microglia", "PROBLEM", 77, 86], ["pathogenic functions", "PROBLEM", 103, 123], ["demyelination", "PROBLEM", 131, 144], ["microglia", "OBSERVATION", 77, 86]]], ["The results reveal that CNS infiltrating BMDM rapidly establish a characteristic profile including M1 and M2 markers, which prevails throughout infection as the population declines.", [["CNS", "ANATOMY", 24, 27], ["infection", "DISEASE", 144, 153], ["CNS infiltrating BMDM", "CELL", 24, 45], ["M1", "CELL", 99, 101], ["M2", "GENE_OR_GENE_PRODUCT", 106, 108], ["BMDM", "CELL_TYPE", 41, 45], ["M1", "PROTEIN", 99, 101], ["M2 markers", "PROTEIN", 106, 116], ["CNS infiltrating BMDM", "PROBLEM", 24, 45], ["CNS", "ANATOMY", 24, 27], ["infiltrating", "OBSERVATION", 28, 40], ["M2", "OBSERVATION_MODIFIER", 106, 108], ["infection", "OBSERVATION", 144, 153]]], ["By contrast, gene expression in microglia is only prominently altered remote from viral control concomitant with demyelination; distinct from BMDM, the gene expression pattern is skewed to a highly pro-inflammatory and phagocytic profile.", [["microglia", "ANATOMY", 32, 41], ["demyelination", "DISEASE", 113, 126], ["microglia", "CELL", 32, 41], ["BMDM", "CELL", 142, 146], ["microglia", "CELL_TYPE", 32, 41], ["BMDM", "CELL_TYPE", 142, 146], ["demyelination", "PROBLEM", 113, 126], ["viral control", "OBSERVATION", 82, 95], ["demyelination", "OBSERVATION", 113, 126], ["phagocytic profile", "OBSERVATION", 219, 237]]], ["The results overall highlight the plasticity of microglia responses in distinct inflammatory settings, which may be relevant for MS pathogenesis at distinct stages of disease.Mice ::: Materials and MethodsWild-type (WT) C57BL/6 mice were purchased from the National Cancer Institute (Frederick, MD, USA).", [["microglia", "ANATOMY", 48, 57], ["MS", "DISEASE", 129, 131], ["Cancer", "DISEASE", 266, 272], ["microglia", "CELL", 48, 57], ["Mice", "ORGANISM", 175, 179], ["MethodsWild-type (WT) C57BL/6 mice", "ORGANISM", 198, 232], ["microglia", "CELL_TYPE", 48, 57], ["Mice", "SPECIES", 175, 179], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 228, 232], ["MS pathogenesis", "PROBLEM", 129, 144], ["disease", "PROBLEM", 167, 174], ["MethodsWild", "TEST", 198, 209], ["microglia responses", "OBSERVATION", 48, 67], ["distinct", "OBSERVATION_MODIFIER", 71, 79], ["inflammatory settings", "OBSERVATION", 80, 101], ["may be", "UNCERTAINTY", 109, 115], ["disease", "OBSERVATION", 167, 174]]], ["Homozygous CCL2 deficient (CCL2\u2212/\u2212) mice were originally obtained from B. J. Rollins (Dana-Farber Cancer Institute, Boston, MA, USA).", [["Cancer", "DISEASE", 98, 104], ["CCL2", "GENE_OR_GENE_PRODUCT", 11, 15], ["CCL2", "PROTEIN", 11, 15], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["Homozygous CCL2 deficient", "PROBLEM", 0, 25], ["CCL2 deficient", "OBSERVATION", 11, 25]]], ["CX3CR1GFP/GFP (B6.129P-Cx3cr1tm1Litt/J) and CCR2RFP/RFP (B6.129(Cg)-Ccr2tm2.1Ifc/J) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and crossed to generate CX3CR1GFP/+CCR2RFP/+ mice.", [["CX3CR1GFP", "GENE_OR_GENE_PRODUCT", 0, 9], ["GFP", "GENE_OR_GENE_PRODUCT", 10, 13], ["CCR2RFP", "GENE_OR_GENE_PRODUCT", 44, 51], ["RFP", "GENE_OR_GENE_PRODUCT", 52, 55], ["CX3CR1GFP", "GENE_OR_GENE_PRODUCT", 178, 187], ["CCR2RFP", "GENE_OR_GENE_PRODUCT", 189, 196], ["CX3CR1GFP", "PROTEIN", 0, 9], ["GFP", "PROTEIN", 10, 13], ["B6.129P", "PROTEIN", 15, 22], ["Cx3cr1tm1Litt", "PROTEIN", 23, 36], ["CCR2RFP", "PROTEIN", 44, 51], ["RFP", "PROTEIN", 52, 55], ["CX3CR1GFP", "PROTEIN", 178, 187], ["CCR2RFP", "PROTEIN", 189, 196], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 199, 203], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 199, 203], ["CX3CR1GFP", "TEST", 0, 9], ["GFP", "TEST", 10, 13], ["B6", "TEST", 15, 17], ["Cx3cr1tm1Litt", "TEST", 23, 36], ["CCR2RFP", "TEST", 44, 51], ["RFP", "TEST", 52, 55], ["B6", "TEST", 57, 59], ["Cg", "TEST", 64, 66], ["CX3CR1GFP", "TEST", 178, 187], ["CCR2RFP", "TEST", 189, 196]]], ["Transgenic mice were bred and maintained at the Biological Research Institute under sterile conditions.", [["mice", "ORGANISM", 11, 15], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15]]], ["All procedures were preformed in compliance with the Cleveland Clinic Institutional Animal Care and Use Committee approved protocols.Virus and Infections ::: Materials and MethodsThe glia tropic JHMV neutralizing monoclonal antibody (mAb)-derived 2.2v-1 variant was used for all infections (32).", [["Infections", "DISEASE", 143, 153], ["infections", "DISEASE", 279, 289], ["Virus", "ORGANISM", 133, 138], ["glia", "CELL", 183, 187], ["glia tropic JHMV neutralizing monoclonal antibody", "PROTEIN", 183, 232], ["mAb", "PROTEIN", 234, 237], ["All procedures", "TREATMENT", 0, 14], ["Methods", "TEST", 172, 179], ["The glia tropic JHMV neutralizing monoclonal antibody", "TEST", 179, 232], ["mAb", "TEST", 234, 237], ["all infections", "PROBLEM", 275, 289], ["Infections", "OBSERVATION", 143, 153]]], ["Mice of both sexes between 6 and 7 weeks of age were infected in the left hemisphere with 1,000 PFU of JHMV diluted in endotoxin-free Dulbecco\u2019s phosphate-buffered saline (PBS) in a final volume of 30 \u00b5l.", [["left hemisphere", "ANATOMY", 69, 84], ["JHMV", "CHEMICAL", 103, 107], ["endotoxin", "CHEMICAL", 119, 128], ["phosphate", "CHEMICAL", 145, 154], ["phosphate", "CHEMICAL", 145, 154], ["Mice", "ORGANISM", 0, 4], ["endotoxin", "SIMPLE_CHEMICAL", 119, 128], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 145, 170], ["Mice", "SPECIES", 0, 4], ["JHMV", "SPECIES", 103, 107], ["JHMV", "TEST", 103, 107], ["endotoxin", "TEST", 119, 128], ["phosphate", "TREATMENT", 145, 154], ["buffered saline (PBS", "TREATMENT", 155, 175], ["a final volume", "TEST", 180, 194], ["infected", "OBSERVATION", 53, 61], ["left hemisphere", "ANATOMY", 69, 84]]], ["Mice were monitored daily for clinical disease severity according to the following scale: 0, healthy; 1, hunched back and ruffled fur; 2, partial hind limb paralysis or inability to maintain the upright position; 3, complete hind limb paralysis; 4, moribund or dead.Isolation of CNS Mononuclear Cells, Flow Cytometry, and Cell Sorting ::: Materials and MethodsFor analytical flow cytometry, anesthetized mice were perfused with ice-cold PBS, and resected brains and spinal cords homogenized using a Ten-Broeck tissue grinder as described (33).", [["hind limb", "ANATOMY", 146, 155], ["hind limb", "ANATOMY", 225, 234], ["CNS Mononuclear Cells", "ANATOMY", 279, 300], ["Cell", "ANATOMY", 322, 326], ["brains", "ANATOMY", 455, 461], ["spinal cords", "ANATOMY", 466, 478], ["tissue", "ANATOMY", 510, 516], ["paralysis", "DISEASE", 156, 165], ["paralysis", "DISEASE", 235, 244], ["Mice", "ORGANISM", 0, 4], ["hind limb", "ORGANISM_SUBDIVISION", 146, 155], ["hind limb", "ORGANISM_SUBDIVISION", 225, 234], ["CNS Mononuclear Cells", "CELL", 279, 300], ["Cell", "CELL", 322, 326], ["mice", "ORGANISM", 404, 408], ["brains", "ORGAN", 455, 461], ["spinal cords", "ORGAN", 466, 478], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 404, 408], ["mice", "SPECIES", 404, 408], ["clinical disease severity", "PROBLEM", 30, 55], ["partial hind limb paralysis", "PROBLEM", 138, 165], ["complete hind limb paralysis", "PROBLEM", 216, 244], ["CNS Mononuclear Cells", "TEST", 279, 300], ["Flow Cytometry", "TEST", 302, 316], ["analytical flow cytometry", "TEST", 364, 389], ["anesthetized mice", "TREATMENT", 391, 408], ["ice-cold PBS", "TREATMENT", 428, 440], ["resected brains and spinal cords", "PROBLEM", 446, 478], ["a Ten-Broeck tissue grinder", "TREATMENT", 497, 524], ["hind limb", "ANATOMY", 146, 155], ["paralysis", "OBSERVATION", 156, 165], ["hind limb", "ANATOMY", 225, 234], ["paralysis", "OBSERVATION", 235, 244], ["CNS", "ANATOMY", 279, 282], ["Mononuclear Cells", "OBSERVATION", 283, 300], ["Flow Cytometry", "OBSERVATION", 302, 316], ["resected", "OBSERVATION", 446, 454], ["spinal cords", "ANATOMY", 466, 478]]], ["Tissue homogenates were adjusted to 30% percoll (Pharmacia, Uppsala, Sweden) and underlaid with 1 ml 70% percoll prior to centrifugation at 850 g for 30 min at 4\u00b0C. CNS mononuclear cell were recovered from the 30/70% interface, washed and resuspended in FACS buffer (PBS + 1% bovine serum albumin).", [["Tissue homogenates", "ANATOMY", 0, 18], ["CNS mononuclear cell", "ANATOMY", 165, 185], ["serum", "ANATOMY", 283, 288], ["Tissue homogenates", "ORGANISM_SUBSTANCE", 0, 18], ["CNS mononuclear cell", "CELL", 165, 185], ["bovine", "ORGANISM", 276, 282], ["serum", "ORGANISM_SUBSTANCE", 283, 288], ["albumin", "GENE_OR_GENE_PRODUCT", 289, 296], ["CNS mononuclear cell", "CELL_TYPE", 165, 185], ["bovine", "SPECIES", 276, 282], ["bovine", "SPECIES", 276, 282], ["Tissue homogenates", "TREATMENT", 0, 18], ["CNS mononuclear cell", "PROBLEM", 165, 185], ["PBS", "TEST", 267, 270], ["1% bovine serum albumin", "TREATMENT", 273, 296], ["mononuclear cell", "OBSERVATION", 169, 185]]], ["Cells were blocked with anti-mouse CD16/CD32 (clone 2.4G2) mAb for 15 min on ice prior to staining.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["CD16", "GENE_OR_GENE_PRODUCT", 35, 39], ["CD32", "GENE_OR_GENE_PRODUCT", 40, 44], ["anti-mouse CD16", "PROTEIN", 24, 39], ["CD32", "PROTEIN", 40, 44], ["clone 2.4G2) mAb", "PROTEIN", 46, 62], ["Cells", "TEST", 0, 5], ["anti-mouse CD16/CD32 (clone", "TREATMENT", 24, 51]]], ["Staining was performed for 30 min on ice using fluorescein isothiocyanate, phycoerythrin, peridin chlorophyll protein complex (PerCP), or allophycocyanin (APC) conjugated mAb (all from BD Biosciences except where indicated) specific for CD45 (clone Ly-5), CD11b (clone M1/70), F4/80 (Serotec, Raleigh, NC, USA) and major histocompatibility complex (MHC) class II (clone 2G9).", [["fluorescein isothiocyanate", "CHEMICAL", 47, 73], ["fluorescein isothiocyanate", "CHEMICAL", 47, 73], ["phycoerythrin", "CHEMICAL", 75, 88], ["peridin chlorophyll", "CHEMICAL", 90, 109], ["APC", "CHEMICAL", 155, 158], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 47, 73], ["phycoerythrin", "SIMPLE_CHEMICAL", 75, 88], ["peridin chlorophyll protein complex", "GENE_OR_GENE_PRODUCT", 90, 125], ["PerCP", "SIMPLE_CHEMICAL", 127, 132], ["allophycocyanin", "SIMPLE_CHEMICAL", 138, 153], ["APC", "GENE_OR_GENE_PRODUCT", 155, 158], ["CD45", "GENE_OR_GENE_PRODUCT", 237, 241], ["clone Ly-5", "GENE_OR_GENE_PRODUCT", 243, 253], ["CD11b", "GENE_OR_GENE_PRODUCT", 256, 261], ["Serotec", "GENE_OR_GENE_PRODUCT", 284, 291], ["USA", "GENE_OR_GENE_PRODUCT", 306, 309], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 315, 347], ["phycoerythrin, peridin chlorophyll protein complex", "PROTEIN", 75, 125], ["PerCP", "PROTEIN", 127, 132], ["allophycocyanin (APC) conjugated mAb", "PROTEIN", 138, 174], ["BD Biosciences", "PROTEIN", 185, 199], ["CD45", "PROTEIN", 237, 241], ["clone Ly-5", "PROTEIN", 243, 253], ["CD11b", "PROTEIN", 256, 261], ["M1", "PROTEIN", 269, 271], ["70", "PROTEIN", 272, 274], ["F4", "PROTEIN", 277, 279], ["Serotec", "PROTEIN", 284, 291], ["Raleigh", "PROTEIN", 293, 300], ["NC", "PROTEIN", 302, 304], ["USA", "PROTEIN", 306, 309], ["major histocompatibility complex (MHC) class II", "PROTEIN", 315, 362], ["clone 2G9", "PROTEIN", 364, 373], ["Staining", "TEST", 0, 8], ["fluorescein isothiocyanate", "TREATMENT", 47, 73], ["phycoerythrin", "TREATMENT", 75, 88], ["peridin chlorophyll protein complex (PerCP)", "TREATMENT", 90, 133], ["allophycocyanin (APC) conjugated mAb", "TREATMENT", 138, 174], ["BD Biosciences", "TEST", 185, 199], ["CD45", "TEST", 237, 241], ["clone Ly", "TEST", 243, 251], ["CD11b", "TEST", 256, 261], ["Serotec", "TEST", 284, 291], ["NC", "ANATOMY", 302, 304]]], ["Cells were then washed twice in FACS buffer prior to analysis using a BD Accuri flow cytometer (BD Biosciences) and FlowJo software (Tree Star Inc., Ashland, OR, USA).Isolation of CNS Mononuclear Cells, Flow Cytometry, and Cell Sorting ::: Materials and MethodsFor cell purification, spinal cords from PBS-perfused CX3CR1GFP/+CCR2RFP/+ mice were finely minced with a razor blade.", [["Cells", "ANATOMY", 0, 5], ["CNS Mononuclear Cells", "ANATOMY", 180, 201], ["Cell", "ANATOMY", 223, 227], ["cell", "ANATOMY", 265, 269], ["spinal cords", "ANATOMY", 284, 296], ["Cells", "CELL", 0, 5], ["CNS Mononuclear Cells", "CELL", 180, 201], ["Cell", "CELL", 223, 227], ["cell", "CELL", 265, 269], ["spinal cords", "MULTI-TISSUE_STRUCTURE", 284, 296], ["CX3CR1GFP", "GENE_OR_GENE_PRODUCT", 315, 324], ["CCR2RFP", "GENE_OR_GENE_PRODUCT", 326, 333], ["mice", "ORGANISM", 336, 340], ["CCR2RFP", "PROTEIN", 326, 333], ["mice", "SPECIES", 336, 340], ["mice", "SPECIES", 336, 340], ["analysis", "TEST", 53, 61], ["a BD Accuri flow cytometer", "TREATMENT", 68, 94], ["FlowJo software", "TEST", 116, 131], ["CNS Mononuclear Cells", "TEST", 180, 201], ["Flow Cytometry", "TEST", 203, 217], ["Methods", "TREATMENT", 254, 261], ["cell purification", "TREATMENT", 265, 282], ["spinal cords", "TEST", 284, 296], ["PBS", "TEST", 302, 305], ["CX3CR1GFP", "TEST", 315, 324], ["CCR2RFP/+ mice", "TREATMENT", 326, 340], ["a razor blade", "TREATMENT", 365, 378], ["CNS", "ANATOMY", 180, 183], ["Mononuclear Cells", "OBSERVATION", 184, 201], ["Flow Cytometry", "OBSERVATION", 203, 217], ["spinal cords", "ANATOMY", 284, 296]]], ["Minced tissues were enzymatically digested in RPMI 1640 medium containing 10% fetal calf serum, 0.5% collagenase D (100 mg/ml) Roche, Basel, Switzerland and 1% DNase I (1 mg/ml) (Sigma Aldrich, St. Louis, MO, USA) for 40 min at 37\u00b0C. Collagenase was then inactivated by addition of 1% 0.1 M EDTA for 5 min at 37\u00b0C prior centrifugation at 400 g for 7 min at 4\u00b0C. Spinal cord-derived cells from seven mice were pooled and isolated using percoll gradients as described above and then stained with CD11b-PerCP and CD45-APC for 30 min on ice.", [["tissues", "ANATOMY", 7, 14], ["fetal calf serum", "ANATOMY", 78, 94], ["Spinal cord-derived cells", "ANATOMY", 362, 387], ["EDTA", "CHEMICAL", 291, 295], ["tissues", "TISSUE", 7, 14], ["fetal calf", "ORGANISM_SUBSTANCE", 78, 88], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["collagenase D", "SIMPLE_CHEMICAL", 101, 114], ["DNase I", "GENE_OR_GENE_PRODUCT", 160, 167], ["Collagenase", "GENE_OR_GENE_PRODUCT", 234, 245], ["EDTA", "SIMPLE_CHEMICAL", 291, 295], ["Spinal cord-derived cells", "CELL", 362, 387], ["mice", "ORGANISM", 399, 403], ["CD11b", "GENE_OR_GENE_PRODUCT", 494, 499], ["PerCP", "GENE_OR_GENE_PRODUCT", 500, 505], ["CD45", "GENE_OR_GENE_PRODUCT", 510, 514], ["APC", "GENE_OR_GENE_PRODUCT", 515, 518], ["Spinal cord-derived cells", "CELL_TYPE", 362, 387], ["CD11b", "PROTEIN", 494, 499], ["PerCP", "PROTEIN", 500, 505], ["CD45", "PROTEIN", 510, 514], ["APC", "CELL_TYPE", 515, 518], ["calf", "SPECIES", 84, 88], ["mice", "SPECIES", 399, 403], ["calf", "SPECIES", 84, 88], ["mice", "SPECIES", 399, 403], ["RPMI", "TEST", 46, 50], ["fetal calf serum", "TEST", 78, 94], ["1% DNase I", "TREATMENT", 157, 167], ["Collagenase", "TREATMENT", 234, 245], ["C prior centrifugation", "TREATMENT", 312, 334], ["percoll gradients", "TREATMENT", 435, 452], ["CD11b", "TEST", 494, 499], ["PerCP", "TEST", 500, 505], ["tissues", "ANATOMY", 7, 14], ["calf", "ANATOMY", 84, 88], ["cord", "ANATOMY", 369, 373]]], ["Spinal cord-derived BMDM (CD45hiCD11b+CCR2RFP+) and microglia (CD45lowCD11b+CX3CR1GFP+) were purified using a FACSAria cell sorter (BD Biosciences) and resuspended in Trizol.", [["Spinal cord", "ANATOMY", 0, 11], ["BMDM", "ANATOMY", 20, 24], ["CD45hiCD11b+CCR2RFP+)", "ANATOMY", 26, 47], ["microglia", "ANATOMY", 52, 61], ["CD45lowCD11b+CX3CR1GFP+", "ANATOMY", 63, 86], ["cell", "ANATOMY", 119, 123], ["cord", "ORGAN", 7, 11], ["BMDM", "CELL", 20, 24], ["CD45hiCD11b", "GENE_OR_GENE_PRODUCT", 26, 37], ["CCR2RFP", "GENE_OR_GENE_PRODUCT", 38, 45], ["microglia", "CELL", 52, 61], ["CD45lowCD11b", "GENE_OR_GENE_PRODUCT", 63, 75], ["cell", "CELL", 119, 123], ["BMDM", "CELL_TYPE", 20, 24], ["CD45hiCD11b", "PROTEIN", 26, 37], ["CCR2RFP", "PROTEIN", 38, 45], ["microglia", "CELL_TYPE", 52, 61], ["CD45lowCD11b", "PROTEIN", 63, 75], ["CX3CR1GFP", "PROTEIN", 76, 85], ["FACSAria cell sorter", "CELL_LINE", 110, 130], ["Spinal cord", "TEST", 0, 11], ["BMDM", "TEST", 20, 24], ["CD45hiCD11b", "TEST", 26, 37], ["CCR2RFP", "TEST", 38, 45], ["microglia", "TEST", 52, 61], ["CD45lowCD11", "TEST", 63, 74], ["CX3CR1GFP", "TEST", 76, 85], ["a FACSAria cell sorter", "TREATMENT", 108, 130], ["Trizol", "TREATMENT", 167, 173], ["cord", "ANATOMY", 7, 11], ["BMDM", "OBSERVATION", 20, 24]]], ["Yields from 7-pooled mice ranged between 5.4\u201320 \u00d7 105 cells for BMDM and 0.5\u20131.2 \u00d7 105 cells for microglia depending on the time p.i.", [["cells", "ANATOMY", 54, 59], ["BMDM", "ANATOMY", 64, 68], ["cells", "ANATOMY", 87, 92], ["microglia", "ANATOMY", 97, 106], ["mice", "ORGANISM", 21, 25], ["cells", "CELL", 54, 59], ["BMDM", "CELL", 64, 68], ["cells", "CELL", 87, 92], ["microglia", "CELL", 97, 106], ["BMDM", "CELL_TYPE", 64, 68], ["microglia", "CELL_TYPE", 97, 106], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["Yields", "TEST", 0, 6], ["BMDM", "TEST", 64, 68], ["cells", "TEST", 87, 92], ["microglia", "PROBLEM", 97, 106]]], ["Microglia from na\u00efve mice were used to assess baseline expression, whereas circulating monocytes were used as controls for CNS infiltrated BMDM after infection.", [["Microglia", "ANATOMY", 0, 9], ["monocytes", "ANATOMY", 87, 96], ["CNS", "ANATOMY", 123, 126], ["BMDM", "ANATOMY", 139, 143], ["infection", "DISEASE", 150, 159], ["Microglia", "CELL", 0, 9], ["mice", "ORGANISM", 21, 25], ["monocytes", "CELL", 87, 96], ["BMDM", "CELL", 139, 143], ["Microglia", "CELL_TYPE", 0, 9], ["circulating monocytes", "CELL_TYPE", 75, 96], ["BMDM", "CELL_TYPE", 139, 143], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["circulating monocytes", "TEST", 75, 96], ["CNS infiltrated BMDM", "PROBLEM", 123, 143], ["infection", "PROBLEM", 150, 159], ["infection", "OBSERVATION", 150, 159]]], ["Monocytes were isolated from blood treated with Gey\u2019s solution to lyse red blood cells prior to staining and cell sorting.Gene Expression Profiling Using nCounter Analysis ::: Materials and MethodsRNA was prepared by extraction with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and Direct-zol RNA mini prep (Zymo Research, Irvine, CA, USA) according to the manufacturer\u2019s instructions.", [["Monocytes", "ANATOMY", 0, 9], ["blood", "ANATOMY", 29, 34], ["red blood cells", "ANATOMY", 71, 86], ["cell", "ANATOMY", 109, 113], ["Monocytes", "CELL", 0, 9], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["Gey", "SIMPLE_CHEMICAL", 48, 51], ["red blood cells", "CELL", 71, 86], ["cell", "CELL", 109, 113], ["Monocytes", "CELL_TYPE", 0, 9], ["red blood cells", "CELL_TYPE", 71, 86], ["Monocytes", "TEST", 0, 9], ["blood", "TEST", 29, 34], ["Gey\u2019s solution", "TREATMENT", 48, 62], ["lyse red blood cells", "TREATMENT", 66, 86], ["staining", "TEST", 96, 104], ["cell sorting", "TEST", 109, 121], ["MethodsRNA", "TREATMENT", 190, 200], ["TRIzol reagent", "TREATMENT", 233, 247], ["Invitrogen", "TREATMENT", 249, 259], ["Carlsbad", "TREATMENT", 261, 269], ["Direct-zol RNA", "TREATMENT", 284, 298]]], ["Gene expression profiles were analyzed using the nCounter mouse Myeloid Innate Immune panel comprising 754 targets representing all major myeloid cell types and generated according to the manufacturer\u2019s protocol (NanoString Technologies, Seattle, WA, USA).", [["myeloid cell", "ANATOMY", 138, 150], ["mouse", "ORGANISM", 58, 63], ["myeloid cell", "CELL", 138, 150], ["myeloid cell types", "CELL_TYPE", 138, 156], ["mouse", "SPECIES", 58, 63], ["mouse", "SPECIES", 58, 63], ["Gene expression profiles", "TEST", 0, 24], ["Immune panel", "TEST", 79, 91], ["all major myeloid cell types", "PROBLEM", 128, 156], ["major myeloid cell types", "OBSERVATION", 132, 156]]], ["The NanoString nCounter system directly captures and counts individual mRNA transcripts using a multiplexed measurement system thereby omitting cDNA based amplification (34).", [["mRNA transcripts", "RNA", 71, 87], ["The NanoString nCounter system", "TREATMENT", 0, 30], ["a multiplexed measurement system", "TREATMENT", 94, 126]]], ["Analysis was performed using nSolver Analysis Software v3.0 and Ingenuity pathway analysis (Qiagen, Hilden, Germany).", [["Analysis", "TEST", 0, 8], ["Analysis Software", "TEST", 37, 54], ["Ingenuity pathway analysis", "TEST", 64, 90]]], ["Venn diagrams from individual gene lists and protein-protein interaction networks were constructed using Genespring (Agilent, Inc.) and STRING software (http://www.string-db.org).Reverse Transcription and Real-Time PCR ::: Materials and MethodsTo confirm validity of Nanostring nCounter analysis, a small set of selected genes were analyzed by real-time PCR (Figure S1 in Supplementary Material).", [["protein-protein interaction networks", "PROTEIN", 45, 81], ["Nanostring nCounter", "DNA", 267, 286], ["Venn diagrams", "TEST", 0, 13], ["Nanostring nCounter analysis", "TEST", 267, 295], ["a small set of selected genes", "PROBLEM", 297, 326], ["small", "OBSERVATION_MODIFIER", 299, 304]]], ["Following RNA extraction as described above, first-strand cDNA was synthesized using reverse transcriptase (Invitrogen) with oligo-dT and random primers (Promega, Madison, WI, USA) as described (35).", [["first-strand cDNA", "DNA", 45, 62], ["reverse transcriptase", "PROTEIN", 85, 106], ["RNA extraction", "TREATMENT", 10, 24], ["strand cDNA", "TREATMENT", 51, 62], ["reverse transcriptase (Invitrogen", "TREATMENT", 85, 118], ["oligo-dT", "TREATMENT", 125, 133], ["random primers", "TREATMENT", 138, 152]]], ["Gene expression analysis was performed using a 7500 Fast real-time PCR system (Applied Biosystems, Foster city, CA, USA), SYBR Green Master mix (Applied Biosystems) and the following primers: GAPDH, 5\u2032-CATGGCCTTCCGTGTTCCTA-3\u2032 (forward) and 5\u2032-ATGCCTGCTTCACCACCTTCT-3\u2032 (reverse); IL15, 5\u2032-TGAGGCTGGCATTCATGTCTT-3\u2032 (forward) and 5\u2032-TCCAGTTGGCCTCTGTTTTAGG-3\u2032 (reverse); IL1rn 5\u2032-AGATAGACATGGTGCCTATTGACCTT-3\u2032 (forward) and 5\u2032-CATCTCCAGACTTGGCACAAGA-3\u2032 (reverse) and Arg1 5\u2032-TGGGTGGATGCTCACACTGA-3\u2032 (forward) and 5\u2032-CAGGTTGCCCATGCAGATT-3\u2032 (reverse).", [["GAPDH", "GENE_OR_GENE_PRODUCT", 192, 197], ["5\u2032-TCCAGTTGGCCTCTGTTTTAGG-3", "GENE_OR_GENE_PRODUCT", 327, 354], ["5\u2032-CATCTCCAGACTTGGCACAAGA-3", "GENE_OR_GENE_PRODUCT", 420, 447], ["IL1rn 5", "DNA", 367, 374], ["3\u2032", "DNA", 403, 405], ["Arg1 5", "DNA", 463, 469], ["Gene expression analysis", "TEST", 0, 24], ["GAPDH", "TEST", 192, 197], ["CATGGCCTTCCGTGTTCCTA", "TEST", 202, 222], ["ATGCCTGCTTCACCACCTTCT", "TEST", 243, 264], ["IL15", "TEST", 279, 283], ["TGAGGCTGGCATTCATGTCTT", "TEST", 288, 309], ["TCCAGTTGGCCTCTGTTTTAGG", "TEST", 330, 352], ["IL1rn", "TEST", 367, 372], ["AGATAGACATGGTGCCTATTGACCTT", "TEST", 376, 402], ["CATCTCCAGACTTGGCACAAGA", "TEST", 423, 445], ["Arg1", "TEST", 463, 467], ["TGGGTGGATGCTCACACTGA", "TEST", 471, 491], ["CAGGTTGCCCATGCAGATT", "TEST", 512, 531]]], ["Transcripts levels were normalized to the housekeeping gene GAPDH and converted to a linearized value using the following formula: 2(CTGAPDH-CTgene) \u00d7 1,000, where CT represents the threshold cycle value.Histological Analysis ::: Materials and MethodsFollowing PBS perfusion, spinal cords were fixed in 10% neutral buffered Formalin, embedded in paraffin and sections stained with Luxol Fast Blue as described to visualize demyelination (36).", [["spinal cords", "ANATOMY", 276, 288], ["sections", "ANATOMY", 359, 367], ["demyelination", "DISEASE", 423, 436], ["Formalin", "CHEMICAL", 324, 332], ["paraffin", "CHEMICAL", 346, 354], ["GAPDH", "GENE_OR_GENE_PRODUCT", 60, 65], ["spinal cords", "MULTI-TISSUE_STRUCTURE", 276, 288], ["Formalin", "SIMPLE_CHEMICAL", 324, 332], ["housekeeping gene", "DNA", 42, 59], ["GAPDH", "DNA", 60, 65], ["Transcripts levels", "TEST", 0, 18], ["the housekeeping gene GAPDH", "PROBLEM", 38, 65], ["CT", "TEST", 164, 166], ["the threshold cycle value", "TEST", 178, 203], ["Histological Analysis", "TEST", 204, 225], ["MethodsFollowing PBS perfusion", "TEST", 244, 274], ["neutral buffered Formalin", "TREATMENT", 307, 332], ["demyelination", "PROBLEM", 423, 436], ["spinal cords", "ANATOMY", 276, 288]]], ["For analysis of Iba1+ cells spinal cords from ice-cold PBS-perfused mice were quickly embedded in OCT and kept at \u221280\u00b0C until 10 \u00b5m sections were prepared.", [["Iba1+ cells spinal cords", "ANATOMY", 16, 40], ["\u00b5m sections", "ANATOMY", 129, 140], ["Iba1", "GENE_OR_GENE_PRODUCT", 16, 20], ["spinal cords", "MULTI-TISSUE_STRUCTURE", 28, 40], ["mice", "ORGANISM", 68, 72], ["Iba1", "PROTEIN", 16, 20], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 68, 72], ["analysis", "TEST", 4, 12], ["Iba1+ cells spinal cords", "PROBLEM", 16, 40], ["OCT", "TEST", 98, 101], ["spinal cords", "ANATOMY", 28, 40]]], ["Sections were fixed with paraformaldehyde for 20 min, treated with blocking solution for 30 min and then stained with rabbit anti-Iba1 mAb (Wako, Osaka, Japan) overnight at 4\u00b0C. Goat anti-rabbit secondary Ab (Invitrogen) was added for 1 h at room temperature and sections mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA).", [["sections", "ANATOMY", 263, 271], ["paraformaldehyde", "CHEMICAL", 25, 41], ["paraformaldehyde", "SIMPLE_CHEMICAL", 25, 41], ["rabbit", "ORGANISM", 118, 124], ["Iba1", "GENE_OR_GENE_PRODUCT", 130, 134], ["Wako", "ORGANISM_SUBSTANCE", 140, 144], ["Iba1 mAb", "PROTEIN", 130, 138], ["Goat anti-rabbit secondary Ab", "PROTEIN", 178, 207], ["rabbit", "SPECIES", 118, 124], ["Goat", "SPECIES", 178, 182], ["anti-rabbit", "SPECIES", 183, 194], ["rabbit", "SPECIES", 118, 124], ["Goat", "SPECIES", 178, 182], ["paraformaldehyde", "TREATMENT", 25, 41], ["blocking solution", "TREATMENT", 67, 84], ["rabbit anti-Iba1 mAb", "TREATMENT", 118, 138], ["Goat anti-rabbit secondary Ab (Invitrogen)", "TREATMENT", 178, 220]]], ["Sections were analyzed using a Leica TCS confocal microscope.Infiltrating Macrophages Are Dispensable to JHMV-Induced Demyelination ::: ResultsTo better characterize reactivity of microglia and infiltrating BMDM following JHMV infection, we initially monitored CNS infiltration of BMDM, as well as upregulation of MHC class II as an activation marker on both CNS BMDM and microglia by flow cytometry.", [["Macrophages", "ANATOMY", 74, 85], ["microglia", "ANATOMY", 180, 189], ["BMDM", "ANATOMY", 207, 211], ["CNS", "ANATOMY", 261, 264], ["BMDM", "ANATOMY", 281, 285], ["CNS BMDM", "ANATOMY", 359, 367], ["microglia", "ANATOMY", 372, 381], ["JHMV infection", "DISEASE", 222, 236], ["TCS", "CHEMICAL", 37, 40], ["Macrophages", "CELL", 74, 85], ["microglia", "CELL", 180, 189], ["BMDM", "CELL", 207, 211], ["JHMV", "CELL", 222, 226], ["CNS", "ANATOMICAL_SYSTEM", 261, 264], ["BMDM", "CELL", 281, 285], ["MHC class II", "GENE_OR_GENE_PRODUCT", 314, 326], ["CNS BMDM", "CELL", 359, 367], ["microglia", "CELL", 372, 381], ["microglia", "CELL_TYPE", 180, 189], ["BMDM", "CELL_TYPE", 207, 211], ["BMDM", "CELL_TYPE", 281, 285], ["MHC class II", "PROTEIN", 314, 326], ["CNS BMDM", "CELL_TYPE", 359, 367], ["microglia", "CELL_TYPE", 372, 381], ["JHMV", "SPECIES", 222, 226], ["Infiltrating Macrophages", "PROBLEM", 61, 85], ["microglia", "PROBLEM", 180, 189], ["infiltrating BMDM", "PROBLEM", 194, 211], ["JHMV infection", "PROBLEM", 222, 236], ["BMDM", "PROBLEM", 281, 285], ["an activation marker", "TEST", 330, 350], ["flow cytometry", "TEST", 385, 399], ["Macrophages", "OBSERVATION", 74, 85], ["Demyelination", "OBSERVATION", 118, 131], ["microglia", "OBSERVATION", 180, 189], ["infiltrating BMDM", "OBSERVATION", 194, 211], ["infection", "OBSERVATION", 227, 236], ["CNS", "ANATOMY", 359, 362]]], ["BMDM with a typical CD45hiCD11b+F4/80+ phenotype comprised the majority of inflammatory leukocytes as early as day 3 p.i. and then progressively decreased as virus replication is controlled by T cells.", [["BMDM", "ANATOMY", 0, 4], ["inflammatory leukocytes", "ANATOMY", 75, 98], ["T cells", "ANATOMY", 193, 200], ["BMDM", "CELL", 0, 4], ["CD45hiCD11b", "GENE_OR_GENE_PRODUCT", 20, 31], ["leukocytes", "CELL", 88, 98], ["T cells", "CELL", 193, 200], ["BMDM", "CELL_TYPE", 0, 4], ["CD45hiCD11b", "PROTEIN", 20, 31], ["inflammatory leukocytes", "CELL_TYPE", 75, 98], ["T cells", "CELL_TYPE", 193, 200], ["BMDM", "PROBLEM", 0, 4], ["a typical CD45hiCD11b", "TEST", 10, 31], ["phenotype", "PROBLEM", 39, 48], ["inflammatory leukocytes", "PROBLEM", 75, 98], ["virus replication", "PROBLEM", 158, 175], ["inflammatory leukocytes", "OBSERVATION", 75, 98], ["decreased", "OBSERVATION_MODIFIER", 145, 154], ["virus replication", "OBSERVATION", 158, 175]]], ["At the onset of demyelination at day 10 p.i., the BMDM population stabilized at ~10% of the infiltrating leukocytes (Figure 1A).", [["infiltrating leukocytes", "ANATOMY", 92, 115], ["demyelination", "DISEASE", 16, 29], ["BMDM", "CELL", 50, 54], ["leukocytes", "CELL", 105, 115], ["BMDM population", "CELL_LINE", 50, 65], ["infiltrating leukocytes", "CELL_TYPE", 92, 115], ["demyelination", "PROBLEM", 16, 29], ["the BMDM population", "TEST", 46, 65], ["demyelination", "OBSERVATION", 16, 29], ["infiltrating leukocytes", "OBSERVATION", 92, 115]]], ["BMDM initially infiltrated as MHC class IIlo expressing cells, but the vast majority upregulated MHC class II by day 7 p.i.", [["cells", "ANATOMY", 56, 61], ["BMDM", "CELL", 0, 4], ["cells", "CELL", 56, 61], ["MHC class II", "GENE_OR_GENE_PRODUCT", 97, 109], ["MHC class IIlo expressing cells", "CELL_TYPE", 30, 61], ["MHC class II", "PROTEIN", 97, 109], ["BMDM", "PROBLEM", 0, 4], ["infiltrated", "PROBLEM", 15, 26], ["infiltrated", "OBSERVATION", 15, 26]]], ["MHC class II expression on microglia was sparse at days 3 and 5 p.i., but rapidly increased by day 7 p.i. and then gradually declined by day 14 p.i.", [["microglia", "ANATOMY", 27, 36], ["MHC class II", "GENE_OR_GENE_PRODUCT", 0, 12], ["microglia", "CELL", 27, 36], ["MHC class II", "PROTEIN", 0, 12], ["microglia", "CELL_TYPE", 27, 36], ["rapidly", "OBSERVATION_MODIFIER", 74, 81], ["increased", "OBSERVATION_MODIFIER", 82, 91]]], ["These kinetics supported that microglia and BMDM activation peaks delayed relative to peak BMDM accumulation and coincides with peak T cell IFN-\u03b3 production (36, 37).", [["microglia", "ANATOMY", 30, 39], ["BMDM", "ANATOMY", 44, 48], ["T cell", "ANATOMY", 133, 139], ["microglia", "CELL", 30, 39], ["BMDM", "CELL", 44, 48], ["BMDM", "CELL", 91, 95], ["T cell IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 133, 145], ["microglia", "CELL_TYPE", 30, 39], ["IFN", "PROTEIN", 140, 143], ["\u03b3", "PROTEIN", 144, 145], ["microglia and BMDM activation", "TEST", 30, 59], ["peak BMDM accumulation", "PROBLEM", 86, 108], ["peak T cell IFN", "TEST", 128, 143], ["cell IFN", "OBSERVATION", 135, 143]]], ["Enhanced activation of microglia at day 7 p.i., compared to earlier times p.i., was also supported by progression of morphological changes, evidenced by enlarged cell bodies and retracted and thickened processes (Figure 1B).", [["microglia", "ANATOMY", 23, 32], ["cell bodies", "ANATOMY", 162, 173], ["microglia", "CELL", 23, 32], ["cell bodies", "CELLULAR_COMPONENT", 162, 173], ["microglia", "CELL_TYPE", 23, 32], ["morphological changes", "PROBLEM", 117, 138], ["enlarged cell bodies", "PROBLEM", 153, 173], ["retracted and thickened processes", "PROBLEM", 178, 211], ["progression", "OBSERVATION_MODIFIER", 102, 113], ["morphological changes", "OBSERVATION", 117, 138], ["enlarged", "OBSERVATION_MODIFIER", 153, 161], ["cell bodies", "OBSERVATION", 162, 173], ["retracted", "OBSERVATION_MODIFIER", 178, 187], ["thickened", "OBSERVATION", 192, 201]]], ["The decline of BMDM, but an ongoing activation phenotype of microglia at the time of evident demyelination implicated microglia as mediators of tissue damage during JHMV encephalomyelitis.Infiltrating Macrophages Are Dispensable to JHMV-Induced Demyelination ::: ResultsBiochemical depletion of peripheral monocytes indeed supported that BMDM are not essential to tissue destruction in JHMV-infected mice (30).", [["microglia", "ANATOMY", 60, 69], ["microglia", "ANATOMY", 118, 127], ["tissue", "ANATOMY", 144, 150], ["Macrophages", "ANATOMY", 201, 212], ["peripheral monocytes", "ANATOMY", 295, 315], ["BMDM", "ANATOMY", 338, 342], ["tissue", "ANATOMY", 364, 370], ["demyelination", "DISEASE", 93, 106], ["tissue damage", "DISEASE", 144, 157], ["encephalomyelitis", "DISEASE", 170, 187], ["BMDM", "CELL", 15, 19], ["microglia", "CELL", 60, 69], ["microglia", "CELL", 118, 127], ["tissue", "TISSUE", 144, 150], ["Macrophages", "CELL", 201, 212], ["peripheral monocytes", "CELL", 295, 315], ["BMDM", "CELL", 338, 342], ["tissue", "TISSUE", 364, 370], ["JHMV", "GENE_OR_GENE_PRODUCT", 386, 390], ["mice", "ORGANISM", 400, 404], ["BMDM", "CELL_TYPE", 15, 19], ["microglia", "CELL_TYPE", 60, 69], ["microglia", "CELL_TYPE", 118, 127], ["peripheral monocytes", "CELL_TYPE", 295, 315], ["BMDM", "CELL_TYPE", 338, 342], ["mice", "SPECIES", 400, 404], ["JHMV encephalomyelitis", "SPECIES", 165, 187], ["JHMV", "SPECIES", 386, 390], ["mice", "SPECIES", 400, 404], ["BMDM", "PROBLEM", 15, 19], ["an ongoing activation phenotype of microglia", "PROBLEM", 25, 69], ["demyelination", "PROBLEM", 93, 106], ["tissue damage", "PROBLEM", 144, 157], ["JHMV encephalomyelitis", "PROBLEM", 165, 187], ["Infiltrating Macrophages", "PROBLEM", 188, 212], ["peripheral monocytes", "PROBLEM", 295, 315], ["BMDM", "PROBLEM", 338, 342], ["tissue destruction", "PROBLEM", 364, 382], ["BMDM", "OBSERVATION", 15, 19], ["activation phenotype", "OBSERVATION", 36, 56], ["microglia", "OBSERVATION", 60, 69], ["demyelination", "OBSERVATION", 93, 106], ["encephalomyelitis", "OBSERVATION", 170, 187], ["Macrophages", "OBSERVATION", 201, 212], ["Demyelination", "OBSERVATION", 245, 258], ["peripheral monocytes", "OBSERVATION", 295, 315], ["to tissue", "OBSERVATION_MODIFIER", 361, 370], ["destruction", "OBSERVATION", 371, 382], ["infected", "OBSERVATION_MODIFIER", 391, 399]]], ["Data from our own laboratory further demonstrated that the chemokine CCL2 is essential for BMDM accumulation within the CNS (31).", [["BMDM", "ANATOMY", 91, 95], ["CNS", "ANATOMY", 120, 123], ["CCL2", "GENE_OR_GENE_PRODUCT", 69, 73], ["BMDM", "CELL", 91, 95], ["CNS", "ANATOMICAL_SYSTEM", 120, 123], ["chemokine", "PROTEIN", 59, 68], ["CCL2", "PROTEIN", 69, 73], ["the chemokine CCL2", "TEST", 55, 73], ["BMDM accumulation", "PROBLEM", 91, 108], ["CNS", "ANATOMY", 120, 123]]], ["The absence of CCL2 resulted in an ~80% reduction of BMDM at all time points, including day 14 p.i.", [["CCL2", "GENE_OR_GENE_PRODUCT", 15, 19], ["BMDM", "CELL", 53, 57], ["CCL2", "PROTEIN", 15, 19], ["BMDM", "CELL_TYPE", 53, 57], ["BMDM", "PROBLEM", 53, 57], ["CCL2", "OBSERVATION", 15, 19]]], ["(31) and (Figure 1C) when demyelination is prominently evident in WT mice.", [["demyelination", "DISEASE", 26, 39], ["WT mice", "ORGANISM", 66, 73], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 69, 73], ["demyelination", "PROBLEM", 26, 39]]], ["Nevertheless, microglia activation, as monitored by MHC class II expression, was independent of CCL2 (Figure 1D).", [["microglia", "ANATOMY", 14, 23], ["microglia", "CELL", 14, 23], ["MHC class II", "GENE_OR_GENE_PRODUCT", 52, 64], ["CCL2", "GENE_OR_GENE_PRODUCT", 96, 100], ["microglia", "CELL_TYPE", 14, 23], ["MHC class II", "PROTEIN", 52, 64], ["CCL2", "PROTEIN", 96, 100], ["microglia activation", "OBSERVATION", 14, 34]]], ["Most importantly, the absence of CCL2-dependent BMDM within the CNS did not alter demyelination (Figure 1E).", [["CNS", "ANATOMY", 64, 67], ["demyelination", "DISEASE", 82, 95], ["CCL2", "GENE_OR_GENE_PRODUCT", 33, 37], ["BMDM", "CELL", 48, 52], ["CNS", "ANATOMICAL_SYSTEM", 64, 67], ["CCL2", "PROTEIN", 33, 37], ["BMDM", "CELL_TYPE", 48, 52], ["CCL2-dependent BMDM", "PROBLEM", 33, 52], ["demyelination", "PROBLEM", 82, 95], ["dependent", "OBSERVATION_MODIFIER", 38, 47], ["BMDM", "OBSERVATION", 48, 52], ["CNS", "ANATOMY", 64, 67]]], ["Similar myelin loss at day 21 p.i. comparing WT and CCL2\u2212/\u2212 infected mice supported the concept that microglia mediate demyelination during JHMV infection.Characterization of BMDM and Microglia Under Homeostatic Conditions ::: ResultsWe next evaluated effector functions of BMDM versus microglia associated with JHMV-induced demyelination by comparing gene expression profiles using nCounter analysis of mRNA isolated from purified BMDM and microglia of infected CX3CR1GFP/+CCR2RFP/+ mice.", [["myelin", "ANATOMY", 8, 14], ["microglia", "ANATOMY", 101, 110], ["JHMV", "ANATOMY", 140, 144], ["BMDM", "ANATOMY", 274, 278], ["microglia", "ANATOMY", 286, 295], ["BMDM", "ANATOMY", 432, 436], ["microglia", "ANATOMY", 441, 450], ["myelin loss", "DISEASE", 8, 19], ["demyelination", "DISEASE", 119, 132], ["infection", "DISEASE", 145, 154], ["JHMV", "CHEMICAL", 312, 316], ["demyelination", "DISEASE", 325, 338], ["myelin", "GENE_OR_GENE_PRODUCT", 8, 14], ["CCL2\u2212", "GENE_OR_GENE_PRODUCT", 52, 57], ["\u2212", "GENE_OR_GENE_PRODUCT", 58, 59], ["mice", "ORGANISM", 69, 73], ["microglia", "CELL", 101, 110], ["JHMV", "CANCER", 140, 144], ["BMDM", "CELL", 175, 179], ["Microglia", "CELL", 184, 193], ["BMDM", "CELL", 274, 278], ["microglia", "CELL", 286, 295], ["JHMV", "CELL", 312, 316], ["BMDM", "CELL", 432, 436], ["microglia", "CELL", 441, 450], ["CX3CR1GFP", "GENE_OR_GENE_PRODUCT", 463, 472], ["CCR2RFP", "GENE_OR_GENE_PRODUCT", 474, 481], ["microglia", "CELL_TYPE", 101, 110], ["BMDM", "CELL_TYPE", 175, 179], ["Microglia", "CELL_TYPE", 184, 193], ["BMDM", "CELL_TYPE", 274, 278], ["microglia", "CELL_TYPE", 286, 295], ["mRNA", "RNA", 404, 408], ["BMDM", "CELL_TYPE", 432, 436], ["microglia", "CELL_TYPE", 441, 450], ["CCR2RFP", "PROTEIN", 474, 481], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 484, 488], ["mice", "SPECIES", 69, 73], ["JHMV", "SPECIES", 140, 144], ["mice", "SPECIES", 484, 488], ["Similar myelin loss", "PROBLEM", 0, 19], ["WT", "TEST", 45, 47], ["microglia mediate demyelination", "PROBLEM", 101, 132], ["JHMV infection", "PROBLEM", 140, 154], ["BMDM", "PROBLEM", 175, 179], ["BMDM", "PROBLEM", 274, 278], ["microglia", "PROBLEM", 286, 295], ["JHMV", "PROBLEM", 312, 316], ["induced demyelination", "PROBLEM", 317, 338], ["mRNA", "TEST", 404, 408], ["purified BMDM", "PROBLEM", 423, 436], ["infected CX3CR1GFP", "TEST", 454, 472], ["CCR2RFP", "TEST", 474, 481], ["myelin loss", "OBSERVATION", 8, 19], ["demyelination", "OBSERVATION", 119, 132], ["infection", "OBSERVATION", 145, 154], ["BMDM", "OBSERVATION", 175, 179], ["demyelination", "OBSERVATION", 325, 338]]], ["Characteristic expression of CX3CR1GFP and CCR2RFP on CD45highCD11b+ BMDM (population #1) and CD45lowCD11b+ microglia (population #2) is shown in Figure 2 throughout days 5\u201314 p.i.", [["CD45highCD11b+ BMDM", "ANATOMY", 54, 73], ["CD45lowCD11b+ microglia", "ANATOMY", 94, 117], ["CX3CR1GFP", "GENE_OR_GENE_PRODUCT", 29, 38], ["CCR2RFP", "GENE_OR_GENE_PRODUCT", 43, 50], ["CD45highCD11b", "GENE_OR_GENE_PRODUCT", 54, 67], ["CD45lowCD11b", "GENE_OR_GENE_PRODUCT", 94, 106], ["CX3CR1GFP", "PROTEIN", 29, 38], ["CCR2RFP", "PROTEIN", 43, 50], ["CD45highCD11b", "PROTEIN", 54, 67], ["BMDM", "CELL_TYPE", 69, 73], ["CD45lowCD11b", "CELL_LINE", 94, 106], ["microglia", "CELL_TYPE", 108, 117], ["CX3CR1GFP", "TEST", 29, 38], ["CCR2RFP", "TEST", 43, 50], ["CD45highCD11", "TEST", 54, 66], ["BMDM", "PROBLEM", 69, 73], ["CD45lowCD11b", "TEST", 94, 106], ["microglia", "ANATOMY", 108, 117]]], ["Microglia were characterized by high expression of CX3CR1 and undetectable CCR2 expression (Figures 2B,C) similar to other inflammatory models (17, 38).", [["Microglia", "ANATOMY", 0, 9], ["Microglia", "CELL", 0, 9], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 51, 57], ["CCR2", "GENE_OR_GENE_PRODUCT", 75, 79], ["Microglia", "CELL_TYPE", 0, 9], ["CX3CR1", "PROTEIN", 51, 57], ["CCR2", "PROTEIN", 75, 79], ["Microglia", "TEST", 0, 9], ["CX3CR1", "TEST", 51, 57], ["CCR2 expression", "TEST", 75, 90], ["Figures", "TEST", 92, 99], ["other inflammatory models", "TEST", 117, 142], ["high expression", "OBSERVATION_MODIFIER", 32, 47], ["CX3CR1", "OBSERVATION", 51, 57], ["undetectable", "OBSERVATION_MODIFIER", 62, 74], ["CCR2 expression", "OBSERVATION", 75, 90], ["inflammatory", "OBSERVATION_MODIFIER", 123, 135]]], ["In contrast, CNS infiltrating BMDM expressed CCR2 and low levels of CX3CR1 compared to microglia (Figure 2B).", [["CNS infiltrating BMDM", "ANATOMY", 13, 34], ["microglia", "ANATOMY", 87, 96], ["CNS infiltrating BMDM", "CELL", 13, 34], ["CCR2", "GENE_OR_GENE_PRODUCT", 45, 49], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 68, 74], ["microglia", "CELL", 87, 96], ["BMDM", "CELL_TYPE", 30, 34], ["CCR2", "PROTEIN", 45, 49], ["CX3CR1", "PROTEIN", 68, 74], ["microglia", "CELL_TYPE", 87, 96], ["CNS infiltrating BMDM", "PROBLEM", 13, 34], ["CCR2", "TEST", 45, 49], ["low levels of CX3CR1", "PROBLEM", 54, 74], ["CNS", "ANATOMY", 13, 16], ["infiltrating", "OBSERVATION", 17, 29], ["low levels", "OBSERVATION_MODIFIER", 54, 64]]], ["Co-expression of CCR2 and CX3CR1 was maintained on BMDM at all time points p.i. and no CX3CR1\u2212 cells were detectable (Figure 2C).Characterization of BMDM and Microglia Under Homeostatic Conditions ::: ResultsAs both microglia and infiltrating BMDM retained their phenotype throughout infection, CD45lowCD11b+CX3CR1GFPhiCCR2\u2212 and CD45hiCD11b+CX3CR1GFPlowCCR2+ populations were isolated by FACS from spinal cords at days 5, 7, 10, and 14 p.i. for subsequent mRNA expression analysis.", [["BMDM", "ANATOMY", 51, 55], ["CX3CR1\u2212 cells", "ANATOMY", 87, 100], ["BMDM", "ANATOMY", 149, 153], ["microglia", "ANATOMY", 216, 225], ["BMDM", "ANATOMY", 243, 247], ["CD45lowCD11b+CX3CR1GFPhiCCR2\u2212", "ANATOMY", 295, 324], ["CD45hiCD11b+CX3CR1GFPlowCCR2+ populations", "ANATOMY", 329, 370], ["spinal cords", "ANATOMY", 398, 410], ["infection", "DISEASE", 284, 293], ["CCR2", "GENE_OR_GENE_PRODUCT", 17, 21], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 26, 32], ["BMDM", "CELL", 51, 55], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 87, 93], ["BMDM", "CELL", 149, 153], ["Microglia", "CELL", 158, 167], ["microglia", "CELL", 216, 225], ["BMDM", "CELL", 243, 247], ["CD45lowCD11b", "GENE_OR_GENE_PRODUCT", 295, 307], ["CX3CR1GFPhiCCR2", "GENE_OR_GENE_PRODUCT", 308, 323], ["CD45hiCD11b", "GENE_OR_GENE_PRODUCT", 329, 340], ["spinal cords", "MULTI-TISSUE_STRUCTURE", 398, 410], ["CCR2", "PROTEIN", 17, 21], ["CX3CR1", "PROTEIN", 26, 32], ["BMDM", "CELL_TYPE", 51, 55], ["CX3CR1", "PROTEIN", 87, 93], ["BMDM", "CELL_TYPE", 149, 153], ["Microglia", "CELL_TYPE", 158, 167], ["microglia", "CELL_TYPE", 216, 225], ["BMDM", "CELL_TYPE", 243, 247], ["CX3CR1GFPhiCCR2", "PROTEIN", 308, 323], ["CX3CR1GFPlowCCR2", "PROTEIN", 341, 357], ["CCR2", "TEST", 17, 21], ["CX3CR1", "TEST", 26, 32], ["CX3CR1\u2212 cells", "TEST", 87, 100], ["BMDM", "PROBLEM", 149, 153], ["infiltrating BMDM", "PROBLEM", 230, 247], ["their phenotype throughout infection", "PROBLEM", 257, 293], ["CD45lowCD11", "TEST", 295, 306], ["CX3CR1GFPhiCCR2", "TEST", 308, 323], ["CD45hiCD11", "TEST", 329, 339], ["CX3CR1GFPlowCCR2", "TEST", 341, 357], ["populations", "PROBLEM", 359, 370], ["subsequent mRNA expression analysis", "TEST", 445, 480], ["CCR2", "ANATOMY", 17, 21], ["no", "UNCERTAINTY", 84, 86], ["BMDM", "OBSERVATION", 149, 153], ["infiltrating BMDM", "OBSERVATION", 230, 247], ["infection", "OBSERVATION", 284, 293], ["spinal cords", "ANATOMY", 398, 410]]], ["Age-matched na\u00efve animals were used to isolate microglia and blood circulating monocytes as precursors of CNS-infiltrating BMDM.", [["microglia", "ANATOMY", 47, 56], ["blood", "ANATOMY", 61, 66], ["monocytes", "ANATOMY", 79, 88], ["CNS", "ANATOMY", 106, 109], ["BMDM", "ANATOMY", 123, 127], ["animals", "ORGANISM", 18, 25], ["microglia", "CELL", 47, 56], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["monocytes", "CELL", 79, 88], ["CNS-infiltrating BMDM", "CELL", 106, 127], ["microglia", "CELL_TYPE", 47, 56], ["blood circulating monocytes", "CELL_TYPE", 61, 88], ["infiltrating BMDM", "CELL_TYPE", 110, 127], ["matched na\u00efve animals", "PROBLEM", 4, 25], ["microglia", "TEST", 47, 56], ["blood circulating monocytes", "TEST", 61, 88], ["infiltrating BMDM", "PROBLEM", 110, 127], ["CNS", "ANATOMY", 106, 109], ["infiltrating BMDM", "OBSERVATION", 110, 127]]], ["Gene expression profiles for all purified populations were obtained using nCounter analysis and the Innate Myeloid Immune panel.", [["Gene expression profiles", "TEST", 0, 24], ["all purified populations", "TEST", 29, 53], ["nCounter analysis", "TEST", 74, 91], ["the Innate Myeloid Immune panel", "TEST", 96, 127]]], ["The respective na\u00efve populations were used to assess signature gene expression profiles under homeostatic conditions (Figure 3).Characterization of BMDM and Microglia Under Homeostatic Conditions ::: ResultsFigure 3A shows the top 50 highly expressed genes within each population relative to three nCounter platform housekeeping genes, namely G6pdx, Polr1b, and Tbp, selected for three high, medium, and low expression, respectively, in this part of analysis platform.", [["BMDM", "CELL", 148, 152], ["Microglia", "CELL", 157, 166], ["G6pdx", "GENE_OR_GENE_PRODUCT", 343, 348], ["Polr1b", "GENE_OR_GENE_PRODUCT", 350, 356], ["Tbp", "GENE_OR_GENE_PRODUCT", 362, 365], ["na\u00efve populations", "CELL_LINE", 15, 32], ["BMDM", "CELL_TYPE", 148, 152], ["Microglia", "CELL_TYPE", 157, 166], ["nCounter platform housekeeping genes", "DNA", 298, 334], ["G6pdx", "DNA", 343, 348], ["Polr1b", "DNA", 350, 356], ["Tbp", "DNA", 362, 365], ["The respective na\u00efve populations", "TREATMENT", 0, 32], ["BMDM", "PROBLEM", 148, 152], ["Tbp", "TEST", 362, 365], ["BMDM", "OBSERVATION", 148, 152], ["low expression", "OBSERVATION_MODIFIER", 404, 418]]], ["Figure 3B lists the top 50 enriched genes specific for microglia compared to monocytes, or monocytes versus microglia, respectively.", [["microglia", "ANATOMY", 55, 64], ["monocytes", "ANATOMY", 77, 86], ["monocytes", "ANATOMY", 91, 100], ["microglia", "ANATOMY", 108, 117], ["microglia", "CELL", 55, 64], ["monocytes", "CELL", 77, 86], ["monocytes", "CELL", 91, 100], ["microglia", "CELL", 108, 117], ["top 50 enriched genes", "DNA", 20, 41], ["microglia", "CELL_TYPE", 55, 64], ["monocytes", "CELL_TYPE", 77, 86], ["monocytes", "CELL_TYPE", 91, 100], ["microglia", "CELL_TYPE", 108, 117], ["microglia", "PROBLEM", 55, 64], ["monocytes", "TEST", 77, 86], ["monocytes", "PROBLEM", 91, 100], ["microglia", "TEST", 108, 117], ["monocytes", "OBSERVATION", 91, 100]]], ["Among the top 50 genes highly expressed in microglia, 15 were also specific and included genes of the complement cascade (C1qa, C1qb, C1qc, and C3ar1) and Trem2, encoding a cell surface receptor involved in phagocytic functions and known to be expressed by microglia (39).", [["microglia", "ANATOMY", 43, 52], ["cell surface", "ANATOMY", 173, 185], ["microglia", "ANATOMY", 257, 266], ["microglia", "CELL", 43, 52], ["C1qa", "GENE_OR_GENE_PRODUCT", 122, 126], ["C1qb", "GENE_OR_GENE_PRODUCT", 128, 132], ["C1qc", "GENE_OR_GENE_PRODUCT", 134, 138], ["C3ar1", "GENE_OR_GENE_PRODUCT", 144, 149], ["Trem2", "GENE_OR_GENE_PRODUCT", 155, 160], ["cell", "CELL", 173, 177], ["microglia", "CELL", 257, 266], ["microglia", "CELL_TYPE", 43, 52], ["C1qa", "PROTEIN", 122, 126], ["C1qb", "PROTEIN", 128, 132], ["C1qc", "PROTEIN", 134, 138], ["C3ar1", "DNA", 144, 149], ["Trem2", "DNA", 155, 160], ["cell surface receptor", "PROTEIN", 173, 194], ["microglia", "CELL_TYPE", 257, 266], ["the complement cascade", "PROBLEM", 98, 120], ["Trem2", "PROBLEM", 155, 160], ["a cell surface receptor", "TREATMENT", 171, 194]]], ["Other genes, such as Adamts1, F11r or Hpgds, found within the top 50 enriched genes expressed by microglia (Figure 3B) were also previously described as microglia specific (17, 40).", [["microglia", "ANATOMY", 97, 106], ["microglia", "ANATOMY", 153, 162], ["Adamts1", "GENE_OR_GENE_PRODUCT", 21, 28], ["F11r", "GENE_OR_GENE_PRODUCT", 30, 34], ["Hpgds", "GENE_OR_GENE_PRODUCT", 38, 43], ["microglia", "CELL", 97, 106], ["Figure 3B", "GENE_OR_GENE_PRODUCT", 108, 117], ["microglia", "CELL", 153, 162], ["Adamts1", "DNA", 21, 28], ["F11r", "DNA", 30, 34], ["Hpgds", "DNA", 38, 43], ["top 50 enriched genes", "DNA", 62, 83], ["microglia", "CELL_TYPE", 97, 106], ["microglia", "CELL_TYPE", 153, 162], ["microglia", "ANATOMY", 97, 106]]], ["Cx3cr1 mRNA encoding the fractalkine receptor and used as a marker for microglia (41), was also among the top 50 highly expressed genes (Figure 3A), but not unique, consistent with the CX3CR1lo phenotype on circulating monocytes.", [["microglia", "ANATOMY", 71, 80], ["monocytes", "ANATOMY", 219, 228], ["Cx3cr1", "GENE_OR_GENE_PRODUCT", 0, 6], ["fractalkine receptor", "GENE_OR_GENE_PRODUCT", 25, 45], ["microglia (41)", "GENE_OR_GENE_PRODUCT", 71, 85], ["CX3CR1lo", "GENE_OR_GENE_PRODUCT", 185, 193], ["monocytes", "CELL", 219, 228], ["Cx3cr1 mRNA", "RNA", 0, 11], ["fractalkine receptor", "PROTEIN", 25, 45], ["microglia", "CELL_TYPE", 71, 80], ["circulating monocytes", "CELL_TYPE", 207, 228], ["the fractalkine receptor", "TREATMENT", 21, 45], ["the CX3CR1lo phenotype on circulating monocytes", "PROBLEM", 181, 228], ["consistent with", "UNCERTAINTY", 165, 180], ["circulating monocytes", "OBSERVATION", 207, 228]]], ["Similarly, CCR2 expression characteristic of monocytes was confirmed by ccr2 mRNA as the second in place of the top 50 expressed genes specific for circulating monocytes (Figure 3B).", [["monocytes", "ANATOMY", 45, 54], ["monocytes", "ANATOMY", 160, 169], ["CCR2", "GENE_OR_GENE_PRODUCT", 11, 15], ["monocytes", "CELL", 45, 54], ["ccr2", "GENE_OR_GENE_PRODUCT", 72, 76], ["monocytes", "CELL", 160, 169], ["CCR2", "PROTEIN", 11, 15], ["monocytes", "CELL_TYPE", 45, 54], ["ccr2 mRNA", "RNA", 72, 81], ["top 50 expressed genes", "DNA", 112, 134], ["circulating monocytes", "CELL_TYPE", 148, 169], ["monocytes", "PROBLEM", 45, 54], ["ccr2 mRNA", "TEST", 72, 81], ["circulating monocytes", "TEST", 148, 169], ["monocytes", "OBSERVATION", 45, 54]]], ["Other specific signature genes of monocytes are related to motility and migration/tissue invasion, e.g., S100a4, S100a8, S100a9, Fn1, Sema4, Mmp8, and to a lesser extent MHC class II antigen presentation, e.g., H2-Ab1, CD74, and Fas.", [["monocytes", "ANATOMY", 34, 43], ["tissue", "ANATOMY", 82, 88], ["monocytes", "CELL", 34, 43], ["tissue", "TISSUE", 82, 88], ["S100a4", "GENE_OR_GENE_PRODUCT", 105, 111], ["S100a8", "GENE_OR_GENE_PRODUCT", 113, 119], ["S100a9", "GENE_OR_GENE_PRODUCT", 121, 127], ["Fn1", "GENE_OR_GENE_PRODUCT", 129, 132], ["Sema4", "GENE_OR_GENE_PRODUCT", 134, 139], ["Mmp8", "GENE_OR_GENE_PRODUCT", 141, 145], ["MHC class II antigen", "GENE_OR_GENE_PRODUCT", 170, 190], ["H2-Ab1", "GENE_OR_GENE_PRODUCT", 211, 217], ["CD74", "GENE_OR_GENE_PRODUCT", 219, 223], ["Fas", "GENE_OR_GENE_PRODUCT", 229, 232], ["monocytes", "CELL_TYPE", 34, 43], ["S100a4", "PROTEIN", 105, 111], ["S100a8", "PROTEIN", 113, 119], ["S100a9", "PROTEIN", 121, 127], ["Fn1", "PROTEIN", 129, 132], ["Sema4", "PROTEIN", 134, 139], ["Mmp8", "PROTEIN", 141, 145], ["MHC class II antigen", "PROTEIN", 170, 190], ["H2", "PROTEIN", 211, 213], ["Ab1", "PROTEIN", 214, 217], ["CD74", "PROTEIN", 219, 223], ["Fas", "PROTEIN", 229, 232], ["monocytes", "PROBLEM", 34, 43], ["migration/tissue invasion", "TEST", 72, 97], ["S100a4", "TEST", 105, 111], ["S100a8", "TEST", 113, 119], ["S100a9", "TEST", 121, 127], ["Fn1", "TEST", 129, 132], ["Sema4", "TEST", 134, 139], ["Mmp8", "TEST", 141, 145], ["H2", "TEST", 211, 213], ["Ab1", "TEST", 214, 217], ["CD74", "TEST", 219, 223], ["Fas", "TEST", 229, 232], ["monocytes", "OBSERVATION", 34, 43], ["tissue", "ANATOMY", 82, 88], ["invasion", "OBSERVATION", 89, 97]]], ["Microglia and circulating monocytes also shared 17 highly expressed genes, including genes characteristic of the myeloid lineage such as Csf1r, a gene coding for a cell surface receptor essential for hematopoietic precursors differentiation into myeloid cells and Mpeg1, a gene coding for a membrane protein with a perforin domain expressed on myeloid cells (Figure 3A).", [["Microglia", "ANATOMY", 0, 9], ["monocytes", "ANATOMY", 26, 35], ["myeloid lineage", "ANATOMY", 113, 128], ["cell surface", "ANATOMY", 164, 176], ["hematopoietic precursors", "ANATOMY", 200, 224], ["myeloid cells", "ANATOMY", 246, 259], ["membrane", "ANATOMY", 291, 299], ["myeloid cells", "ANATOMY", 344, 357], ["Microglia", "CELL", 0, 9], ["monocytes", "CELL", 26, 35], ["myeloid lineage", "CELL", 113, 128], ["Csf1r", "GENE_OR_GENE_PRODUCT", 137, 142], ["cell", "CELL", 164, 168], ["myeloid cells", "CELL", 246, 259], ["Mpeg1", "GENE_OR_GENE_PRODUCT", 264, 269], ["membrane", "CELLULAR_COMPONENT", 291, 299], ["perforin", "GENE_OR_GENE_PRODUCT", 315, 323], ["myeloid cells", "CELL", 344, 357], ["Figure 3A", "CELL", 359, 368], ["Microglia", "CELL_TYPE", 0, 9], ["circulating monocytes", "CELL_TYPE", 14, 35], ["myeloid lineage", "CELL_TYPE", 113, 128], ["Csf1r", "DNA", 137, 142], ["cell surface receptor", "PROTEIN", 164, 185], ["hematopoietic precursors", "CELL_TYPE", 200, 224], ["myeloid cells", "CELL_TYPE", 246, 259], ["Mpeg1", "PROTEIN", 264, 269], ["membrane protein", "PROTEIN", 291, 307], ["perforin domain", "PROTEIN", 315, 330], ["myeloid cells", "CELL_TYPE", 344, 357], ["Microglia", "TEST", 0, 9], ["circulating monocytes", "TEST", 14, 35], ["a cell surface receptor", "TEST", 162, 185], ["hematopoietic precursors differentiation into myeloid cells", "PROBLEM", 200, 259], ["a membrane protein", "TREATMENT", 289, 307], ["a perforin domain", "TREATMENT", 313, 330], ["circulating monocytes", "OBSERVATION", 14, 35], ["myeloid lineage", "OBSERVATION", 113, 128], ["myeloid cells", "OBSERVATION", 246, 259], ["myeloid cells", "OBSERVATION", 344, 357]]], ["Altogether, these results highlight unique as well as common basal expression signatures of each purified myeloid population, thus providing a basis for characterization of altered expression patterns following JHMV infection.BMDM and Microglia Display Overall Distinct Patterns of Gene Expression as Well as Temporal Regulation Throughout JHMV Infection ::: ResultsFollowing JHMV infection, the majority of commonly expressed genes in microglia and circulating monocytes were regulated similarly within the CNS over time.", [["myeloid population", "ANATOMY", 106, 124], ["microglia", "ANATOMY", 436, 445], ["monocytes", "ANATOMY", 462, 471], ["CNS", "ANATOMY", 508, 511], ["infection", "DISEASE", 216, 225], ["JHMV infection", "DISEASE", 376, 390], ["myeloid population", "CELL", 106, 124], ["JHMV", "GENE_OR_GENE_PRODUCT", 211, 215], ["BMDM", "CELL", 226, 230], ["Microglia", "CELL", 235, 244], ["microglia", "CELL", 436, 445], ["monocytes", "CELL", 462, 471], ["CNS", "ANATOMICAL_SYSTEM", 508, 511], ["purified myeloid population", "CELL_TYPE", 97, 124], ["BMDM", "CELL_TYPE", 226, 230], ["microglia", "CELL_TYPE", 436, 445], ["circulating monocytes", "CELL_TYPE", 450, 471], ["JHMV", "SPECIES", 211, 215], ["JHMV", "SPECIES", 376, 380], ["altered expression patterns", "PROBLEM", 173, 200], ["JHMV infection", "PROBLEM", 211, 225], ["BMDM", "PROBLEM", 226, 230], ["Gene Expression", "PROBLEM", 282, 297], ["JHMV infection", "PROBLEM", 376, 390], ["commonly expressed genes in microglia and circulating monocytes", "PROBLEM", 408, 471], ["myeloid population", "OBSERVATION", 106, 124], ["infection", "OBSERVATION", 216, 225], ["Gene Expression", "OBSERVATION", 282, 297], ["Infection", "OBSERVATION", 345, 354], ["infection", "OBSERVATION", 381, 390], ["microglia", "ANATOMY", 436, 445], ["circulating monocytes", "OBSERVATION", 450, 471]]], ["For example, Selpig mRNA was downregulated at all time points during JHMV infection, while Apoe was specifically upregulated at days 10 and 14 p.i. in both BMDM and microglia (Figure 4A).", [["BMDM", "ANATOMY", 156, 160], ["microglia", "ANATOMY", 165, 174], ["infection", "DISEASE", 74, 83], ["Selpig", "GENE_OR_GENE_PRODUCT", 13, 19], ["JHMV", "GENE_OR_GENE_PRODUCT", 69, 73], ["Apoe", "GENE_OR_GENE_PRODUCT", 91, 95], ["BMDM", "CELL", 156, 160], ["microglia", "CELL", 165, 174], ["Selpig mRNA", "RNA", 13, 24], ["Apoe", "PROTEIN", 91, 95], ["BMDM", "CELL_TYPE", 156, 160], ["microglia", "CELL_TYPE", 165, 174], ["JHMV", "SPECIES", 69, 73], ["Selpig mRNA", "PROBLEM", 13, 24], ["JHMV infection", "PROBLEM", 69, 83], ["infection", "OBSERVATION", 74, 83]]], ["Ctss mRNA, encoding for Cathepsin S, a lysosomal cysteine proteinase participating in the MHC Class II molecule antigen presentation pathway as well as nociception (42, 43), was specifically upregulated within BMDM, with highest levels observed at days 10 and 14 p.i.", [["BMDM", "ANATOMY", 210, 214], ["cysteine", "CHEMICAL", 49, 57], ["Ctss", "GENE_OR_GENE_PRODUCT", 0, 4], ["Cathepsin S", "GENE_OR_GENE_PRODUCT", 24, 35], ["lysosomal cysteine proteinase", "GENE_OR_GENE_PRODUCT", 39, 68], ["BMDM", "CELL", 210, 214], ["Ctss mRNA", "RNA", 0, 9], ["Cathepsin S", "PROTEIN", 24, 35], ["lysosomal cysteine proteinase", "PROTEIN", 39, 68], ["MHC Class II molecule", "PROTEIN", 90, 111], ["BMDM", "CELL_TYPE", 210, 214], ["Cathepsin S", "TEST", 24, 35], ["a lysosomal cysteine proteinase", "TREATMENT", 37, 68], ["nociception", "TEST", 152, 163]]], ["(Figure 4A), when demyelination increases.", [["demyelination", "DISEASE", 18, 31], ["demyelination", "PROBLEM", 18, 31]]], ["By contrast, microglia transiently downregulated Ctss mRNA at day 7 p.i.", [["microglia", "ANATOMY", 13, 22], ["microglia", "CELL", 13, 22], ["Ctss", "GENE_OR_GENE_PRODUCT", 49, 53], ["microglia", "CELL_TYPE", 13, 22], ["Ctss mRNA", "RNA", 49, 58]]], ["Opposite regulation was also observed for Dusp1 mRNA (Figure 4A).", [["Dusp1", "GENE_OR_GENE_PRODUCT", 42, 47], ["Dusp1 mRNA", "RNA", 42, 52]]], ["Dusp1 mRNA encodes the dual specificity protein phosphatase 1, an enzyme involved in the cellular stress response and a negative regulator of cell proliferation (44).", [["cellular", "ANATOMY", 89, 97], ["cell", "ANATOMY", 142, 146], ["Dusp1", "GENE_OR_GENE_PRODUCT", 0, 5], ["protein phosphatase 1", "GENE_OR_GENE_PRODUCT", 40, 61], ["cellular", "CELL", 89, 97], ["cell", "CELL", 142, 146], ["Dusp1 mRNA", "RNA", 0, 10], ["dual specificity protein phosphatase 1", "PROTEIN", 23, 61], ["Dusp1 mRNA", "TEST", 0, 10], ["the dual specificity protein phosphatase", "TEST", 19, 59], ["an enzyme", "TEST", 63, 72], ["cell proliferation", "TEST", 142, 160], ["cellular stress response", "OBSERVATION", 89, 113], ["cell proliferation", "OBSERVATION", 142, 160]]], ["While Dusp1 mRNA levels were vastly upregulated early following BMDM accumulation, but declined by day 7 p.i. and thereafter, levels were rapidly downregulated within microglia (Figure 4B).", [["microglia", "ANATOMY", 167, 176], ["Dusp1", "GENE_OR_GENE_PRODUCT", 6, 11], ["BMDM", "CELL", 64, 68], ["microglia", "CELL", 167, 176], ["Dusp1 mRNA", "RNA", 6, 16], ["microglia", "CELL_TYPE", 167, 176], ["Dusp1 mRNA levels", "TEST", 6, 23], ["BMDM accumulation", "PROBLEM", 64, 81], ["levels", "TEST", 126, 132]]], ["Finally, Tyrobp mRNA encoding for the TREM2 adaptor DAP12 and known to regulate microglia phagocytic functions (39), was downregulated in BMDM throughout infection, but specifically upregulated within microglia at days 10 and 14 p.i.", [["microglia", "ANATOMY", 80, 89], ["BMDM", "ANATOMY", 138, 142], ["microglia", "ANATOMY", 201, 210], ["infection", "DISEASE", 154, 163], ["Tyrobp", "GENE_OR_GENE_PRODUCT", 9, 15], ["TREM2", "GENE_OR_GENE_PRODUCT", 38, 43], ["DAP12", "GENE_OR_GENE_PRODUCT", 52, 57], ["microglia", "CELL", 80, 89], ["BMDM", "CELL", 138, 142], ["microglia", "CELL", 201, 210], ["Tyrobp mRNA", "RNA", 9, 20], ["TREM2 adaptor", "PROTEIN", 38, 51], ["DAP12", "PROTEIN", 52, 57], ["BMDM", "CELL_TYPE", 138, 142], ["microglia", "CELL_TYPE", 201, 210], ["the TREM2 adaptor DAP12", "TREATMENT", 34, 57], ["microglia phagocytic functions", "TEST", 80, 110], ["BMDM throughout infection", "PROBLEM", 138, 163], ["microglia phagocytic", "OBSERVATION", 80, 100], ["infection", "OBSERVATION", 154, 163]]], ["This expression pattern on microglia correlated with the onset of myelin loss and supported TREM2 signaling specifically by microglia in response to tissue damage.BMDM and Microglia Display Overall Distinct Patterns of Gene Expression as Well as Temporal Regulation Throughout JHMV Infection ::: ResultsTo determine whether apparently differential functions of BMDM and microglia associated with JHMV-induced demyelination are reflected in distinct gene profiles, we monitored overall up- and downregulation of gene expression relative to basal levels in each population.", [["microglia", "ANATOMY", 27, 36], ["myelin", "ANATOMY", 66, 72], ["microglia", "ANATOMY", 124, 133], ["tissue", "ANATOMY", 149, 155], ["microglia", "ANATOMY", 370, 379], ["myelin loss", "DISEASE", 66, 77], ["tissue damage", "DISEASE", 149, 162], ["JHMV", "CHEMICAL", 396, 400], ["demyelination", "DISEASE", 409, 422], ["microglia", "CELL", 27, 36], ["myelin", "GENE_OR_GENE_PRODUCT", 66, 72], ["TREM2", "GENE_OR_GENE_PRODUCT", 92, 97], ["microglia", "CELL", 124, 133], ["tissue", "TISSUE", 149, 155], ["BMDM", "CELL", 163, 167], ["Microglia", "CELL", 172, 181], ["BMDM", "CELL", 361, 365], ["microglia", "CELL", 370, 379], ["JHMV", "GENE_OR_GENE_PRODUCT", 396, 400], ["microglia", "CELL_TYPE", 27, 36], ["TREM2", "PROTEIN", 92, 97], ["microglia", "CELL_TYPE", 124, 133], ["BMDM", "CELL_TYPE", 163, 167], ["BMDM", "CELL_TYPE", 361, 365], ["microglia", "CELL_TYPE", 370, 379], ["myelin loss", "PROBLEM", 66, 77], ["TREM2 signaling", "PROBLEM", 92, 107], ["tissue damage", "PROBLEM", 149, 162], ["BMDM", "PROBLEM", 163, 167], ["Gene Expression", "PROBLEM", 219, 234], ["BMDM", "PROBLEM", 361, 365], ["microglia", "PROBLEM", 370, 379], ["JHMV", "PROBLEM", 396, 400], ["induced demyelination", "PROBLEM", 401, 422], ["gene expression", "PROBLEM", 511, 526], ["myelin loss", "OBSERVATION", 66, 77], ["TREM2", "OBSERVATION", 92, 97], ["Gene Expression", "OBSERVATION", 219, 234], ["Infection", "OBSERVATION", 282, 291], ["demyelination", "OBSERVATION", 409, 422]]], ["Analysis times were chosen to correlate with innate responses (d5 p.i.), peak T cell effector function (d7 p.i.), resolution of infection and initiation of demyelination (d10 p.i.), and finally viral clearance and overt demyelination (d14 p.i.).", [["T cell", "ANATOMY", 78, 84], ["infection", "DISEASE", 128, 137], ["demyelination", "DISEASE", 156, 169], ["demyelination", "DISEASE", 220, 233], ["T cell", "CELL", 78, 84], ["Analysis", "TEST", 0, 8], ["infection", "PROBLEM", 128, 137], ["demyelination", "PROBLEM", 156, 169], ["overt demyelination", "PROBLEM", 214, 233], ["infection", "OBSERVATION", 128, 137], ["demyelination", "OBSERVATION", 220, 233]]], ["At day 5 p.i. a higher number of genes were differentially regulated within infiltrating BMDM compared to microglia (231 versus 76; Figure 5A).", [["BMDM", "ANATOMY", 89, 93], ["microglia", "ANATOMY", 106, 115], ["BMDM", "CELL", 89, 93], ["microglia", "CELL", 106, 115], ["infiltrating BMDM", "CELL_TYPE", 76, 93], ["microglia", "CELL_TYPE", 106, 115], ["infiltrating BMDM", "PROBLEM", 76, 93], ["microglia", "TEST", 106, 115], ["infiltrating BMDM", "OBSERVATION", 76, 93]]], ["Moreover, almost 80% of the genes showing altered expression in early infiltrated BMDM were increased compared to basal levels, while only 54% were increased in microglia; the remaining differentially expressed mRNAs were decreased (Figure 5B).", [["BMDM", "ANATOMY", 82, 86], ["microglia", "ANATOMY", 161, 170], ["BMDM", "CELL", 82, 86], ["microglia", "CELL", 161, 170], ["BMDM", "CELL_TYPE", 82, 86], ["microglia", "CELL_TYPE", 161, 170], ["mRNAs", "RNA", 211, 216], ["altered expression", "PROBLEM", 42, 60], ["early infiltrated BMDM", "PROBLEM", 64, 86], ["basal levels", "TEST", 114, 126], ["altered", "OBSERVATION_MODIFIER", 42, 49], ["expression", "OBSERVATION_MODIFIER", 50, 60], ["early", "OBSERVATION_MODIFIER", 64, 69], ["infiltrated BMDM", "OBSERVATION", 70, 86], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["increased", "OBSERVATION_MODIFIER", 148, 157], ["decreased", "OBSERVATION_MODIFIER", 222, 231]]], ["The overall number of differentially expressed genes slightly declined in BMDM by day 7 p.i., when T cells exert maximal effector function (37), and remained fairly constant throughout day 14 p.i.", [["BMDM", "ANATOMY", 74, 78], ["T cells", "ANATOMY", 99, 106], ["BMDM", "CELL", 74, 78], ["T cells", "CELL", 99, 106], ["BMDM", "CELL_TYPE", 74, 78], ["T cells", "CELL_TYPE", 99, 106], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["genes", "OBSERVATION_MODIFIER", 47, 52], ["slightly", "OBSERVATION_MODIFIER", 53, 61], ["declined", "OBSERVATION_MODIFIER", 62, 70], ["fairly", "OBSERVATION_MODIFIER", 158, 164], ["constant", "OBSERVATION", 165, 173]]], ["Furthermore, the relative decline in the proportion of upregulated mRNAs coincided with an increased proportion of downregulated genes, reaching a roughly equal distribution at days 10\u201314 p.i., when virus is largely controlled (Figure 5B).", [["upregulated mRNAs", "RNA", 55, 72], ["downregulated genes", "DNA", 115, 134], ["the relative decline", "PROBLEM", 13, 33], ["upregulated mRNAs", "PROBLEM", 55, 72], ["downregulated genes", "PROBLEM", 115, 134], ["virus", "PROBLEM", 199, 204], ["relative", "OBSERVATION_MODIFIER", 17, 25], ["decline", "OBSERVATION_MODIFIER", 26, 33], ["upregulated mRNAs", "OBSERVATION", 55, 72], ["increased", "OBSERVATION_MODIFIER", 91, 100], ["proportion", "OBSERVATION_MODIFIER", 101, 111], ["downregulated genes", "OBSERVATION", 115, 134]]], ["In contrast, microglia altered their gene expression pattern extensively at day 7 p.i.", [["microglia", "ANATOMY", 13, 22], ["microglia", "CELL", 13, 22], ["microglia", "CELL_TYPE", 13, 22]]], ["(97 genes, Figure 5A) with 67% of differentially regulated genes showing increases (Figure 5B).", [["differentially regulated genes", "DNA", 34, 64], ["Figure 5A", "TEST", 11, 20], ["differentially regulated genes", "PROBLEM", 34, 64]]], ["By day 10 p.i., overall altered gene expression remained stable relative to day 7 p.i., with equal proportions showing increases and decreases.", [["overall altered gene expression", "PROBLEM", 16, 47], ["stable", "OBSERVATION_MODIFIER", 57, 63], ["increases", "OBSERVATION_MODIFIER", 119, 128], ["decreases", "OBSERVATION_MODIFIER", 133, 142]]], ["However, as myelin loss progresses by day 14 p.i., differentially regulated genes increased again in numbers, with the proportion of upregulated mRNAs reaching 95% (Figure 5A).", [["myelin", "ANATOMY", 12, 18], ["myelin loss", "DISEASE", 12, 23], ["myelin", "GENE_OR_GENE_PRODUCT", 12, 18], ["upregulated mRNAs", "RNA", 133, 150], ["myelin loss", "PROBLEM", 12, 23], ["upregulated mRNAs", "PROBLEM", 133, 150], ["genes", "OBSERVATION_MODIFIER", 76, 81], ["increased", "OBSERVATION_MODIFIER", 82, 91]]], ["Altogether these data show unique regulation of gene profiles in BMDM compared to microglia throughout the course of infection.", [["BMDM", "ANATOMY", 65, 69], ["microglia", "ANATOMY", 82, 91], ["infection", "DISEASE", 117, 126], ["BMDM", "CELL", 65, 69], ["microglia", "CELL", 82, 91], ["BMDM", "CELL_TYPE", 65, 69], ["microglia", "CELL_TYPE", 82, 91], ["these data", "TEST", 11, 21], ["gene profiles in BMDM", "PROBLEM", 48, 69], ["infection", "PROBLEM", 117, 126], ["infection", "OBSERVATION", 117, 126]]], ["While most changes were evident in BMDM following initial CNS accumulation, microglia revealed most pronounced changes at the time of myelin loss.BMDM and Microglia Display Overall Distinct Patterns of Gene Expression as Well as Temporal Regulation Throughout JHMV Infection ::: ResultsWe further analyzed differential gene expression across time points focusing on upregulated genes using Venn diagrams to reveal the relative proportion of genes that were commonly increased at all time points (Figure 5C).", [["CNS", "ANATOMY", 58, 61], ["microglia", "ANATOMY", 76, 85], ["myelin", "ANATOMY", 134, 140], ["myelin loss", "DISEASE", 134, 145], ["BMDM", "CELL", 35, 39], ["CNS", "ANATOMICAL_SYSTEM", 58, 61], ["microglia", "CELL", 76, 85], ["myelin", "GENE_OR_GENE_PRODUCT", 134, 140], ["BMDM", "CELL", 146, 150], ["Microglia", "CELL", 155, 164], ["BMDM", "CELL_TYPE", 35, 39], ["microglia", "CELL_TYPE", 76, 85], ["BMDM", "CELL_TYPE", 146, 150], ["upregulated genes", "DNA", 366, 383], ["Venn diagrams", "DNA", 390, 403], ["initial CNS accumulation", "PROBLEM", 50, 74], ["microglia", "PROBLEM", 76, 85], ["most pronounced changes", "PROBLEM", 95, 118], ["myelin loss", "PROBLEM", 134, 145], ["BMDM", "PROBLEM", 146, 150], ["Gene Expression", "PROBLEM", 202, 217], ["Venn diagrams", "TEST", 390, 403], ["most pronounced", "OBSERVATION_MODIFIER", 95, 110], ["myelin loss", "OBSERVATION", 134, 145], ["Gene Expression", "OBSERVATION", 202, 217], ["Infection", "OBSERVATION", 265, 274]]], ["Of the 183 upregulated genes in BMDM at day 5 p.i., 62 were unique to day 5.", [["BMDM", "ANATOMY", 32, 36], ["BMDM", "CELL", 32, 36], ["BMDM", "CELL_TYPE", 32, 36]]], ["On the other hand, 77 genes (representing 42% of all upregulated genes) remained highly expressed at all other time points (Figure 5C).", [["77 genes", "DNA", 19, 27], ["upregulated genes", "DNA", 53, 70]]], ["Similarly, only 4 gene transcripts were specifically elevated at day 10 p.i., 7 were unique to both days 10 and 14, and only one was unique to day 14 p.i.", [["elevated", "OBSERVATION_MODIFIER", 53, 61]]], ["These results indicate that the gene expression profile characterizing BMDM is established early following infection, with sparse unique alterations as BMDM decline during infection.", [["infection", "DISEASE", 107, 116], ["infection", "DISEASE", 172, 181], ["BMDM", "CELL", 71, 75], ["BMDM", "CELL", 152, 156], ["BMDM", "CELL_TYPE", 71, 75], ["the gene expression profile characterizing BMDM", "PROBLEM", 28, 75], ["infection", "PROBLEM", 107, 116], ["sparse unique alterations", "PROBLEM", 123, 148], ["BMDM decline during infection", "PROBLEM", 152, 181], ["infection", "OBSERVATION", 107, 116], ["infection", "OBSERVATION", 172, 181]]], ["In stark contrast, only 3 of 41 gene transcripts upregulated in microglia at day 5 p.i. were unique to day 5, and no gene transcript was commonly upregulated across all time points analyzed.", [["microglia", "ANATOMY", 64, 73], ["microglia", "CELL", 64, 73], ["41 gene transcripts", "RNA", 29, 48], ["microglia", "CELL_TYPE", 64, 73], ["gene transcript", "PROBLEM", 117, 132]]], ["Furthermore, distinct from BMDM, 59 gene transcripts were uniquely upregulated by day 7 p.i., with none common to day 10 p.i., and only six overlapping with those upregulated at day 14 p.i.", [["BMDM", "CELL", 27, 31], ["BMDM", "CELL_TYPE", 27, 31], ["59 gene transcripts", "RNA", 33, 52]]], ["Although no gene transcripts were upregulated uniquely at day 10 p.i., 22 overlapped with those upregulated at day 14 p.i.", [["gene transcripts", "PROBLEM", 12, 28], ["no", "UNCERTAINTY", 9, 11]]], ["A further 76 genes, comprising 53% of all upregulated genes at day 14 p.i., were specifically expressed at elevated levels at day 14 p.i. coinciding with overt myelin loss (Figure 5C).", [["myelin", "ANATOMY", 160, 166], ["myelin loss", "DISEASE", 160, 171], ["myelin", "GENE_OR_GENE_PRODUCT", 160, 166], ["upregulated genes", "DNA", 42, 59], ["elevated levels", "PROBLEM", 107, 122], ["overt myelin loss", "PROBLEM", 154, 171], ["myelin loss", "OBSERVATION", 160, 171]]], ["These profiles reveal a dynamic range of responses and extensive plasticity of gene expression profiles in microglia throughout JHMV infection (Figure 5C).Gene Expression Profiles Characterizing BMDM and Microglia at Peak of Demyelination ::: ResultsWe next used a protein\u2013protein network connection constructed based on differential gene expression to specifically examine upregulation of gene transcripts within BMDM and microglia correlating with demyelination at day 14 p.i.", [["microglia", "ANATOMY", 107, 116], ["Microglia", "ANATOMY", 204, 213], ["BMDM", "ANATOMY", 414, 418], ["microglia", "ANATOMY", 423, 432], ["infection", "DISEASE", 133, 142], ["demyelination", "DISEASE", 450, 463], ["microglia", "CELL", 107, 116], ["BMDM", "CELL", 195, 199], ["Microglia", "CELL", 204, 213], ["BMDM", "CELL", 414, 418], ["microglia", "CELL", 423, 432], ["microglia", "CELL_TYPE", 107, 116], ["BMDM", "CELL_TYPE", 195, 199], ["Microglia", "CELL_TYPE", 204, 213], ["BMDM", "CELL_TYPE", 414, 418], ["microglia", "CELL_TYPE", 423, 432], ["JHMV", "SPECIES", 128, 132], ["These profiles", "TEST", 0, 14], ["gene expression profiles in microglia throughout JHMV infection", "PROBLEM", 79, 142], ["BMDM", "PROBLEM", 195, 199], ["a protein\u2013protein network connection", "TREATMENT", 263, 299], ["gene transcripts", "PROBLEM", 390, 406], ["demyelination", "PROBLEM", 450, 463], ["gene expression", "OBSERVATION", 79, 94], ["infection", "OBSERVATION", 133, 142], ["BMDM", "OBSERVATION", 195, 199], ["Demyelination", "OBSERVATION", 225, 238]]], ["For comparison, we also analyzed the network connection at day 5 p.i., when expression profiles were most prominently altered in BMDM, but more modestly in microglia.", [["BMDM", "ANATOMY", 129, 133], ["microglia", "ANATOMY", 156, 165], ["BMDM", "CELL", 129, 133], ["microglia", "CELL", 156, 165], ["BMDM", "CELL_TYPE", 129, 133], ["microglia", "CELL_TYPE", 156, 165], ["most prominently", "OBSERVATION_MODIFIER", 101, 117], ["altered", "OBSERVATION_MODIFIER", 118, 125], ["BMDM", "OBSERVATION", 129, 133], ["microglia", "OBSERVATION", 156, 165]]], ["This comparative analysis was chosen to provide clues about specific functions and involvement of microglia relative to BMDM in tissue destruction (Figures 6 and 7).", [["microglia", "ANATOMY", 98, 107], ["BMDM", "ANATOMY", 120, 124], ["tissue", "ANATOMY", 128, 134], ["microglia", "CELL", 98, 107], ["BMDM", "CELL", 120, 124], ["tissue", "TISSUE", 128, 134], ["microglia", "CELL_TYPE", 98, 107], ["BMDM", "CELL_TYPE", 120, 124], ["This comparative analysis", "TEST", 0, 25], ["microglia", "PROBLEM", 98, 107], ["BMDM in tissue destruction", "PROBLEM", 120, 146], ["microglia", "ANATOMY", 98, 107], ["tissue", "ANATOMY", 128, 134], ["destruction", "OBSERVATION", 135, 146]]], ["Our initial focus was on temporally altered networks in BMDM (Figure 6).", [["BMDM", "CELL", 56, 60], ["BMDM", "CELL_TYPE", 56, 60]]], ["At day 5 p.i., early infiltrated BMDM expressed a wide array of chemokines regulating CNS infiltration of both innate (CXCL2, CCL2, CCL4, CCL5, CCL7, and CCL12) and adaptive (CXCL9, CXCL10) immune cells (Figure 6A).", [["BMDM", "ANATOMY", 33, 37], ["CNS", "ANATOMY", 86, 89], ["immune cells", "ANATOMY", 190, 202], ["BMDM", "CELL", 33, 37], ["CNS", "ANATOMICAL_SYSTEM", 86, 89], ["CXCL2", "GENE_OR_GENE_PRODUCT", 119, 124], ["CCL2", "GENE_OR_GENE_PRODUCT", 126, 130], ["CCL4", "GENE_OR_GENE_PRODUCT", 132, 136], ["CCL5", "GENE_OR_GENE_PRODUCT", 138, 142], ["CCL7", "GENE_OR_GENE_PRODUCT", 144, 148], ["CCL12", "GENE_OR_GENE_PRODUCT", 154, 159], ["CXCL9", "GENE_OR_GENE_PRODUCT", 175, 180], ["CXCL10", "GENE_OR_GENE_PRODUCT", 182, 188], ["immune cells", "CELL", 190, 202], ["BMDM", "CELL_TYPE", 33, 37], ["chemokines", "PROTEIN", 64, 74], ["CXCL2", "PROTEIN", 119, 124], ["CCL2", "PROTEIN", 126, 130], ["CCL4", "PROTEIN", 132, 136], ["CCL5", "PROTEIN", 138, 142], ["CCL7", "PROTEIN", 144, 148], ["CCL12", "PROTEIN", 154, 159], ["CXCL9", "PROTEIN", 175, 180], ["CXCL10", "PROTEIN", 182, 188], ["immune cells", "CELL_TYPE", 190, 202], ["early infiltrated BMDM", "PROBLEM", 15, 37], ["CXCL2", "TEST", 119, 124], ["CCL2", "TEST", 126, 130], ["CCL5", "TEST", 138, 142], ["CCL7", "TEST", 144, 148], ["CXCL9", "TEST", 175, 180], ["infiltrated BMDM", "OBSERVATION", 21, 37], ["CNS", "ANATOMY", 86, 89], ["infiltration", "OBSERVATION", 90, 102]]], ["A large cluster of molecules regulating the innate immune response, essential to limit early viral replication (45, 46), was also expressed by BMDM (Figure 6A).", [["BMDM", "CELL", 143, 147], ["BMDM", "CELL_TYPE", 143, 147], ["A large cluster of molecules", "PROBLEM", 0, 28], ["large", "OBSERVATION_MODIFIER", 2, 7], ["cluster", "OBSERVATION_MODIFIER", 8, 15]]], ["These include pathogen recognition receptors such as TLRs (TLR1-4 and TLR9) and molecules linked to the TNF pathway (TNF, TRAF6, etc.).", [["TLRs", "GENE_OR_GENE_PRODUCT", 53, 57], ["TLR1-4", "GENE_OR_GENE_PRODUCT", 59, 65], ["TLR9", "GENE_OR_GENE_PRODUCT", 70, 74], ["TNF", "GENE_OR_GENE_PRODUCT", 104, 107], ["TNF", "GENE_OR_GENE_PRODUCT", 117, 120], ["TRAF6", "GENE_OR_GENE_PRODUCT", 122, 127], ["pathogen recognition receptors", "PROTEIN", 14, 44], ["TLRs", "PROTEIN", 53, 57], ["TLR1", "PROTEIN", 59, 63], ["TLR9", "PROTEIN", 70, 74], ["TNF", "PROTEIN", 104, 107], ["TNF", "PROTEIN", 117, 120], ["TRAF6", "PROTEIN", 122, 127], ["TLRs (TLR1-4 and TLR9)", "TREATMENT", 53, 75]]], ["Finally, BMDM expressed molecules involved in antigen presentation, including Tap1 and Tap2, as well as T cell activating co-stimulatory molecules (CD80 and CD86) or IL-12, which induce Th1 differentiation (Figure 6A).", [["T cell", "ANATOMY", 104, 110], ["BMDM", "CELL", 9, 13], ["antigen", "GENE_OR_GENE_PRODUCT", 46, 53], ["Tap1", "GENE_OR_GENE_PRODUCT", 78, 82], ["Tap2", "GENE_OR_GENE_PRODUCT", 87, 91], ["T cell activating co-stimulatory molecules", "GENE_OR_GENE_PRODUCT", 104, 146], ["CD80", "GENE_OR_GENE_PRODUCT", 148, 152], ["CD86", "GENE_OR_GENE_PRODUCT", 157, 161], ["IL-12", "GENE_OR_GENE_PRODUCT", 166, 171], ["BMDM", "PROTEIN", 9, 13], ["Tap1", "PROTEIN", 78, 82], ["Tap2", "PROTEIN", 87, 91], ["T cell activating co-stimulatory molecules", "PROTEIN", 104, 146], ["CD80", "PROTEIN", 148, 152], ["CD86", "PROTEIN", 157, 161], ["IL-12", "PROTEIN", 166, 171], ["Tap1", "TEST", 78, 82], ["Tap2", "TEST", 87, 91], ["T cell activating co-stimulatory molecules", "PROBLEM", 104, 146], ["CD80", "TEST", 148, 152], ["CD86", "TEST", 157, 161], ["IL", "TEST", 166, 168]]], ["These results indicate that early infiltrating BMDM orchestrate the acute innate immune response crucial for limiting CNS viral spread, as well as initiating the adaptive immune response by recruiting and activating T cells.", [["BMDM", "ANATOMY", 47, 51], ["CNS", "ANATOMY", 118, 121], ["T cells", "ANATOMY", 216, 223], ["BMDM", "CELL", 47, 51], ["CNS", "ANATOMICAL_SYSTEM", 118, 121], ["T cells", "CELL", 216, 223], ["BMDM", "CELL_TYPE", 47, 51], ["T cells", "CELL_TYPE", 216, 223], ["early infiltrating BMDM", "PROBLEM", 28, 51], ["CNS viral spread", "PROBLEM", 118, 134], ["the adaptive immune response", "TREATMENT", 158, 186], ["early", "OBSERVATION_MODIFIER", 28, 33], ["infiltrating BMDM", "OBSERVATION", 34, 51], ["acute", "OBSERVATION_MODIFIER", 68, 73]]], ["At day 14 p.i., correlating with peak demyelination, a more restrained number of mRNA transcripts were upregulated in BMDM (Figure 6B).", [["demyelination", "DISEASE", 38, 51], ["BMDM", "CELL", 118, 122], ["mRNA transcripts", "RNA", 81, 97], ["BMDM", "CELL_TYPE", 118, 122], ["peak demyelination", "PROBLEM", 33, 51], ["mRNA transcripts", "TREATMENT", 81, 97], ["peak demyelination", "OBSERVATION", 33, 51]]], ["The cluster of chemokines mobilizing immune cells was sustained (Figure 6B).", [["immune cells", "ANATOMY", 37, 49], ["immune cells", "CELL", 37, 49], ["chemokines", "PROTEIN", 15, 25], ["immune cells", "CELL_TYPE", 37, 49], ["chemokines mobilizing immune cells", "TREATMENT", 15, 49], ["immune cells", "OBSERVATION", 37, 49]]], ["In contrast, the molecular network extended from TNF was more limited at d14 p.i. compared to d5 p.i.", [["TNF", "GENE_OR_GENE_PRODUCT", 49, 52], ["TNF", "PROTEIN", 49, 52]]], ["Molecules regulating primarily the CD4 T cell response were expressed at day 14 p.i. and comprised gene transcripts involved in antigen presentation including MHC class II (H2-Ab1) and co-stimulatory molecules such as CD80 and CD86 (Figure 6B).", [["CD4 T cell", "ANATOMY", 35, 45], ["CD4", "GENE_OR_GENE_PRODUCT", 35, 38], ["MHC class II", "GENE_OR_GENE_PRODUCT", 159, 171], ["H2-Ab1", "GENE_OR_GENE_PRODUCT", 173, 179], ["CD80", "GENE_OR_GENE_PRODUCT", 218, 222], ["CD86", "GENE_OR_GENE_PRODUCT", 227, 231], ["Figure 6B", "GENE_OR_GENE_PRODUCT", 233, 242], ["CD4", "PROTEIN", 35, 38], ["MHC class II", "PROTEIN", 159, 171], ["H2", "PROTEIN", 173, 175], ["Ab1", "PROTEIN", 176, 179], ["co-stimulatory molecules", "PROTEIN", 185, 209], ["CD80", "PROTEIN", 218, 222], ["CD86", "PROTEIN", 227, 231], ["Figure 6B", "PROTEIN", 233, 242], ["H2-Ab1", "TEST", 173, 179], ["co-stimulatory molecules", "TEST", 185, 209], ["CD80", "TEST", 218, 222], ["CD86", "TEST", 227, 231]]], ["Interestingly, among the more restricted number of gene transcripts upregulated at day 14 p.i. in BMDM, several were transcripts encoding M2 molecules, which included Arg1, Il1rn and Tgm2 (Figure 6B).Gene Expression Profiles Characterizing BMDM and Microglia at Peak of Demyelination ::: ResultsIn contrast to the vast number of genes upregulated early following infection in BMDM, a significantly lower number of upregulated genes characterized microglia at day 5 p.i.", [["Microglia", "ANATOMY", 249, 258], ["BMDM", "ANATOMY", 376, 380], ["microglia", "ANATOMY", 446, 455], ["infection", "DISEASE", 363, 372], ["BMDM", "CELL", 98, 102], ["M2", "GENE_OR_GENE_PRODUCT", 138, 140], ["Arg1", "GENE_OR_GENE_PRODUCT", 167, 171], ["Il1rn", "GENE_OR_GENE_PRODUCT", 173, 178], ["Tgm2 (Figure 6B", "GENE_OR_GENE_PRODUCT", 183, 198], ["BMDM", "CELL", 240, 244], ["Microglia", "CELL", 249, 258], ["BMDM", "CELL", 376, 380], ["microglia", "CELL", 446, 455], ["gene transcripts", "RNA", 51, 67], ["BMDM", "CELL_TYPE", 98, 102], ["M2 molecules", "PROTEIN", 138, 150], ["Arg1", "PROTEIN", 167, 171], ["Il1rn", "PROTEIN", 173, 178], ["Tgm2", "PROTEIN", 183, 187], ["Figure 6B", "PROTEIN", 189, 198], ["BMDM", "CELL_TYPE", 240, 244], ["Microglia", "CELL_TYPE", 249, 258], ["BMDM", "CELL_TYPE", 376, 380], ["upregulated genes", "DNA", 414, 431], ["microglia", "CELL_TYPE", 446, 455], ["BMDM", "PROBLEM", 240, 244], ["infection in BMDM", "PROBLEM", 363, 380], ["BMDM", "OBSERVATION", 240, 244], ["Demyelination", "OBSERVATION", 270, 283], ["upregulated", "OBSERVATION_MODIFIER", 335, 346], ["early", "OBSERVATION_MODIFIER", 347, 352], ["infection", "OBSERVATION", 363, 372]]], ["Transcripts for chemokines regulating migration of both innate and adaptive immune cells, such as CCL2, CCL3, CCL4, CCL12, CXCL10, and CXCL16, were expressed by microglia at day 5 p.i.", [["immune cells", "ANATOMY", 76, 88], ["microglia", "ANATOMY", 161, 170], ["immune cells", "CELL", 76, 88], ["CCL2", "GENE_OR_GENE_PRODUCT", 98, 102], ["CCL3", "GENE_OR_GENE_PRODUCT", 104, 108], ["CCL4", "GENE_OR_GENE_PRODUCT", 110, 114], ["CCL12", "GENE_OR_GENE_PRODUCT", 116, 121], ["CXCL10", "GENE_OR_GENE_PRODUCT", 123, 129], ["CXCL16", "GENE_OR_GENE_PRODUCT", 135, 141], ["microglia", "CELL", 161, 170], ["chemokines", "PROTEIN", 16, 26], ["immune cells", "CELL_TYPE", 76, 88], ["CCL2", "PROTEIN", 98, 102], ["CCL3", "PROTEIN", 104, 108], ["CCL4", "PROTEIN", 110, 114], ["CCL12", "PROTEIN", 116, 121], ["CXCL10", "PROTEIN", 123, 129], ["CXCL16", "PROTEIN", 135, 141], ["microglia", "CELL_TYPE", 161, 170], ["chemokines regulating migration", "TREATMENT", 16, 47], ["CCL2", "TEST", 98, 102], ["CCL3", "TEST", 104, 108], ["CCL4", "TEST", 110, 114], ["CCL12", "TEST", 116, 121], ["CXCL10", "TEST", 123, 129], ["CXCL16", "TEST", 135, 141], ["immune cells", "OBSERVATION", 76, 88], ["CCL3", "ANATOMY", 104, 108], ["CCL4", "ANATOMY", 110, 114]]], ["Transcripts for TNF and other inflammatory cytokines generally associated with the innate responses, e.g., IL1a, IL1b, and IL18 were also upregulated early in microglia (Figure 7A).", [["microglia", "ANATOMY", 159, 168], ["TNF", "GENE_OR_GENE_PRODUCT", 16, 19], ["IL1a", "GENE_OR_GENE_PRODUCT", 107, 111], ["IL1b", "GENE_OR_GENE_PRODUCT", 113, 117], ["IL18", "GENE_OR_GENE_PRODUCT", 123, 127], ["microglia", "CELL", 159, 168], ["TNF", "PROTEIN", 16, 19], ["inflammatory cytokines", "PROTEIN", 30, 52], ["IL1a", "PROTEIN", 107, 111], ["IL1b", "PROTEIN", 113, 117], ["IL18", "PROTEIN", 123, 127], ["microglia", "CELL_TYPE", 159, 168], ["TNF", "PROBLEM", 16, 19], ["other inflammatory cytokines", "PROBLEM", 24, 52], ["IL1b", "TEST", 113, 117], ["IL18", "PROBLEM", 123, 127], ["inflammatory", "OBSERVATION_MODIFIER", 30, 42]]], ["Another extended network of TNF comprised Psmb8 and Psmb9, subunits of the immuno-proteasome, essential for antigen presentation by MHC class I molecules.", [["TNF", "GENE_OR_GENE_PRODUCT", 28, 31], ["Psmb8", "GENE_OR_GENE_PRODUCT", 42, 47], ["Psmb9", "GENE_OR_GENE_PRODUCT", 52, 57], ["TNF", "PROTEIN", 28, 31], ["Psmb8", "PROTEIN", 42, 47], ["Psmb9", "PROTEIN", 52, 57], ["immuno-proteasome", "PROTEIN", 75, 92], ["MHC class I molecules", "PROTEIN", 132, 153], ["TNF", "TEST", 28, 31], ["Psmb8", "TEST", 42, 47], ["Psmb9", "TEST", 52, 57], ["the immuno-proteasome", "TREATMENT", 71, 92]]], ["By day 14 p.i., the number of upregulated transcripts extensively increased in microglia (Figure 7B).", [["microglia", "ANATOMY", 79, 88], ["microglia", "CELL", 79, 88], ["microglia", "CELL_TYPE", 79, 88], ["upregulated transcripts", "TREATMENT", 30, 53], ["increased", "OBSERVATION_MODIFIER", 66, 75]]], ["The most clustered network comprised proteins like CCL5, CXCL9, CXCL10, CXCL13, CXCL16, and CXCR4, all chemokines and chemokine receptors regulating migration and arrest of adaptive immune cells within the CNS during inflammation (47).", [["immune cells", "ANATOMY", 182, 194], ["CNS", "ANATOMY", 206, 209], ["inflammation", "DISEASE", 217, 229], ["CCL5", "GENE_OR_GENE_PRODUCT", 51, 55], ["CXCL9", "GENE_OR_GENE_PRODUCT", 57, 62], ["CXCL10", "GENE_OR_GENE_PRODUCT", 64, 70], ["CXCL13", "GENE_OR_GENE_PRODUCT", 72, 78], ["CXCL16", "GENE_OR_GENE_PRODUCT", 80, 86], ["CXCR4", "GENE_OR_GENE_PRODUCT", 92, 97], ["immune cells", "CELL", 182, 194], ["CNS", "ANATOMICAL_SYSTEM", 206, 209], ["CCL5", "PROTEIN", 51, 55], ["CXCL9", "PROTEIN", 57, 62], ["CXCL10", "PROTEIN", 64, 70], ["CXCL13", "PROTEIN", 72, 78], ["CXCL16", "PROTEIN", 80, 86], ["CXCR4", "PROTEIN", 92, 97], ["chemokines", "PROTEIN", 103, 113], ["chemokine receptors", "PROTEIN", 118, 137], ["adaptive immune cells", "CELL_TYPE", 173, 194], ["CCL5", "TEST", 51, 55], ["CXCL9", "TEST", 57, 62], ["CXCL10", "TEST", 64, 70], ["CXCL13", "TEST", 72, 78], ["CXCL16", "TEST", 80, 86], ["CXCR4", "TEST", 92, 97], ["all chemokines", "TREATMENT", 99, 113], ["chemokine receptors regulating migration", "TREATMENT", 118, 158], ["arrest", "PROBLEM", 163, 169], ["adaptive immune cells", "PROBLEM", 173, 194], ["inflammation", "PROBLEM", 217, 229], ["CCL5", "ANATOMY", 51, 55], ["immune cells", "OBSERVATION", 182, 194], ["CNS", "ANATOMY", 206, 209]]], ["This chemokine cluster was linked to TNF and inflammatory cytokines previously detected at d5 p.i., e.g., IL1a, IL1b, and IL18.", [["TNF", "GENE_OR_GENE_PRODUCT", 37, 40], ["IL1a", "GENE_OR_GENE_PRODUCT", 106, 110], ["IL1b", "GENE_OR_GENE_PRODUCT", 112, 116], ["IL18", "GENE_OR_GENE_PRODUCT", 122, 126], ["chemokine", "PROTEIN", 5, 14], ["TNF", "PROTEIN", 37, 40], ["inflammatory cytokines", "PROTEIN", 45, 67], ["IL1a", "PROTEIN", 106, 110], ["IL1b", "PROTEIN", 112, 116], ["IL18", "PROTEIN", 122, 126], ["This chemokine cluster", "TREATMENT", 0, 22], ["TNF", "TEST", 37, 40], ["inflammatory cytokines", "PROBLEM", 45, 67], ["IL1a", "TREATMENT", 106, 110], ["IL1b", "TREATMENT", 112, 116], ["IL18", "TREATMENT", 122, 126], ["inflammatory", "OBSERVATION_MODIFIER", 45, 57]]], ["Another extended network of TNF comprised Psmb8 and Psm9, also present at d5 p.i., Ctnnb1 encoding b-catenin, a cellular adhesion molecule, and cdkn1a, a cyclin inhibitor.", [["cellular", "ANATOMY", 112, 120], ["TNF", "GENE_OR_GENE_PRODUCT", 28, 31], ["Psmb8", "GENE_OR_GENE_PRODUCT", 42, 47], ["Psm9", "GENE_OR_GENE_PRODUCT", 52, 56], ["Ctnnb1", "GENE_OR_GENE_PRODUCT", 83, 89], ["b-catenin", "GENE_OR_GENE_PRODUCT", 99, 108], ["cellular adhesion molecule", "GENE_OR_GENE_PRODUCT", 112, 138], ["cdkn1a", "GENE_OR_GENE_PRODUCT", 144, 150], ["cyclin", "GENE_OR_GENE_PRODUCT", 154, 160], ["TNF", "PROTEIN", 28, 31], ["Psmb8", "PROTEIN", 42, 47], ["Psm9", "PROTEIN", 52, 56], ["Ctnnb1", "PROTEIN", 83, 89], ["b-catenin", "PROTEIN", 99, 108], ["cellular adhesion molecule", "PROTEIN", 112, 138], ["cdkn1a", "PROTEIN", 144, 150], ["cyclin inhibitor", "PROTEIN", 154, 170], ["TNF", "TEST", 28, 31], ["Psm9", "TEST", 52, 56], ["Ctnnb1 encoding b-catenin", "TREATMENT", 83, 108], ["a cellular adhesion molecule", "TREATMENT", 110, 138], ["cdkn1a", "PROBLEM", 144, 150], ["a cyclin inhibitor", "TREATMENT", 152, 170], ["cellular", "OBSERVATION", 112, 120], ["adhesion molecule", "OBSERVATION", 121, 138]]], ["Other upregulated gene transcripts associated with class I antigen presentation, e.g., tap1 and tap2, were also linked through a network associated with complement component genes (C3, C3ar1, C4b, C1qa, C1qb, C1qc), which are highly expressed within microglia under homeostatic conditions (Figure 3).", [["microglia", "ANATOMY", 250, 259], ["class I antigen", "GENE_OR_GENE_PRODUCT", 51, 66], ["tap1", "GENE_OR_GENE_PRODUCT", 87, 91], ["tap2", "GENE_OR_GENE_PRODUCT", 96, 100], ["C3", "GENE_OR_GENE_PRODUCT", 181, 183], ["C3ar1", "GENE_OR_GENE_PRODUCT", 185, 190], ["C4b", "GENE_OR_GENE_PRODUCT", 192, 195], ["C1qa", "GENE_OR_GENE_PRODUCT", 197, 201], ["C1qb", "GENE_OR_GENE_PRODUCT", 203, 207], ["C1qc", "GENE_OR_GENE_PRODUCT", 209, 213], ["microglia", "CELL", 250, 259], ["class I antigen", "PROTEIN", 51, 66], ["tap1", "PROTEIN", 87, 91], ["tap2", "PROTEIN", 96, 100], ["complement component genes", "DNA", 153, 179], ["C3", "DNA", 181, 183], ["C3ar1", "DNA", 185, 190], ["C4b", "DNA", 192, 195], ["C1qa", "DNA", 197, 201], ["C1qb", "DNA", 203, 207], ["C1qc", "DNA", 209, 213], ["microglia", "CELL_TYPE", 250, 259], ["tap1 and tap2", "TREATMENT", 87, 100], ["C4b", "TEST", 192, 195], ["gene transcripts", "OBSERVATION", 18, 34], ["C3", "OBSERVATION_MODIFIER", 181, 183]]], ["Similarly, tyrobp and Trem2, which formed phagocytic synapses (48), are both highly expressed in microglia during myelin loss.", [["phagocytic synapses", "ANATOMY", 42, 61], ["microglia", "ANATOMY", 97, 106], ["myelin", "ANATOMY", 114, 120], ["myelin loss", "DISEASE", 114, 125], ["tyrobp", "GENE_OR_GENE_PRODUCT", 11, 17], ["Trem2", "GENE_OR_GENE_PRODUCT", 22, 27], ["microglia", "CELL", 97, 106], ["myelin", "GENE_OR_GENE_PRODUCT", 114, 120], ["tyrobp", "PROTEIN", 11, 17], ["Trem2", "PROTEIN", 22, 27], ["microglia", "CELL_TYPE", 97, 106], ["phagocytic synapses", "TEST", 42, 61], ["myelin loss", "PROBLEM", 114, 125], ["Trem2", "OBSERVATION", 22, 27], ["phagocytic synapses", "OBSERVATION", 42, 61], ["microglia", "OBSERVATION", 97, 106], ["myelin loss", "OBSERVATION", 114, 125]]], ["Finally, a wide variety of upregulated gene transcripts are associated with MHC class II antigen presentation and modulation of T cell function.", [["T cell", "ANATOMY", 128, 134], ["MHC class II antigen", "GENE_OR_GENE_PRODUCT", 76, 96], ["T cell", "CELL", 128, 134], ["MHC class II antigen", "PROTEIN", 76, 96], ["modulation of T cell function", "PROBLEM", 114, 143], ["gene transcripts", "OBSERVATION", 39, 55], ["T cell function", "OBSERVATION", 128, 143]]], ["This includes H2-Ab1, encoding for the MHC class II molecules and H2-DM, encoding for a second accessory protein, which facilitates peptide loading.", [["H2-Ab1", "GENE_OR_GENE_PRODUCT", 14, 20], ["H2-DM", "GENE_OR_GENE_PRODUCT", 66, 71], ["H2", "PROTEIN", 14, 16], ["Ab1", "PROTEIN", 17, 20], ["MHC class II molecules", "PROTEIN", 39, 61], ["H2", "PROTEIN", 66, 68], ["DM", "PROTEIN", 69, 71], ["accessory protein", "PROTEIN", 95, 112], ["H2-Ab1", "TREATMENT", 14, 20], ["H2-DM", "PROBLEM", 66, 71], ["a second accessory protein", "TREATMENT", 86, 112], ["peptide loading", "TREATMENT", 132, 147]]], ["Similarly, genes associated with the invariant chain of MHC class II were increasingly expressed within microglia, such as Cd74 and Ctss (Cathepsin S, which cleaves invariant chain thereby promoting loading on MHC Class II).", [["microglia", "ANATOMY", 104, 113], ["MHC class II", "GENE_OR_GENE_PRODUCT", 56, 68], ["microglia", "CELL", 104, 113], ["Cd74", "GENE_OR_GENE_PRODUCT", 123, 127], ["Ctss", "GENE_OR_GENE_PRODUCT", 132, 136], ["Cathepsin S", "GENE_OR_GENE_PRODUCT", 138, 149], ["MHC class II", "PROTEIN", 56, 68], ["microglia", "CELL_TYPE", 104, 113], ["Cd74", "PROTEIN", 123, 127], ["Ctss", "PROTEIN", 132, 136], ["Cathepsin S", "PROTEIN", 138, 149], ["cleaves invariant chain", "PROTEIN", 157, 180], ["MHC Class II", "PROTEIN", 210, 222], ["Cd74", "TEST", 123, 127], ["Ctss (Cathepsin S", "TREATMENT", 132, 149], ["chain", "OBSERVATION_MODIFIER", 47, 52]]], ["In addition, genes encoding for modulators of the CD4 T cell response, such as Itgax (CD11c), Cd86 and Cd83 were also expressed by microglia (Figure 7B).", [["CD4 T cell", "ANATOMY", 50, 60], ["microglia", "ANATOMY", 131, 140], ["CD4", "GENE_OR_GENE_PRODUCT", 50, 53], ["Itgax", "GENE_OR_GENE_PRODUCT", 79, 84], ["CD11c", "GENE_OR_GENE_PRODUCT", 86, 91], ["Cd86", "GENE_OR_GENE_PRODUCT", 94, 98], ["Cd83", "GENE_OR_GENE_PRODUCT", 103, 107], ["microglia", "CELL", 131, 140], ["CD4", "PROTEIN", 50, 53], ["Itgax", "PROTEIN", 79, 84], ["CD11c", "PROTEIN", 86, 91], ["Cd86", "PROTEIN", 94, 98], ["Cd83", "PROTEIN", 103, 107], ["microglia", "CELL_TYPE", 131, 140], ["Cd86", "TEST", 94, 98], ["Cd83", "TEST", 103, 107]]], ["Overall, the upregulated networks are related to complement activation, enhanced class I and class 2 antigen processing and presentation (potentially related to IFN-\u03b3 responses) as well as migration and phagocytic activity.", [["class 2 antigen", "GENE_OR_GENE_PRODUCT", 93, 108], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 161, 166], ["IFN", "PROTEIN", 161, 164], ["\u03b3", "PROTEIN", 165, 166], ["IFN", "TEST", 161, 164], ["phagocytic activity", "OBSERVATION", 203, 222]]], ["However, there does not appear to be a bias toward phagocytic receptors over other components activated by pro-inflammatory mediators.Microglia Repressed Anti-Inflammatory Genes During JHMV-Induced Demyelination ::: ResultsPathogenic versus protective functions of myeloid cells following activation have also been correlated to expression of key molecules defined as M1 versus M2 markers.", [["myeloid cells", "ANATOMY", 265, 278], ["Microglia", "CELL", 134, 143], ["myeloid cells", "CELL", 265, 278], ["M1", "CELL", 368, 370], ["M2", "GENE_OR_GENE_PRODUCT", 378, 380], ["phagocytic receptors", "PROTEIN", 51, 71], ["pro-inflammatory mediators", "PROTEIN", 107, 133], ["Microglia", "CELL_TYPE", 134, 143], ["myeloid cells", "CELL_TYPE", 265, 278], ["M1", "PROTEIN", 368, 370], ["M2 markers", "PROTEIN", 378, 388], ["myeloid cells", "PROBLEM", 265, 278], ["not appear to be", "UNCERTAINTY", 20, 36], ["Anti-Inflammatory Genes", "OBSERVATION", 154, 177], ["Demyelination", "OBSERVATION", 198, 211], ["myeloid cells", "OBSERVATION", 265, 278]]], ["While the strict classification of myeloid cells into the M1 or M2 category has been tempered based on a more dynamic and mixed phenotype during inflammatory responses (49, 50), the M1 and M2 markers remain helpful to gage overall effector functions.", [["myeloid cells", "ANATOMY", 35, 48], ["M1", "ANATOMY", 58, 60], ["myeloid cells", "CELL", 35, 48], ["M1", "CELL", 58, 60], ["M2", "GENE_OR_GENE_PRODUCT", 64, 66], ["M1", "CELL", 182, 184], ["M2", "GENE_OR_GENE_PRODUCT", 189, 191], ["myeloid cells", "CELL_TYPE", 35, 48], ["M1 and M2 markers", "PROTEIN", 182, 199], ["myeloid cells", "PROBLEM", 35, 48], ["a more dynamic and mixed phenotype during inflammatory responses", "PROBLEM", 103, 167], ["myeloid cells", "OBSERVATION", 35, 48], ["M1", "ANATOMY_MODIFIER", 58, 60], ["inflammatory", "OBSERVATION_MODIFIER", 145, 157], ["M1", "ANATOMY", 182, 184]]], ["Among the 89 analyzed gene transcripts in the Nanostring myeloid panel related to M1/M2 polarization (51 M1 and 38 M2 genes), between 50 and 59% were upregulated across the course of JHMV infection with no difference comparing M1 versus M2 genes (Figure 8A).Microglia Repressed Anti-Inflammatory Genes During JHMV-Induced Demyelination ::: ResultsAmong the total upregulated M1 markers, about 50% were commonly increased within both infiltrating BMDM and microglia; representative genes were Il12b and Il15Ra (Figures 8A,B).", [["myeloid panel", "ANATOMY", 57, 70], ["BMDM", "ANATOMY", 446, 450], ["microglia", "ANATOMY", 455, 464], ["JHMV infection", "DISEASE", 183, 197], ["Nanostring myeloid panel", "CANCER", 46, 70], ["M2", "GENE_OR_GENE_PRODUCT", 85, 87], ["JHMV", "CANCER", 183, 187], ["M2", "GENE_OR_GENE_PRODUCT", 237, 239], ["Microglia", "CELL", 258, 267], ["BMDM", "CELL", 446, 450], ["microglia", "CELL", 455, 464], ["Il12b", "GENE_OR_GENE_PRODUCT", 492, 497], ["Il15Ra", "GENE_OR_GENE_PRODUCT", 502, 508], ["B", "GENE_OR_GENE_PRODUCT", 521, 522], ["M2 genes", "DNA", 115, 123], ["M2 genes", "DNA", 237, 245], ["Microglia", "CELL_TYPE", 258, 267], ["M1 markers", "PROTEIN", 375, 385], ["infiltrating BMDM", "CELL_TYPE", 433, 450], ["microglia", "CELL_TYPE", 455, 464], ["Il12b", "DNA", 492, 497], ["Il15Ra", "DNA", 502, 508], ["JHMV", "SPECIES", 183, 187], ["the Nanostring myeloid panel", "TEST", 42, 70], ["JHMV infection", "PROBLEM", 183, 197], ["Il12b", "TEST", 492, 497], ["M2", "ANATOMY_MODIFIER", 85, 87], ["infection", "OBSERVATION", 188, 197], ["no", "UNCERTAINTY", 203, 205], ["Anti-Inflammatory Genes", "OBSERVATION", 278, 301], ["Demyelination", "OBSERVATION", 322, 335], ["M1", "OBSERVATION_MODIFIER", 375, 377], ["increased", "OBSERVATION_MODIFIER", 411, 420], ["infiltrating BMDM", "OBSERVATION", 433, 450]]], ["However, while high levels of Il12b mRNA were observed in both BMDM and microglia at d5 p.i., expression was only sustained in microglia at day 7 p.i. and thereafter (Figure 8B).", [["BMDM", "ANATOMY", 63, 67], ["microglia", "ANATOMY", 72, 81], ["microglia", "ANATOMY", 127, 136], ["Il12b", "GENE_OR_GENE_PRODUCT", 30, 35], ["BMDM", "CELL", 63, 67], ["microglia", "CELL", 72, 81], ["microglia", "CELL", 127, 136], ["Il12b mRNA", "RNA", 30, 40], ["BMDM", "CELL_TYPE", 63, 67], ["microglia", "CELL_TYPE", 72, 81], ["microglia", "CELL_TYPE", 127, 136], ["Il12b mRNA", "PROBLEM", 30, 40]]], ["By contrast, IL15ra was increased in both BMDM and to a lesser extent in microglia at d5 p.i., but was decreased in both populations at later time points p.i.", [["BMDM", "ANATOMY", 42, 46], ["microglia", "ANATOMY", 73, 82], ["IL15ra", "GENE_OR_GENE_PRODUCT", 13, 19], ["BMDM", "CELL", 42, 46], ["microglia", "CELL", 73, 82], ["IL15ra", "PROTEIN", 13, 19], ["BMDM", "CELL_TYPE", 42, 46], ["microglia", "CELL_TYPE", 73, 82], ["IL15ra", "TREATMENT", 13, 19], ["lesser extent", "OBSERVATION_MODIFIER", 56, 69], ["decreased", "OBSERVATION_MODIFIER", 103, 112]]], ["In addition, between 35 and 45% of M1 markers were specifically expressed by infiltrating BMDM during the course of JHMV infection (Figure 8A), including Cd86, atf3, Ifng, Ptgs2, Ccr7, Cxcl11, and Cxcl12 transcripts (Figure 8B and data not shown).", [["BMDM", "ANATOMY", 90, 94], ["JHMV infection", "DISEASE", 116, 130], ["BMDM", "CELL", 90, 94], ["JHMV", "CANCER", 116, 120], ["Cd86", "GENE_OR_GENE_PRODUCT", 154, 158], ["atf3", "GENE_OR_GENE_PRODUCT", 160, 164], ["Ifng", "GENE_OR_GENE_PRODUCT", 166, 170], ["Ptgs2", "GENE_OR_GENE_PRODUCT", 172, 177], ["Ccr7", "GENE_OR_GENE_PRODUCT", 179, 183], ["Cxcl11", "GENE_OR_GENE_PRODUCT", 185, 191], ["Cxcl12", "GENE_OR_GENE_PRODUCT", 197, 203], ["M1 markers", "PROTEIN", 35, 45], ["infiltrating BMDM", "CELL_TYPE", 77, 94], ["Cd86, atf3, Ifng, Ptgs2, Ccr7, Cxcl11, and Cxcl12 transcripts", "RNA", 154, 215], ["JHMV", "SPECIES", 116, 120], ["infiltrating BMDM", "PROBLEM", 77, 94], ["JHMV infection", "PROBLEM", 116, 130], ["Cd86", "TEST", 154, 158], ["atf3", "TEST", 160, 164], ["Ifng", "TEST", 166, 170], ["Ptgs2", "TEST", 172, 177], ["Ccr7", "TEST", 179, 183], ["Cxcl11", "TEST", 185, 191], ["Cxcl12 transcripts", "TEST", 197, 215], ["Figure 8B and data", "TEST", 217, 235], ["infiltrating BMDM", "OBSERVATION", 77, 94], ["infection", "OBSERVATION", 121, 130]]], ["However, only 5 M1 related gene transcripts were specifically upregulated in microglia at the time of demyelination, including Ccl5, Fas, Cxcl13, Tnfsf10, and Psmb9.", [["microglia", "ANATOMY", 77, 86], ["demyelination", "DISEASE", 102, 115], ["microglia", "CELL", 77, 86], ["Ccl5", "GENE_OR_GENE_PRODUCT", 127, 131], ["Fas", "GENE_OR_GENE_PRODUCT", 133, 136], ["Cxcl13", "GENE_OR_GENE_PRODUCT", 138, 144], ["Tnfsf10", "GENE_OR_GENE_PRODUCT", 146, 153], ["Psmb9", "GENE_OR_GENE_PRODUCT", 159, 164], ["M1", "PROTEIN", 16, 18], ["microglia", "CELL_TYPE", 77, 86], ["Ccl5", "PROTEIN", 127, 131], ["Fas", "PROTEIN", 133, 136], ["Cxcl13", "PROTEIN", 138, 144], ["Tnfsf10", "PROTEIN", 146, 153], ["Psmb9", "PROTEIN", 159, 164], ["gene transcripts", "PROBLEM", 27, 43], ["demyelination", "PROBLEM", 102, 115], ["Ccl5", "TEST", 127, 131], ["Fas", "TEST", 133, 136], ["Cxcl13", "TEST", 138, 144], ["Tnfsf10", "TEST", 146, 153], ["Psmb9", "TEST", 159, 164], ["demyelination", "OBSERVATION", 102, 115]]], ["(Figures 8A,B and data not shown).Microglia Repressed Anti-Inflammatory Genes During JHMV-Induced Demyelination ::: ResultsImportantly, the most prominent difference between microglia and BMDM was noted in M2 marker regulation.", [["microglia", "ANATOMY", 174, 183], ["BMDM", "ANATOMY", 188, 192], ["Microglia", "CELL", 34, 43], ["microglia", "CELL", 174, 183], ["BMDM", "CELL", 188, 192], ["M2", "GENE_OR_GENE_PRODUCT", 206, 208], ["Microglia", "CELL_TYPE", 34, 43], ["microglia", "CELL_TYPE", 174, 183], ["BMDM", "CELL_TYPE", 188, 192], ["Anti-Inflammatory Genes", "OBSERVATION", 54, 77], ["Demyelination", "OBSERVATION", 98, 111], ["most prominent", "OBSERVATION_MODIFIER", 140, 154], ["difference", "OBSERVATION_MODIFIER", 155, 165], ["microglia", "OBSERVATION", 174, 183], ["BMDM", "OBSERVATION", 188, 192]]], ["Among the 50\u201358% M2 gene transcripts upregulated following JHMV infection, only a small proportion (21\u201332%) was expressed by microglia (Figure 8A).", [["microglia", "ANATOMY", 125, 134], ["infection", "DISEASE", 64, 73], ["M2", "GENE_OR_GENE_PRODUCT", 17, 19], ["JHMV", "GENE_OR_GENE_PRODUCT", 59, 63], ["microglia", "CELL", 125, 134], ["50\u201358% M2 gene transcripts", "RNA", 10, 36], ["microglia", "CELL_TYPE", 125, 134], ["JHMV", "SPECIES", 59, 63], ["JHMV infection", "PROBLEM", 59, 73], ["infection", "OBSERVATION", 64, 73], ["small", "OBSERVATION_MODIFIER", 82, 87]]], ["Fn1 was the only M2 marker specifically expressed by microglia at the time of demyelination (Figure 8A).", [["microglia", "ANATOMY", 53, 62], ["demyelination", "DISEASE", 78, 91], ["Fn1", "GENE_OR_GENE_PRODUCT", 0, 3], ["M2", "GENE_OR_GENE_PRODUCT", 17, 19], ["microglia", "CELL", 53, 62], ["Fn1", "PROTEIN", 0, 3], ["M2 marker", "PROTEIN", 17, 26], ["microglia", "CELL_TYPE", 53, 62], ["demyelination", "PROBLEM", 78, 91], ["microglia", "OBSERVATION", 53, 62], ["demyelination", "OBSERVATION", 78, 91]]], ["Although Il1rn transcript expression was elevated in both BMDM and microglia, the increase was at best modest in microglia (Figure 8C).", [["BMDM", "ANATOMY", 58, 62], ["microglia", "ANATOMY", 67, 76], ["microglia", "ANATOMY", 113, 122], ["Il1rn", "GENE_OR_GENE_PRODUCT", 9, 14], ["BMDM", "CELL", 58, 62], ["microglia", "CELL", 67, 76], ["microglia", "CELL", 113, 122], ["Il1rn", "PROTEIN", 9, 14], ["BMDM", "CELL_TYPE", 58, 62], ["microglia", "CELL_TYPE", 67, 76], ["microglia", "CELL_TYPE", 113, 122], ["Il1rn transcript expression", "PROBLEM", 9, 36], ["elevated", "PROBLEM", 41, 49], ["elevated", "OBSERVATION_MODIFIER", 41, 49], ["both", "ANATOMY_MODIFIER", 53, 57], ["BMDM", "ANATOMY", 58, 62], ["microglia", "ANATOMY", 67, 76], ["increase", "OBSERVATION_MODIFIER", 82, 90]]], ["The majority (86\u201395%) of M2 markers upregulated during JHMV infection were rather expressed by infiltrating BMDM, including Arg1, Erg2, Il-10, and Ccl22 (Figures 8A,C and data not shown).", [["BMDM", "ANATOMY", 108, 112], ["infection", "DISEASE", 60, 69], ["M2", "GENE_OR_GENE_PRODUCT", 25, 27], ["JHMV", "GENE_OR_GENE_PRODUCT", 55, 59], ["BMDM", "CELL", 108, 112], ["Arg1", "GENE_OR_GENE_PRODUCT", 124, 128], ["Erg2", "GENE_OR_GENE_PRODUCT", 130, 134], ["Il-10", "GENE_OR_GENE_PRODUCT", 136, 141], ["Ccl22", "GENE_OR_GENE_PRODUCT", 147, 152], ["M2 markers", "PROTEIN", 25, 35], ["infiltrating BMDM", "CELL_TYPE", 95, 112], ["Arg1", "PROTEIN", 124, 128], ["Erg2", "PROTEIN", 130, 134], ["Il-10", "PROTEIN", 136, 141], ["Ccl22", "PROTEIN", 147, 152], ["JHMV", "SPECIES", 55, 59], ["M2 markers", "TEST", 25, 35], ["JHMV infection", "PROBLEM", 55, 69], ["infiltrating BMDM", "PROBLEM", 95, 112], ["Arg1", "TEST", 124, 128], ["Erg2", "TEST", 130, 134], ["Il", "TEST", 136, 138], ["Ccl22", "TEST", 147, 152], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["infection", "OBSERVATION", 60, 69], ["infiltrating BMDM", "OBSERVATION", 95, 112]]], ["Increased transcript levels were most pronounces at days 5 and 7 p.i., but dropped off thereafter.", [["Increased transcript levels", "PROBLEM", 0, 27]]], ["Altogether, these data showed that while infiltrating BMDM express a mixed phenotype of M1 and M2 markers during JHMV infection, microglia expressed primarily pro-inflammatory genes while not expressing M2 markers.DiscussionMicroglia and infiltrating macrophages are major components of MS active lesions (51).", [["BMDM", "ANATOMY", 54, 58], ["microglia", "ANATOMY", 129, 138], ["Microglia", "ANATOMY", 224, 233], ["infiltrating macrophages", "ANATOMY", 238, 262], ["lesions", "ANATOMY", 297, 304], ["infection", "DISEASE", 118, 127], ["BMDM", "CELL", 54, 58], ["M1", "CELL", 88, 90], ["M2", "GENE_OR_GENE_PRODUCT", 95, 97], ["JHMV", "GENE_OR_GENE_PRODUCT", 113, 117], ["microglia", "CELL", 129, 138], ["M2", "GENE_OR_GENE_PRODUCT", 203, 205], ["Microglia", "CELL", 224, 233], ["infiltrating macrophages", "CELL", 238, 262], ["MS active lesions", "CANCER", 287, 304], ["BMDM", "CELL_TYPE", 54, 58], ["M1 and M2 markers", "PROTEIN", 88, 105], ["microglia", "CELL_TYPE", 129, 138], ["pro-inflammatory genes", "DNA", 159, 181], ["M2 markers", "PROTEIN", 203, 213], ["Microglia", "CELL_TYPE", 224, 233], ["infiltrating macrophages", "CELL_TYPE", 238, 262], ["JHMV", "SPECIES", 113, 117], ["these data", "TEST", 12, 22], ["infiltrating BMDM", "PROBLEM", 41, 58], ["a mixed phenotype of M1 and M2 markers", "PROBLEM", 67, 105], ["JHMV infection", "PROBLEM", 113, 127], ["infiltrating macrophages", "PROBLEM", 238, 262], ["MS active lesions", "PROBLEM", 287, 304], ["M1", "ANATOMY", 88, 90], ["infection", "OBSERVATION", 118, 127], ["pro-inflammatory genes", "OBSERVATION", 159, 181], ["infiltrating macrophages", "OBSERVATION", 238, 262], ["MS", "OBSERVATION_MODIFIER", 287, 289], ["active", "OBSERVATION_MODIFIER", 290, 296], ["lesions", "OBSERVATION", 297, 304]]], ["Their effector functions are highly heterogeneous as evidenced by both pathogenic and protective functions during the course of MS (7).", [["MS", "DISEASE", 128, 130], ["highly", "OBSERVATION_MODIFIER", 29, 35], ["heterogeneous", "OBSERVATION_MODIFIER", 36, 49], ["both", "OBSERVATION_MODIFIER", 66, 70], ["pathogenic", "OBSERVATION", 71, 81], ["protective", "OBSERVATION_MODIFIER", 86, 96]]], ["They can promote tissue damage by releasing toxic and pro-inflammatory molecules, mediate demyelinated axons through phagocytosis as well as propagate inflammation by recruiting and activating adaptive immune cells.", [["tissue", "ANATOMY", 17, 23], ["demyelinated axons", "ANATOMY", 90, 108], ["immune cells", "ANATOMY", 202, 214], ["inflammation", "DISEASE", 151, 163], ["tissue", "TISSUE", 17, 23], ["demyelinated axons", "CELLULAR_COMPONENT", 90, 108], ["immune cells", "CELL", 202, 214], ["pro-inflammatory molecules", "PROTEIN", 54, 80], ["adaptive immune cells", "CELL_TYPE", 193, 214], ["tissue damage", "PROBLEM", 17, 30], ["releasing toxic and pro-inflammatory molecules", "PROBLEM", 34, 80], ["mediate demyelinated axons through phagocytosis", "PROBLEM", 82, 129], ["propagate inflammation", "PROBLEM", 141, 163], ["activating adaptive immune cells", "TREATMENT", 182, 214], ["inflammation", "OBSERVATION", 151, 163]]], ["On the other hand, both populations also display protective functions by clearing myelin debris, which facilitates remyelination, as well as releasing trophic and anti-inflammatory factors, which promote tissue repair.", [["myelin debris", "ANATOMY", 82, 95], ["tissue", "ANATOMY", 204, 210], ["myelin debris", "CELLULAR_COMPONENT", 82, 95], ["tissue", "TISSUE", 204, 210], ["anti-inflammatory factors", "PROTEIN", 163, 188], ["clearing myelin debris", "PROBLEM", 73, 95], ["anti-inflammatory factors", "TREATMENT", 163, 188], ["tissue repair", "TREATMENT", 204, 217], ["clearing", "OBSERVATION_MODIFIER", 73, 81], ["myelin debris", "OBSERVATION", 82, 95], ["anti-inflammatory factors", "OBSERVATION", 163, 188], ["tissue repair", "OBSERVATION", 204, 217]]], ["While it remains a challenge to distinguish infiltrating macrophages from microglia in MS lesions due to morphological and phenotypic similarities, they are disparate effector cells based on animal MS models (17, 52).", [["macrophages", "ANATOMY", 57, 68], ["microglia", "ANATOMY", 74, 83], ["MS lesions", "ANATOMY", 87, 97], ["cells", "ANATOMY", 176, 181], ["macrophages", "CELL", 57, 68], ["microglia", "CELL", 74, 83], ["MS lesions", "PATHOLOGICAL_FORMATION", 87, 97], ["cells", "CELL", 176, 181], ["infiltrating macrophages", "CELL_TYPE", 44, 68], ["microglia", "CELL_TYPE", 74, 83], ["effector cells", "CELL_TYPE", 167, 181], ["infiltrating macrophages", "PROBLEM", 44, 68], ["microglia in MS lesions", "PROBLEM", 74, 97], ["morphological and phenotypic similarities", "PROBLEM", 105, 146], ["disparate effector cells", "PROBLEM", 157, 181], ["animal MS models", "TEST", 191, 207], ["infiltrating", "OBSERVATION_MODIFIER", 44, 56], ["macrophages", "OBSERVATION", 57, 68], ["microglia", "OBSERVATION_MODIFIER", 74, 83], ["effector cells", "OBSERVATION", 167, 181]]], ["Questions relating to the pathogenicity of infiltrating macrophages and/or microglia in MS remain unanswered.", [["infiltrating macrophages", "ANATOMY", 43, 67], ["microglia", "ANATOMY", 75, 84], ["MS", "DISEASE", 88, 90], ["macrophages", "CELL", 56, 67], ["microglia", "CELL", 75, 84], ["infiltrating macrophages", "CELL_TYPE", 43, 67], ["microglia", "CELL_TYPE", 75, 84], ["infiltrating macrophages", "PROBLEM", 43, 67], ["microglia in MS", "PROBLEM", 75, 90], ["infiltrating macrophages", "OBSERVATION", 43, 67]]], ["Do they display dynamic functions throughout the evolution of MS lesions?", [["MS lesions", "ANATOMY", 62, 72], ["MS", "DISEASE", 62, 64], ["MS lesions", "CANCER", 62, 72], ["MS lesions", "PROBLEM", 62, 72], ["dynamic functions", "OBSERVATION", 16, 33], ["lesions", "OBSERVATION", 65, 72]]], ["Deciphering the respective roles of macrophages versus microglia in facilitating tissue damage and/or repair is essential to our understanding of MS pathogenesis and development of effective therapeutic strategies.DiscussionIn the murine EAE model of MS, infiltrating BMDM are essential in mediating demyelination (53).", [["macrophages", "ANATOMY", 36, 47], ["microglia", "ANATOMY", 55, 64], ["tissue", "ANATOMY", 81, 87], ["BMDM", "ANATOMY", 268, 272], ["MS", "DISEASE", 146, 148], ["EAE", "DISEASE", 238, 241], ["MS", "DISEASE", 251, 253], ["demyelination", "DISEASE", 300, 313], ["macrophages", "CELL", 36, 47], ["microglia", "CELL", 55, 64], ["tissue", "TISSUE", 81, 87], ["murine", "ORGANISM", 231, 237], ["BMDM", "CELL", 268, 272], ["macrophages", "CELL_TYPE", 36, 47], ["microglia", "CELL_TYPE", 55, 64], ["BMDM", "CELL_TYPE", 268, 272], ["murine", "SPECIES", 231, 237], ["macrophages", "PROBLEM", 36, 47], ["microglia", "PROBLEM", 55, 64], ["facilitating tissue damage", "PROBLEM", 68, 94], ["repair", "TREATMENT", 102, 108], ["MS pathogenesis", "PROBLEM", 146, 161], ["effective therapeutic strategies", "TREATMENT", 181, 213], ["MS", "PROBLEM", 251, 253], ["infiltrating BMDM", "PROBLEM", 255, 272], ["mediating demyelination", "PROBLEM", 290, 313], ["macrophages", "OBSERVATION", 36, 47], ["tissue damage", "OBSERVATION", 81, 94], ["effective", "OBSERVATION_MODIFIER", 181, 190], ["infiltrating BMDM", "OBSERVATION", 255, 272], ["demyelination", "OBSERVATION", 300, 313]]], ["Gene expression profiles demonstrated that BMDM are indeed highly phagocytic and inflammatory at disease onset, while microglia display a repressed phenotype (17).", [["microglia", "ANATOMY", 118, 127], ["BMDM", "CELL", 43, 47], ["microglia", "CELL", 118, 127], ["BMDM", "CELL_TYPE", 43, 47], ["microglia", "CELL_TYPE", 118, 127], ["Gene expression profiles", "TEST", 0, 24], ["BMDM", "PROBLEM", 43, 47], ["inflammatory at disease onset", "PROBLEM", 81, 110], ["highly", "OBSERVATION_MODIFIER", 59, 65], ["phagocytic", "OBSERVATION_MODIFIER", 66, 76], ["inflammatory", "OBSERVATION_MODIFIER", 81, 93]]], ["By contrast, during JHMV-induced demyelination, recruited BMDM are dispensable for the demyelinating process (30).", [["BMDM", "ANATOMY", 58, 62], ["JHMV", "CHEMICAL", 20, 24], ["demyelination", "DISEASE", 33, 46], ["BMDM", "CELL", 58, 62], ["BMDM", "CELL_TYPE", 58, 62], ["demyelination", "PROBLEM", 33, 46], ["the demyelinating process", "PROBLEM", 83, 108], ["demyelination", "OBSERVATION", 33, 46]]], ["Distinct from EAE, where microglia activation precedes CNS infiltration of BMDM (52), JHMV infection elicits early BMDM infiltration, prior to microglia activation.", [["microglia", "ANATOMY", 25, 34], ["CNS", "ANATOMY", 55, 58], ["BMDM", "ANATOMY", 115, 119], ["microglia", "ANATOMY", 143, 152], ["EAE", "DISEASE", 14, 17], ["infection", "DISEASE", 91, 100], ["microglia", "CELL", 25, 34], ["CNS", "ANATOMICAL_SYSTEM", 55, 58], ["JHMV", "GENE_OR_GENE_PRODUCT", 86, 90], ["BMDM", "CELL", 115, 119], ["microglia", "CELL", 143, 152], ["microglia", "CELL_TYPE", 25, 34], ["microglia", "CELL_TYPE", 143, 152], ["JHMV", "SPECIES", 86, 90], ["CNS infiltration of BMDM", "PROBLEM", 55, 79], ["JHMV infection", "PROBLEM", 86, 100], ["early BMDM infiltration", "PROBLEM", 109, 132], ["EAE", "OBSERVATION", 14, 17], ["infection", "OBSERVATION", 91, 100], ["early", "OBSERVATION_MODIFIER", 109, 114], ["BMDM infiltration", "OBSERVATION", 115, 132], ["microglia activation", "OBSERVATION", 143, 163]]], ["These distinct kinetics of BMDM recruitment relative to microglia activation thus appear to correlate with the apparently opposing roles of microglia as demyelinating populations.", [["microglia", "ANATOMY", 56, 65], ["microglia", "ANATOMY", 140, 149], ["BMDM", "CELL", 27, 31], ["microglia", "CELL", 56, 65], ["microglia", "CELL", 140, 149], ["microglia", "CELL_TYPE", 56, 65], ["microglia", "CELL_TYPE", 140, 149], ["BMDM recruitment", "TREATMENT", 27, 43], ["microglia as demyelinating populations", "PROBLEM", 140, 178], ["distinct", "OBSERVATION_MODIFIER", 6, 14], ["kinetics", "OBSERVATION_MODIFIER", 15, 23], ["BMDM recruitment", "OBSERVATION", 27, 43], ["microglia activation", "OBSERVATION", 56, 76], ["microglia", "OBSERVATION", 140, 149]]], ["These data further suggest that early responses set the stage or imprint subsequent effector functions of BMDM and microglia.", [["BMDM", "ANATOMY", 106, 110], ["microglia", "ANATOMY", 115, 124], ["BMDM", "CELL", 106, 110], ["microglia", "CELL", 115, 124], ["BMDM", "CELL_TYPE", 106, 110], ["microglia", "CELL_TYPE", 115, 124], ["BMDM", "PROBLEM", 106, 110], ["microglia", "PROBLEM", 115, 124]]], ["Using a similar approach with Nanostring analysis as in EAE, the present study used gene expression profiling to characterize both BMDM and microglia myeloid functions at various times post JHMV infection.", [["BMDM", "ANATOMY", 131, 135], ["microglia myeloid", "ANATOMY", 140, 157], ["EAE", "DISEASE", 56, 59], ["infection", "DISEASE", 195, 204], ["BMDM", "CELL", 131, 135], ["microglia myeloid", "CELL", 140, 157], ["JHMV", "ORGANISM", 190, 194], ["BMDM", "CELL_TYPE", 131, 135], ["microglia", "CELL_TYPE", 140, 149], ["JHMV", "SPECIES", 190, 194], ["Nanostring analysis", "TEST", 30, 49], ["the present study", "TEST", 61, 78], ["gene expression profiling", "TEST", 84, 109], ["both BMDM and microglia myeloid functions", "PROBLEM", 126, 167], ["JHMV infection", "PROBLEM", 190, 204], ["microglia myeloid", "OBSERVATION", 140, 157], ["infection", "OBSERVATION", 195, 204]]], ["Analysis of overall gene expression patterns revealed that the most extensive changes in BMDM were evident early after infection, while microglia showed a more dynamic profile throughout the course of viral encephalomyelitis.", [["microglia", "ANATOMY", 136, 145], ["infection", "DISEASE", 119, 128], ["viral encephalomyelitis", "DISEASE", 201, 224], ["BMDM", "CELL", 89, 93], ["microglia", "CELL", 136, 145], ["BMDM", "CELL_TYPE", 89, 93], ["microglia", "CELL_TYPE", 136, 145], ["overall gene expression patterns", "TEST", 12, 44], ["the most extensive changes in BMDM", "PROBLEM", 59, 93], ["infection", "PROBLEM", 119, 128], ["microglia", "TEST", 136, 145], ["viral encephalomyelitis", "PROBLEM", 201, 224], ["most", "OBSERVATION_MODIFIER", 63, 67], ["extensive", "OBSERVATION_MODIFIER", 68, 77], ["BMDM", "OBSERVATION", 89, 93], ["infection", "OBSERVATION", 119, 128], ["viral encephalomyelitis", "OBSERVATION", 201, 224]]], ["Importantly, the most drastic gene upregulation in microglia was observed coincident with demyelination, at which time peak viral load and T cell effector function have substantially subsided (54).", [["microglia", "ANATOMY", 51, 60], ["T cell", "ANATOMY", 139, 145], ["demyelination", "DISEASE", 90, 103], ["microglia", "CELL", 51, 60], ["T cell", "CELL", 139, 145], ["microglia", "CELL_TYPE", 51, 60], ["demyelination", "PROBLEM", 90, 103], ["peak viral load", "TEST", 119, 134], ["T cell effector function", "TEST", 139, 163], ["drastic", "OBSERVATION_MODIFIER", 22, 29], ["gene upregulation", "OBSERVATION", 30, 47], ["microglia", "ANATOMY", 51, 60], ["demyelination", "OBSERVATION", 90, 103], ["viral load", "OBSERVATION", 124, 134]]], ["Our data contrast with EAE (17), where BMDM upregulated far more genes compared to microglia at disease onset, supporting opposing functions of BMDM and microglia in mediating demyelination in these two models.", [["microglia", "ANATOMY", 83, 92], ["BMDM", "ANATOMY", 144, 148], ["microglia", "ANATOMY", 153, 162], ["EAE", "DISEASE", 23, 26], ["demyelination", "DISEASE", 176, 189], ["BMDM", "CELL", 39, 43], ["microglia", "CELL", 83, 92], ["BMDM", "CELL", 144, 148], ["microglia", "CELL", 153, 162], ["microglia", "CELL_TYPE", 83, 92], ["BMDM", "CELL_TYPE", 144, 148], ["microglia", "CELL_TYPE", 153, 162], ["Our data contrast", "TEST", 0, 17], ["microglia at disease onset", "PROBLEM", 83, 109], ["BMDM", "PROBLEM", 144, 148], ["microglia in mediating demyelination", "PROBLEM", 153, 189], ["BMDM", "OBSERVATION", 144, 148], ["demyelination", "OBSERVATION", 176, 189]]], ["Further, while BMDM exhibited a mixed expression profile of both pro- and anti-inflammatory markers, microglia expressed a highly pro-inflammatory profile and repressed most of the M2 markers across the entire time course of JHMV encephalomyelitis.DiscussionAnalysis of protein-interacting networks within genes upregulated in microglia at the time of myelin loss revealed several key functions linked to promoting tissue damage.", [["microglia", "ANATOMY", 101, 110], ["microglia", "ANATOMY", 327, 336], ["myelin", "ANATOMY", 352, 358], ["tissue", "ANATOMY", 415, 421], ["encephalomyelitis", "DISEASE", 230, 247], ["myelin loss", "DISEASE", 352, 363], ["tissue damage", "DISEASE", 415, 428], ["BMDM", "CELL", 15, 19], ["microglia", "CELL", 101, 110], ["M2", "GENE_OR_GENE_PRODUCT", 181, 183], ["microglia", "CELL", 327, 336], ["myelin", "GENE_OR_GENE_PRODUCT", 352, 358], ["tissue", "TISSUE", 415, 421], ["BMDM", "CELL_TYPE", 15, 19], ["anti-inflammatory markers", "PROTEIN", 74, 99], ["microglia", "CELL_TYPE", 101, 110], ["M2 markers", "PROTEIN", 181, 191], ["microglia", "CELL_TYPE", 327, 336], ["JHMV encephalomyelitis", "SPECIES", 225, 247], ["JHMV encephalomyelitis", "PROBLEM", 225, 247], ["protein", "TEST", 270, 277], ["myelin loss", "PROBLEM", 352, 363], ["tissue damage", "PROBLEM", 415, 428], ["anti-inflammatory markers", "OBSERVATION", 74, 99], ["JHMV encephalomyelitis", "OBSERVATION", 225, 247], ["promoting tissue", "OBSERVATION_MODIFIER", 405, 421], ["damage", "OBSERVATION", 422, 428]]], ["Genes associated with complement activation were notably increased, although they were already highly expressed by microglia under homeostatic conditions.", [["microglia", "ANATOMY", 115, 124], ["complement", "GENE_OR_GENE_PRODUCT", 22, 32], ["microglia", "CELL", 115, 124], ["microglia", "CELL_TYPE", 115, 124], ["complement activation", "PROBLEM", 22, 43], ["increased", "OBSERVATION_MODIFIER", 57, 66]]], ["Complement activation as a pathogenic component in MS has been reported following detection of deposits of the activated products of the complement component C3 in MS lesions (55).", [["MS lesions", "ANATOMY", 164, 174], ["MS", "DISEASE", 51, 53], ["Complement", "GENE_OR_GENE_PRODUCT", 0, 10], ["complement component C3", "GENE_OR_GENE_PRODUCT", 137, 160], ["MS lesions", "CANCER", 164, 174], ["complement component C3", "PROTEIN", 137, 160], ["a pathogenic component in MS", "PROBLEM", 25, 53], ["deposits", "PROBLEM", 95, 103], ["MS lesions", "PROBLEM", 164, 174], ["pathogenic", "OBSERVATION_MODIFIER", 27, 37], ["component", "OBSERVATION_MODIFIER", 38, 47], ["deposits", "OBSERVATION", 95, 103], ["component", "OBSERVATION_MODIFIER", 148, 157], ["C3", "OBSERVATION_MODIFIER", 158, 160]]], ["The classical complement pathway has also been shown to mediate OLG death thus promoting demyelination (56).", [["death", "DISEASE", 68, 73], ["demyelination", "DISEASE", 89, 102], ["OLG", "GENE_OR_GENE_PRODUCT", 64, 67], ["demyelination", "PROBLEM", 89, 102], ["demyelination", "OBSERVATION", 89, 102]]], ["Microglia phagocytic activity may also initiate tissue damage by directly removing myelin from axons, especially at the node of Ranvier (17).", [["Microglia", "ANATOMY", 0, 9], ["tissue", "ANATOMY", 48, 54], ["myelin", "ANATOMY", 83, 89], ["axons", "ANATOMY", 95, 100], ["node", "ANATOMY", 120, 124], ["Microglia", "CELL", 0, 9], ["tissue", "TISSUE", 48, 54], ["myelin", "GENE_OR_GENE_PRODUCT", 83, 89], ["axons", "CELLULAR_COMPONENT", 95, 100], ["Microglia phagocytic activity", "PROBLEM", 0, 29], ["tissue damage", "PROBLEM", 48, 61], ["myelin from axons", "PROBLEM", 83, 100], ["phagocytic activity", "OBSERVATION", 10, 29], ["damage", "OBSERVATION", 55, 61], ["node", "ANATOMY", 120, 124]]], ["Genes associated with TREM2/DAP12 signaling were also highly expressed by microglia at time of demyelination.", [["microglia", "ANATOMY", 74, 83], ["demyelination", "DISEASE", 95, 108], ["TREM2", "GENE_OR_GENE_PRODUCT", 22, 27], ["DAP12", "GENE_OR_GENE_PRODUCT", 28, 33], ["microglia", "CELL", 74, 83], ["TREM2", "PROTEIN", 22, 27], ["DAP12", "PROTEIN", 28, 33], ["microglia", "CELL_TYPE", 74, 83], ["TREM2/DAP12 signaling", "PROBLEM", 22, 43], ["demyelination", "PROBLEM", 95, 108], ["demyelination", "OBSERVATION", 95, 108]]], ["TREM2 modulates phagocytic capacity of myeloid cells via DAP12 signaling (57) and is expressed on myelin-loaded myeloid cells in MS lesions (58), supporting a role in MS pathogenesis.", [["myeloid cells", "ANATOMY", 39, 52], ["myelin-loaded myeloid cells", "ANATOMY", 98, 125], ["MS lesions", "ANATOMY", 129, 139], ["MS", "DISEASE", 167, 169], ["TREM2", "GENE_OR_GENE_PRODUCT", 0, 5], ["myeloid cells", "CELL", 39, 52], ["DAP12", "GENE_OR_GENE_PRODUCT", 57, 62], ["myelin", "GENE_OR_GENE_PRODUCT", 98, 104], ["myeloid cells", "CELL", 112, 125], ["MS lesions", "CANCER", 129, 139], ["TREM2", "PROTEIN", 0, 5], ["myeloid cells", "CELL_TYPE", 39, 52], ["DAP12", "PROTEIN", 57, 62], ["myelin-loaded myeloid cells", "CELL_TYPE", 98, 125], ["phagocytic capacity", "TEST", 16, 35], ["myeloid cells", "PROBLEM", 39, 52], ["DAP12 signaling", "TEST", 57, 72], ["myelin", "TEST", 98, 104], ["myeloid cells", "PROBLEM", 112, 125], ["MS lesions", "PROBLEM", 129, 139], ["MS pathogenesis", "PROBLEM", 167, 182], ["phagocytic capacity", "OBSERVATION", 16, 35], ["myeloid cells", "OBSERVATION", 39, 52], ["myeloid cells", "OBSERVATION", 112, 125]]], ["Similar to JHMV infection, TREM2 is predominantly expressed by microglia during EAE and cuprizone-induced demyelination (59\u201361).", [["microglia", "ANATOMY", 63, 72], ["infection", "DISEASE", 16, 25], ["EAE", "DISEASE", 80, 83], ["cuprizone", "CHEMICAL", 88, 97], ["demyelination", "DISEASE", 106, 119], ["cuprizone", "CHEMICAL", 88, 97], ["JHMV", "GENE_OR_GENE_PRODUCT", 11, 15], ["TREM2", "GENE_OR_GENE_PRODUCT", 27, 32], ["microglia", "CELL", 63, 72], ["cuprizone", "SIMPLE_CHEMICAL", 88, 97], ["TREM2", "PROTEIN", 27, 32], ["microglia", "CELL_TYPE", 63, 72], ["JHMV", "SPECIES", 11, 15], ["JHMV infection", "PROBLEM", 11, 25], ["TREM2", "PROBLEM", 27, 32], ["EAE", "PROBLEM", 80, 83], ["cuprizone", "TREATMENT", 88, 97], ["demyelination", "PROBLEM", 106, 119], ["JHMV", "OBSERVATION_MODIFIER", 11, 15], ["infection", "OBSERVATION", 16, 25], ["TREM2", "OBSERVATION", 27, 32], ["microglia", "OBSERVATION_MODIFIER", 63, 72], ["demyelination", "OBSERVATION", 106, 119]]], ["However, TREM2-modulated phagocytic functions are essential for removal of myelin debris and remyelination implicating repair-promoting functions of microglia in the specific tissue environments defining these two demyelination models (17, 62).", [["myelin debris", "ANATOMY", 75, 88], ["microglia", "ANATOMY", 149, 158], ["tissue", "ANATOMY", 175, 181], ["demyelination", "DISEASE", 214, 227], ["TREM2", "GENE_OR_GENE_PRODUCT", 9, 14], ["myelin debris", "CELLULAR_COMPONENT", 75, 88], ["microglia", "CELL", 149, 158], ["tissue", "TISSUE", 175, 181], ["TREM2", "PROTEIN", 9, 14], ["microglia", "CELL_TYPE", 149, 158], ["TREM2", "TEST", 9, 14], ["removal", "TREATMENT", 64, 71], ["myelin debris", "PROBLEM", 75, 88], ["repair", "TREATMENT", 119, 125], ["phagocytic functions", "OBSERVATION", 25, 45], ["myelin debris", "OBSERVATION", 75, 88], ["repair", "OBSERVATION", 119, 125], ["microglia", "OBSERVATION_MODIFIER", 149, 158]]], ["Preferential TREM2 expression within microglia compared to BMDM following JHMV infection support a more pathogenic role of TREM-2 in JHMV-induced demyelination, potentially by promoting myelin stripping after recognition of glycolipids and phospholipids exposed on damaged myelin.", [["microglia", "ANATOMY", 37, 46], ["BMDM", "ANATOMY", 59, 63], ["myelin", "ANATOMY", 186, 192], ["myelin", "ANATOMY", 273, 279], ["infection", "DISEASE", 79, 88], ["demyelination", "DISEASE", 146, 159], ["TREM2", "GENE_OR_GENE_PRODUCT", 13, 18], ["microglia", "CELL", 37, 46], ["BMDM", "CELL", 59, 63], ["JHMV", "GENE_OR_GENE_PRODUCT", 74, 78], ["TREM-2", "GENE_OR_GENE_PRODUCT", 123, 129], ["JHMV", "ORGANISM", 133, 137], ["myelin", "GENE_OR_GENE_PRODUCT", 186, 192], ["phospholipids", "SIMPLE_CHEMICAL", 240, 253], ["myelin", "CELLULAR_COMPONENT", 273, 279], ["TREM2", "PROTEIN", 13, 18], ["microglia", "CELL_TYPE", 37, 46], ["BMDM", "CELL_TYPE", 59, 63], ["TREM-2", "PROTEIN", 123, 129], ["JHMV", "SPECIES", 74, 78], ["Preferential TREM2 expression within microglia", "PROBLEM", 0, 46], ["JHMV infection", "PROBLEM", 74, 88], ["TREM", "TEST", 123, 127], ["JHMV", "PROBLEM", 133, 137], ["demyelination", "PROBLEM", 146, 159], ["myelin stripping", "TREATMENT", 186, 202], ["glycolipids", "TREATMENT", 224, 235], ["phospholipids", "TREATMENT", 240, 253], ["damaged myelin", "PROBLEM", 265, 279], ["TREM2", "OBSERVATION", 13, 18], ["infection", "OBSERVATION", 79, 88], ["demyelination", "OBSERVATION", 146, 159], ["myelin stripping", "OBSERVATION", 186, 202]]], ["In this context, it is critical to note that JHMV infection is associated with extensive transient production of IFN-\u03b3 and its inducible genes, i.e., iNOS, and CXCR3 ligands, which may drive a more phagocytic pathway in microglia in efforts to remove damaged proteins and lipids (54).", [["microglia", "ANATOMY", 220, 229], ["infection", "DISEASE", 50, 59], ["JHMV", "GENE_OR_GENE_PRODUCT", 45, 49], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 113, 118], ["iNOS", "GENE_OR_GENE_PRODUCT", 150, 154], ["CXCR3", "GENE_OR_GENE_PRODUCT", 160, 165], ["microglia", "CELL", 220, 229], ["lipids", "SIMPLE_CHEMICAL", 272, 278], ["IFN-\u03b3", "PROTEIN", 113, 118], ["iNOS", "PROTEIN", 150, 154], ["CXCR3", "PROTEIN", 160, 165], ["microglia", "CELL_TYPE", 220, 229], ["JHMV", "SPECIES", 45, 49], ["JHMV infection", "PROBLEM", 45, 59], ["extensive transient production of IFN", "PROBLEM", 79, 116], ["its inducible genes", "PROBLEM", 123, 142], ["CXCR3 ligands", "TEST", 160, 173], ["lipids", "TEST", 272, 278], ["infection", "OBSERVATION", 50, 59], ["extensive", "OBSERVATION_MODIFIER", 79, 88], ["transient", "OBSERVATION_MODIFIER", 89, 98], ["production", "OBSERVATION_MODIFIER", 99, 109]]], ["Further investigation is required to define inflammatory conditions under which TREM-2 modulated or other phagocytic pathways promote tissue damage or repair and whether these are transient and reversible.", [["tissue", "ANATOMY", 134, 140], ["TREM-2", "GENE_OR_GENE_PRODUCT", 80, 86], ["tissue", "TISSUE", 134, 140], ["TREM-2", "PROTEIN", 80, 86], ["Further investigation", "TEST", 0, 21], ["inflammatory conditions", "PROBLEM", 44, 67], ["TREM", "TEST", 80, 84], ["other phagocytic pathways", "TREATMENT", 100, 125], ["tissue damage", "PROBLEM", 134, 147], ["repair", "TREATMENT", 151, 157], ["inflammatory", "OBSERVATION", 44, 56], ["repair", "OBSERVATION", 151, 157]]], ["Microglia may also induce demyelination by secreting toxic factors including inflammatory cytokines that are highly expressed by microglia at time of demyelination, including TNF.", [["Microglia", "ANATOMY", 0, 9], ["microglia", "ANATOMY", 129, 138], ["demyelination", "DISEASE", 26, 39], ["demyelination", "DISEASE", 150, 163], ["Microglia", "CELL", 0, 9], ["microglia", "CELL", 129, 138], ["TNF", "GENE_OR_GENE_PRODUCT", 175, 178], ["Microglia", "CELL_TYPE", 0, 9], ["toxic factors", "PROTEIN", 53, 66], ["inflammatory cytokines", "PROTEIN", 77, 99], ["microglia", "CELL_TYPE", 129, 138], ["TNF", "PROTEIN", 175, 178], ["Microglia", "PROBLEM", 0, 9], ["demyelination", "PROBLEM", 26, 39], ["secreting toxic factors", "PROBLEM", 43, 66], ["inflammatory cytokines", "PROBLEM", 77, 99], ["demyelination", "PROBLEM", 150, 163], ["TNF", "PROBLEM", 175, 178], ["may also induce", "UNCERTAINTY", 10, 25], ["demyelination", "OBSERVATION", 26, 39], ["secreting", "OBSERVATION_MODIFIER", 43, 52], ["toxic", "OBSERVATION_MODIFIER", 53, 58], ["inflammatory", "OBSERVATION_MODIFIER", 77, 89], ["demyelination", "OBSERVATION", 150, 163]]], ["TNF can induce OLG death (63, 64) and is expressed in active MS lesions, as well as elevated TNF in serum and cerebral spinal fluid correlates with enhanced MS pathology (65, 66).", [["MS lesions", "ANATOMY", 61, 71], ["serum", "ANATOMY", 100, 105], ["cerebral spinal fluid", "ANATOMY", 110, 131], ["death", "DISEASE", 19, 24], ["MS", "DISEASE", 157, 159], ["TNF", "GENE_OR_GENE_PRODUCT", 0, 3], ["OLG", "GENE_OR_GENE_PRODUCT", 15, 18], ["MS lesions", "CANCER", 61, 71], ["TNF", "GENE_OR_GENE_PRODUCT", 93, 96], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["cerebral spinal fluid", "ORGANISM_SUBSTANCE", 110, 131], ["TNF", "PROTEIN", 0, 3], ["TNF", "PROTEIN", 93, 96], ["OLG death", "PROBLEM", 15, 24], ["active MS lesions", "PROBLEM", 54, 71], ["elevated TNF in serum and cerebral spinal fluid", "PROBLEM", 84, 131], ["enhanced MS pathology", "PROBLEM", 148, 169], ["active", "OBSERVATION_MODIFIER", 54, 60], ["MS", "OBSERVATION_MODIFIER", 61, 63], ["lesions", "OBSERVATION", 64, 71], ["elevated", "OBSERVATION_MODIFIER", 84, 92], ["TNF", "OBSERVATION", 93, 96], ["cerebral spinal", "ANATOMY", 110, 125], ["fluid", "OBSERVATION", 126, 131]]], ["Finally, microglia functions during JHMV infection were also associated with promoting adaptive immune response.", [["microglia", "ANATOMY", 9, 18], ["infection", "DISEASE", 41, 50], ["microglia", "CELL", 9, 18], ["JHMV", "GENE_OR_GENE_PRODUCT", 36, 40], ["microglia", "CELL_TYPE", 9, 18], ["JHMV", "SPECIES", 36, 40], ["JHMV infection", "PROBLEM", 36, 50]]], ["An extensive network of chemokines and chemokines receptors relating to the recruitment and arrest of T and B cells within the inflamed CNS were highly expressed by microglia.", [["T", "ANATOMY", 102, 103], ["B cells", "ANATOMY", 108, 115], ["CNS", "ANATOMY", 136, 139], ["microglia", "ANATOMY", 165, 174], ["T", "CELL", 102, 103], ["B cells", "CELL", 108, 115], ["CNS", "ANATOMICAL_SYSTEM", 136, 139], ["microglia", "CELL", 165, 174], ["chemokines", "PROTEIN", 24, 34], ["chemokines receptors", "PROTEIN", 39, 59], ["T and B cells", "CELL_TYPE", 102, 115], ["microglia", "CELL_TYPE", 165, 174], ["chemokines and chemokines receptors", "TREATMENT", 24, 59], ["the recruitment", "PROBLEM", 72, 87], ["arrest of T and B cells", "PROBLEM", 92, 115], ["the inflamed CNS", "PROBLEM", 123, 139], ["extensive", "OBSERVATION_MODIFIER", 3, 12], ["recruitment", "OBSERVATION_MODIFIER", 76, 87], ["inflamed CNS", "ANATOMY", 127, 139], ["microglia", "OBSERVATION", 165, 174]]], ["Similarly, several genes associated with antigen processing and presentation by MHC class I and II molecules were upregulated within microglia, suggesting that microglia promote T cell reactivation upon CNS entry.", [["microglia", "ANATOMY", 133, 142], ["microglia", "ANATOMY", 160, 169], ["T cell", "ANATOMY", 178, 184], ["CNS", "ANATOMY", 203, 206], ["antigen", "GENE_OR_GENE_PRODUCT", 41, 48], ["MHC class I", "GENE_OR_GENE_PRODUCT", 80, 91], ["microglia", "CELL", 133, 142], ["microglia", "CELL", 160, 169], ["T cell", "CELL", 178, 184], ["CNS", "ANATOMICAL_SYSTEM", 203, 206], ["MHC class I and II molecules", "PROTEIN", 80, 108], ["microglia", "CELL_TYPE", 133, 142], ["microglia", "CELL_TYPE", 160, 169], ["antigen processing", "PROBLEM", 41, 59], ["microglia promote T cell reactivation", "PROBLEM", 160, 197], ["cell reactivation", "OBSERVATION", 180, 197]]], ["However, microglia explanted during EAE, TMEV as well as JHMV infections failed to support myelin-specific CD4 T cell responses ex vivo, despite detection of internalized myelin (67\u201369).", [["microglia", "ANATOMY", 9, 18], ["myelin", "ANATOMY", 91, 97], ["CD4 T cell", "ANATOMY", 107, 117], ["myelin", "ANATOMY", 171, 177], ["EAE", "DISEASE", 36, 39], ["infections", "DISEASE", 62, 72], ["microglia", "CELL", 9, 18], ["TMEV", "ORGANISM", 41, 45], ["myelin", "GENE_OR_GENE_PRODUCT", 91, 97], ["CD4 T cell", "CELL", 107, 117], ["myelin", "CELLULAR_COMPONENT", 171, 177], ["microglia", "CELL_TYPE", 9, 18], ["CD4", "PROTEIN", 107, 110], ["TMEV", "SPECIES", 41, 45], ["JHMV", "SPECIES", 57, 61], ["TMEV", "PROBLEM", 41, 45], ["JHMV infections", "PROBLEM", 57, 72], ["myelin", "TEST", 91, 97], ["internalized myelin", "PROBLEM", 158, 177]]], ["A potential deficit in antigen processing was supported by the ability of exogenous peptide to overcome the inability of microglia to prime myelin-specific CD4 T cells (69).", [["microglia", "ANATOMY", 121, 130], ["myelin", "ANATOMY", 140, 146], ["CD4 T cells", "ANATOMY", 156, 167], ["antigen", "GENE_OR_GENE_PRODUCT", 23, 30], ["microglia", "CELL", 121, 130], ["myelin", "GENE_OR_GENE_PRODUCT", 140, 146], ["CD4", "GENE_OR_GENE_PRODUCT", 156, 159], ["microglia", "CELL_TYPE", 121, 130], ["CD4 T cells", "CELL_TYPE", 156, 167], ["A potential deficit in antigen processing", "PROBLEM", 0, 41], ["exogenous peptide", "PROBLEM", 74, 91], ["potential", "UNCERTAINTY", 2, 11], ["deficit", "OBSERVATION", 12, 19]]], ["Nevertheless, this notion is opposed by our microglia profiling showing upregulation of genes involved in protein degradation and class II peptide loading, e.g. CD74 (Invariant chain), H2-DMa (peptide loading), Ctss (Cathepsin S), which cleaves invariant chain.", [["microglia", "CELL", 44, 53], ["class II peptide", "GENE_OR_GENE_PRODUCT", 130, 146], ["CD74", "GENE_OR_GENE_PRODUCT", 161, 165], ["H2-DMa", "GENE_OR_GENE_PRODUCT", 185, 191], ["Ctss", "GENE_OR_GENE_PRODUCT", 211, 215], ["Cathepsin S", "GENE_OR_GENE_PRODUCT", 217, 228], ["CD74", "PROTEIN", 161, 165], ["Invariant chain", "PROTEIN", 167, 182], ["H2", "PROTEIN", 185, 187], ["DMa", "PROTEIN", 188, 191], ["Ctss", "PROTEIN", 211, 215], ["Cathepsin S", "PROTEIN", 217, 228], ["invariant chain", "PROTEIN", 245, 260], ["our microglia profiling", "TEST", 40, 63], ["upregulation of genes", "PROBLEM", 72, 93], ["protein degradation", "PROBLEM", 106, 125], ["class II peptide loading", "PROBLEM", 130, 154], ["CD74", "TEST", 161, 165], ["H2-DMa (peptide loading)", "TREATMENT", 185, 209], ["Ctss (Cathepsin S)", "TREATMENT", 211, 229], ["chain", "OBSERVATION_MODIFIER", 255, 260]]], ["The apparent inability of microglia to elicit CD4 T cell effector function ex vivo thus remains intriguing.DiscussionOur present study reveals new insights into the plasticity of microglia in adapting to inflammation and expressing pathogenic functions associated with demyelination, characteristics which have previously been ascribed to BMDM (17).", [["microglia", "ANATOMY", 26, 35], ["CD4 T cell", "ANATOMY", 46, 56], ["microglia", "ANATOMY", 179, 188], ["inflammation", "DISEASE", 204, 216], ["demyelination", "DISEASE", 269, 282], ["microglia", "CELL", 26, 35], ["CD4", "GENE_OR_GENE_PRODUCT", 46, 49], ["microglia", "CELL", 179, 188], ["BMDM", "CELL", 339, 343], ["microglia", "CELL_TYPE", 26, 35], ["CD4", "PROTEIN", 46, 49], ["microglia", "CELL_TYPE", 179, 188], ["The apparent inability of microglia", "PROBLEM", 0, 35], ["CD4", "TEST", 46, 49], ["DiscussionOur present study", "TEST", 107, 134], ["inflammation", "PROBLEM", 204, 216], ["expressing pathogenic functions", "PROBLEM", 221, 252], ["demyelination", "PROBLEM", 269, 282], ["new", "OBSERVATION_MODIFIER", 143, 146], ["microglia", "OBSERVATION", 179, 188], ["inflammation", "OBSERVATION", 204, 216], ["demyelination", "OBSERVATION", 269, 282]]], ["Moreover, altered BMDM expression profiles coincided with their early infiltration into the CNS and remained largely similar throughout infection.", [["CNS", "ANATOMY", 92, 95], ["infection", "DISEASE", 136, 145], ["BMDM", "CELL", 18, 22], ["CNS", "ANATOMICAL_SYSTEM", 92, 95], ["BMDM", "PROTEIN", 18, 22], ["altered BMDM expression profiles", "PROBLEM", 10, 42], ["their early infiltration into the CNS", "PROBLEM", 58, 95], ["early", "OBSERVATION_MODIFIER", 64, 69], ["infiltration", "OBSERVATION", 70, 82], ["CNS", "ANATOMY", 92, 95], ["largely", "OBSERVATION_MODIFIER", 109, 116], ["similar", "OBSERVATION", 117, 124], ["infection", "OBSERVATION", 136, 145]]], ["While altered microglia gene expression coincided with the time of early, yet robust demyelination, it remains to be determined whether these changes are sustained at later time points during JHMV persistence, when clinical disease improves and remyelination occurs.", [["demyelination", "DISEASE", 85, 98], ["remyelination", "DISEASE", 245, 258], ["microglia", "CELL", 14, 23], ["robust demyelination", "PROBLEM", 78, 98], ["clinical disease", "PROBLEM", 215, 231], ["remyelination", "PROBLEM", 245, 258], ["microglia gene", "OBSERVATION", 14, 28], ["demyelination", "OBSERVATION", 85, 98]]], ["It will be of specific interest to assess whether the microglia pro-inflammatory phenotype evolves to an anti-inflammatory, repair-promoting phenotype, as evidenced by the plasticity of myeloid cells in CNS autoimmunity (70).", [["microglia", "ANATOMY", 54, 63], ["myeloid cells", "ANATOMY", 186, 199], ["CNS", "ANATOMY", 203, 206], ["autoimmunity", "DISEASE", 207, 219], ["microglia", "CELL", 54, 63], ["myeloid cells", "CELL", 186, 199], ["CNS", "ANATOMICAL_SYSTEM", 203, 206], ["myeloid cells", "CELL_TYPE", 186, 199], ["the microglia pro-inflammatory phenotype", "PROBLEM", 50, 90], ["repair", "TREATMENT", 124, 130], ["promoting phenotype", "PROBLEM", 131, 150], ["myeloid cells", "PROBLEM", 186, 199], ["anti-inflammatory", "OBSERVATION_MODIFIER", 105, 122], ["myeloid cells", "OBSERVATION", 186, 199]]], ["Furthermore, our study emphasizes that the distinct tissue environments during EAE and JHMV infection drive opposite effector functions of microglia versus infiltrating macrophages.", [["tissue", "ANATOMY", 52, 58], ["microglia", "ANATOMY", 139, 148], ["infiltrating macrophages", "ANATOMY", 156, 180], ["EAE", "DISEASE", 79, 82], ["infection", "DISEASE", 92, 101], ["tissue", "TISSUE", 52, 58], ["microglia", "CELL", 139, 148], ["macrophages", "CELL", 169, 180], ["microglia", "CELL_TYPE", 139, 148], ["infiltrating macrophages", "CELL_TYPE", 156, 180], ["JHMV", "SPECIES", 87, 91], ["our study", "TEST", 13, 22], ["the distinct tissue environments", "PROBLEM", 39, 71], ["EAE", "PROBLEM", 79, 82], ["JHMV infection", "PROBLEM", 87, 101], ["infiltrating macrophages", "PROBLEM", 156, 180], ["infection", "OBSERVATION", 92, 101], ["microglia", "OBSERVATION", 139, 148]]], ["The interplay between T cells, infiltrating macrophages and microglia, as well as astrocytes drives MS pathogenesis, yet mechanisms ultimately leading to loss of repair remain unclear.", [["T cells", "ANATOMY", 22, 29], ["infiltrating macrophages", "ANATOMY", 31, 55], ["microglia", "ANATOMY", 60, 69], ["astrocytes", "ANATOMY", 82, 92], ["MS", "DISEASE", 100, 102], ["loss of repair", "DISEASE", 154, 168], ["T cells", "CELL", 22, 29], ["macrophages", "CELL", 44, 55], ["microglia", "CELL", 60, 69], ["astrocytes", "CELL", 82, 92], ["T cells", "CELL_TYPE", 22, 29], ["infiltrating macrophages", "CELL_TYPE", 31, 55], ["microglia", "CELL_TYPE", 60, 69], ["astrocytes", "CELL_TYPE", 82, 92], ["infiltrating macrophages", "PROBLEM", 31, 55], ["microglia", "PROBLEM", 60, 69], ["MS pathogenesis", "PROBLEM", 100, 115], ["repair", "TREATMENT", 162, 168], ["infiltrating macrophages", "OBSERVATION", 31, 55], ["microglia", "ANATOMY", 60, 69], ["repair", "OBSERVATION", 162, 168]]], ["Taking advantage of demyelinating models characterized by distinct inflammatory factors such as both Th1 and Th17 cells in EAE (11), strong Th1 polarized responses during JHMV infection, distinct kinetics of BMDM recruitment versus glia activation promises to reveal essential new insights into the interplay of microglia and BMDM functions in debris clearance versus active myelin stripping and ongoing axonal damage.", [["Th17 cells", "ANATOMY", 109, 119], ["glia", "ANATOMY", 232, 236], ["microglia", "ANATOMY", 312, 321], ["BMDM", "ANATOMY", 326, 330], ["debris", "ANATOMY", 344, 350], ["myelin", "ANATOMY", 375, 381], ["axonal", "ANATOMY", 404, 410], ["EAE", "DISEASE", 123, 126], ["infection", "DISEASE", 176, 185], ["axonal damage", "DISEASE", 404, 417], ["Th1", "CELL", 101, 104], ["Th17 cells", "CELL", 109, 119], ["BMDM", "CELL", 208, 212], ["glia", "CELL", 232, 236], ["microglia", "CELL", 312, 321], ["BMDM", "CELL", 326, 330], ["debris", "TISSUE", 344, 350], ["axonal", "MULTI-TISSUE_STRUCTURE", 404, 410], ["inflammatory factors", "PROTEIN", 67, 87], ["Th1 and Th17 cells", "CELL_TYPE", 101, 119], ["microglia", "CELL_TYPE", 312, 321], ["JHMV", "SPECIES", 171, 175], ["demyelinating models", "PROBLEM", 20, 40], ["distinct inflammatory factors", "PROBLEM", 58, 87], ["JHMV infection", "PROBLEM", 171, 185], ["BMDM recruitment", "TREATMENT", 208, 224], ["debris clearance", "PROBLEM", 344, 360], ["active myelin stripping", "TREATMENT", 368, 391], ["ongoing axonal damage", "PROBLEM", 396, 417], ["distinct", "OBSERVATION_MODIFIER", 58, 66], ["inflammatory", "OBSERVATION", 67, 79], ["Th17 cells", "OBSERVATION", 109, 119], ["infection", "OBSERVATION", 176, 185], ["BMDM recruitment", "OBSERVATION", 208, 224], ["new", "OBSERVATION_MODIFIER", 277, 280], ["microglia", "ANATOMY", 312, 321], ["debris", "OBSERVATION_MODIFIER", 344, 350], ["active", "OBSERVATION_MODIFIER", 368, 374], ["myelin stripping", "OBSERVATION", 375, 391], ["axonal damage", "OBSERVATION", 404, 417]]], ["Longitudinal studies will aid in developing efficient future therapies to combat MS pathogenesis.Ethics StatementAll procedures were performed in compliance with protocols approved by the Cleveland Clinic Institutional Animal Care and Use Committee.Author ContributionsCS designed and performed experiments, collected and interpreted the data, and wrote the manuscript.", [["MS", "DISEASE", 81, 83], ["Longitudinal studies", "TEST", 0, 20], ["efficient future therapies", "TREATMENT", 44, 70], ["MS pathogenesis", "PROBLEM", 81, 96]]]], "b1a4d0d9eac3e1265532e7c12fb292328e3805c4": [["While news are looped on TV, a very few specialists know deeply on COVID-19.", [["COVID-19", "DNA", 67, 75], ["COVID", "TEST", 67, 72]]], ["Both in-deep analyses and overviews on a large quantity of research papers can help decision makers or even citizens to be better educated on the state of the art.", [["deep", "ANATOMY_MODIFIER", 8, 12]]], ["For people, it can help move aside fake news.", [["people", "ORGANISM", 4, 10], ["people", "SPECIES", 4, 10]]], ["It can also help new comers in the COVID-19 research field providing overviews of subtopics first (main publication venues, main authors, ...INTRODUCTIONIndeed the research in the domain is quite huge specifically if we consider other forms of COVIDs, Severe Acute Respiratory Syndrome, and Middle East Respiratory Syndrome.", [["COVIDs", "DISEASE", 244, 250], ["Acute Respiratory Syndrome", "DISEASE", 259, 285], ["Middle East Respiratory Syndrome", "DISEASE", 291, 323], ["the COVID", "TREATMENT", 31, 40], ["COVIDs", "PROBLEM", 244, 250], ["Severe Acute Respiratory Syndrome", "PROBLEM", 252, 285], ["Middle East Respiratory Syndrome", "PROBLEM", 291, 323], ["Severe", "OBSERVATION_MODIFIER", 252, 258], ["Acute", "OBSERVATION_MODIFIER", 259, 264], ["Respiratory Syndrome", "OBSERVATION", 265, 285], ["Middle", "ANATOMY_MODIFIER", 291, 297], ["Respiratory Syndrome", "OBSERVATION", 303, 323]]], ["For example, the recently released collection named COVID-19 Open Research Dataset 1 consists of more than 40,000 articles.", [["the recently released collection", "PROBLEM", 13, 45], ["COVID", "TEST", 52, 57], ["collection", "OBSERVATION", 35, 45]]], ["This paper aims at providing a systematic methodology to mine such a large publication set while giving some specific focuses on topics of interest.INTRODUCTIONThe rest of this paper is organized as follows: Section 2 presents some related works; Section 3 describes the analysis framework including the data description and the methodology for analysis that was followed; Section 4 describes the methodology we developed to get insights oo a specific sub-topic or on latest research.", [["a systematic methodology", "TREATMENT", 29, 53], ["a large publication set", "TREATMENT", 67, 90], ["analysis", "TEST", 345, 353], ["large", "OBSERVATION_MODIFIER", 69, 74], ["publication", "OBSERVATION", 75, 86]]], ["Section 5 focuses on a deeper analysis on the origins of COVID-19.", [["COVID-19", "DNA", 57, 65], ["a deeper analysis", "TEST", 21, 38], ["COVID", "TEST", 57, 62]]], ["Section 6 focuses on the analysis of the terminology related to the latest research.", [["the analysis", "TEST", 21, 33]]], ["For example, the report from Nature Medecine 6 presents a focus on clinical trials and human studies, Preclinical studies, and Epidemiology.", [["human", "ORGANISM", 87, 92], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["clinical trials", "TEST", 67, 82], ["human studies", "TEST", 87, 100], ["Preclinical studies", "TEST", 102, 121]]], ["In most of the cases, it is difficult to know that level as it is not necessarily depicted.", [["not necessarily", "UNCERTAINTY", 66, 81]]], ["For example, 6 seems to be a manual analysis of a few papers on the topic since the references are few.", [["a manual analysis", "TEST", 27, 44], ["few", "OBSERVATION_MODIFIER", 99, 102]]], ["Harapan et al. 11 presents a literature review on Coronavirus disease 2019 .", [["Coronavirus disease", "DISEASE", 50, 69], ["Coronavirus disease", "PROBLEM", 50, 69]]], ["This study cites 74 references and presents a comprehensive state of the art on different sub-topics such as COVID-19 transmission, risk factors, diagnosis or treatments.", [["This study", "TEST", 0, 10], ["treatments", "TREATMENT", 159, 169]]], ["Huang et al. 15 reviewed 1,281 abstracts from which they identified 322 manuscripts relevant to 5 areas of interest for their study.", [["their study", "TEST", 120, 131]]], ["The five topics they chose are as follows: antibody kinetics, correlates of protection, immunopathogenesis, antigenic diversity and crossreactivity, and population seroprevalence.", [["antibody kinetics", "PROBLEM", 43, 60], ["immunopathogenesis", "PROBLEM", 88, 106]]], ["Dousset et al. 8 presents a short analysis of a larger dataset which size is similar to the one that we are using in this study.", [["this study", "TEST", 117, 127], ["size", "OBSERVATION_MODIFIER", 69, 73]]], ["However their study does not go in deep in the publication content but rather analyze the collaborations between researchers and countries.", [["their study", "TEST", 8, 19]]], ["They do not analyze any specific topic.INTRODUCTIONDifferent from the previous analysis, this paper combines (a) the analysis of a large data set of about 25,000 references and (b) highly assisted analysis.", [["the previous analysis", "TEST", 66, 87], ["the analysis", "TEST", 113, 125]]], ["While the methodology could be apply to various COVID-19 subtopics, we focus here on two main topics: the origin of the virus and the use of other disease treatment.Mining scientific publicationsMost of the work in automatic publication analysis is related to scientometrics 26 which as been defined as \"quantitative study of science, communication in science, and science policy\" 13 .", [["the virus", "PROBLEM", 116, 125], ["other disease treatment", "TREATMENT", 141, 164], ["automatic publication analysis", "TEST", 215, 245], ["virus", "OBSERVATION", 120, 125]]], ["In this paper, publication mining is not strictly a question of scientometrics, rather the objective is to build knowledge from a large set of publications.Mining scientific publicationsShibata et al. 31 uses citation network analysis in order to detect emerging research.", [["scientometrics", "PROBLEM", 64, 78], ["a large set of publications", "PROBLEM", 128, 155], ["citation network analysis", "TEST", 209, 234], ["large", "OBSERVATION_MODIFIER", 130, 135], ["publications", "OBSERVATION", 143, 155]]], ["Small et al. also use direct citation and co-citation analysis in order to identify emerging topics 32 .", [["Small et al", "PROBLEM", 0, 11], ["direct citation", "TEST", 22, 37], ["co-citation analysis", "TEST", 42, 62], ["et al", "OBSERVATION", 6, 11]]], ["As in our approach, the authors use existing natural language processing and mining tools in their approach; however, they focus on the tex-tual parts of the publications.", [["natural language processing", "TREATMENT", 45, 72]]], ["Ronzano and Saggion developped a platform to automatically extract and enrich structural and semantic aspects of scientific publications.", [["Ronzano", "CHEMICAL", 0, 7], ["Ronzano", "SIMPLE_CHEMICAL", 0, 7], ["Ronzano", "TREATMENT", 0, 7], ["Saggion", "TREATMENT", 12, 19]]], ["In their paper, they focus on detecting the main collaborations, focusing on the geographical structure of a domain 24 .COVID-19 scientific publication setRecently, publishers have released the COVID-19 Open Research Dataset.", [["domain 24", "PROTEIN", 109, 118], ["COVID-19 Open Research Dataset", "DNA", 194, 224], ["COVID", "TEST", 120, 125], ["the COVID", "TEST", 190, 199]]], ["This data set consists of multiple files.COVID-19 scientific publication setAmong them, the Metadata file (60Mb) is a CSV file corresponding to 44,270 research articles with links to PubMed, Microsoft Academic and the WHO COVID-19 database of publications.", [["This data", "TEST", 0, 9], ["COVID", "TEST", 41, 46]]], ["For this reason we also considered a more complete set regarding the attributes that are provided.COVID-19 scientific publication setWe chose to focus on the documents from PubMed only 2 , which is known to be realable source.", [["COVID", "TEST", 98, 103]]], ["It does not contains all the 44k scientific papers from the COVID-19 Open Research Dataset but about 24,000 papers.", [["the COVID", "TEST", 56, 65]]], ["The query used to query the PubMed collection (https://www.ncbi.nlm.nih.gov/pubmed) was the same as the one used in the submentioned data set: \"COVID-19\" OR \"covid19\" OR \"Coronavirus\" OR \"Corona virus\" OR \"2019-nCoV\" OR \"SARS-CoV\" OR \"MERS-CoV\" OR \u00e2\u0102\u0132Severe Acute Respiratory Syndrome\u00e2\u0102\u0130 OR \u00e2\u0102\u0132Middle East Respiratory Syndrome\u00e2\u0102\u0130A few elements of the document collectionA few statistics are presented in Table 1 where the top 7 authors (the ones that authored the larger number of publications in the analyzed collection) are listed in Table 2 .", [["SARS", "DISEASE", 221, 225], ["Acute Respiratory Syndrome", "DISEASE", 258, 284], ["SARS-CoV", "SPECIES", 221, 229], ["Acute Respiratory Syndrome\u00e2\u0102\u0130 OR \u00e2\u0102\u0132Middle East Respiratory Syndrome\u00e2\u0102\u0130A", "SPECIES", 258, 330], ["Coronavirus", "PROBLEM", 171, 182], ["Acute Respiratory Syndrome", "PROBLEM", 258, 284], ["Respiratory Syndrome", "PROBLEM", 306, 326], ["the document collection", "PROBLEM", 347, 370], ["Acute", "OBSERVATION_MODIFIER", 258, 263], ["Respiratory Syndrome", "OBSERVATION", 264, 284], ["Respiratory Syndrome", "OBSERVATION", 306, 326]]], ["In average, there is 5.6 authors per publications.", [["average", "OBSERVATION_MODIFIER", 3, 10]]], ["While researchers have their topic of interest driven by their funding, project and research, topic of interest also come from the civil society on COVID-19.Topics of interestIt is worth to mention that NIST/TREC has formed a joint effort called TREC-COVID 5 .", [["joint", "ANATOMY", 226, 231]]], ["A topic of interest is for example the \"Coronavirus origin\" or \"early symptoms\".Topics of interestThese topics also echo the most popular questions web searchers are interested on.", [["early symptoms", "PROBLEM", 64, 78], ["echo", "TEST", 116, 120]]], ["Google trends mentions \"Where did coronavirius start?\" and \"How to know if you have coronarius\" among the most asked questions.Topics of interestFinally, these topics also echo the ones that have been considered in some related work papers 6, 11 that generally target the COVID-19 origins, its symptoms, spreading, risk factors and treatments.METHODOLOGY4.1 Overview.METHODOLOGYThe information we use is the data as collected.", [["echo", "TEST", 172, 176], ["its symptoms", "PROBLEM", 290, 302], ["treatments", "TREATMENT", 332, 342]]], ["While automatic analysis helps in handling large quantities of publications, the conclusions drawn have to be handle with caution because there is no manual analysis of the content and no checking.", [["automatic analysis", "TEST", 6, 24], ["caution", "TREATMENT", 122, 129], ["manual analysis", "TEST", 150, 165], ["large", "OBSERVATION_MODIFIER", 43, 48]]], ["Moreover, we did not solved content anomalies such as variants of entities spelling (e.g. author names).", [["content anomalies", "PROBLEM", 28, 45]]], ["There are also missing values that we did not consider either and not resolved (See Table 1 ).METHODOLOGYThe methods we use are usual data mining tools like frequency, graph-based visualization, factorial analysis.", [["missing values", "PROBLEM", 15, 29], ["METHODOLOGYThe methods", "TREATMENT", 94, 116], ["factorial analysis", "TEST", 195, 213]]], ["We consider crossing meta-data with content-based information from free texts as detailed later on.METHODOLOGYThe analysis considers both meta-data, such as the source, publication date and author fields and free text data such as the title and abstract fields.", [["METHODOLOGYThe analysis", "TEST", 99, 122], ["free text data", "TEST", 208, 222]]], ["With regard to the titles and abstracts, we consider both single words as well as phrases that we automatically extracted.Keyphrase extraction.", [["Keyphrase", "CHEMICAL", 122, 131], ["Keyphrase", "SIMPLE_CHEMICAL", 122, 131], ["Keyphrase extraction", "TREATMENT", 122, 142]]], ["Different methods have been developed to extract key-phrases from free texts 2, 12 ; among the most popular are graph-based extraction 3, 4, 25 , co-occurrence-based methods 16 and more recently embeddings 30 .Keyphrase extractionIn our approach, we use a n-gram word extraction where we skip stop words.", [["Keyphrase", "CHEMICAL", 210, 219], ["Keyphrase", "SIMPLE_CHEMICAL", 210, 219], ["Keyphrase extraction", "TREATMENT", 210, 230], ["a n-gram word extraction", "TREATMENT", 254, 278]]], ["More precisely, we extract the most frequent n-grams after stop word removal, but without stemming to keep more precise semantics.", [["word removal", "TREATMENT", 64, 76]]], ["We also consider an initial lexicon from composed terms (as written by the authors e.g. \"anti-malagia\" or \"animal-origin\") as initial phrases that are enriched by the n-gram extracted ones.Graph-based visualizationGraphs are among visualization tools the most used in the literature, as linking concepts or objects is the most common mining technique 24 .", [["visualization tools", "TEST", 231, 250]]], ["Graph-based visualizations are widely used to visualize bibliometric networks 9, 34 .Graph-based visualizationIn this paper, we mainly use bipartite graphs.", [["bibliometric networks", "TEST", 56, 77]]], ["A bipartite graph is a graph whose vertices (nodes) can be divided into two disjoint and independent sets and where edges connect a node of each type.", [["node", "ANATOMY", 132, 136], ["nodes", "MULTI-TISSUE_STRUCTURE", 45, 50], ["bipartite graph", "OBSERVATION", 2, 17], ["nodes", "OBSERVATION", 45, 50], ["node", "OBSERVATION", 132, 136]]], ["A bipartite graph does not contain any odd-length cycle (Wikipedia).", [["A bipartite graph", "TEST", 0, 17]]], ["This type of representation is also widely used for document analysis and visualizations 1, 7 .", [["document analysis", "TEST", 52, 69], ["visualizations", "TEST", 74, 88]]], ["In this paper, bipartite graphs are used to visualize the results of crossing meta-data and keyphrases extracted from publications.ProcessIn this paper, we developed two different processes: the first one can be applied to focus on any specific sub-topic of interest, this is the process we applied to the \"Origin\" of the virus sub-topic (See Section 5).", [["bipartite graphs", "TEST", 15, 31], ["crossing meta-data", "PROBLEM", 69, 87], ["keyphrases", "PROBLEM", 92, 102]]], ["The second process is related to the latest research and we apply it to detect some topic clusters (See Section 6).Getting insights on a specific topicThis process consists into three steps:Getting insights on a specific topic\u2022 Select the keyphrases related to the topic of interest.", [["a specific topicThis process", "TREATMENT", 135, 163]]], ["\"ORIGINALITY\")Getting insights on a specific topic\u2022 Build a bipartite graph where vertices are key-phrases in the one hand and publication identifiers in the other hand.", [["hand", "ORGANISM_SUBDIVISION", 164, 168], ["hand", "ANATOMY", 164, 168]]], ["This graph shows the most \"important\" authors related to that term (who are likely to be specialists).", [["This graph", "TEST", 0, 10]]], ["This step results in sub-topics of interest consisting of terms of various nature but often used together in recent publications;Getting the latest research topic of interest\u2022 Build bipartite graphs where vertices of the first type are the terms from one community and vertices of the second type are publication identifiers to identify the relevant publications with regard to the group of terms.Getting the latest research topic of interestThis process is used to get the latest research topics and associated publications.ORIGINSThe topic of interest we tackle in this section is related to the COVID-19 origins and uses the first process as described in Section 4.", [["COVID-19 origins", "DNA", 598, 614]]], ["We also used these terms to extract the associated publications.", [["the associated publications", "PROBLEM", 36, 63], ["publications", "OBSERVATION", 51, 63]]], ["These terms are used in the graph from Figure 1 (c) as blue nodes.", [["blue nodes", "MULTI-TISSUE_STRUCTURE", 55, 65], ["Figure 1 (c) as blue nodes", "PROBLEM", 39, 65], ["blue nodes", "OBSERVATION", 55, 65]]], ["Figure 1 (c) is a bipartite graph where blue nodes are the ORIGIN terms while the red nodes are the publication identifiers.", [["red nodes", "ANATOMY", 82, 91], ["blue nodes", "MULTI-TISSUE_STRUCTURE", 40, 50], ["red nodes", "MULTI-TISSUE_STRUCTURE", 82, 91], ["a bipartite graph", "TEST", 16, 33], ["blue nodes", "PROBLEM", 40, 50], ["blue nodes", "OBSERVATION", 40, 50], ["ORIGIN terms", "OBSERVATION_MODIFIER", 59, 71], ["red nodes", "OBSERVATION", 82, 91]]], ["From this graph, we can also identify the publications that mentions several of the ORIGIN terms as PMID-26689940 14 , 31996437 35 and 23719724 22 which mention both \"ANIMAL-ORIGIN\" and \"BAT-ORIGIN\".", [["PMID-26689940", "CHEMICAL", 100, 113]]], ["Another example is PMID-16012012 18 which mention both \"HUMAN-ORIGIN\" and \"ANIMAL-ORIGIN\" (See Figure 1(c) ).", [["PMID-16012012", "CHEMICAL", 19, 32], ["PMID-16012012", "CHEMICAL", 19, 32]]], ["In this figure, the only blue node is BAT-ORIGIN term, while the red nodes are authors of publications that mention this term.", [["blue node", "ANATOMY", 25, 34], ["red nodes", "ANATOMY", 65, 74], ["blue node", "MULTI-TISSUE_STRUCTURE", 25, 34], ["red nodes", "MULTI-TISSUE_STRUCTURE", 65, 74], ["the red nodes", "PROBLEM", 61, 74], ["blue node", "OBSERVATION", 25, 34], ["ORIGIN term", "OBSERVATION_MODIFIER", 42, 53], ["red", "OBSERVATION_MODIFIER", 65, 68], ["nodes", "OBSERVATION", 69, 74]]], ["The value on the link indicates the number of publications a researcher authored that mention BAT-ORIGIN.", [["The value", "TEST", 0, 9], ["ORIGIN", "ANATOMY_MODIFIER", 98, 104]]], ["The thickness of the link is an indication of the number of publications as well as the size of the nodes.LATEST RESEARCHWhile in the previous section we did not consider the year of publication, in this section, we focus on the latest research and the associated terminology.", [["nodes", "ANATOMY", 100, 105], ["thickness", "OBSERVATION_MODIFIER", 4, 13], ["number", "OBSERVATION_MODIFIER", 50, 56], ["publications", "OBSERVATION", 60, 72], ["size", "OBSERVATION_MODIFIER", 88, 92], ["nodes", "OBSERVATION", 100, 105]]], ["We then built a graph where nodes ( keyphrases) are linked when cooccuring in a publication.", [["nodes", "OBSERVATION", 28, 33]]], ["This is a weighted graph (the more the two keyphrases co-occur, the higher the weight).", [["a weighted graph", "TEST", 8, 24]]], ["We then extracted clusters of terms that are closely related as communities (nodes that are highly inter-connected together and weakly connected with other nodes) considering different focuses.LATEST RESEARCHThe example in Figure 3 (a) focuses on the Chloroquine-treatment while Figure 3 (b) is related to Obesity risk factor.", [["Chloroquine", "CHEMICAL", 251, 262], ["Obesity", "DISEASE", 306, 313], ["Chloroquine", "CHEMICAL", 251, 262], ["Chloroquine", "SIMPLE_CHEMICAL", 251, 262], ["Obesity risk factor", "PROTEIN", 306, 325], ["the Chloroquine", "TREATMENT", 247, 262], ["treatment", "TREATMENT", 263, 272], ["Obesity risk factor", "PROBLEM", 306, 325], ["clusters", "OBSERVATION_MODIFIER", 18, 26], ["nodes", "OBSERVATION", 77, 82], ["nodes", "OBSERVATION", 156, 161], ["Obesity", "OBSERVATION", 306, 313]]], ["From these figures, we can also identify the related terms.LATEST RESEARCHCOVID-19 is an infectious disease caused by SARS-CoV-2 and several papers investigate the use of existing anti-viral treatments.", [["infectious disease", "DISEASE", 89, 107], ["SARS-CoV-2", "ORGANISM", 118, 128], ["SARS-CoV", "SPECIES", 118, 126], ["LATEST RESEARCHCOVID", "TEST", 59, 79], ["an infectious disease", "PROBLEM", 86, 107], ["existing anti-viral treatments", "TREATMENT", 171, 201], ["infectious", "OBSERVATION", 89, 99], ["anti-viral treatments", "OBSERVATION", 180, 201]]], ["For examples, some of the publications mention \"anti-\" (e.g. anti-flu, antimalaria, ..).", [["anti-flu", "SIMPLE_CHEMICAL", 61, 69], ["antimalaria", "PROBLEM", 71, 82]]], ["We thus had a closer look to the network related to treatment used for other diseases consid- ering various \"anti-\" terms as shown in Figure 4 .", [["treatment", "TREATMENT", 52, 61], ["other diseases", "PROBLEM", 71, 85]]], ["The PMID of these publications as well as related terms are presented in Figure 5 .", [["publications", "OBSERVATION", 18, 30]]], ["For example, PMID 32277367 23 , which is marked up with a black square on the right-bottom part of Figure 5 , was published on the 10th of April, in J Neurooncol. and results from a collaborative work of India, Russia, and UK and concludes that \"it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice\".", [["PMID 32277367", "CHEMICAL", 13, 26], ["glucocorticoids", "CHEMICAL", 291, 306], ["infections", "DISEASE", 441, 451], ["PMID 32277367", "CHEMICAL", 13, 26], ["glucocorticoids", "SIMPLE_CHEMICAL", 291, 306], ["patients", "ORGANISM", 367, 375], ["patients", "SPECIES", 367, 375], ["glucocorticoids", "TREATMENT", 291, 306], ["other disease", "PROBLEM", 311, 324], ["modifying antirheumatic drugs", "TREATMENT", 325, 354], ["DMARDs", "TREATMENT", 356, 362], ["these therapies", "TREATMENT", 386, 401], ["DMARDs", "TREATMENT", 427, 433], ["infections", "PROBLEM", 441, 451], ["marked", "OBSERVATION_MODIFIER", 41, 47], ["right", "ANATOMY_MODIFIER", 78, 83]]], ["This paper also mentions various evidence that suggest potential benefits of various drugs.", [["various drugs", "TREATMENT", 77, 90]]], ["As an example, anti-rheumatic is mentioned in 9 of the displayed publications.LATEST RESEARCHAmong these publications, we can quote Perricone 27 (PMID-32317220) discusses the anti-viral aspect of immunosuppressants for searching for a potential treatment for SARS-CoV-2 infection.", [["PMID-32317220", "CHEMICAL", 146, 159], ["SARS-CoV-2 infection", "DISEASE", 259, 279], ["PMID-32317220", "CHEMICAL", 146, 159], ["SARS-CoV-2", "ORGANISM", 259, 269], ["SARS-CoV-2", "SPECIES", 259, 269], ["anti-rheumatic", "TREATMENT", 15, 29], ["immunosuppressants", "TREATMENT", 196, 214], ["a potential treatment", "TREATMENT", 233, 254], ["SARS", "PROBLEM", 259, 263], ["CoV", "PROBLEM", 264, 267], ["2 infection", "PROBLEM", 268, 279], ["anti-rheumatic", "OBSERVATION", 15, 29], ["publications", "OBSERVATION", 65, 77], ["infection", "OBSERVATION", 270, 279]]], ["Lehrer et al. 19 (PMID-32313883) discusses the effects of biguanides on influenza and coronavirus.", [["PMID-32313883", "CHEMICAL", 18, 31], ["biguanides", "CHEMICAL", 58, 68], ["influenza and coronavirus", "DISEASE", 72, 97], ["biguanides", "CHEMICAL", 58, 68], ["biguanides", "SIMPLE_CHEMICAL", 58, 68], ["coronavirus", "ORGANISM", 86, 97], ["coronavirus", "SPECIES", 86, 97], ["biguanides", "TREATMENT", 58, 68], ["influenza", "PROBLEM", 72, 81], ["coronavirus", "PROBLEM", 86, 97]]], ["Kumar -yearold female rheumatoid arthritis; she was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine.", [["rheumatoid arthritis", "DISEASE", 22, 42], ["lopinavir/ritonavir", "CHEMICAL", 83, 102], ["cDMARDs", "CHEMICAL", 124, 131], ["hydroxychloroquine", "CHEMICAL", 156, 174], ["lopinavir", "CHEMICAL", 83, 92], ["ritonavir", "CHEMICAL", 93, 102], ["hydroxychloroquine", "CHEMICAL", 156, 174], ["lopinavir", "SIMPLE_CHEMICAL", 83, 92], ["ritonavir", "SIMPLE_CHEMICAL", 93, 102], ["cDMARDs", "SIMPLE_CHEMICAL", 124, 131], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 156, 174], ["rheumatoid arthritis", "PROBLEM", 22, 42], ["antiviral agents", "TREATMENT", 65, 81], ["lopinavir", "TREATMENT", 83, 92], ["ritonavir", "TREATMENT", 93, 102], ["treatment", "TREATMENT", 109, 118], ["cDMARDs", "TREATMENT", 124, 131], ["hydroxychloroquine", "TREATMENT", 156, 174], ["rheumatoid arthritis", "OBSERVATION", 22, 42]]], ["Her symptoms gradually improved and three weeks later, real-time PCR for COVID-19 showed negative conversion 33 .CONCLUSIONThis paper presents two analytical processes in order to mine scientific papers that are illustrated on COVID-19 scientific publications.", [["Her symptoms", "PROBLEM", 0, 12], ["real-time PCR", "TEST", 55, 68], ["COVID", "TEST", 73, 78]]]], "66e2f847cb24139e4ff713aee9672cf4e63cb366": [["IntroductionAs of September 21, 2020 COVID-19 has infected more than 31 million people and caused nearly 1 million deaths worldwide 1 .", [["COVID-19", "CHEMICAL", 37, 45], ["deaths", "DISEASE", 115, 121], ["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86], ["COVID", "TEST", 37, 42]]], ["This disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which primarily gains entry to cells via binding of SARS-CoV-2 50IntroductionSpike glycoprotein to angiotensin converting enzyme 2 (ACE-2) and subsequent endocytosis [2] [3] [4] . regulated kinase (PLCg/ERK) 16 .", [["cells", "ANATOMY", 118, 123], ["acute respiratory syndrome coronavirus", "DISEASE", 33, 71], ["angiotensin", "CHEMICAL", 186, 197], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 26, 73], ["SARS-CoV-2", "ORGANISM", 75, 85], ["cells", "CELL", 118, 123], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 139, 149], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 186, 217], ["ACE-2", "GENE_OR_GENE_PRODUCT", 219, 224], ["[2] [3] [4]", "SIMPLE_CHEMICAL", 253, 264], ["regulated kinase", "GENE_OR_GENE_PRODUCT", 267, 283], ["PLCg/ERK) 16", "GENE_OR_GENE_PRODUCT", 285, 297], ["SARS-CoV-2 50IntroductionSpike glycoprotein", "PROTEIN", 139, 182], ["angiotensin converting enzyme 2", "PROTEIN", 186, 217], ["ACE-2", "PROTEIN", 219, 224], ["regulated kinase (PLCg/ERK) 16", "PROTEIN", 267, 297], ["severe acute respiratory syndrome coronavirus", "SPECIES", 26, 71], ["SARS-CoV", "SPECIES", 75, 83], ["This disease", "PROBLEM", 0, 12], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 26, 71], ["SARS-CoV", "TEST", 75, 83], ["SARS", "TEST", 139, 143], ["CoV", "TEST", 144, 147], ["Spike glycoprotein", "TREATMENT", 164, 182], ["angiotensin converting enzyme", "TEST", 186, 215], ["ACE", "TEST", 219, 222], ["subsequent endocytosis", "TEST", 230, 252], ["kinase (PLCg/ERK)", "TREATMENT", 277, 294], ["disease", "OBSERVATION", 5, 12], ["caused by", "UNCERTAINTY", 16, 25], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["respiratory syndrome", "OBSERVATION", 39, 59]]], ["Clinical findings that VEGF-A contributes to pain are supported by observations that in osteoarthritis increased VEGF expression in synovial fluids has been associated with higher pain scores 22 .", [["synovial fluids", "ANATOMY", 132, 147], ["pain", "DISEASE", 45, 49], ["osteoarthritis", "DISEASE", 88, 102], ["pain", "DISEASE", 180, 184], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 23, 29], ["VEGF", "GENE_OR_GENE_PRODUCT", 113, 117], ["synovial fluids", "ORGANISM_SUBSTANCE", 132, 147], ["VEGF-A", "PROTEIN", 23, 29], ["VEGF", "PROTEIN", 113, 117], ["pain", "PROBLEM", 45, 49], ["osteoarthritis increased VEGF expression in synovial fluids", "PROBLEM", 88, 147], ["higher pain scores", "PROBLEM", 173, 191], ["osteoarthritis", "OBSERVATION", 88, 102], ["synovial", "ANATOMY", 132, 140]]], ["VEGF-A has been reported to enhance pain behaviors in 95 normal, nerve-injured and diabetic animals 17, 23 .IntroductionIt is known that neuropilins are entry points for several viruses, including human Tlymphotropic virus-1 (HTLV-1) 24 and Epstein-Barr virus (EBV) 25 .", [["nerve", "ANATOMY", 65, 70], ["VEGF-A", "CHEMICAL", 0, 6], ["pain", "DISEASE", 36, 40], ["diabetic", "DISEASE", 83, 91], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 0, 6], ["nerve", "MULTI-TISSUE_STRUCTURE", 65, 70], ["neuropilins", "GENE_OR_GENE_PRODUCT", 137, 148], ["human Tlymphotropic virus-1", "ORGANISM", 197, 224], ["HTLV-1) 24", "ORGANISM", 226, 236], ["Epstein-Barr virus", "ORGANISM", 241, 259], ["EBV", "ORGANISM", 261, 264], ["VEGF", "PROTEIN", 0, 4], ["neuropilins", "PROTEIN", 137, 148], ["human", "SPECIES", 197, 202], ["Tlymphotropic virus-1", "SPECIES", 203, 224], ["HTLV-1", "SPECIES", 226, 232], ["human Tlymphotropic virus-1", "SPECIES", 197, 224], ["HTLV-1", "SPECIES", 226, 232], ["Epstein-Barr virus", "SPECIES", 241, 259], ["EBV", "SPECIES", 261, 264], ["pain behaviors", "PROBLEM", 36, 50], ["several viruses", "PROBLEM", 170, 185], ["human Tlymphotropic virus", "TEST", 197, 222], ["HTLV", "TEST", 226, 230], ["Epstein-Barr virus (EBV)", "TREATMENT", 241, 265], ["nerve", "ANATOMY", 65, 70]]], ["In both cases, furin processing of viral glycoproteins results in polybasic CendR motifs that directly interact with the VEGF-A site on the NRP-1 b1 domain 26 .", [["furin", "GENE_OR_GENE_PRODUCT", 15, 20], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 121, 127], ["NRP-1", "GENE_OR_GENE_PRODUCT", 140, 145], ["furin", "PROTEIN", 15, 20], ["viral glycoproteins", "PROTEIN", 35, 54], ["polybasic CendR motifs", "PROTEIN", 66, 88], ["VEGF-A site", "DNA", 121, 132], ["NRP-1 b1 domain 26", "DNA", 140, 158], ["viral glycoproteins", "TREATMENT", 35, 54], ["polybasic CendR motifs", "TREATMENT", 66, 88], ["the NRP", "TEST", 136, 143]]], ["Compared to SARS-CoV-1, the causative agent of 100 SARS, mutation in the furin cleavage site of SARS-CoV-2 results in production of a CendR motif ( 682 RRAR 685 ) which was shown to bind to the neuropilin b1 VEGF-A site, suggesting NRP-1 as a possible route of viral entry 5, 6 .", [["SARS", "DISEASE", 12, 16], ["SARS", "DISEASE", 51, 55], ["SARS-CoV-1", "ORGANISM", 12, 22], ["furin", "GENE_OR_GENE_PRODUCT", 73, 78], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 96, 106], ["neuropilin b1", "GENE_OR_GENE_PRODUCT", 194, 207], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 208, 214], ["NRP-1", "GENE_OR_GENE_PRODUCT", 232, 237], ["furin cleavage site", "DNA", 73, 92], ["SARS-CoV-2", "DNA", 96, 106], ["CendR motif", "DNA", 134, 145], ["682 RRAR 685", "DNA", 148, 160], ["neuropilin b1 VEGF-A site", "DNA", 194, 219], ["NRP-1", "DNA", 232, 237], ["SARS-CoV-1", "SPECIES", 12, 22], ["SARS", "TEST", 12, 16], ["CoV", "TEST", 17, 20], ["mutation", "PROBLEM", 57, 65], ["a CendR motif", "TREATMENT", 132, 145], ["viral", "OBSERVATION", 261, 266]]], ["The importance of NRP-1 is supported by recent evidence of upregulated NRP-1 in lung samples from COVID-19 patients 5 .IntroductionThese connections raise an interesting question: does interference with the VEGF-105 A/NRP-1 signaling pathway by SARS-CoV-2 result in dampened pain?", [["lung samples", "ANATOMY", 80, 92], ["pain", "DISEASE", 275, 279], ["NRP-1", "GENE_OR_GENE_PRODUCT", 18, 23], ["NRP-1", "GENE_OR_GENE_PRODUCT", 71, 76], ["lung samples", "CANCER", 80, 92], ["patients", "ORGANISM", 107, 115], ["VEGF-105 A", "GENE_OR_GENE_PRODUCT", 207, 217], ["NRP-1", "GENE_OR_GENE_PRODUCT", 218, 223], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 245, 255], ["NRP-1", "PROTEIN", 18, 23], ["NRP-1", "PROTEIN", 71, 76], ["VEGF", "PROTEIN", 207, 211], ["NRP", "PROTEIN", 218, 221], ["patients", "SPECIES", 107, 115], ["upregulated NRP", "PROBLEM", 59, 74], ["COVID", "TEST", 98, 103], ["the VEGF", "TEST", 203, 211], ["CoV", "TEST", 250, 253], ["dampened pain", "PROBLEM", 266, 279], ["lung", "ANATOMY", 80, 84], ["dampened", "OBSERVATION_MODIFIER", 266, 274], ["pain", "OBSERVATION", 275, 279]]], ["This question has been examined by our laboratory; we recently showed that SARS-CoV-2 Spike protein binding to NRP-1 prevents VEGF-A signaling and reduces neuropathic pain in an animal model 27 .", [["neuropathic pain", "DISEASE", 155, 171], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 75, 85], ["NRP-1", "GENE_OR_GENE_PRODUCT", 111, 116], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 126, 132], ["SARS-CoV-2 Spike protein", "PROTEIN", 75, 99], ["NRP-1", "PROTEIN", 111, 116], ["VEGF", "PROTEIN", 126, 130], ["SARS", "TEST", 75, 79], ["CoV", "TEST", 80, 83], ["Spike protein binding", "PROBLEM", 86, 107], ["NRP", "TEST", 111, 114], ["VEGF", "PROBLEM", 126, 130], ["A signaling", "PROBLEM", 131, 142], ["neuropathic pain", "PROBLEM", 155, 171], ["an animal model", "TEST", 175, 190], ["neuropathic", "OBSERVATION_MODIFIER", 155, 166]]], ["Thus, NRP-1 represents a novel target for treating neuropathic pain 27 .", [["neuropathic pain", "DISEASE", 51, 67], ["NRP-1", "GENE_OR_GENE_PRODUCT", 6, 11], ["NRP-1", "PROTEIN", 6, 11], ["treating neuropathic pain", "PROBLEM", 42, 67]]], ["Furthermore, targeting NRP-1 also presents a unique approach to inhibiting viral entry and/or re-entry into cells to reduce viral 110 load.", [["cells", "ANATOMY", 108, 113], ["NRP-1", "GENE_OR_GENE_PRODUCT", 23, 28], ["cells", "CELL", 108, 113], ["NRP-1", "PROTEIN", 23, 28], ["viral 110 load", "PROBLEM", 124, 138]]], ["Due to its role in cancer, NRP-1 has been a target for drug design for over 20 years.", [["cancer", "ANATOMY", 19, 25], ["cancer", "DISEASE", 19, 25], ["cancer", "CANCER", 19, 25], ["NRP-1", "GENE_OR_GENE_PRODUCT", 27, 32], ["NRP-1", "PROTEIN", 27, 32], ["cancer", "PROBLEM", 19, 25], ["cancer", "OBSERVATION", 19, 25]]], ["During this time, discovery efforts have focused on development of NRP-1 antibody therapies 9, 28-33 , including a recent dual-specificity antibody to VEGFA and NRP-1 32, 33 , peptides that target transmembrane domain interactions 11, 34-37 or the CendR interaction site 12, 31, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] , as well as small-molecules that target the CendR site [54] [55] [56] [57] [58] [59] [60] [61] .", [["transmembrane", "ANATOMY", 197, 210], ["9, 28-33", "CHEMICAL", 92, 100], ["NRP-1", "GENE_OR_GENE_PRODUCT", 67, 72], ["VEGFA", "GENE_OR_GENE_PRODUCT", 151, 156], ["NRP-1", "GENE_OR_GENE_PRODUCT", 161, 166], ["[38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53]", "SIMPLE_CHEMICAL", 279, 358], ["CendR", "SIMPLE_CHEMICAL", 404, 409], ["[54] [55] [56] [57] [58] [59] [60] [61]", "SIMPLE_CHEMICAL", 415, 454], ["NRP", "PROTEIN", 67, 70], ["VEGFA", "PROTEIN", 151, 156], ["NRP", "PROTEIN", 161, 164], ["transmembrane domain interactions 11, 34-37", "PROTEIN", 197, 240], ["NRP", "TEST", 67, 70], ["antibody therapies", "TEST", 73, 91], ["VEGFA", "TEST", 151, 156], ["NRP", "TEST", 161, 164], ["peptides", "TEST", 176, 184], ["transmembrane domain interactions", "TEST", 197, 230], ["the CendR interaction site", "TEST", 244, 270]]], ["With one exception 43 , the CendR site targeting peptides contain a CendR motif, even those which are cyclical 39, 45, 46, 49 or branched 51, 53 .", [["CendR", "GENE_OR_GENE_PRODUCT", 28, 33], ["CendR site", "DNA", 28, 38], ["CendR motif", "DNA", 68, 79], ["a CendR motif", "TEST", 66, 79]]], ["Two of the most well-known small molecule NRP-1 inhibitors, EG00229 and EG01377, contain a terminal Arg-like moiety and carboxyl group known to be key to interaction with NRP-1 54, 61 as does the newly developed fluorescent compound based on EG01377 62 .", [["EG00229", "CHEMICAL", 60, 67], ["EG01377", "CHEMICAL", 72, 79], ["EG01377", "CHEMICAL", 242, 249], ["EG00229", "CHEMICAL", 60, 67], ["EG01377", "CHEMICAL", 72, 79], ["Arg", "CHEMICAL", 100, 103], ["carboxyl", "CHEMICAL", 120, 128], ["EG01377", "CHEMICAL", 242, 249], ["NRP-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["EG00229", "SIMPLE_CHEMICAL", 60, 67], ["EG01377", "SIMPLE_CHEMICAL", 72, 79], ["NRP-1", "GENE_OR_GENE_PRODUCT", 171, 176], ["NRP", "PROTEIN", 171, 174], ["small molecule NRP", "TREATMENT", 27, 45], ["a terminal Arg-like moiety", "TREATMENT", 89, 115], ["carboxyl group", "TREATMENT", 120, 134], ["fluorescent compound", "PROBLEM", 212, 232]]], ["The remaining known small molecule compounds consist of an arginine-derivative series 60 and several diverse 120 chemotypes such as acylthioureas 56 , benzamidosulfonamides 59 , bis-guanidines 55 , or aryl benzylethers 58 .", [["arginine", "CHEMICAL", 59, 67], ["acylthioureas 56 , benzamidosulfonamides 59 , bis-guanidines 55 , or aryl benzylethers", "CHEMICAL", 132, 218], ["arginine", "CHEMICAL", 59, 67], ["acylthioureas", "CHEMICAL", 132, 145], ["benzamidosulfonamides", "CHEMICAL", 151, 172], ["bis-guanidines", "CHEMICAL", 178, 192], ["aryl benzylethers", "CHEMICAL", 201, 218], ["arginine", "SIMPLE_CHEMICAL", 59, 67], ["acylthioureas 56 , benzamidosulfonamides 59", "SIMPLE_CHEMICAL", 132, 175], ["bis-guanidines 55", "SIMPLE_CHEMICAL", 178, 195], ["aryl benzylethers 58", "SIMPLE_CHEMICAL", 201, 221], ["small molecule compounds", "PROBLEM", 20, 44], ["an arginine-derivative series", "TEST", 56, 85], ["several diverse 120 chemotypes", "PROBLEM", 93, 123], ["acylthioureas", "TEST", 132, 145], ["benzamidosulfonamides", "TREATMENT", 151, 172], ["bis-guanidines", "TREATMENT", 178, 192], ["aryl benzylethers", "TEST", 201, 218], ["small", "OBSERVATION_MODIFIER", 20, 25], ["molecule compounds", "OBSERVATION", 26, 44]]], ["Many of these small molecule compounds contain functional groups of suboptimal physico-chemical and ADME properties.IntroductionIn order to identify unique compounds that could be used to interrogate the role of these signaling complexes in pain, we conducted a virtual screen of nearly 0.5 million compounds 125 against the NRP-1 CendR site, resulting in nearly 1,000 hits.", [["pain", "DISEASE", 241, 245], ["NRP-1", "GENE_OR_GENE_PRODUCT", 325, 330], ["signaling complexes", "PROTEIN", 218, 237], ["NRP-1 CendR site", "DNA", 325, 341], ["these small molecule compounds", "PROBLEM", 8, 38], ["pain", "PROBLEM", 241, 245], ["a virtual screen", "TEST", 260, 276], ["small", "OBSERVATION_MODIFIER", 14, 19], ["molecule compounds", "OBSERVATION", 20, 38], ["functional", "OBSERVATION_MODIFIER", 47, 57], ["groups", "OBSERVATION_MODIFIER", 58, 64], ["hits", "OBSERVATION", 369, 373]]], ["Here, we present 9 chemical series of synthetic and natural compounds with lead-or drug-like physico-chemical properties and identify a pharmacophore model which will guide future design of compounds.", [["synthetic and natural compounds", "TREATMENT", 38, 69], ["a pharmacophore model", "TREATMENT", 134, 155]]], ["We also show that six of the compounds interfere with VEGF-A binding more effectively than EG00229, a known NRP-1 inhibitor and three interfere with VEGF-A binding as well as the furin-cleaved 130 Spike S1 domain.", [["EG00229", "CHEMICAL", 91, 98], ["EG00229", "CHEMICAL", 91, 98], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 54, 60], ["EG00229", "SIMPLE_CHEMICAL", 91, 98], ["NRP-1", "GENE_OR_GENE_PRODUCT", 108, 113], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 149, 155], ["furin", "GENE_OR_GENE_PRODUCT", 179, 184], ["VEGF", "PROTEIN", 54, 58], ["VEGF", "PROTEIN", 149, 153], ["furin-cleaved 130 Spike S1 domain", "PROTEIN", 179, 212], ["a known NRP-1 inhibitor", "TREATMENT", 100, 123], ["the furin", "TEST", 175, 184]]], ["Furthermore, our compounds show inhibition of VEGF-A triggered VEGFR2 phosphorylation in a cell-based assay.", [["cell", "ANATOMY", 91, 95], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 46, 52], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 63, 69], ["cell", "CELL", 91, 95], ["VEGF", "PROTEIN", 46, 50], ["VEGFR2", "PROTEIN", 63, 69], ["inhibition of VEGF", "PROBLEM", 32, 50], ["A triggered VEGFR2 phosphorylation", "PROBLEM", 51, 85], ["VEGF", "OBSERVATION", 46, 50]]], ["Finally, two of the compounds inhibited antiviral activity.Results and DiscussionWe conducted virtual screens against the VEGF-A binding site on the NRP-1 b1 domain 135 using three libraries: a ~211 K synthetic compound library (DIV) from ChemBridge; a ~257 K natural compound library (NC1) obtained from the COlleCtion of Open NatUral producTs (COCONUT) resource 63 ; and a ~20 K (NC2) natural compound library from the ZINC15 database 64 .", [["VEGF-A", "GENE_OR_GENE_PRODUCT", 122, 128], ["VEGF-A binding site", "DNA", 122, 141], ["NRP-1 b1 domain 135", "DNA", 149, 168], ["NC1", "PROTEIN", 286, 289], ["virtual screens", "TEST", 94, 109], ["A binding site", "PROBLEM", 127, 141], ["the NRP", "TEST", 145, 152], ["Open NatUral producTs", "TREATMENT", 323, 344], ["the ZINC15 database", "TEST", 417, 436], ["antiviral activity", "OBSERVATION", 40, 58]]], ["The screens were run once without ligand-receptor interaction constraints and repeated with the constraint that compounds form a hydrogen bond to Asp 320, a key residue for 140 coordinating the terminal arginine in the CendR motif 14 .", [["Asp 320", "CHEMICAL", 146, 153], ["arginine", "CHEMICAL", 203, 211], ["hydrogen", "CHEMICAL", 129, 137], ["Asp", "CHEMICAL", 146, 149], ["arginine", "CHEMICAL", 203, 211], ["Asp 320", "AMINO_ACID", 146, 153], ["arginine", "AMINO_ACID", 203, 211], ["CendR motif 14", "PROTEIN", 219, 233], ["The screens", "TEST", 0, 11], ["Asp", "TEST", 146, 149], ["the terminal arginine", "TREATMENT", 190, 211]]], ["This constraint was used in attempt to select for compounds that interact in a similar way as observed for VEGF-A 14 , known inhibitors 42, 54, 60, 61 and modeled SARS-CoV-219 CendR terminal arginine 6 .", [["arginine", "CHEMICAL", 191, 199], ["arginine", "CHEMICAL", 191, 199], ["VEGF-A 14", "GENE_OR_GENE_PRODUCT", 107, 116], ["VEGF", "PROTEIN", 107, 111], ["VEGF", "TEST", 107, 111], ["known inhibitors", "TEST", 119, 135], ["modeled SARS", "TEST", 155, 167], ["CoV", "TEST", 168, 171], ["CendR terminal arginine", "TREATMENT", 176, 199]]], ["However, application of this constraint led to reduced overall scores and strained conformations for most compounds in the DIV and NC1 libraries.", [["NC1", "GENE_OR_GENE_PRODUCT", 131, 134], ["DIV and NC1 libraries", "DNA", 123, 144], ["reduced overall scores", "PROBLEM", 47, 69], ["strained conformations", "PROBLEM", 74, 96]]], ["Therefore, we report only the unconstrained screen 145 results for these libraries and both constrained and unconstrained results for the NC2 screen.Selection of top compoundsThe combined output of the four screens produced a total of 1,147 hits.", [["the unconstrained screen", "TEST", 26, 50], ["these libraries", "TEST", 67, 82], ["the NC2 screen", "TEST", 134, 148], ["Selection of top compounds", "TREATMENT", 149, 175], ["The combined output", "TEST", 175, 194], ["the four screens", "TEST", 198, 214], ["top compounds", "OBSERVATION", 162, 175], ["output", "OBSERVATION_MODIFIER", 188, 194]]], ["Compounds from each screen were sorted by Glide XP GScore (kcal/mol) and visually inspected for substructure 150 match of core scaffolds and patterns of chemically reactive moieties while considering the diversity of chemotypes.", [["each screen", "TEST", 15, 26], ["core scaffolds", "TREATMENT", 122, 136], ["chemically reactive moieties", "PROBLEM", 153, 181], ["chemotypes", "PROBLEM", 217, 227], ["chemically", "OBSERVATION_MODIFIER", 153, 163], ["reactive moieties", "OBSERVATION", 164, 181], ["chemotypes", "OBSERVATION", 217, 227]]], ["Compound representatives with scaffold decoration that suggested initial structure activity relationships (SAR) were extracted and grouped into series resulting in a set of nine diverse chemotypes (series).", [["scaffold decoration", "PROBLEM", 30, 49], ["scaffold decoration", "OBSERVATION", 30, 49], ["structure activity", "OBSERVATION", 73, 91], ["diverse", "OBSERVATION_MODIFIER", 178, 185], ["chemotypes", "OBSERVATION", 186, 196]]], ["These series include both small synthetic molecules and natural products ( Table 1) .", [["These series", "TEST", 0, 12], ["both small synthetic molecules", "TREATMENT", 21, 51], ["small", "OBSERVATION_MODIFIER", 26, 31], ["synthetic molecules", "OBSERVATION", 32, 51]]], ["While calculated property ranges vary for the chemotype and drug 155 guidelines were derived for orally available small molecules, we did not use this binary parameter for the classification of natural products.", [["this binary parameter", "TREATMENT", 146, 167], ["natural products", "TREATMENT", 194, 210], ["natural products", "OBSERVATION", 194, 210]]], ["Also, since solubility and CNS penetration rules originated from small molecule sets, these calculations are not applicable to natural products and were also omitted.", [["CNS", "ANATOMY", 27, 30], ["CNS penetration rules", "PROBLEM", 27, 48], ["small molecule sets", "PROBLEM", 65, 84], ["these calculations", "TEST", 86, 104], ["CNS", "ANATOMY", 27, 30], ["penetration", "OBSERVATION", 31, 42], ["small", "OBSERVATION_MODIFIER", 65, 70], ["molecule sets", "OBSERVATION", 71, 84]]], ["Furthermore, detailed inspection of data of Table 1 revealed that 165 natural product compounds 11, 12, and 15 are in fact small molecule chemotypes.Selection of top compoundsCorrespondingly, all molecular descriptors were calculated for these compounds and they were considered part of the small molecule set.Selection of top compoundsSince one objective of inhibiting the VEGF-A/NRP-1 interaction is disruption of pain signals, the full therapeutic effect will require drug exposure in the central nervous system 170 (CNS).", [["central nervous system", "ANATOMY", 492, 514], ["CNS", "ANATOMY", 520, 523], ["pain", "DISEASE", 416, 420], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 374, 380], ["NRP-1", "GENE_OR_GENE_PRODUCT", 381, 386], ["central nervous system", "ANATOMICAL_SYSTEM", 492, 514], ["CNS", "ANATOMICAL_SYSTEM", 520, 523], ["VEGF-A", "PROTEIN", 374, 380], ["NRP", "PROTEIN", 381, 384], ["detailed inspection of data of Table 1", "TEST", 13, 51], ["small molecule chemotypes", "PROBLEM", 123, 148], ["Selection of top compounds", "TREATMENT", 149, 175], ["Selection of top compounds", "TREATMENT", 310, 336], ["pain signals", "PROBLEM", 416, 428], ["drug exposure", "TREATMENT", 471, 484], ["small", "OBSERVATION_MODIFIER", 123, 128], ["molecule chemotypes", "OBSERVATION", 129, 148], ["top compounds", "OBSERVATION", 162, 175], ["top compounds", "OBSERVATION", 323, 336], ["central", "ANATOMY_MODIFIER", 492, 499], ["nervous system", "ANATOMY", 500, 514]]], ["Correspondingly, the optimization strategy for these compounds will include modifications beneficial for crossing the blood-brain barrier (BBB), for example, decreasing the number of hydrogen bond donors and polarity.", [["blood-brain barrier", "ANATOMY", 118, 137], ["hydrogen", "CHEMICAL", 183, 191], ["blood", "MULTI-TISSUE_STRUCTURE", 118, 123], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 124, 137], ["BBB", "MULTI-TISSUE_STRUCTURE", 139, 142], ["these compounds", "TREATMENT", 47, 62], ["hydrogen bond donors", "TREATMENT", 183, 203], ["brain", "ANATOMY", 124, 129], ["hydrogen bond", "OBSERVATION", 183, 196]]], ["To supplement traditional medicinal chemistry approaches to increasing CNS exposure, we implemented the BBB score algorithm of Weaver et al. 67 as one of the optimization parameters.", [["CNS", "ANATOMY", 71, 74], ["CNS", "ANATOMICAL_SYSTEM", 71, 74], ["traditional medicinal chemistry", "TREATMENT", 14, 45], ["increasing CNS exposure", "PROBLEM", 60, 83], ["the BBB score algorithm", "TEST", 100, 123], ["the optimization parameters", "TEST", 154, 181]]], ["Values of the BBB score in the range of 4 to 6 175 correctly predict 90% of CNS drugs 67 .", [["CNS", "ANATOMY", 76, 79], ["BBB", "MULTI-TISSUE_STRUCTURE", 14, 17], ["Values", "TEST", 0, 6], ["the BBB score", "TEST", 10, 23], ["CNS drugs", "TEST", 76, 85]]], ["While the brain/plasma ratio will be experimentally assessed for series representatives, optimization will be additionally guided by surrogate estimates of passive diffusion (PAMPA) and assessment of efflux and transporter proteins using assays in MDCK cell lines.", [["brain", "ANATOMY", 10, 15], ["plasma", "ANATOMY", 16, 22], ["MDCK cell lines", "ANATOMY", 248, 263], ["brain", "ORGAN", 10, 15], ["plasma", "ORGANISM_SUBSTANCE", 16, 22], ["MDCK cell lines", "CELL", 248, 263], ["transporter proteins", "PROTEIN", 211, 231], ["MDCK cell lines", "CELL_LINE", 248, 263], ["the brain/plasma ratio", "TEST", 6, 28], ["efflux", "PROBLEM", 200, 206], ["transporter proteins", "TEST", 211, 231], ["assays", "TEST", 238, 244], ["MDCK cell lines", "TREATMENT", 248, 263], ["brain", "ANATOMY", 10, 15], ["MDCK cell lines", "OBSERVATION", 248, 263]]], ["Overall, predicted physico-chemical properties of all small molecule hit series (series 1-6) fall within ranges of lead-like and/or drug-like molecules ( Table 1) .", [["chemical properties", "OBSERVATION_MODIFIER", 27, 46], ["small", "OBSERVATION_MODIFIER", 54, 59]]], ["180Selection of top compoundsMoreover, several representatives of series 1 and 2 are expected to have acceptable CNS exposure.Series analysis and docked binding modesAfter initial ranking and selection of the top 20 hits, we proceeded to a more detailed 185 analysis of structural and chemical features of the compounds.", [["CNS", "ANATOMY", 113, 116], ["CNS", "ANATOMICAL_SYSTEM", 113, 116], ["Series analysis", "TEST", 126, 141], ["docked binding modes", "TEST", 146, 166], ["top", "OBSERVATION_MODIFIER", 16, 19], ["compounds", "OBSERVATION_MODIFIER", 20, 29], ["acceptable", "OBSERVATION_MODIFIER", 102, 112], ["CNS exposure", "OBSERVATION", 113, 125]]], ["Chemical structures of all twenty hits and one virtual SAR analog are shown in Figure 2 .", [["all", "OBSERVATION_MODIFIER", 23, 26], ["twenty hits", "OBSERVATION", 27, 38]]], ["Hits are grouped by common core motifs and molecular fragments that engage in productive hydrogen bond (HB) and alkyl/aryl \u03c0contacts within the binding pocket.", [["alkyl", "CHEMICAL", 112, 117], ["hydrogen", "CHEMICAL", 89, 97], ["aryl", "CHEMICAL", 118, 122], ["alkyl/aryl \u03c0contacts", "SIMPLE_CHEMICAL", 112, 132], ["molecular fragments", "PROBLEM", 43, 62], ["productive hydrogen bond (HB)", "PROBLEM", 78, 107], ["alkyl/aryl \u03c0contacts within the binding pocket", "PROBLEM", 112, 158], ["molecular fragments", "OBSERVATION", 43, 62], ["productive", "OBSERVATION_MODIFIER", 78, 88], ["hydrogen bond", "OBSERVATION", 89, 102], ["binding pocket", "OBSERVATION", 144, 158]]], ["Inspection of aligned 2-D structures makes it apparent that the 2(1H)-pyridone core of structure 15 (highlighted in Figure 2 ) is the minimal motif of all 190 small molecule hits (discussed further below).", [["2(1H)-pyridone", "CHEMICAL", 64, 78], ["2(1H)-pyridone", "CHEMICAL", 64, 78], ["2(1H)-pyridone", "SIMPLE_CHEMICAL", 64, 78], ["the 2(1H)-pyridone core of structure", "TREATMENT", 60, 96], ["small molecule hits", "PROBLEM", 159, 178], ["molecule hits", "OBSERVATION", 165, 178]]], ["This core binds near the top of a central hydrophobic box formed by residues Tyr297, Tyr253, Trp301, and the methyl group of Thr316 ( Figure 3 ).", [["methyl", "CHEMICAL", 109, 115], ["Tyr297", "CHEMICAL", 77, 83], ["Tyr253", "CHEMICAL", 85, 91], ["Trp301", "CHEMICAL", 93, 99], ["methyl", "CHEMICAL", 109, 115], ["Thr", "CHEMICAL", 125, 128], ["Tyr297", "AMINO_ACID", 77, 83], ["Tyr253", "AMINO_ACID", 85, 91], ["Trp301", "AMINO_ACID", 93, 99], ["methyl", "SIMPLE_CHEMICAL", 109, 115], ["Thr316", "AMINO_ACID", 125, 131], ["central hydrophobic box", "PROTEIN", 34, 57], ["This core binds", "PROBLEM", 0, 15], ["the methyl group of Thr", "TREATMENT", 105, 128], ["top", "OBSERVATION_MODIFIER", 25, 28], ["central", "ANATOMY_MODIFIER", 34, 41], ["hydrophobic box", "OBSERVATION", 42, 57]]], ["As expected, all of the hits bind within this box with the aryl or alkyl (e.g. isobutyl) groups engaged in hydrophobic interactions with these residues.", [["aryl", "CHEMICAL", 59, 63], ["alkyl", "CHEMICAL", 67, 72], ["isobutyl", "CHEMICAL", 79, 87], ["aryl", "CHEMICAL", 59, 63], ["isobutyl", "CHEMICAL", 79, 87], ["aryl", "SIMPLE_CHEMICAL", 59, 63], ["alkyl", "SIMPLE_CHEMICAL", 67, 72], ["these residues", "TREATMENT", 137, 151]]], ["Indeed, it is these hydrophobic interactions that are drivers of the overall binding affinity as judged by the Glide XP Gscore. contacts with S346, T349, and Y353 ( Figure 4E) .", [["contacts", "ANATOMY", 128, 136], ["S346, T349, and Y353", "CHEMICAL", 142, 162], ["hydrophobic", "OBSERVATION_MODIFIER", 20, 31]]], ["Thus, all of compounds are able to partially mimic the terminal carboxyl contacts that are considered to be critical for anchoring the terminal Arg of CendR peptides 12, 31, 38-42, 44-53 ( Figure 1C ) or known small molecule mimetics and inhibitors that contain a terminal guanidyl from Arg moiety and carboxylic group 54, 61, 62 .Series analysis and docked binding modesAll of the hit molecules occupying Mode I are synthetic compound chemotypes, 205Series analysis and docked binding modesincluding 11, 12, and 15 from the NC1 and NC2 libraries, as noted above.", [["guanidyl", "CHEMICAL", 273, 281], ["Arg", "CHEMICAL", 287, 290], ["carboxylic", "CHEMICAL", 302, 312], ["carboxyl", "CHEMICAL", 64, 72], ["Arg", "CHEMICAL", 144, 147], ["guanidyl", "CHEMICAL", 273, 281], ["Arg", "CHEMICAL", 287, 290], ["carboxylic", "CHEMICAL", 302, 312], ["Arg moiety", "SIMPLE_CHEMICAL", 287, 297], ["Mode I", "GENE_OR_GENE_PRODUCT", 406, 412], ["NC1", "GENE_OR_GENE_PRODUCT", 525, 528], ["Mode I", "PROTEIN", 406, 412], ["NC1", "PROTEIN", 525, 528], ["NC2", "PROTEIN", 533, 536], ["known small molecule mimetics", "PROBLEM", 204, 233], ["inhibitors", "TREATMENT", 238, 248], ["a terminal guanidyl from Arg moiety", "TREATMENT", 262, 297], ["carboxylic group", "TEST", 302, 318], ["Series analysis", "TEST", 331, 346], ["docked binding modes", "TEST", 351, 371], ["synthetic compound chemotypes", "PROBLEM", 417, 446], ["Series analysis", "TEST", 451, 466], ["docked binding modesincluding", "TEST", 471, 500], ["small", "OBSERVATION_MODIFIER", 210, 215], ["molecule mimetics", "OBSERVATION", 216, 233]]], ["Functional groups in 1, 2, 4, 5, 10, 12, 13 are involved in one or more potential hydrogen bond contacts with polar side chains Ser298 and Asn300 (Figure 4C, D) .", [["hydrogen", "CHEMICAL", 82, 90], ["Ser298", "CHEMICAL", 128, 134], ["Asn300", "CHEMICAL", 139, 145], ["polar side chains Ser298", "SIMPLE_CHEMICAL", 110, 134], ["Asn300", "SIMPLE_CHEMICAL", 139, 145], ["polar side chains", "TREATMENT", 110, 127], ["hydrogen bond", "OBSERVATION", 82, 95]]], ["No other heteroatoms nor N-H hydrogen in pyrimidone (1, 4, 5, 10, 11), 2-pyrimidone (2, 3, 6), or 4H-1,2,4-triazin-5-one (7, 8) scaffolds are seemingly engaged in productive binding.", [["N-H", "CHEMICAL", 25, 28], ["pyrimidone", "CHEMICAL", 41, 51], ["1, 4, 5, 10, 11), 2-pyrimidone", "CHEMICAL", 53, 83], ["2, 3, 6)", "CHEMICAL", 85, 93], ["4H-1,2,4-triazin-5-one", "CHEMICAL", 98, 120], ["N-H", "CHEMICAL", 25, 28], ["hydrogen", "CHEMICAL", 29, 37], ["pyrimidone", "CHEMICAL", 41, 51], ["2-pyrimidone", "CHEMICAL", 71, 83], ["4H-1,2,4-triazin-5-one", "CHEMICAL", 98, 120], ["N-H hydrogen", "SIMPLE_CHEMICAL", 25, 37], ["pyrimidone", "SIMPLE_CHEMICAL", 41, 51], ["1, 4, 5, 10, 11), 2-pyrimidone (2, 3, 6)", "SIMPLE_CHEMICAL", 53, 93], ["4H-1,2,4-triazin-5-one (7, 8) scaffolds", "SIMPLE_CHEMICAL", 98, 137], ["other heteroatoms", "PROBLEM", 3, 20], ["hydrogen in pyrimidone", "TREATMENT", 29, 51], ["triazin", "TREATMENT", 107, 114], ["heteroatoms", "OBSERVATION", 9, 20], ["productive binding", "OBSERVATION", 163, 181]]], ["Such \"silent\" polar sites provide the opportunity for 210 replacement and optimization of ADME properties (e.g., oral absorption, systemic/CNS distribution) of these compounds.", [["oral", "ANATOMY", 113, 117], ["CNS", "ANATOMY", 139, 142], ["oral", "ORGANISM_SUBDIVISION", 113, 117], ["CNS", "ANATOMICAL_SYSTEM", 139, 142], ["Such \"silent\" polar sites", "PROBLEM", 0, 25], ["210 replacement", "TREATMENT", 54, 69], ["ADME properties", "TREATMENT", 90, 105], ["oral absorption", "TREATMENT", 113, 128], ["systemic/CNS distribution", "TREATMENT", 130, 155], ["polar", "ANATOMY_MODIFIER", 14, 19], ["CNS", "ANATOMY", 139, 142]]], ["Interestingly, upon detailed analysis of hydrogen-bond patterns, we noticed that series 1, 3 but also 2-6 feature H-donor/H-acceptor topology of kinase inhibitors, including the presence of hydrophobic residues found in hinge-binding ATP mimics.Series analysis and docked binding modesSuch features warrant the inclusion of kinase selectivity panels in the optimization stage.", [["ATP", "CHEMICAL", 234, 237], ["hydrogen", "CHEMICAL", 41, 49], ["ATP", "CHEMICAL", 234, 237], ["H-donor", "SIMPLE_CHEMICAL", 114, 121], ["ATP", "SIMPLE_CHEMICAL", 234, 237], ["hinge", "PROTEIN", 220, 225], ["hydrogen-bond patterns", "TEST", 41, 63], ["kinase inhibitors", "TREATMENT", 145, 162], ["hydrophobic residues", "PROBLEM", 190, 210], ["Series analysis", "TEST", 245, 260], ["docked binding modes", "TEST", 265, 285], ["kinase selectivity panels", "TEST", 324, 349], ["hydrophobic residues", "OBSERVATION", 190, 210]]], ["While 215 kinase activity might be a feature to optimize out, our validation experiments support that binding of compounds from our series to the CendR site on NRP-1 (discussed below).Series analysis and docked binding modesMode II, with the exception of compound 9, features skeletons of natural compounds.Series analysis and docked binding modesThe functional groups in molecules 14 and 16-20 possess extensions toward the base of the pocket that form ionic or hydrogen bond contacts to residue Asp320 ( Figure 4E ).", [["compound 9", "CHEMICAL", 255, 265], ["hydrogen", "CHEMICAL", 463, 471], ["Asp320", "CHEMICAL", 497, 503], ["NRP-1", "GENE_OR_GENE_PRODUCT", 160, 165], ["215 kinase", "PROTEIN", 6, 16], ["CendR site", "DNA", 146, 156], ["NRP-1", "DNA", 160, 165], ["binding of compounds", "PROBLEM", 102, 122], ["Series analysis", "TEST", 184, 199], ["docked binding modes", "TEST", 204, 224], ["compound 9", "PROBLEM", 255, 265], ["Series analysis", "TEST", 307, 322], ["docked binding modes", "TEST", 327, 347], ["natural compounds", "OBSERVATION", 289, 306], ["base", "ANATOMY_MODIFIER", 425, 429], ["hydrogen bond", "OBSERVATION", 463, 476]]], ["Furthermore, 220 compound 9 extends toward the open region of the binding pocket bordered by Gly318 and Glu319 ( Figure 4F ).", [["compound 9", "CHEMICAL", 17, 27], ["Gly318", "CHEMICAL", 93, 99], ["Glu319", "CHEMICAL", 104, 110], ["Gly318", "SIMPLE_CHEMICAL", 93, 99], ["Glu319", "PROTEIN", 104, 110], ["the binding pocket", "PROBLEM", 62, 80], ["binding pocket", "OBSERVATION", 66, 80]]], ["In preliminary SAR for compound 9, we found that augmenting these interactions by the replacement of 5-methylisoxazole with 5-aminopyrazole (9a, Figure 2 ) led to an improvement in the Glide XP Gscore of 1.4 kcal/mol.", [["compound 9", "CHEMICAL", 23, 33], ["5-methylisoxazole", "CHEMICAL", 101, 118], ["5-aminopyrazole", "CHEMICAL", 124, 139], ["5-methylisoxazole", "CHEMICAL", 101, 118], ["5-aminopyrazole", "CHEMICAL", 124, 139], ["5-methylisoxazole", "SIMPLE_CHEMICAL", 101, 118], ["5-aminopyrazole", "SIMPLE_CHEMICAL", 124, 139], ["the replacement", "TREATMENT", 82, 97], ["methylisoxazole", "TREATMENT", 103, 118], ["aminopyrazole", "TREATMENT", 126, 139], ["improvement", "OBSERVATION_MODIFIER", 166, 177]]], ["Exploration of the interaction patterns observed in both binding modes is expected to improve binding affinity and compound 225 selectivity.Series analysis and docked binding modesWe note that molecules 13 and 16, while having the key pharmacophores present, had their geometry altered during the ligand preparation, likely a result of missing or incorrect chiral information in the COCONUT library, a known potential issue 63 .", [["molecules 13 and 16", "PROTEIN", 193, 212], ["the interaction patterns", "PROBLEM", 15, 39], ["Series analysis", "TEST", 140, 155], ["docked binding modes", "TEST", 160, 180], ["the ligand preparation", "TREATMENT", 293, 315]]], ["The hydroxycinnamyl group in inverted to (R)-configuration.", [["hydroxycinnamyl", "CHEMICAL", 4, 19], ["hydroxycinnamyl", "CHEMICAL", 4, 19], ["hydroxycinnamyl", "SIMPLE_CHEMICAL", 4, 19], ["The hydroxycinnamyl group", "TREATMENT", 0, 25]]], ["Such alterations made both analogs unavailable from commercial sources of natural products.", [["Such alterations", "PROBLEM", 0, 16], ["natural products", "TREATMENT", 74, 90], ["natural products", "OBSERVATION", 74, 90]]], ["However, due to the availability of both precursors, derivatives 13 and 16 can be synthesized.", [["derivatives", "TEST", 53, 64]]], ["Finally, the last two compounds (19, 20) are ionic, moderately reactive compounds which are not considered to be drug-like.", [["moderately reactive compounds", "PROBLEM", 52, 81], ["moderately", "OBSERVATION_MODIFIER", 52, 62], ["reactive compounds", "OBSERVATION", 63, 81]]], ["Nevertheless, since both match the key features of CendR peptides (N-acylarginine), they provide valuable points for SAR.", [["N-acylarginine", "CHEMICAL", 67, 81], ["N-acylarginine", "CHEMICAL", 67, 81], ["CendR peptides", "GENE_OR_GENE_PRODUCT", 51, 65], ["N-acylarginine", "SIMPLE_CHEMICAL", 67, 81], ["CendR peptides", "TREATMENT", 51, 65], ["SAR", "PROBLEM", 117, 120]]], ["235Comparison to known small moleculesTo enable comparison with small molecules reported by others we docked and calculated physico-chemical properties of seven compounds that also target the NRP-1 CendR site 54-56, 58-61 .Comparison to known small moleculesBased on chemotypes, we assigned these six molecules into unique series 10-14 ( Figure 5) .", [["small molecules", "PROTEIN", 23, 38], ["NRP-1 CendR site 54-56, 58-61", "DNA", 192, 221], ["small molecules", "PROTEIN", 243, 258], ["small molecules", "PROBLEM", 23, 38], ["the NRP", "TEST", 188, 195], ["known small molecules", "PROBLEM", 237, 258], ["unique series", "TEST", 316, 329], ["small molecules", "OBSERVATION", 23, 38], ["small", "OBSERVATION_MODIFIER", 243, 248], ["molecules", "OBSERVATION", 249, 258]]], ["240Comparison to known small moleculesThese molecules all exhibited lower docking scores than our hits ( Table 1) .", [["small molecules", "PROTEIN", 23, 38], ["small molecules", "PROBLEM", 23, 38], ["lower docking scores", "PROBLEM", 68, 88], ["small molecules", "OBSERVATION", 23, 38], ["lower", "OBSERVATION_MODIFIER", 68, 73]]], ["Moreover, several of compounds A-F feature functional groups known for contributing to suboptimal physicochemical and ADME properties, such as solubility, low intestinal absorption, metal chelation, and lability in liver microsomes or hepatocytes ( Table 1) .", [["intestinal", "ANATOMY", 159, 169], ["liver microsomes", "ANATOMY", 215, 231], ["hepatocytes", "ANATOMY", 235, 246], ["A-F", "SIMPLE_CHEMICAL", 31, 34], ["intestinal", "ORGAN", 159, 169], ["metal", "SIMPLE_CHEMICAL", 182, 187], ["liver microsomes", "CELL", 215, 231], ["hepatocytes", "CELL", 235, 246], ["liver microsomes", "CELL_TYPE", 215, 231], ["hepatocytes", "CELL_TYPE", 235, 246], ["suboptimal physicochemical and ADME properties", "PROBLEM", 87, 133], ["low intestinal absorption", "PROBLEM", 155, 180], ["metal chelation", "TREATMENT", 182, 197], ["lability in liver microsomes", "PROBLEM", 203, 231], ["intestinal", "ANATOMY", 159, 169], ["liver", "ANATOMY", 215, 220], ["microsomes", "ANATOMY_MODIFIER", 221, 231], ["hepatocytes", "ANATOMY", 235, 246]]], ["Docking poses for all compounds except E adopted Mode II binding.", [["E", "SIMPLE_CHEMICAL", 39, 40]]], ["245Validation of selected hitsWe evaluated the ability of hit compounds to interfere with the NRP-1/VEGF-A interaction using an enzyme linked immunosorbent assay (ELISA).", [["NRP-1", "GENE_OR_GENE_PRODUCT", 94, 99], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 100, 106], ["NRP-1", "PROTEIN", 94, 99], ["VEGF", "PROTEIN", 100, 104], ["the NRP", "TEST", 90, 97], ["an enzyme linked immunosorbent assay", "TEST", 125, 161]]], ["We coated plates with the extracellular domain of human NRP-1 (containing the a1a2 and the b1b2 regions) and added a 250 selection of our compounds (based on SAR and commercial availability) to disrupt the NRP-1/VEGF-A interaction.", [["extracellular", "ANATOMY", 26, 39], ["human", "ORGANISM", 50, 55], ["NRP-1", "GENE_OR_GENE_PRODUCT", 56, 61], ["a1a2", "GENE_OR_GENE_PRODUCT", 78, 82], ["NRP-1", "GENE_OR_GENE_PRODUCT", 206, 211], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 212, 218], ["extracellular domain", "PROTEIN", 26, 46], ["human NRP-1", "PROTEIN", 50, 61], ["a1a2", "PROTEIN", 78, 82], ["b1b2 regions", "DNA", 91, 103], ["NRP-1", "PROTEIN", 206, 211], ["VEGF", "PROTEIN", 212, 216], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["human NRP", "TEST", 50, 59]]], ["We found that 3 hit compounds blocked more than 50% of VEGF-A binding to NRP-1.", [["VEGF-A", "GENE_OR_GENE_PRODUCT", 55, 61], ["NRP-1", "GENE_OR_GENE_PRODUCT", 73, 78], ["VEGF", "PROTEIN", 55, 59], ["NRP-1", "DNA", 73, 78], ["3 hit compounds", "PROBLEM", 14, 29]]], ["This level of inhibition mimicked that we observed with SARS-CoV-2 Spike protein ( Table 1 ).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 56, 66], ["SARS-CoV-2 Spike protein", "PROTEIN", 56, 80], ["Table 1", "PROTEIN", 83, 90], ["SARS", "TEST", 56, 60], ["CoV", "TEST", 61, 64]]], ["In comparison, EG00229's level of inhibition was outmatched by 6 of the 9 compounds we screened in this assay (Table 1) .", [["EG00229", "CHEMICAL", 15, 22], ["EG00229", "CHEMICAL", 15, 22], ["EG00229", "SIMPLE_CHEMICAL", 15, 22]]], ["Thus, three of the synthetic compounds 255 significantly inhibited the interaction between VEGF-A and NRP-1, confirming that they compete for binding to the CendR site ( Table 1) .Validation of selected hitsCompounds for biochemical evaluation were selected such that each structural feature was complementary to the overall SAR.", [["VEGF-A", "GENE_OR_GENE_PRODUCT", 91, 97], ["NRP-1", "GENE_OR_GENE_PRODUCT", 102, 107], ["VEGF", "PROTEIN", 91, 95], ["NRP-1", "PROTEIN", 102, 107], ["CendR site", "DNA", 157, 167], ["VEGF", "TEST", 91, 95], ["biochemical evaluation", "TEST", 221, 243]]], ["Relative inhibition in the ELISA is reported in Table 1 .Validation of selected hitsUnfortunately, several compounds (12, 14, 15, 18, 19, 20) were not commercially available.", [["Relative inhibition in the ELISA", "PROBLEM", 0, 32]]], ["260Validation of selected hitsSince many of those compounds can be synthesized in two to five steps, we intend to make essential representatives during future SAR optimization.", [["future SAR optimization", "TREATMENT", 152, 175]]], ["Table 1 reveals a correlation between predictions and ELISA data.", [["ELISA data", "TEST", 54, 64]]], ["Most importantly, the binding hypotheses were confirmed as compounds with pyridone and pyrimidone cores, when appropriately decorated, were found to 265 disrupt the VEGF-A/NRP-1 interaction more effectively than EG00229 and to a similar extent as SARS-CoV-2 Spike protein.", [["pyridone", "CHEMICAL", 74, 82], ["pyrimidone", "CHEMICAL", 87, 97], ["pyridone", "CHEMICAL", 74, 82], ["pyrimidone", "CHEMICAL", 87, 97], ["EG00229", "CHEMICAL", 212, 219], ["pyridone", "SIMPLE_CHEMICAL", 74, 82], ["pyrimidone cores", "SIMPLE_CHEMICAL", 87, 103], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 165, 171], ["NRP-1", "GENE_OR_GENE_PRODUCT", 172, 177], ["EG00229", "SIMPLE_CHEMICAL", 212, 219], ["SARS-CoV-2 Spike", "GENE_OR_GENE_PRODUCT", 247, 263], ["VEGF", "PROTEIN", 165, 169], ["NRP", "PROTEIN", 172, 175], ["SARS-CoV-2 Spike protein", "PROTEIN", 247, 271], ["pyridone", "TREATMENT", 74, 82], ["pyrimidone cores", "TREATMENT", 87, 103], ["the VEGF", "TEST", 161, 169], ["SARS", "TEST", 247, 251], ["CoV", "TEST", 252, 255], ["Spike protein", "PROBLEM", 258, 271]]], ["Such a trend is important for the design of new analogs that will expand on underexplored scaffolds (Series 3, compound 11).", [["new analogs", "TREATMENT", 44, 55], ["underexplored scaffolds", "TREATMENT", 76, 99]]], ["As discussed later, we intend to improve binding and inhibition by borrowing structural features from Modes I 270 and II (e.g., compound 9a).Inspection of docking scores and relative inhibition data inNext, we set out to test the compounds for their capacity to inhibit the activation of the VEGF-A pathway.", [["VEGF-A", "GENE_OR_GENE_PRODUCT", 292, 298], ["VEGF", "PROTEIN", 292, 296], ["Inspection of docking scores", "TEST", 141, 169], ["relative inhibition data", "TEST", 174, 198], ["their capacity", "PROBLEM", 244, 258]]], ["VEGF-A binding to the dimeric complex of its receptor VEGFR2 and coreceptor NRP-1 triggers phosphorylation of the VEGFR2 cytoplasmic domain at Y1175 ( Figure 6A ).", [["cytoplasmic", "ANATOMY", 121, 132], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 0, 6], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 54, 60], ["NRP-1", "GENE_OR_GENE_PRODUCT", 76, 81], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 114, 120], ["VEGF", "PROTEIN", 0, 4], ["dimeric complex", "PROTEIN", 22, 37], ["VEGFR2", "PROTEIN", 54, 60], ["coreceptor NRP-1", "PROTEIN", 65, 81], ["VEGFR2 cytoplasmic domain", "PROTEIN", 114, 139], ["Y1175", "PROTEIN", 143, 148], ["Figure 6A", "PROTEIN", 151, 160], ["A binding", "PROBLEM", 5, 14], ["coreceptor NRP", "TEST", 65, 79], ["the VEGFR2 cytoplasmic domain", "TREATMENT", 110, 139]]], ["Using an in-cell Western assay, we tested the compounds for their ability to inhibit 275 increased phosphorylation of VEGFR2 by VEGF-A.", [["cell", "CELL", 12, 16], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 118, 124], ["VEGF-A.", "GENE_OR_GENE_PRODUCT", 128, 135], ["VEGFR2", "PROTEIN", 118, 124], ["VEGF", "PROTEIN", 128, 132]]], ["In this assay, VEGF-A doubled the level of VEGFR2 phosphorylation at Y1175 (Figure 6B ) which could be blocked by SARS-CoV-2 Spike protein as well as by the reference compound EG00229 ( Figure 6C) .", [["EG00229", "CHEMICAL", 176, 183], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 15, 21], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 43, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 114, 124], ["EG00229", "SIMPLE_CHEMICAL", 176, 183], ["VEGF", "PROTEIN", 15, 19], ["VEGFR2", "PROTEIN", 43, 49], ["SARS-CoV-2 Spike protein", "PROTEIN", 114, 138], ["this assay", "TEST", 3, 13], ["VEGFR2 phosphorylation", "TEST", 43, 65], ["SARS", "PROBLEM", 114, 118], ["CoV", "TEST", 119, 122], ["Spike protein", "PROBLEM", 125, 138]]], ["All 9 of our tested compounds significantly blocked the VEGF-A stimulated increased phosphorylation of VEGFR2 ( Figure 6 ).", [["VEGF-A", "GENE_OR_GENE_PRODUCT", 56, 62], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 103, 109], ["VEGF-A", "PROTEIN", 56, 62], ["VEGFR2", "PROTEIN", 103, 109], ["Figure 6", "PROTEIN", 112, 120], ["our tested compounds", "TEST", 9, 29], ["the VEGF", "TEST", 52, 60], ["VEGF", "ANATOMY", 56, 60]]], ["In the absence of stimulation by VEGF-A, only one of the 9 compounds (4) showed 280 inhibition of basal VEGFR2 phosphorylation.", [["VEGF-A", "GENE_OR_GENE_PRODUCT", 33, 39], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 104, 110], ["VEGF", "PROTEIN", 33, 37], ["VEGFR2", "PROTEIN", 104, 110], ["basal VEGFR2 phosphorylation", "TEST", 98, 126]]], ["As mentioned above, several of our compounds do exhibit features that are consistent with known kinase inhibitors which will be addressed during optimization of these hits.Inspection of docking scores and relative inhibition data inFinally, we screened the compounds for antiviral activity using a GFP-expressing vesicular stomatitis virus (VSV) recombinant protein, encoding the SARS-CoV-2 spike protein 285 rather than the native envelope glycoprotein 68 .", [["vesicular stomatitis", "DISEASE", 313, 333], ["GFP", "GENE_OR_GENE_PRODUCT", 298, 301], ["vesicular stomatitis virus", "ORGANISM", 313, 339], ["VSV", "ORGANISM", 341, 344], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 380, 390], ["envelope glycoprotein 68", "GENE_OR_GENE_PRODUCT", 432, 456], ["GFP-expressing vesicular stomatitis virus (VSV) recombinant protein", "PROTEIN", 298, 365], ["SARS-CoV-2 spike protein 285", "PROTEIN", 380, 408], ["native envelope glycoprotein 68", "PROTEIN", 425, 456], ["vesicular stomatitis virus", "SPECIES", 313, 339], ["stomatitis virus", "SPECIES", 323, 339], ["VSV", "SPECIES", 341, 344], ["known kinase inhibitors", "TREATMENT", 90, 113], ["Inspection of docking scores", "TEST", 172, 200], ["relative inhibition data", "TEST", 205, 229], ["antiviral activity", "TREATMENT", 271, 289], ["a GFP", "TEST", 296, 301], ["vesicular stomatitis virus", "PROBLEM", 313, 339], ["the SARS", "TEST", 376, 384], ["CoV", "TEST", 385, 388], ["spike protein", "TEST", 391, 404], ["the native envelope glycoprotein", "TEST", 421, 453], ["consistent with", "UNCERTAINTY", 74, 89], ["vesicular stomatitis", "ANATOMY", 313, 333]]], ["This VSV-eGFP-SARS-CoV-2 mimics SARS-CoV-2 and is a convenient BSL2 platform to assess SARS-CoV-2 Spike-dependency.", [["VSV", "ORGANISM", 5, 8], ["eGFP-SARS-CoV-2", "ORGANISM", 9, 24], ["SARS-CoV-2", "ORGANISM", 32, 42], ["SARS-CoV", "SPECIES", 32, 40], ["This VSV", "TEST", 0, 8], ["eGFP-SARS", "TEST", 9, 18], ["CoV", "TEST", 19, 22], ["SARS", "TEST", 32, 36], ["CoV", "TEST", 37, 40], ["a convenient BSL2 platform", "TEST", 50, 76], ["SARS", "TEST", 87, 91], ["CoV", "TEST", 92, 95], ["Spike-dependency", "PROBLEM", 98, 114]]], ["Vero-E6-TMPRSS2 cells, which overexpress the transmembrane serine protease 2 (TMPRSS2) 68 Figure 7B ).", [["Vero-E6-TMPRSS2 cells", "ANATOMY", 0, 21], ["serine", "CHEMICAL", 59, 65], ["Vero-E6-TMPRSS2 cells", "CELL", 0, 21], ["transmembrane serine protease 2", "GENE_OR_GENE_PRODUCT", 45, 76], ["Vero-E6-TMPRSS2 cells", "CELL_LINE", 0, 21], ["transmembrane serine protease 2 (TMPRSS2) 68 Figure 7B", "PROTEIN", 45, 99], ["Vero-E6-TMPRSS2 cells", "PROBLEM", 0, 21], ["the transmembrane serine protease", "TREATMENT", 41, 74], ["TMPRSS2", "TEST", 78, 85], ["TMPRSS2 cells", "OBSERVATION", 8, 21]]], ["Spike inhibited antiviral activity by ~35% while the known NRP-1 inhibitor EG00229 was ineffective in this assay.Pharmacophore models 295A pharmacophore model was derived from the identified ligands, considering both steric and electronic requirements (Figure 8) .", [["EG00229", "CHEMICAL", 75, 82], ["EG00229", "CHEMICAL", 75, 82], ["Spike", "GENE_OR_GENE_PRODUCT", 0, 5], ["NRP-1", "GENE_OR_GENE_PRODUCT", 59, 64], ["EG00229", "SIMPLE_CHEMICAL", 75, 82], ["Spike inhibited antiviral activity", "PROBLEM", 0, 34], ["Pharmacophore models", "TEST", 113, 133], ["A pharmacophore model", "TEST", 137, 158], ["antiviral activity", "OBSERVATION", 16, 34], ["steric", "OBSERVATION_MODIFIER", 217, 223]]], ["The most critical features are the aromatic rings A1, A2, and the hydrogen bond acceptor HBA.", [["hydrogen", "CHEMICAL", 66, 74], ["HBA", "CHEMICAL", 89, 92], ["A2", "SIMPLE_CHEMICAL", 54, 56], ["hydrogen bond acceptor HBA", "SIMPLE_CHEMICAL", 66, 92], ["most critical", "OBSERVATION_MODIFIER", 4, 17], ["aromatic rings", "OBSERVATION", 35, 49], ["hydrogen bond", "OBSERVATION", 66, 79], ["acceptor HBA", "OBSERVATION", 80, 92]]], ["This HBA is typically a carbonyl oxygen engaged in contacts with the hydroxyl groups of Tyr353 and Thr349.", [["HBA", "CHEMICAL", 5, 8], ["oxygen", "CHEMICAL", 33, 39], ["hydroxyl", "CHEMICAL", 69, 77], ["Thr349", "CHEMICAL", 99, 105], ["HBA", "CHEMICAL", 5, 8], ["carbonyl", "CHEMICAL", 24, 32], ["oxygen", "CHEMICAL", 33, 39], ["hydroxyl", "CHEMICAL", 69, 77], ["Tyr353", "CHEMICAL", 88, 94], ["Thr", "CHEMICAL", 99, 102], ["HBA", "SIMPLE_CHEMICAL", 5, 8], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 24, 39], ["Tyr353", "SIMPLE_CHEMICAL", 88, 94], ["Thr349", "AMINO_ACID", 99, 105], ["a carbonyl oxygen", "TREATMENT", 22, 39], ["the hydroxyl groups", "TREATMENT", 65, 84], ["carbonyl oxygen", "OBSERVATION", 24, 39]]], ["The aryl group in A1 directs the carbonyl oxygen of the HBA toward those residues.", [["aryl", "CHEMICAL", 4, 8], ["oxygen", "CHEMICAL", 42, 48], ["HBA", "CHEMICAL", 56, 59], ["aryl", "CHEMICAL", 4, 8], ["carbonyl", "CHEMICAL", 33, 41], ["oxygen", "CHEMICAL", 42, 48], ["HBA", "CHEMICAL", 56, 59], ["aryl", "SIMPLE_CHEMICAL", 4, 8], ["A1", "SIMPLE_CHEMICAL", 18, 20], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 33, 48], ["HBA", "SIMPLE_CHEMICAL", 56, 59], ["A1", "PROTEIN", 18, 20], ["the carbonyl oxygen", "TREATMENT", 29, 48], ["carbonyl oxygen", "OBSERVATION", 33, 48]]], ["Alternatively, A1 can be presented in an 300 edge-to-face contact with Tyr297.", [["Tyr297", "CHEMICAL", 71, 77], ["A1", "GENE_OR_GENE_PRODUCT", 15, 17], ["Tyr297", "SIMPLE_CHEMICAL", 71, 77], ["A1", "PROTEIN", 15, 17]]], ["There are two additional acceptor sites on the opposite side of the A1 ring, relative to acceptor HBA.", [["HBA", "CHEMICAL", 98, 101], ["acceptor HBA", "SIMPLE_CHEMICAL", 89, 101], ["A1 ring", "PROTEIN", 68, 75], ["two", "OBSERVATION_MODIFIER", 10, 13], ["additional", "OBSERVATION_MODIFIER", 14, 24], ["acceptor sites", "OBSERVATION", 25, 39], ["A1 ring", "ANATOMY", 68, 75], ["acceptor HBA", "OBSERVATION", 89, 101]]], ["These can form hydrogen bonds with the side chain of the Asn300 amide or the Ser298 hydroxyl.", [["Asn300 amide", "CHEMICAL", 57, 69], ["Ser298 hydroxyl", "CHEMICAL", 77, 92], ["hydrogen", "CHEMICAL", 15, 23], ["Asn300 amide", "CHEMICAL", 57, 69], ["Ser298 hydroxyl", "CHEMICAL", 77, 92], ["Asn300 amide", "SIMPLE_CHEMICAL", 57, 69], ["Ser298 hydroxyl", "SIMPLE_CHEMICAL", 77, 92], ["the Asn300 amide", "TREATMENT", 53, 69], ["the Ser298 hydroxyl", "TREATMENT", 73, 92], ["hydrogen bonds", "OBSERVATION", 15, 29]]], ["The area between the HBA and these two additional acceptors (where the label A1 is located) is expected to accommodate a structural molecule of Figure 4A ).", [["HBA", "CHEMICAL", 21, 24], ["HBA", "SIMPLE_CHEMICAL", 21, 24], ["label A1", "PROTEIN", 71, 79], ["the HBA", "TEST", 17, 24], ["HBA", "OBSERVATION_MODIFIER", 21, 24]]], ["By connecting all important pharmacophore features, hybrid synthetic molecules can be envisioned that will merge binding modes I and II and extend into the lower left to fully 315 occupy the available binding pocket.ConclusionsFrom a virtual screen of nearly 0.5 M compounds, we identified nine chemical series comprising small molecules and natural products that occupy the CendR binding site on NRP-1.", [["NRP-1", "GENE_OR_GENE_PRODUCT", 397, 402], ["I and II", "PROTEIN", 127, 135], ["CendR binding site", "DNA", 375, 393], ["NRP-1", "DNA", 397, 402], ["hybrid synthetic molecules", "TREATMENT", 52, 78], ["a virtual screen", "TEST", 232, 248], ["nine chemical series", "PROBLEM", 290, 310], ["small molecules", "PROBLEM", 322, 337], ["natural products", "TREATMENT", 342, 358], ["lower", "ANATOMY_MODIFIER", 156, 161], ["left", "ANATOMY_MODIFIER", 162, 166], ["small molecules", "OBSERVATION", 322, 337]]], ["All 320 compounds identified in our series fall within ranges of lead-like and/or drug-like molecules which enhances their potential for efficacy in in vitro and in vivo assays.", [["lead-like and/or drug-like molecules", "PROBLEM", 65, 101], ["320 compounds", "OBSERVATION_MODIFIER", 4, 17]]], ["This in silico effort allowed us to identify two modes of binding within the CendR pocket.", [["CendR pocket", "PROTEIN", 77, 89], ["binding within the CendR pocket", "PROBLEM", 58, 89], ["binding", "OBSERVATION", 58, 65]]], ["To guide future drug discovery efforts, we propose a hybrid pharmacophore model that will enable design of small molecules that will maximize the pocket occupancy.", [["a hybrid pharmacophore model", "TREATMENT", 51, 79], ["small molecules", "PROBLEM", 107, 122], ["the pocket occupancy", "PROBLEM", 142, 162], ["small molecules", "OBSERVATION", 107, 122], ["pocket occupancy", "OBSERVATION", 146, 162]]], ["Two validation experiments confirmed that guide future drug discovery efforts, we propose a hybrid pharmacophore model that will enable design of small molecules that will maximize pocket occupancy and contacts.", [["Two validation experiments", "TEST", 0, 26], ["a hybrid pharmacophore model", "TREATMENT", 90, 118], ["small molecules", "PROBLEM", 146, 161], ["pocket occupancy", "PROBLEM", 181, 197]]], ["Since the VEGF-A/NRP-1 signaling pathway participates in multiple pathologies including neuropathic pain and cancer, our series of lead compounds represent a first step in a renewed effort to develop small molecule inhibitors for the treatment of these diseases.", [["cancer", "ANATOMY", 109, 115], ["neuropathic pain", "DISEASE", 88, 104], ["cancer", "DISEASE", 109, 115], ["VEGF-A", "GENE_OR_GENE_PRODUCT", 10, 16], ["NRP-1", "GENE_OR_GENE_PRODUCT", 17, 22], ["cancer", "CANCER", 109, 115], ["VEGF-A", "PROTEIN", 10, 16], ["NRP", "PROTEIN", 17, 20], ["the VEGF", "TEST", 6, 14], ["multiple pathologies", "PROBLEM", 57, 77], ["neuropathic pain", "PROBLEM", 88, 104], ["cancer", "PROBLEM", 109, 115], ["lead compounds", "PROBLEM", 131, 145], ["small molecule inhibitors", "TREATMENT", 200, 225], ["these diseases", "PROBLEM", 247, 261], ["multiple", "OBSERVATION_MODIFIER", 57, 65], ["pathologies", "OBSERVATION", 66, 77], ["neuropathic", "OBSERVATION_MODIFIER", 88, 99], ["pain", "OBSERVATION", 100, 104], ["cancer", "OBSERVATION", 109, 115], ["diseases", "OBSERVATION", 253, 261]]], ["Heparin, the widely used anticoagulant drug is routinely used for hospitalized SARS-CoV-2 patients to lower the probability of blood clothing and embolism 69 .", [["blood", "ANATOMY", 127, 132], ["Heparin", "CHEMICAL", 0, 7], ["SARS", "DISEASE", 79, 83], ["blood clothing", "DISEASE", 127, 141], ["embolism", "DISEASE", 146, 154], ["Heparin", "SIMPLE_CHEMICAL", 0, 7], ["SARS-CoV", "ORGANISM", 79, 87], ["patients", "ORGANISM", 90, 98], ["blood", "ORGANISM_SUBSTANCE", 127, 132], ["patients", "SPECIES", 90, 98], ["SARS-CoV", "SPECIES", 79, 87], ["Heparin", "TREATMENT", 0, 7], ["anticoagulant drug", "TREATMENT", 25, 43], ["blood clothing", "TEST", 127, 141], ["embolism", "PROBLEM", 146, 154], ["embolism", "OBSERVATION", 146, 154]]], ["It is also known that heparin prevents infection by a range of viruses 70 and was recently reported to inhibit invasion by SARS-CoV-2 in a cell-based assay 71 .", [["cell", "ANATOMY", 139, 143], ["heparin", "CHEMICAL", 22, 29], ["infection", "DISEASE", 39, 48], ["heparin", "SIMPLE_CHEMICAL", 22, 29], ["CoV-2", "ORGANISM", 128, 133], ["cell", "CELL", 139, 143], ["SARS-CoV", "SPECIES", 123, 131], ["heparin", "TREATMENT", 22, 29], ["infection", "PROBLEM", 39, 48], ["SARS", "TEST", 123, 127], ["CoV", "TEST", 128, 131], ["a cell-based assay", "TEST", 137, 155], ["infection", "OBSERVATION", 39, 48]]], ["Heparin is a required co-receptor for VEGF-A 340 signaling 72 and NRP-1 also binds heparin, mainly through the b1b2 domain, through sites distal to the CendR pocket 73 .", [["Heparin", "CHEMICAL", 0, 7], ["heparin", "CHEMICAL", 83, 90], ["Heparin", "GENE_OR_GENE_PRODUCT", 0, 7], ["VEGF-A 340", "GENE_OR_GENE_PRODUCT", 38, 48], ["NRP-1", "GENE_OR_GENE_PRODUCT", 66, 71], ["heparin", "SIMPLE_CHEMICAL", 83, 90], ["b1b2", "GENE_OR_GENE_PRODUCT", 111, 115], ["VEGF", "PROTEIN", 38, 42], ["NRP-1", "PROTEIN", 66, 71], ["b1b2 domain", "PROTEIN", 111, 122], ["CendR pocket 73", "PROTEIN", 152, 167], ["Heparin", "TREATMENT", 0, 7], ["VEGF", "TEST", 38, 42], ["NRP", "TEST", 66, 69], ["binds heparin", "TREATMENT", 77, 90], ["the b1b2 domain", "TREATMENT", 107, 122], ["the CendR pocket", "TREATMENT", 148, 164], ["pocket", "OBSERVATION_MODIFIER", 158, 164]]], ["This raises the possibility that the interaction of SARS-CoV-2 Spike/RBD with NRP-1 is facilitated by heparin and invites speculation of a potential synergistic effect of heparin and NRP-1 inhibitors as an efficacious drug combination to prevent viral entry.Preparation of receptor protein and grid for virtual screeningPreparation and virtual screening steps were conducted using Schr\u00f6dinger Release 2019-3 (Schr\u00f6dinger, LLC, New York, NY, 2020).", [["SARS", "DISEASE", 52, 56], ["heparin", "CHEMICAL", 102, 109], ["heparin", "CHEMICAL", 171, 178], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 52, 62], ["RBD", "GENE_OR_GENE_PRODUCT", 69, 72], ["NRP-1", "GENE_OR_GENE_PRODUCT", 78, 83], ["heparin", "SIMPLE_CHEMICAL", 102, 109], ["heparin", "SIMPLE_CHEMICAL", 171, 178], ["NRP-1", "GENE_OR_GENE_PRODUCT", 183, 188], ["SARS-CoV-2 Spike", "PROTEIN", 52, 68], ["RBD", "PROTEIN", 69, 72], ["NRP-1", "PROTEIN", 78, 83], ["receptor protein", "PROTEIN", 273, 289], ["SARS", "TEST", 52, 56], ["CoV", "TEST", 57, 60], ["Spike/RBD", "PROBLEM", 63, 72], ["NRP", "TEST", 78, 81], ["heparin", "TREATMENT", 102, 109], ["heparin", "TREATMENT", 171, 178], ["NRP", "TREATMENT", 183, 186], ["1 inhibitors", "TREATMENT", 187, 199], ["an efficacious drug", "TREATMENT", 203, 222], ["viral entry", "PROBLEM", 246, 257], ["receptor protein", "TREATMENT", 273, 289], ["virtual screening", "TEST", 303, 320], ["virtual screening steps", "TEST", 336, 359], ["raises the possibility", "UNCERTAINTY", 5, 27], ["viral entry", "OBSERVATION", 246, 257], ["LLC", "ANATOMY", 422, 425]]], ["The highest resolution structure of the NRP-1 b1 350 domain was selected for docking (PDB ID: 6fmc) 61 .", [["NRP-1", "GENE_OR_GENE_PRODUCT", 40, 45], ["NRP-1 b1 350 domain", "PROTEIN", 40, 59], ["the NRP", "TEST", 36, 43], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["resolution", "OBSERVATION_MODIFIER", 12, 22]]], ["This structure was prepared using the Protein Preparation Wizard 74 to remove all water molecules and alternate conformations, add and refine hydrogen atoms, and conduct restrained minimization (OPLS3e force field, convergence to 0.30 \u00c5).", [["hydrogen", "CHEMICAL", 142, 150], ["hydrogen atoms", "SIMPLE_CHEMICAL", 142, 156], ["the Protein Preparation Wizard", "TREATMENT", 34, 64], ["hydrogen atoms", "TREATMENT", 142, 156], ["conduct restrained minimization (OPLS3e force field", "TREATMENT", 162, 213]]], ["There were no residues with alternate conformations within the binding pocket.", [["residues with alternate conformations within the binding pocket", "PROBLEM", 14, 77], ["no", "UNCERTAINTY", 11, 13], ["residues", "OBSERVATION", 14, 22], ["binding pocket", "OBSERVATION", 63, 77]]], ["A 20x20x20 \u00c5 grid box was centered on the co-crystallized inhibitor EG01377 to target the VEGF-355 A 165 site.", [["EG01377", "CHEMICAL", 68, 75], ["EG01377", "CHEMICAL", 68, 75], ["EG01377", "SIMPLE_CHEMICAL", 68, 75], ["VEGF", "GENE_OR_GENE_PRODUCT", 90, 94], ["20x20x20 \u00c5 grid box", "DNA", 2, 21], ["VEGF-355 A 165 site", "DNA", 90, 109], ["A 20x20x20 \u00c5 grid box", "TREATMENT", 0, 21], ["the co-crystallized inhibitor", "TREATMENT", 38, 67], ["the VEGF", "TEST", 86, 94]]], ["An optional, symmetric constraint was generated that required hit compounds to form a hydrogen bond to the side-chain of Asp 320.Screening librariesThe synthetic compound library (DIV) was obtained by combining ChemBridge Diversity Core 360Screening librariesand Express sets of drug-like compounds.", [["Asp 320", "CHEMICAL", 121, 128], ["hydrogen", "CHEMICAL", 86, 94], ["Asp", "CHEMICAL", 121, 124], ["Asp 320", "AMINO_ACID", 121, 128], ["hit compounds", "PROBLEM", 62, 75], ["Asp", "TEST", 121, 124]]], ["These were prepared for screening in LigPrep using the OPLS3e force field, neutral ionization, desalting, and tautomer generation.", [["LigPrep", "SIMPLE_CHEMICAL", 37, 44], ["screening", "TEST", 24, 33], ["neutral ionization", "TREATMENT", 75, 93]]], ["The virtual screens were first run without and then with the use of the Asp 320 constraint, but only the constrained hits from NC2 were retained due to strained conformations and lower docking scores for the DIV and NC1 screens.", [["Asp", "CHEMICAL", 72, 75], ["NC2", "GENE_OR_GENE_PRODUCT", 127, 130], ["NC1", "GENE_OR_GENE_PRODUCT", 216, 219], ["NC2", "PROTEIN", 127, 130], ["NC1", "PROTEIN", 216, 219], ["The virtual screens", "TEST", 0, 19], ["the Asp", "TEST", 68, 75], ["NC2", "TREATMENT", 127, 130], ["strained conformations", "PROBLEM", 152, 174], ["the DIV and NC1 screens", "TEST", 204, 227]]], ["Thus, a total number of 1,147 virtual hit compounds were obtained from 4 screens.Docking of known NRP-1 targeting compoundsRepresentatives of known compound series 54-56, 58, 59, 61 were prepared for screening in LigPrep using the OPLS3e force field, neutral ionization, desalting, and tautomer generation.", [["NRP-1", "GENE_OR_GENE_PRODUCT", 98, 103], ["LigPrep", "SIMPLE_CHEMICAL", 213, 220], ["NRP", "PROTEIN", 98, 101], ["virtual hit compounds", "TEST", 30, 51], ["known NRP", "PROBLEM", 92, 101], ["known compound series", "TEST", 142, 163], ["screening", "TEST", 200, 209], ["neutral ionization", "TREATMENT", 251, 269]]], ["Docking was run against the VEGF-A 165 binding site of NRP-1 using Glide XP (Schr\u00f6dinger, LLC, New York, NY, 2020) 75 .Compound property calculationsThe following physico-chemical properties were calculated using RDKit 76In cell western for detecting inhibition of VEGFR2 activation by VEGF-A165Mouse neuron derived Cathecholamine A differentiated CAD (ECACC, Cat# 08100805) were grown in standard cell culture conditions, 37 \u00b0C in 5% CO2.", [["cell", "ANATOMY", 398, 402], ["CAD", "DISEASE", 348, 351], ["Cat# 08100805", "CHEMICAL", 360, 373], ["CO2", "CHEMICAL", 435, 438], ["CO2", "CHEMICAL", 435, 438], ["VEGF-A 165", "GENE_OR_GENE_PRODUCT", 28, 38], ["NRP-1", "GENE_OR_GENE_PRODUCT", 55, 60], ["RDKit 76In cell", "CELL", 213, 228], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 265, 271], ["VEGF", "GENE_OR_GENE_PRODUCT", 286, 290], ["cell", "CELL", 398, 402], ["CO2", "SIMPLE_CHEMICAL", 435, 438], ["VEGF-A 165 binding site", "DNA", 28, 51], ["NRP-1", "DNA", 55, 60], ["VEGFR2", "PROTEIN", 265, 271], ["VEGF", "PROTEIN", 286, 290], ["VEGFR2 activation", "PROBLEM", 265, 282], ["VEGF", "TEST", 286, 290], ["A differentiated CAD", "PROBLEM", 331, 351], ["VEGF", "ANATOMY", 28, 32], ["LLC", "ANATOMY", 90, 93]]], ["All media was supplemented with 10% fetal bovine serum (Hyclone) and 1% penicillin/streptomycin sulfate from 10,000 \u00b5g/ml stock.", [["fetal bovine serum", "ANATOMY", 36, 54], ["penicillin", "CHEMICAL", 72, 82], ["streptomycin", "CHEMICAL", 83, 95], ["penicillin", "CHEMICAL", 72, 82], ["streptomycin sulfate", "CHEMICAL", 83, 103], ["bovine", "ORGANISM", 42, 48], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["Hyclone", "ORGANISM_SUBSTANCE", 56, 63], ["penicillin", "SIMPLE_CHEMICAL", 72, 82], ["streptomycin sulfate", "SIMPLE_CHEMICAL", 83, 103], ["bovine", "SPECIES", 42, 48], ["bovine", "SPECIES", 42, 48], ["All media", "TREATMENT", 0, 9], ["10% fetal bovine serum (Hyclone)", "TREATMENT", 32, 64], ["1% penicillin", "TREATMENT", 69, 82], ["streptomycin sulfate", "TREATMENT", 83, 103]]], ["CAD cells were maintained in DMEM/F12 media.", [["CAD cells", "ANATOMY", 0, 9], ["CAD", "DISEASE", 0, 3], ["CAD cells", "CELL", 0, 9], ["CAD cells", "CELL_LINE", 0, 9], ["CAD cells", "PROBLEM", 0, 9]]], ["Cells were plated in a 96 well plate and 420 left overnight.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["left", "ANATOMY_MODIFIER", 45, 49]]], ["The next day, indicated compounds (at 12.5\u00b5M), or SARS-CoV-2 Spike (100 nM, S1 domain) were added in CAD cell complete media supplemented with 1 nM of mouse VEGF-A165 (Cat# RP8672, Invitrogen) and left at 37\u00b0C for 1 hour.", [["cell", "ANATOMY", 105, 109], ["CAD cell", "CELL", 101, 109], ["mouse", "ORGANISM", 151, 156], ["VEGF-A165", "GENE_OR_GENE_PRODUCT", 157, 166], ["Spike", "PROTEIN", 61, 66], ["VEGF", "PROTEIN", 157, 161], ["mouse", "SPECIES", 151, 156], ["mouse", "SPECIES", 151, 156], ["SARS", "PROBLEM", 50, 54], ["CoV", "TEST", 55, 58], ["Spike", "PROBLEM", 61, 66], ["mouse VEGF", "TEST", 151, 161], ["Invitrogen", "TEST", 181, 191], ["left", "ANATOMY_MODIFIER", 197, 201]]], ["Media was removed and the cells rinsed three times with PBS before fixation using ice cold methanol (5 min imaged on an Azure Sapphire apparatus.", [["cells", "ANATOMY", 26, 31], ["methanol", "CHEMICAL", 91, 99], ["cells", "CELL", 26, 31], ["the cells", "TREATMENT", 22, 31], ["PBS", "TREATMENT", 56, 59], ["fixation", "TREATMENT", 67, 75], ["ice cold methanol", "TREATMENT", 82, 99], ["an Azure Sapphire apparatus", "TREATMENT", 117, 144]]], ["Wells that did not receive the primary antibody were used a negative control.", [["primary antibody", "PROTEIN", 31, 47], ["the primary antibody", "TREATMENT", 27, 47]]], ["The signal was normalized to the cell load in each well (using DAPI) and to control wells not treated with VEGF-A165.Cell and viral culture 435Vero-E6-TMPRSS2 cells were cultured in high glucose DMEM supplemented with 10% FBS and 1% penicillin/streptomycin.", [["cell", "ANATOMY", 33, 37], ["Cell", "ANATOMY", 117, 121], ["TMPRSS2 cells", "ANATOMY", 151, 164], ["FBS", "ANATOMY", 222, 225], ["glucose", "CHEMICAL", 187, 194], ["penicillin", "CHEMICAL", 233, 243], ["streptomycin", "CHEMICAL", 244, 256], ["DAPI", "CHEMICAL", 63, 67], ["glucose", "CHEMICAL", 187, 194], ["penicillin", "CHEMICAL", 233, 243], ["streptomycin", "CHEMICAL", 244, 256], ["cell", "CELL", 33, 37], ["VEGF-A165", "GENE_OR_GENE_PRODUCT", 107, 116], ["Cell", "CELL", 117, 121], ["E6", "ORGANISM", 148, 150], ["TMPRSS2 cells", "CELL", 151, 164], ["glucose", "SIMPLE_CHEMICAL", 187, 194], ["FBS", "ORGANISM_SUBSTANCE", 222, 225], ["penicillin", "SIMPLE_CHEMICAL", 233, 243], ["streptomycin", "SIMPLE_CHEMICAL", 244, 256], ["VEGF", "PROTEIN", 107, 111], ["A165", "PROTEIN", 112, 116], ["viral culture 435Vero-E6-TMPRSS2 cells", "CELL_LINE", 126, 164], ["DAPI)", "TREATMENT", 63, 68], ["VEGF", "TEST", 107, 111], ["Cell", "TEST", 117, 121], ["viral culture", "TEST", 126, 139], ["TMPRSS2 cells", "TEST", 151, 164], ["high glucose DMEM", "TREATMENT", 182, 199], ["10% FBS", "TREATMENT", 218, 225], ["penicillin", "TREATMENT", 233, 243], ["streptomycin", "TREATMENT", 244, 256], ["cell load", "OBSERVATION", 33, 42]]], ["Cells were supplemented with 20 \u03bcg/mL blasticidin (Invivogen, ant-bl-1) to maintain stable expression of TMPRSS2 during routine culture.", [["Cells", "ANATOMY", 0, 5], ["blasticidin", "CHEMICAL", 38, 49], ["blasticidin", "CHEMICAL", 38, 49], ["Invivogen", "CHEMICAL", 51, 60], ["Cells", "CELL", 0, 5], ["blasticidin", "SIMPLE_CHEMICAL", 38, 49], ["Invivogen", "SIMPLE_CHEMICAL", 51, 60], ["bl-1", "GENE_OR_GENE_PRODUCT", 66, 70], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 105, 112], ["TMPRSS2", "PROTEIN", 105, 112], ["Cells", "TEST", 0, 5], ["blasticidin", "TREATMENT", 38, 49], ["Invivogen", "TREATMENT", 51, 60], ["TMPRSS2", "PROBLEM", 105, 112], ["routine culture", "TEST", 120, 135], ["stable", "OBSERVATION", 84, 90]]], ["Cells were maintained at 37\u00b0C with 5% CO 2 and passaged every 2-3 days.", [["Cells", "ANATOMY", 0, 5], ["CO 2", "CHEMICAL", 38, 42], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5]]], ["These African green monkey Early kidney cells express NRP-1 which is 99.3% similar within its b1 domain to the human 440 NRP-1.", [["kidney cells", "ANATOMY", 33, 45], ["monkey", "ORGANISM", 20, 26], ["kidney cells", "CELL", 33, 45], ["NRP-1", "GENE_OR_GENE_PRODUCT", 54, 59], ["human", "ORGANISM", 111, 116], ["NRP-1", "GENE_OR_GENE_PRODUCT", 121, 126], ["Early kidney cells", "CELL_TYPE", 27, 45], ["NRP-1", "PROTEIN", 54, 59], ["b1 domain", "PROTEIN", 94, 103], ["human 440 NRP-1", "DNA", 111, 126], ["monkey", "SPECIES", 20, 26], ["human", "SPECIES", 111, 116], ["African green monkey", "SPECIES", 6, 26], ["human", "SPECIES", 111, 116], ["NRP", "TEST", 54, 57], ["kidney", "ANATOMY", 33, 39]]], ["Homology models (not shown) also reveal no differences in NRP-1 passage between these species. infectious VSV-eGFP-SARS-CoV-2 stock was a generous gift from Sean P.J. indicates value not determined.", [["NRP-1", "GENE_OR_GENE_PRODUCT", 58, 63], ["VSV-eGFP-SARS-CoV-2", "ORGANISM", 106, 125], ["NRP", "PROTEIN", 58, 61], ["Homology models", "TEST", 0, 15], ["infectious VSV", "TEST", 95, 109], ["eGFP-SARS", "TEST", 110, 119], ["CoV", "TEST", 120, 123], ["a generous gift", "TREATMENT", 136, 151], ["Sean P.J.", "TEST", 157, 166], ["no", "UNCERTAINTY", 40, 42]]], ["Relative % inhibition (ELISA VEGF-NRP-1 assay -see Methods section) with standard error of the mean (n=11). have the atoms that form potential hydrogen bonds with Asp320, E319, or G318 colored in blue.Figure CaptionsThe common 2(1H)-pyridone core is highlighted with a gray box in structure 15.", [["2(1H)-pyridone", "CHEMICAL", 227, 241], ["hydrogen", "CHEMICAL", 143, 151], ["Asp320", "CHEMICAL", 163, 169], ["E319", "CHEMICAL", 171, 175], ["G318", "CHEMICAL", 180, 184], ["2(1H)-pyridone", "CHEMICAL", 227, 241], ["VEGF", "GENE_OR_GENE_PRODUCT", 29, 33], ["Asp320", "SIMPLE_CHEMICAL", 163, 169], ["E319", "SIMPLE_CHEMICAL", 171, 175], ["G318", "SIMPLE_CHEMICAL", 180, 184], ["2(1H)-pyridone", "SIMPLE_CHEMICAL", 227, 241], ["VEGF", "PROTEIN", 29, 33], ["NRP", "PROTEIN", 34, 37], ["common 2(1H)-pyridone core", "DNA", 220, 246], ["gray box", "DNA", 269, 277], ["ELISA VEGF", "TEST", 23, 33], ["NRP", "TEST", 34, 37], ["hydrogen bonds", "PROBLEM", 143, 157], ["The common 2(1H)-pyridone core", "TREATMENT", 216, 246], ["hydrogen bonds", "OBSERVATION", 143, 157]]], ["Recombinant Spike S1 domain was included at 68 nM.", [["Spike S1", "GENE_OR_GENE_PRODUCT", 12, 20], ["Recombinant Spike S1 domain", "PROTEIN", 0, 27], ["Recombinant Spike S1 domain", "PROBLEM", 0, 27]]], ["Cells were infected for 36h prior to live cell automated microscopy and quantification of sum GFP fluorescence intensity, normalized to cell count by HCS CellMask Blue, was measured and for each well and plotted with Prism 6.Figure CaptionsResults are presented as mean intensity \u00b1 SEM, # P <0.05 vs. mock; p<0.05.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 42, 46], ["cell", "ANATOMY", 136, 140], ["Cells", "CELL", 0, 5], ["cell", "CELL", 42, 46], ["GFP", "GENE_OR_GENE_PRODUCT", 94, 97], ["cell", "CELL", 136, 140], ["live cell automated microscopy", "TEST", 37, 67], ["sum GFP fluorescence intensity", "TEST", 90, 120], ["cell count", "TEST", 136, 146], ["HCS CellMask Blue", "TEST", 150, 167], ["Figure CaptionsResults", "TEST", 225, 247], ["SEM", "TEST", 282, 285], ["P", "TEST", 289, 290]]]], "a76b38e924387b89e7e80a3aa1df2bd116edbde2": [["Respiratory syncytial virus (RSV) is the number one cause of viral lower respiratory tract infection (LRTI) leading to hospitalization in infants worldwide, and the second cause of death in this age group [1, 2] .", [["lower respiratory tract", "ANATOMY", 67, 90], ["Respiratory syncytial virus", "DISEASE", 0, 27], ["RSV", "DISEASE", 29, 32], ["viral lower respiratory tract infection", "DISEASE", 61, 100], ["LRTI", "DISEASE", 102, 106], ["death", "DISEASE", 181, 186], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["RSV", "ORGANISM", 29, 32], ["tract", "ORGANISM_SUBDIVISION", 85, 90], ["infants", "ORGANISM", 138, 145], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["infants", "SPECIES", 138, 145], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["RSV", "SPECIES", 29, 32], ["Respiratory syncytial virus", "PROBLEM", 0, 27], ["viral lower respiratory tract infection", "PROBLEM", 61, 100], ["death", "PROBLEM", 181, 186], ["syncytial virus", "OBSERVATION", 12, 27], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["lower", "ANATOMY_MODIFIER", 67, 72], ["respiratory tract", "ANATOMY", 73, 90], ["infection", "OBSERVATION", 91, 100]]], ["The burden of the disease, however, extends well beyond hospitalization, as it causes significant morbidity in the outpatient setting [3] .", [["the disease", "PROBLEM", 14, 25], ["burden", "OBSERVATION_MODIFIER", 4, 10], ["disease", "OBSERVATION", 18, 25], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["morbidity", "OBSERVATION", 98, 107]]], ["Despite RSV's impact on child health, treatment remains supportive and there is no licensed vaccine, which is due in part to our incomplete understanding of the pathogenesis of the disease and its relation to disease severity.", [["RSV", "ORGANISM", 8, 11], ["RSV", "SPECIES", 8, 11], ["RSV", "PROBLEM", 8, 11], ["treatment", "TREATMENT", 38, 47], ["licensed vaccine", "TREATMENT", 83, 99], ["the disease", "PROBLEM", 177, 188], ["disease severity", "PROBLEM", 209, 225], ["disease", "OBSERVATION", 181, 188]]]], "PMC7299652": [["Case 1 ::: IntroductionJenny2is a model in her mid-20s who presents to hospital at the peak of the COVID-19 pandemic with acute appendicitis.", [["appendicitis", "DISEASE", 128, 140], ["the COVID", "TEST", 95, 104], ["acute appendicitis", "PROBLEM", 122, 140], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["appendicitis", "OBSERVATION", 128, 140]]], ["Her surgeon, Miss Schmidt, approaches Jenny to obtain consent for an open appendectomy.", [["an open appendectomy", "TREATMENT", 66, 86], ["appendectomy", "OBSERVATION", 74, 86]]], ["Miss Schmidt explains the risks of the operative procedure, and the alternative of conservative management (with intravenous antibiotics).", [["intravenous", "ANATOMY", 113, 124], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 124], ["the operative procedure", "TREATMENT", 35, 58], ["conservative management", "TREATMENT", 83, 106], ["intravenous antibiotics", "TREATMENT", 113, 136]]], ["Jenny consents to the procedure.", [["the procedure", "TREATMENT", 18, 31]]], ["However, she develops a postoperative wound infection and an unsightly scar.", [["wound", "ANATOMY", 38, 43], ["scar", "ANATOMY", 71, 75], ["postoperative wound infection", "DISEASE", 24, 53], ["wound", "PATHOLOGICAL_FORMATION", 38, 43], ["scar", "PATHOLOGICAL_FORMATION", 71, 75], ["a postoperative wound infection", "PROBLEM", 22, 53], ["an unsightly scar", "PROBLEM", 58, 75], ["postoperative", "OBSERVATION_MODIFIER", 24, 37], ["wound", "OBSERVATION_MODIFIER", 38, 43], ["infection", "OBSERVATION", 44, 53], ["unsightly", "OBSERVATION_MODIFIER", 61, 70], ["scar", "OBSERVATION", 71, 75]]], ["She does some research and discovers that a laparoscopic procedure would ordinarily have been performed and would have had a lower chance of wound infection.", [["wound", "ANATOMY", 141, 146], ["wound infection", "DISEASE", 141, 156], ["wound", "PATHOLOGICAL_FORMATION", 141, 146], ["a laparoscopic procedure", "TREATMENT", 42, 66], ["wound infection", "PROBLEM", 141, 156], ["wound", "ANATOMY", 141, 146], ["infection", "OBSERVATION", 147, 156]]], ["She sues Miss Schmidt and the hospital trust where she was treated.Case 2 ::: IntroductionJune2s a retired teacher in her early 70s who has well-controlled diabetes and hypertension.", [["diabetes", "DISEASE", 156, 164], ["hypertension", "DISEASE", 169, 181], ["well-controlled diabetes", "PROBLEM", 140, 164], ["hypertension", "PROBLEM", 169, 181], ["well-controlled", "OBSERVATION_MODIFIER", 140, 155], ["diabetes", "OBSERVATION", 156, 164], ["hypertension", "OBSERVATION", 169, 181]]], ["She is active and runs a local food bank.", [["active", "OBSERVATION_MODIFIER", 7, 13]]], ["Immediately prior to the pandemic lockdown in the UK June had an episode of severe chest pain and investigations revealed that she has had a non-ST elevation myocardial infarction.", [["chest", "ANATOMY", 83, 88], ["myocardial", "ANATOMY", 158, 168], ["chest pain", "DISEASE", 83, 93], ["non-ST", "DISEASE", 141, 147], ["myocardial infarction", "DISEASE", 158, 179], ["chest", "ORGANISM_SUBDIVISION", 83, 88], ["myocardial", "MULTI-TISSUE_STRUCTURE", 158, 168], ["severe chest pain", "PROBLEM", 76, 93], ["a non-ST elevation myocardial infarction", "PROBLEM", 139, 179], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["chest", "ANATOMY", 83, 88], ["myocardial", "ANATOMY", 158, 168], ["infarction", "OBSERVATION", 169, 179]]], ["The cardiothoracic surgical team recommends that June undergo a PCI although normally her pattern of coronary artery disease would be treated by CABG.", [["coronary artery", "ANATOMY", 101, 116], ["coronary artery disease", "DISEASE", 101, 124], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 101, 116], ["a PCI", "TREATMENT", 62, 67], ["coronary artery disease", "PROBLEM", 101, 124], ["CABG", "TREATMENT", 145, 149], ["cardiothoracic", "ANATOMY", 4, 18], ["coronary artery", "ANATOMY", 101, 116], ["disease", "OBSERVATION", 117, 124], ["CABG", "OBSERVATION", 145, 149]]], ["When the cardiologist explains that surgery would be normally offered in this situation, and is theoretically superior to PCI, June\u2019s husband becomes angry and demands that June is listed for surgery.In favour of non-disclosure ::: IntroductionIt might appear at first glance that doctors should obviously inform Jenny and June about the usual standard of care.", [["surgery", "TREATMENT", 36, 43], ["angry", "PROBLEM", 150, 155], ["surgery", "TREATMENT", 192, 199]]], ["However, one reason that this may be called into question is that it is not immediately clear how it benefits a patient to be informed about alternatives that are not actually available?", [["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119]]], ["In usual circumstances, doctors are not obliged to inform patients about treatments that are performed overseas but not in the UK.", [["patients", "ORGANISM", 58, 66], ["UK", "GENE_OR_GENE_PRODUCT", 127, 129], ["patients", "SPECIES", 58, 66], ["treatments", "TREATMENT", 73, 83]]], ["In the UK, for example, there is a rigorous process for assessment of new treatments (not including experimental therapies).", [["assessment", "TEST", 56, 66], ["new treatments", "TREATMENT", 70, 84], ["experimental therapies", "TREATMENT", 100, 122]]], ["Some treatments that are available in other jurisdictions have not been deemed by the National Institute for Health and Care Excellence (NICE) to be sufficiently beneficial and cost-effective to be offered by the NHS.", [["Some treatments", "TREATMENT", 0, 15]]], ["It is hard to imagine that a health professional would be found negligent for not discussing with a patient a treatment that NICE has explicitly rejected.", [["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["a treatment", "TREATMENT", 108, 119]]], ["The same might apply for novel therapies that are currently unfunded pending formal evaluation by NICE.In favour of non-disclosure ::: IntroductionOf course, the difference is that the treatments we are discussing have been proven (or are believed) to be beneficial and would normally be provided.", [["novel therapies", "TREATMENT", 25, 40], ["formal evaluation", "TEST", 77, 94], ["the treatments", "TREATMENT", 181, 195]]], ["The Montgomery Ruling of 2015 in the UK established that patients must be informed of material risks of treatment and reasonable alternatives to treatment.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["treatment", "TREATMENT", 104, 113], ["treatment", "TREATMENT", 145, 154]]], ["The Bayley \u2013v- George Eliot Hospital NHS Trust5case established that those reasonable alternative treatments must be \u2018appropriate treatment\u2019 not just a \u2018possible treatment\u20196.", [["alternative treatments", "TREATMENT", 86, 108]]], ["In the current crisis, many previously standard treatments are no longer appropriate given the restrictions outlined.", [["many previously standard treatments", "TREATMENT", 23, 58]]], ["In other circumstances they are appropriate; during a pandemic they are no longer appropriate, even if they become appropriate again at some unknown time in the future.In favour of non-disclosure ::: IntroductionIn both ethical and legal terms, it is widely accepted that, for consent to be valid, if must be given voluntarily by a person who has capacity to consent and who understands the nature and risks of the treatment.", [["person", "SPECIES", 332, 338], ["the treatment", "TREATMENT", 411, 424]]], ["A failure to obtain valid consent, or performing interventions in the absence of consent, could result in criminal proceedings for assault.", [["A failure", "PROBLEM", 0, 9], ["assault", "PROBLEM", 131, 138], ["failure", "OBSERVATION", 2, 9]]], ["Ethically, adequate information about treatments is essential for the patient to enable them to weigh up options and decide which treatments they wish to undertake.", [["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["treatments", "TREATMENT", 38, 48]]], ["However, information about unavailable treatments arguably does not help the patient make an informed decision because it does not give them information that is relevant to consenting or to refusal of treatment that is actually available.", [["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["treatments", "TREATMENT", 39, 49], ["treatment", "TREATMENT", 201, 210]]], ["If Miss Schmidt had given Jenny information about the relative benefits of laparoscopic appendectomy, that could not have helped Jenny\u2019s decision to proceed with surgery.", [["laparoscopic appendectomy", "TREATMENT", 75, 100], ["surgery", "TREATMENT", 162, 169], ["laparoscopic appendectomy", "OBSERVATION", 75, 100]]], ["Her available choices were open appendectomy or no surgery.", [["open appendectomy", "TREATMENT", 27, 44], ["surgery", "TREATMENT", 51, 58], ["appendectomy", "OBSERVATION", 32, 44]]], ["This could cause distress both to the patient and the health professional (who is unable to acquiesce).In favour of non-disclosure ::: IntroductionConsideration might also be paid to the effect on patients of disclosure.", [["patient", "ORGANISM", 38, 45], ["patients", "ORGANISM", 197, 205], ["patient", "SPECIES", 38, 45], ["patients", "SPECIES", 197, 205], ["distress", "PROBLEM", 17, 25]]], ["How would it affect a patient with newly diagnosed cancer to tell them that an alternative, perhaps better therapy, might be routinely available in usual circumstances but is not available now?In favour of non-disclosure ::: IntroductionThere is provision in the Montgomery Ruling, in rare circumstances, for therapeutic exception.", [["cancer", "ANATOMY", 51, 57], ["cancer", "DISEASE", 51, 57], ["patient", "ORGANISM", 22, 29], ["cancer", "CANCER", 51, 57], ["patient", "SPECIES", 22, 29], ["newly diagnosed cancer", "PROBLEM", 35, 57], ["cancer", "OBSERVATION", 51, 57]]], ["That is, if information is significantly detrimental to the health of a patient it might be omitted.", [["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79]]], ["We could imagine a version of the case where Jenny was so intensely anxious about the proposed surgery that her surgeon comes to a sincere belief that discussion of the laparoscopic alternative would be extremely distressing or might even lead her to refuse surgery.", [["the proposed surgery", "TREATMENT", 82, 102], ["the laparoscopic alternative", "TREATMENT", 165, 193], ["surgery", "TREATMENT", 258, 265]]], ["In most cases, though, it would be hard to be sure that the risks of disclosing alternative (non-available) treatments would be so great that non-disclosure would be justified.In favour of disclosure ::: IntroductionIn the UK, professional guidance issued by the GMC (General Medical Council) requires doctors to take a personalised approach to information sharing about treatments by sharing \u2018with patients the information they want or need in order to make decisions\u2019.", [["patients", "ORGANISM", 399, 407], ["patients", "SPECIES", 399, 407], ["alternative (non-available) treatments", "TREATMENT", 80, 118]]], ["The Montgomery judgement of 20157 broadly endorsed the position of the GMC, requiring patients to be told about any material risks and reasonable alternatives relevant to the decision at hand.", [["patients", "ORGANISM", 86, 94], ["hand", "ORGANISM_SUBDIVISION", 187, 191], ["patients", "SPECIES", 86, 94]]], ["The Supreme Court clarifies that materiality here should be judged by reference to a new two-limbed test founded on the notions of the \u2018reasonable person in the patient\u2019s position\u2019 and the \u2018particular patient\u2019.", [["patient", "ORGANISM", 161, 168], ["patient", "ORGANISM", 201, 208], ["person", "SPECIES", 147, 153], ["patient", "SPECIES", 161, 168], ["patient", "SPECIES", 201, 208], ["a new two-limbed test", "TEST", 83, 104]]], ["One practical test might be for the clinician to ask themselves whether patients in general, or this particular patient might wish to know about alternative forms of treatment that would usually be offered.In favour of disclosure ::: IntroductionThe GMC has recently produced pandemic-specific guidance8 on consent and decision-making, but this guidance is focused on managing consent in COVID-19-related interventions.", [["patients", "ORGANISM", 72, 80], ["patient", "ORGANISM", 112, 119], ["patients", "SPECIES", 72, 80], ["patient", "SPECIES", 112, 119], ["treatment", "TREATMENT", 166, 175]]], ["While the GMC takes the view that its consent guidelines continue to apply as far as is practical, it also notes that the patient is enabled to consider the \u2018reasonable alternatives\u2019, and that the doctor is \u2018open and honest with patients about the decision-making process and the criteria for setting priorities in individual cases\u2019.In favour of disclosure ::: IntroductionIn some situations, there might be the option of delaying treatment until later; when other surgical procedures are possible.", [["patient", "ORGANISM", 122, 129], ["patients", "ORGANISM", 229, 237], ["patient", "SPECIES", 122, 129], ["patients", "SPECIES", 229, 237], ["treatment", "TREATMENT", 431, 440], ["surgical procedures", "TREATMENT", 465, 484]]], ["In that setting, it would be important to ensure that the patient is aware of those future options (including the risks of delay).", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65]]], ["For example, if Jenny had symptomatic gallstones, her surgeons might be offering an open cholecystectomy now or the possibility of a laparoscopic surgery at some later point.", [["gallstones", "DISEASE", 38, 48], ["symptomatic gallstones", "PROBLEM", 26, 48], ["an open cholecystectomy", "TREATMENT", 81, 104], ["a laparoscopic surgery", "TREATMENT", 131, 153], ["symptomatic", "OBSERVATION_MODIFIER", 26, 37], ["gallstones", "OBSERVATION", 38, 48], ["cholecystectomy", "OBSERVATION", 89, 104], ["laparoscopic", "OBSERVATION", 133, 145]]], ["Likewise, if June is aware that she is not being offered standard treatment she may wish to delay treatment of her atherosclerosis until a later date.", [["atherosclerosis", "DISEASE", 115, 130], ["standard treatment", "TREATMENT", 57, 75], ["her atherosclerosis", "PROBLEM", 111, 130], ["atherosclerosis", "OBSERVATION", 115, 130]]], ["Of course, such a delay might lead to greater harm overall.", [["a delay", "PROBLEM", 16, 23]]], ["However, it would be ethically permissible to delay treatment if that was the patient\u2019s informed choice (just as it would be permissible for the patient to refuse treatment altogether).In favour of disclosure ::: IntroductionIn the appendicitis case, Jenny does not have the option for delaying her treatment, but the choice for June is more complicated, between immediate PCI which is a second-best treatment versus waiting for standard therapy.", [["appendicitis", "DISEASE", 232, 244], ["patient", "ORGANISM", 78, 85], ["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 78, 85], ["patient", "SPECIES", 145, 152], ["treatment", "TREATMENT", 163, 172], ["her treatment", "TREATMENT", 295, 308], ["immediate PCI", "TREATMENT", 363, 376], ["standard therapy", "TREATMENT", 429, 445], ["appendicitis", "OBSERVATION", 232, 244]]], ["Immediate surgery also raises a risk of acquiring nosocomial COVID-19 infection and June is in an age group and has comorbidities that put her at risk of severe COVID-19 disease.", [["infection", "DISEASE", 70, 79], ["COVID", "DISEASE", 161, 166], ["Immediate surgery", "TREATMENT", 0, 17], ["acquiring nosocomial COVID", "PROBLEM", 40, 66], ["19 infection", "PROBLEM", 67, 79], ["comorbidities", "PROBLEM", 116, 129], ["severe COVID-19 disease", "PROBLEM", 154, 177], ["surgery", "OBSERVATION", 10, 17], ["infection", "OBSERVATION", 70, 79], ["severe", "OBSERVATION_MODIFIER", 154, 160], ["19 disease", "OBSERVATION", 167, 177]]], ["Waiting for surgery leaves June at risk of sudden death.", [["death", "DISEASE", 50, 55], ["surgery", "TREATMENT", 12, 19], ["sudden death", "PROBLEM", 43, 55], ["sudden", "OBSERVATION_MODIFIER", 43, 49], ["death", "OBSERVATION", 50, 55]]], ["For an active and otherwise well patient with coronary disease like June, PCI procedure is not as good a treatment as CABG and June might legitimately wish to take her chances and wait for the standard treatment.", [["coronary", "ANATOMY", 46, 54], ["coronary disease", "DISEASE", 46, 62], ["patient", "ORGANISM", 33, 40], ["coronary", "MULTI-TISSUE_STRUCTURE", 46, 54], ["patient", "SPECIES", 33, 40], ["coronary disease", "PROBLEM", 46, 62], ["PCI procedure", "TREATMENT", 74, 87], ["a treatment", "TREATMENT", 103, 114], ["CABG", "TREATMENT", 118, 122], ["the standard treatment", "TREATMENT", 189, 211], ["active", "OBSERVATION_MODIFIER", 7, 13], ["coronary", "ANATOMY", 46, 54], ["disease", "OBSERVATION", 55, 62]]], ["Patients in this scenario will take different approaches.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Patients will need different amounts of information to form their decisions, many patients will need as much information as is available including information about procedures not currently available to make up their mind.In favour of disclosure ::: IntroductionJune\u2019s husband insists that she should receive the best treatment, and that she should therefore be listed for CABG.", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 82, 90], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 82, 90], ["procedures", "TREATMENT", 165, 175], ["treatment", "TREATMENT", 318, 327], ["CABG", "TREATMENT", 373, 377]]], ["The COVID-19 pandemic of 2020 is being characterised by limitations; liberties curtailed and choices restricted, this is justified by a need to protect healthcare systems from demand exceeding availability.", [["The COVID", "TEST", 0, 9]]], ["While resource allocation is always a relevant ethical concern in publicly funded healthcare systems, it is a dominant concern in a setting where there is a high demand for medical care and scare resources.In favour of disclosure ::: IntroductionIt is well established that competent adult patients can consent to or refuse medical treatment but they cannot demand that health professionals provide treatments that are contrary to their professional judgement or (even more importantly) would consume scarce healthcare resources.", [["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 290, 298], ["medical care", "TREATMENT", 173, 185], ["scare resources", "TREATMENT", 190, 205], ["medical treatment", "TREATMENT", 324, 341], ["treatments", "TREATMENT", 399, 409]]], ["In June\u2019s case, agreeing to perform CABG at a time when large numbers of patients are critically ill with COVID-19 might mean that another patient is denied access to intensive care (and even dies as a result).", [["critically ill", "DISEASE", 86, 100], ["patients", "ORGANISM", 73, 81], ["patient", "ORGANISM", 139, 146], ["patients", "SPECIES", 73, 81], ["patient", "SPECIES", 139, 146], ["CABG", "TREATMENT", 36, 40], ["critically ill", "PROBLEM", 86, 100], ["COVID", "TEST", 106, 111]]], ["Of course, it may be that there are actually available beds in intensive care, and June\u2019s operation would not directly lead to denial of treatment for another patient.", [["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 159, 166], ["operation", "TREATMENT", 90, 99], ["treatment", "TREATMENT", 137, 146]]], ["However, that does not automatically mean that surgery must proceed.", [["surgery", "TREATMENT", 47, 54]]], ["The hospital may have been justified in making a decision to suspend some forms of cardiac surgery.", [["cardiac", "ANATOMY", 83, 90], ["cardiac", "ORGAN", 83, 90], ["cardiac surgery", "TREATMENT", 83, 98], ["cardiac", "ANATOMY", 83, 90], ["surgery", "OBSERVATION", 91, 98]]], ["That could be on the basis of the need to use the dedicated space, staff and equipment of the cardiothoracic critical care unit for patients with COVID-19.", [["COVID-19", "CHEMICAL", 146, 154], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["COVID", "TEST", 146, 151]]], ["Even if all that physical space is not currently occupied if may not be feasible or practical to try to simultaneously accommodate some non-COVID-19 patients.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157]]], ["(There would be a risk that June would contract COVID-19 postoperatively and end up considerably worse off than she would have been if she had instead received PCI.)", [["COVID", "TEST", 48, 53], ["PCI", "TREATMENT", 160, 163]]], ["Moreover, it seems problematic for individual patients to be able to circumvent policies about allocation of resources purely on the basis that they stand to be disadvantaged by the policy.In favour of disclosure ::: IntroductionPerhaps the most significant benefit of disclosure of non-options is transparency and honesty.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["most significant", "OBSERVATION_MODIFIER", 241, 257]]], ["We suggest that the main reason why Miss Schmidt ought to have included discussion of the laparoscopic alternative is so that Jenny understands the reasoning behind the decision.", [["the laparoscopic alternative", "TREATMENT", 86, 114]]], ["If Miss Schmidt had explained to Jenny that in the current circumstances laparoscopic surgery has been stopped, that might have helped her to appreciate that she was being offered the best available management.", [["laparoscopic surgery", "TREATMENT", 73, 93]]], ["It might have enabled a frank discussion about the challenges faced by health professionals in the context of the pandemic and the inevitable need for compromise.", [["the pandemic", "PROBLEM", 110, 122], ["compromise", "PROBLEM", 151, 161]]], ["It may have avoided awkward discussions later after Jenny developed her complication.In favour of disclosure ::: IntroductionTransparent disclosure should not mean that patients can demand treatment.", [["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["her complication", "PROBLEM", 68, 84], ["demand treatment", "TREATMENT", 182, 198]]], ["But it might mean that patients could appeal against a particular policy if they feel that it has been reached unfairly, or applied unfairly.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["For example, if June became aware that some patients were still being offered CABG, she might (or might not) be justified in appealing against the decision not to offer it to her.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["CABG", "TREATMENT", 78, 82]]], ["Obviously such an appeal would only be possible if the patient were aware of the alternatives that they were being denied.In favour of disclosure ::: IntroductionFor patients faced by decisions such as that faced by June, balancing risks of either option is highly personal; individuals need to weigh up these decisions for them and require all of the information available to do so.", [["patient", "ORGANISM", 55, 62], ["patients", "ORGANISM", 166, 174], ["patient", "SPECIES", 55, 62], ["patients", "SPECIES", 166, 174]]], ["Some information is readily available, for example, the rate of infection for Jenny and the risk of death without treatment for June.", [["infection", "DISEASE", 64, 73], ["death", "DISEASE", 100, 105], ["infection", "PROBLEM", 64, 73], ["Jenny", "PROBLEM", 78, 83], ["death", "PROBLEM", 100, 105], ["treatment", "TREATMENT", 114, 123], ["infection", "OBSERVATION", 64, 73]]], ["But other risks are unknown, such as the risk of acquiring nosocomial infection with COVID-19.", [["nosocomial infection", "DISEASE", 59, 79], ["COVID-19", "CHEMICAL", 85, 93], ["COVID-19", "CHEMICAL", 85, 93], ["acquiring nosocomial infection", "PROBLEM", 49, 79], ["COVID", "TEST", 85, 90]]], ["Doctors might feel discomfort talking about unquantifiable risks, but we argue that it is important that the patient has all available information to weigh up options for them, including information that is unknown.ConclusionIn a pandemic, as in other times, doctors should ensure that they offer appropriate medical treatment, based on the needs of an individual.", [["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["discomfort", "PROBLEM", 19, 29], ["appropriate medical treatment", "TREATMENT", 297, 326]]], ["They should aim to provide available treatment that is beneficial and should not offer treatment that is unavailable or contrary to the patient best interests.", [["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 136, 143], ["available treatment", "TREATMENT", 27, 46], ["treatment", "TREATMENT", 87, 96]]], ["It is ethical; indeed it is vital within a public healthcare system, to consider distributive justice in the allocation of treatment.", [["treatment", "TREATMENT", 123, 132]]], ["Where treatment is scarce, it may not be possible or appropriate to offer to patients some treatments that would be beneficial and desired by them.ConclusionInformed consent needs to be individualised.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["treatment", "TREATMENT", 6, 15], ["some treatments", "TREATMENT", 86, 101]]], ["We suggest that in the current climate this should include, for most patients, a nuanced open discussion about alternative treatments that would have been available to them in usual circumstances.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["alternative treatments", "TREATMENT", 111, 133]]]]}